



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Version 1.2026 — July 10, 2025

NCCN.org

NCCN recognizes the importance of clinical trials and encourages participation when applicable and available.
Trials should be designed to maximize inclusiveness and broad representative enrollment.

Continue



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

***Mary B. Daly, MD, PhD/Chair** † ▣
Fox Chase Cancer Center

***Tuya Pal, MD/Vice-Chair** ▣
Vanderbilt-Ingram Cancer Center

Zahraa AlHilli, MD ¶
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Institute

Banu Arun, MD †
The University of Texas
MD Anderson Cancer Center

Heather H. Cheng, MD, PhD †
Fred Hutchinson Cancer Center

Jane Churpek, MD, MS † ‡
University of Wisconsin Carbone Cancer Center

Sarah Colonna, MD, MSCI † ‡
Huntsman Cancer Institute at the University of Utah

Susan M. Domchek, MD †
Abramson Cancer Center
at the University of Pennsylvania

Susan Friedman, DVM ¥
FORCE: Facing Our Risk of Cancer Empowered

Veda N. Giri, MD †
Yale Cancer Center/Smilow Cancer Hospital

Michael Goggins, MD ▣
Johns Hopkins Kimmel Cancer Center

Andrea Hagemann, MD, MSCI Ω
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Ashley Hendrix, MD, MBA ¶
St. Jude Children's Research Hospital/
The University of Tennessee
Health Science Center

Dezheng Huo, PhD &
The UChicago Medicine
Comprehensive Cancer Center

Mollie L. Hutton, MS, CGC Δ
Roswell Park Comprehensive Cancer Center

Beth Y. Karlan, MD Ω Δ
UCLA Jonsson Comprehensive Cancer Center

Nawal Kassem, MD, MS †
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Seema Khan, MD ¶
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Katia Khoury, MD †
O'Neal Comprehensive Cancer Center at UAB

Allison W. Kurian, MD, MSc † ‡ Δ
Stanford Cancer Institute

Christine Laronga, MD ¶
Moffitt Cancer Center

Julie S. Mak, MS, MSc, CGC Δ
UCSF Helen Diller Family
Comprehensive Cancer Center

Kara N. Maxwell, MD, PhD †
Abramson Cancer Center
at the University of Pennsylvania

Kevin McDonnell, MD, PhD †
City of Hope National Medical Center

Carolyn S. Menendez, MD ¶ Δ
Duke Cancer Institute

Sofia D. Merajver, MD, PhD † ‡ †
University of Michigan
Rogel Cancer Center

Jacqueline Mersch, MS, CGC Δ
UT Southwestern Simmons
Comprehensive Cancer Center

Barbara S. Norquist, MD Ω
Fred Hutchinson Cancer Center

Kenneth Offit, MD, MPH † ‡ Δ
Memorial Sloan Kettering Cancer Center

Dominique Rash, MD §
UC San Diego Moores Cancer Center

Gwen Reiser, MS, CGC Δ
Fred & Pamela Buffett Cancer Center

Leigha Senter-Jamieson, MS, CGC Δ
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Kristen Mahoney Shannon, MS, CGC Δ
Mass General Cancer Center

Jeanna Welborn, MD †
UC Davis Comprehensive Cancer Center

Myra J. Wick, MD, PhD Ω ▣
Mayo Clinic Comprehensive Cancer Center

Marie Wood, MD †
University of Colorado Cancer Center

Matthew B. Yurgelun, MD † ‡ †
Dana-Farber/Brigham and
Women's Cancer Center

NCCN

Susan Darlow, PhD

Zeenat Diwan, MS, PhD

Mary Dwyer, MS

¶ Breast surgical oncology	‡ Hematology/ Hematology oncology
▣ Clinical genetics & Epidemiology	‡ Internal medicine
Δ Genetic counseling	† Medical oncology
▣ Gastroenterology	§ Radiation oncology
Ω Gynecologic oncology/ Gynecology	¥ Patient advocacy
	* Discussion Writing Committee Member

Continue



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

[NCCN Genetic/Familial High-Risk Assessment Panel Members](#) [Summary of the Guidelines Updates](#)

Principles of Cancer Risk Assessment and Counseling

- [Pre-Test Counseling \(EVAL-A 1 of 11\)](#)
- [Testing Considerations Prior to Testing \(EVAL-A 2 of 11\)](#)
- [Choice of Multigene Testing \(EVAL-A 3 of 11\)](#)
- [Evaluating the Source of Genetic Testing Information \(EVAL-A 4 of 11\)](#)
- [Tumor Genomic Testing: Potential Implications for Germline Testing \(EVAL-A 5 of 11\)](#)
 - ▶ [Circulating Tumor DNA \(ctDNA\)](#)
- [Post-Test Counseling \(EVAL-A 6 of 11\)](#)
 - ▶ [Positive Results](#)
 - ▶ [Negative Results](#)
 - ▶ [Variants of Uncertain Significance](#)
- [Pedigree: First-, Second-, and Third-Degree Relatives of Proband \(EVAL-B\)](#)

Hereditary Testing Criteria

- [General Testing Criteria \(CRIT-1\)](#)
- [Testing Criteria for High-Penetrance Breast Cancer Susceptibility Genes \(CRIT-2\)](#)
- [Testing Criteria for Ovarian Cancer Susceptibility Genes \(CRIT-4\)](#)
- [Testing Criteria for Pancreatic Cancer Susceptibility Genes \(CRIT-5\)](#)
- [Testing Criteria for Prostate Cancer Susceptibility Genes \(CRIT-6\)](#)
- [Testing Criteria for Li-Fraumeni Syndrome \(CRIT-7\)](#)
- [Testing Criteria for Cowden Syndrome/*PTEN* Hamartoma Tumor Syndrome \(CRIT-8\)](#)

Gene Summary: Risks and Management

- [Testing Criteria Met \(GENE-1\)](#)
- [Cancer Risk Management Based on Genetic Test Results \(GENE-A\)](#)
- [Autosomal Recessive Risk in Cancer Genes – Multigene Panel Testing \(GENE-B\)](#)

Management/Screening

- [BRCA Pathogenic/Likely Pathogenic Variant-Positive Management \(BRCA-A\)](#)
- [Pancreatic Cancer Screening \(PANC-A\)](#)
- [TP53 P/LP Variant Workup \(LIFR-A\)](#)
- [Cowden Syndrome/PHTS Management \(COWD-A\)](#)

Find an NCCN Member Institution:
<https://www.nccn.org/home/member-institutions>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

- [Breast, Ovarian, Uterine, and Prostate Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender Diverse People with Hereditary Cancer Syndromes \(TNBGD-1\)](#)
- [Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines \(SUMM-1\)](#)
- [Abbreviations \(ABBR-1\)](#)
- For chemoprevention options, see [NCCN Guidelines for Breast Cancer Risk Reduction](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2025.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

Global Updates

- References updated throughout the guideline.

[EVAL-A \(5 of 11\)](#)

- 2nd bullet revised by adding: Regardless of findings in the tumor, when germline testing is clinically indicated *based on personal and familial factors*, it should be...

[EVAL-A \(7 of 11\)](#)

- Positive results, added bullet for "For patients of reproductive age".
 - ▶ 2nd sub-bullet revised by adding: P/LP variant prevalence provides information regarding reproductive risk.

[EVAL-A \(8 of 11\)](#)

- Negative results, 4th sub-bullet, 2nd sentence revised: See appropriate screening based on family history in the *NCCN Guidelines for Breast Cancer Screening and Diagnosis as well as the outlined in...*

[EVAL-A \(9 of 11\)](#)

- VUS, 8th sub-bullet added: Updated results of VUS provided by the testing laboratory should be shared with the patient, and patients should be advised to recontact their testing provider periodically (every 3–5 years) to ask about updated results and/or medical re-review.

[EVAL-A \(10 of 11\)](#)

- Principles of genetic testing for patients with cancer,
 - ▶ Post-test, 2nd sub-bullet, 2nd sub-sub-bullet added: For patients of reproductive age, see EVAL-A 7 of 11.

CRIT-1

- General Testing Criteria

- ▶ Testing is clinically indicated in the following scenarios

- ◊ 4th bullet revised: To aid in systemic therapy and surgical decision-making (*eg, PARP inhibitors for breast cancer*).

CRIT-1A

- Footnote c added: Consideration of the limitations of unknown or limited family structure is indicated. See EVAL-A. (Also for CRIT-6A)
- Footnote e revised: In addition to the BRCA1 and BRCA2 PV in those of Ashkenazi ancestry, there are other ancestries that demonstrate "Founder mutations." ~~In these circumstances, the decision to test will depend on the prevalence of the PV in the local population, family history, clinical features, and age of cancer diagnosis. Some additional examples where ancestry may, along with personal and/or family history, contribute to decisions about genetic testing include the following associations:~~ BRCA1 PV in those of Polish ancestry; BRCA2 PV in those of Icelandic ancestry; BRCA1 and BRCA2 PV in those of French Canadian ancestry; numerous BRCA1 and BRCA2 PV in those of Spanish, Mexican, and Central and South American ancestry; BRCA1 and BRCA2 PV in those of Bahamian ancestry; and BRCA1 and BRCA2 PV in those of Hungarian ancestry. The TP53 PV c.1010G>A (p.Arg337His) is seen in a subset of those of Brazilian ancestry, and CDKN2A founder c.225–243del (p.Ala76fs) in those of Dutch ancestry. While emerging data derived from populations of Asian, African, and Middle Eastern origin have documented recurring mutations in BRCA1 and BRCA2 and other genes, population allele frequency data are not yet available to inform testing individuals based solely on ancestry in the absence of personal and/or family history. The same is true for founder mutations in lower penetrance genes (*eg, CHEK2 c.1100delC in those of northern European ancestry*), where family and personal history inform decisions for testing. See Discussion.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

[CRIT-4](#)

- Testing Criteria for Ovarian Cancer Susceptibility Genes

- ▶ Testing is clinically indicated in the following scenarios, 3rd bullet added: Personal history of non-epithelial ovarian cancer (sex-cord tumors with annular tubules [SCTAT], small cell carcinoma of the ovary (hypercalcemic type) (SCCOHT) at any age.
- ▶ Testing may be considered in the following scenarios, bullet added: Personal history of serous tubal intraepithelial carcinoma (STIC) at any age.

- Footnotes

- ▶ Footnote z revised by adding: The Panel acknowledges that testing for DICER1 and SMARCA4 is appropriate. Management guidelines are evolving and consultation with an expert gynecologic oncologist is recommended.
- ▶ Footnote aa added: There is evolving evidence that suggests STIC could be associated with higher rates of BRCA1/2 P/LP variants.

[CRIT-5](#)

- Testing Criteria for Pancreatic Cancer Susceptibility Genes

- ▶ Exocrine pancreatic cancers
 - ◊ 1st sub-bullet revised: All individuals diagnosed with exocrine pancreatic cancer *including acinar cell carcinoma*.

[CRIT-6](#)

- Testing Criteria for Prostate Cancer Susceptibility Genes

- ▶ Subheader revised by adding: PALB2.
- ▶ Family history criteria section, sub-bullet revised: Individual with a first-degree *or second-degree* blood relative meeting any of the criteria listed above (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making)

[CRIT-6A](#)

- Footnote ii revised: Referring to data (Ewing C, et al N Engl J Med 2012;366:141-149; Kote-Jarai Z, et al. Ann Oncol 2015;26:756-761; Witte JS, et al. Cancer Epidemiol Biomarkers Prev 2013;22:675-680; Karlsson Q, et al; PRACTICAL consortium. *Rare germline variants in ATM predispose to prostate cancer: A PRACTICAL consortium study. Eur Urol Oncol 2021;4:570-579*) regarding early onset prostate cancer ~~with HOXB13~~.

[CRIT-7](#)

- Testing Criteria for Li-Fraumeni Syndrome

- ▶ Added family history criteria: unaffected; or affected but does not meet criteria above -Individual with a first-degree or second-degree untested, deceased blood relative meeting any of the criteria listed above.
- ▶ Revised statement: Other cancers associated with LFS but not in the testing criteria include: melanoma, colorectal, gastric, *malignant phyllodes*, and prostate.

[CRIT-8](#)

- Testing Criteria for Cowden Syndrome

- ▶ Added family history criteria: unaffected; or affected but does not meet criteria above -Individual with a first-degree or second-degree untested, deceased blood relative meeting any of the criteria listed above.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

[GENE-A \(1 of 11\)](#)

- Statement removed: The inclusion of a gene in this table below does not imply the endorsement either for or against multigene testing for moderate-penetrance genes. (All GENE pages)
- ATM
 - ▶ Comments section revised: ATM missense c.7271T>G variant is an *example* of a higher penetrance allele (60% by age 80 y; Goldgar DE, et al. Breast Cancer Res 2011;13:R73) (Hall MJ, et al. Cancer Prev Res (Phila) 2021;14:433-440; Southey MC, et al. J Med Genet 2016;53:800-811) and *risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history.* See GENE-B for reproductive implications/recessive disease and partner testing considerations.

[GENE-A \(2 of 11\)](#)

- BRCA1
 - ▶ Prostate cancer, added: strength of evidence of association with cancer added: Strong
 - ▶ Comments section revised: See GENE-B for reproductive implications/recessive disease and partner testing considerations. *The risk for breast cancer appears to be lower for variants (eg, BRCA1 R1699Q) (24% by age 70 y) (Spurdle AB, et al. J Med Genet 2012;49:525-532; Pal T, et al. NPJ Precis Oncol 2024;8:247) and risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history. Screening should be individualized based on personal and family history.*
- BRCA2
 - ▶ Prostate cancer, added: strength of evidence of association with cancer added: Very strong
 - ▶ Comments section revised: See GENE-B for reproductive implications/recessive disease and partner testing considerations. *The risk for breast cancer appears to be lower for certain missense and splicing variants (Pal T, et al. NPJ Precis Oncol 2024;8:247; Huang H, et al. Nature 2025;638:528-537) and risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history.*

[GENE-A \(3 of 11\)](#)

- BRIP1
 - ▶ Primary Breast Cancer
 - ◊ Revised: Strength of evidence of association with cancer: Limited; ~~potential increase in female breast cancer~~
 - ▶ Comments section revised: See GENE-B for reproductive implications/recessive disease and partner testing considerations.
- CDH1
 - ▶ Comments section revised by adding: There is some evidence that certain CDH1 pathogenic variants (in particular c.760G>A, p.Asp254Asn) are associated with nonsyndromic cleft lip with or without cleft palate but may not be associated with elevated cancer risk (Gossner L, et al. Genes (Basel) 2024;15:1475; Brito LA, et al. Hum Mutat 2015;36:1029-1033). Additionally, CDH1 pathogenic variants associated with blepharocheilodontic syndrome also may not be associated with increased cancer risk (Kievit A, et al. Eur J Hum Genet 2018;26:210-219).

[GENE-A \(4 of 11\)](#)

- CDKN2A
 - ▶ Comments section, 2nd sentence revised: Because P/LP variants that specifically disrupt *both* the p14ARF and p16INK4A proteins cause a...
- CHEK2
 - ▶ Comment revised: *The above* risk data are based only on frameshift and missense P/LP variants *other than* Ile157Thr, Ser428Phe, and Thr476Met. There is emerging evidence that not all missense P/LP variants are low penetrance. For ~~some P/LP variants, such as~~ Ile157Thr, Ser428Phe, and Thr476Met, the risk for breast cancer... *Findings are conflicting for male breast cancer, potentially due to a lack of evidence in populations where c.1100del is prevalent.*

[Continued](#)

UPDATES



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

[GENE-A \(6 of 11\)](#)

• PALB2

- ▶ Prostate cancer, added: Emerging evidence for association with increased risk. Consider prostate cancer screening starting at age 40 y (NCCN Guidelines for Prostate Cancer Early Detection)
- ▶ Comments section revised: See GENE-B for reproductive implications/recessive disease *and partner testing considerations*.

[GENE-A \(8 of 11\)](#)

• STK11

- ▶ Other cancer risks, clarified header: Non-epithelial ovarian ~~cancer~~ *neoplasms (usually benign)* (sex cord tumor with annular tubules)

• TP53

- ▶ Prostate cancer, added:
 - ◊ Absolute risk: 25%–50%
 - ◊ Management: Prostate cancer screening starting at age 40 y (NCCN Guidelines for Prostate Cancer Early Detection).
 - ◊ Strength of Evidence: Strong
- ▶ Other cancers, bullet 2 revised: Many other cancers have been associated with LFS, especially melanoma, colorectal, and gastric, prostate.

[GENE-A \(9 of 11\)](#)

- Footnote f revised: Breast awareness ~~starting at age 18 years~~; *and* clinical breast exam, every 6–12 months,...
- Footnote k revised by adding: Further details about salpingectomy included in the BRCA Pathogenic/Likely Pathogenic Variant-Positive Management (BRCA-A 3 of 5).
- Added population risk for prostate cancer: 12%–13%.

BRCA Pathogenic/Likely Pathogenic Variant-Positive Management

[BRCA-A \(1 of 5\)](#)

• Breast cancer

- ▶ 1st bullet revised: Breast awareness ~~starting at age 18 years~~. (Also for LIFR-A 4 of 6 and COWD-A 1 of 2)
- ▶ 3rd bullet, 5th sub-bullet, 2nd sub-sub bullet added: Screening with clinical breast exam should continue after RRM. Routine screening with mammogram and breast MRI are not indicated.

[BRCA-A \(2 of 5\)](#)

• Ovarian/Fallopian Tube/Peritoneal/Uterine Cancers

- ▶ Surgical risk reduction with bilateral salpingo-oophorectomy, 6th bullet added: There is a residual risk for primary peritoneal cancer after risk reducing RRSO. See Discussion.

[BRCA-A \(3 of 5\)](#)

• Ovarian/Fallopian Tube/Peritoneal/Uterine Cancers

- ▶ Salpingectomy, 2nd bullet revised: *If patients undergo salpingectomy*, completion oophorectomy is recommended as per gene-specific guidelines, *unless specified by clinical trial protocol*.
- ▶ Hormone replacement options after risk-reducing surgery, 2nd bullet added: Studies examining the risk of subsequent breast cancer associated with HRT use after RRSO have primarily focused on average durations of HRT use up to 3–5 years, and the safety of longer-term use remains uncertain.

[BRCA-A \(4 of 5\)](#)

- Reproductive options, 2nd bullet added: See GENE-B for reproductive implications/recessive disease and partner testing considerations.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

Pancreatic Cancer Screening

PANC-A (1 of 2)

- 1st bullet revised: ~~Emerging data have examined the efficacy of pancreatic cancer screening in select individuals at increased risk for exocrine pancreatic cancer. Data on the efficacy of pancreatic cancer screening are largely derived from studies of individuals with P/LP germline variants in pancreatic cancer susceptibility genes and/or a family history of pancreatic cancer. This guideline addresses pancreatic cancer screening specifically in individuals with a germline P/LP variant associated with increased risk of exocrine pancreatic cancer. See table below for gene-specific recommendations. To date, most such studies have restricted pancreatic cancer screening to individuals with:~~
 - ▶ ~~A known P/LP germline variant in a pancreatic cancer susceptibility gene (ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, EPCAM, PALB2, STK11, and TP53; see GENE-A) and a family history of pancreatic cancer (first-degree or second-degree relative) from the same side of the family as the germline P/LP variant; or~~
 - ▶ ~~A family history of exocrine pancreatic cancer in ≥1 first-degree and ≥1 second-degree relatives from the same side of the family, even in the absence of a known P/LP germline variant; or~~
 - ▶ ~~Some groups have recommended pancreas surveillance for P/LP variant carriers in the absence of a family history.~~
- Screening table revised:
 - ▶ 4th row, 2nd sub-bullet revised from, "The Panel does not currently recommend pancreatic cancer screening for carriers of P/LP variants in genes other than ATM, BRCA2, STK11, and CDKN2A in the absence of a close family history of exocrine pancreatic cancer" to "There are currently insufficient data regarding the yield and benefits of pancreatic cancer screening for carriers of P/LP variants in genes other than ATM, BRCA2, STK11, and CDKN2A in the absence of a close family history of exocrine pancreatic cancer."

PANC-A (2 of 2)

- Hereditary Pancreatitis Genes
 - ▶ Bullet revised: For individuals with P/LP variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis.

Li-Fraumeni Syndrome

LIFR-A (4 of 6)

- Other cancer risks
 - ▶ 2nd bullet added: Complete blood count with differential every 3–6 months in patients with prior cytotoxic chemotherapy or radiation exposures
 - ▶ 4th bullet revised: Annual dermatologic examination ~~starting at 18 y~~

LIFR-A (5 of 6)

- Other aspects of managing LFS
 - ▶ 7th bullet revised from, "Provide education regarding signs and symptoms of cancer" to "Provide education on signs and symptoms (eg, new sites of persistent pain without known explanation) that should be reported promptly to the care team for evaluation."
 - ▶ 8th bullet revised by adding: Consider mental health screening at each visit and offer assistance with finding an appropriate mental health provider for any interested patient.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

Updates in Version 1.2026 of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate from Version 3.2025 include:

Li-Fraumeni Syndrome (continued)

LIFR-A (6 of 6)

• Pediatric surveillance

- ▶ 1st bullet revised: Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors every 6–12 3–4 mo beginning in infancy.
- ▶ 2nd bullet added: Complete blood count with differential every 3–4 months in patients with prior cytotoxic chemotherapy or radiation exposures.
- ▶ 3rd bullet, sub-bullet added: Whole body MRI should include upper and lower extremities, whenever technically feasible, for osteosarcoma risk.
- ▶ 5th bullet revised: For ACC, ultrasound every 3–4 mo beginning in infancy. *Blood biochemistry (total testosterone, dehydroepiandrosterone sulfate, and androstenedione) if unsatisfactory ultrasound quality.*
- ▶ 6th bullet added: Annual dermatologic examination.
- ▶ 7th bullet added: For breast cancer surveillance, see LIFR-A 4 of 6.

Cowden Syndrome (CS)/PTEN Hamartoma Tumor Syndrome (PHTS)

COWD-A (2 of 2)

- Thyroid, bullet revised: Annual thyroid ultrasound starting at age 7 12 years.

PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- Risk assessment and discussion of genetic testing involves three related stages:
 - 1) Pre-test counseling done prior to ordering testing
 - 2) Consideration of the most appropriate tests to order
 - 3) Post-test counseling done when results are disclosed¹⁻⁶
- It is recommended that a genetic counselor, clinical geneticist, oncologist, surgeon, oncology nurse, or other health professional with expertise and experience in cancer genetics be involved at each stage whenever possible.
 - For principles of genetic testing for patients with cancer (active diagnoses and previous history) when testing is performed outside of specialty genetics setting, see [EVAL-A 10 of 11](#).
- Testing should be considered in appropriate individuals where it is likely to impact the risk management and/or treatment of the tested individuals and/or their family members who also have increased risk.

Pre-test counseling includes the following elements:

- Evaluate patient's needs and concerns regarding:
 - Knowledge of genetic testing for cancer risk, including benefits, risks, and limitations
 - Variant-specific cancer risks
 - Goals for cancer family risk assessment
- Detailed family history including:
 - Collection of a comprehensive family history
 - ◊ Assessment of family history; close blood relatives include first-, second-, and third-degree relatives on each side of the family, particularly around individuals with a diagnosis of cancer ([EVAL-B](#))
 - ◊ Types of cancer, bilaterality, age at diagnosis, subtype, and pathology report confirmation
 - ◊ Ethnicity (specifically Ashkenazi Jewish ancestry)
- Detailed medical and surgical history including:
 - Documentation of prior genetic testing results for patients and their family members
 - Personal cancer history (eg, age, histology, laterality)
 - Pathology reports of primary cancers and/or benign lesions (eg, breast biopsies)
 - Carcinogen exposure (eg, history of radiation therapy [RT])
 - Reproductive history
 - Hormone or oral contraceptive use
 - History of risk-reducing surgeries
 - Smoking, alcohol, or other exposures related to cancer risk
- Focused physical exam (conducted by qualified clinician) when indicated:
 - Cowden syndrome (CS)/PTEN hamartoma tumor syndrome (PHTS) specific: dermatologic,^a including oral mucosa, head circumference, and thyroid (enlarged or nodular on palpation)
- Generate a differential diagnosis and educate the patient on inheritance patterns, penetrance, variable expressivity, and the possibility of genetic heterogeneity.

[Pre-test counseling continued](#)

^a For CS/PHTS dermatologic manifestations, see [CRIT-8](#) and for Peutz-Jeghers syndrome (PJS) dermatologic manifestations, see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#).

[References on
EVAL-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.

**EVAL-A
1 OF 11**



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Pre-test counseling includes the following elements (con't):

- Prepare for the possible outcomes of testing, including positive (pathogenic/likely pathogenic [P/LP]) (person is a carrier of an alteration in a known cancer-predisposing gene), true negative (person is not a carrier of a known cancer-predisposing gene that has been positively identified in another family member), uninformative negative (person is not a carrier of a known cancer-predisposing gene, and the carrier status of other family members is either also negative or unknown), uncertain variants (person is a carrier of an alteration in a gene that currently has no known significance), and mosaic results (occurrence of 2 or more cell lines with different genetic or chromosomal makeup, within a single individual or tissue).
- Obtain written informed consent, and document the informed consent in the patient's medical record.
- Discuss plan for results disclosure when appropriate, including the possibility of the patient consenting to Release of Information of test results to a close relative or spouse when results are released in case patient is deceased or incapacitated.
- Discuss possible management options if a P/LP variant is identified (enhanced surveillance, risk-reducing agents, and risk-reducing surgery).
- Discuss that their results may be important to therapeutic decision-making as directed by a qualified health care provider (eg, oncologist).
- Advise about possible inherited cancer risk to relatives, and options for risk assessment, testing, and management.
- Discuss cost of genetic testing.
- Provide overview of current legislation regarding genetic discrimination and the privacy of genetic information.^b

Prior to genetic testing, the following should be taken into consideration:

- The probability of P/LP variant detection associated with these criteria will vary based on family structure, which includes size of the family, age of the family members, early death, adoption, and number of male and female relatives. Individuals with unknown or limited family history/structure, such as fewer than 2 female first- or second-degree relatives having lived beyond age 45 in either lineage, may have an underestimated probability of familial P/LP variant detection. The estimated likelihood of P/LP variant detection may be low in families with a large number of unaffected and/or male relatives.
- Patients who have received an allogeneic bone marrow transplant or with active or recent hematologic malignancies should not have molecular genetic testing via blood, saliva, or buccal samples (due to unreliable test results from contamination or due to somatic pathogenic variants [PVs] associated with the hematologic malignancy) until other technologies are available. If available, DNA should be extracted from a fibroblast culture. If this source of DNA is not possible, buccal samples can be considered, subject to the risk of donor DNA contamination or malignant cells from the hematologic malignancy.
- If more than one family member is affected with cancers highly associated with a particular inherited cancer susceptibility syndrome, consider initial testing of a family member with youngest age at diagnosis, bilateral disease, multiple primary cancers, or other cancers associated with the syndrome, or most closely related to the proband/patient. If there are no available family members with cancer that is a cardinal feature of the syndrome in question, consider testing first- or second-degree family members affected with other cancers thought to be related to the gene in question (eg, prostate or pancreas with *BRCA1/2*).
- While testing an affected family member is most informative, it is also appropriate to test unaffected family members who meet testing criteria. Limitations of interpreting negative test results in unaffected individuals should be discussed.
- In children <18 years, genetic testing is generally not recommended when results would not impact medical management.⁷
- LP variants are usually clinically managed similarly to PVs, while patients with variants of uncertain significance (VUS) and likely benign variants should be cared for based on the cancers present in the family.
- For choice of multigene testing, see [EVAL-A 3 of 10](#).

^b Genetic Information Nondiscrimination Act of 2008 (GINA). Vol. Public Law No.110-233. Available at: <https://www.eeoc.gov/laws/statutes/gina.cfm>.



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Choice of Multigene Testing

- The introduction of multigene testing for hereditary forms of cancer has rapidly altered the clinical approach to hereditary cancer testing of patients at increased risk of inherited susceptibility to cancer and their families. Based on next-generation sequencing (NGS) technology, these tests simultaneously analyze a set of genes that are associated with a specific family cancer phenotype or multiple phenotypes.
- An individual's personal and/or family history may be explained by more than one inherited cancer syndrome; thus, phenotype-directed testing based on personal and family history through a tailored^c multigene panel test is often more efficient and cost-effective and increases the yield of detecting a P/LP variant in a gene that will impact medical management for the individual or their family members with increased risk.
- There may also be a role for multigene testing in individuals who have tested negative for a single syndrome, but whose personal or family history remains suggestive of an inherited susceptibility.
- Some individuals may carry P/LP germline variants in more than one cancer susceptibility gene; thus, consideration of a multigene panel for individuals already known to carry a single P/LP germline variant from phenotype-directed testing may be considered on a case-by-case basis, based on the degree of suspicion for there being additional variants. For individuals of Ashkenazi Jewish descent, complete gene panel analysis including specific AJ founder mutations should be considered based on family history; testing limited to AJ founder testing may be appropriate for families segregating known mutations, or in population screening in which a negative test is followed by more complete testing depending on personal and/or family history.
- Because commercially available tests differ in the specific genes analyzed, variant classification, and other factors (eg, methods of DNA/RNA analysis or option to reflex from a narrow to a larger panel; provision of financial assistance for cascade testing of relatives), it is important to consider the indication for testing and expertise of the laboratory when choosing the specific laboratory and test panel.
- Multigene testing can include "intermediate" penetrant (moderate-risk) genes.^d For many of these genes, there are limited data on the degree of cancer risk, and there may currently be no clear guidelines on risk management for carriers of P/LP variants. Not all genes included on available multigene tests will change risk management compared to that based on other risk factors such as family history.
- It may be possible to refine risks associated with both moderate and high-penetrance genes, taking into account the influence of gene/gene or gene/environment interactions. In addition, certain P/LP variants in a gene may pose higher or lower risk than other P/LP variants in that same gene. This information should be taken into consideration when assigning risks and management recommendations for individuals and their relatives who also have increased risk.
- P/LP variants in many breast, ovarian, pancreatic, and prostate cancer susceptibility genes involved in DNA repair may be associated with rare autosomal recessive conditions, thus posing risks to offspring if the partner is also a carrier.
- As more genes are tested, there is an increased likelihood of finding VUS, mosaicism, and clonal hematopoiesis of indeterminate potential (CHIP).
- When a P/LP variant with clinical implications for the patient and/or their family members is found on tumor genomic testing, germline confirmatory testing should be recommended.
- There are significant limitations in interpretation of polygenic risk scores (PRS). PRS should not be used for clinical management at this time and use is recommended in the context of a clinical trial, ideally including diverse populations. See [Discussion](#).

^c Tailored is defined as a disease-focused multigene panel of clinically actionable cancer susceptibility genes, in contrast to large multigene panels of uncertain or unknown clinical relevance.

^d Research is evolving, and individuals with P/LP variants in cancer susceptibility genes should be encouraged to participate in clinical trials or genetic registries. Individuals with P/LP variants are also encouraged to recontact their genetics providers every few years for updates.

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
3 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Evaluating the Source of Genetic Testing Information

- Prior to using any germline findings for medical management, it is important to establish whether the reported findings were obtained from a laboratory that is certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) to issue a report of germline findings directly to ordering health care providers. Some states (eg, New York) may have additional reporting requirements.
- Confirmatory germline testing through an appropriately certified laboratory is clinically indicated when a potential P/LP variant is identified through various data sources as noted below:
 - ▶ Commercial entities providing ancestry (and sometimes health) information typically do so through microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. Third-party software applications can be used by consumers to obtain an interpretation of the raw data provided by these companies. Raw data and third-party software are not able to provide information that is appropriate for medical management, as these services are not subject to quality-control processes and recent research suggests that the error rate (40%) is substantial.⁸ In addition, the current tests only provide limited founder PV results without the benefit of family history. More comprehensive genetic counseling and testing for PVs in other inherited cancer risk genes may be appropriate at the time of confirmation testing.
 - ▶ Commercial laboratories utilizing consumer-initiated or direct-to-consumer (DTC) marketing of DNA sequence-based cancer predisposition tests vary substantially in providing information necessary to make informed decisions regarding results and may vary in accuracy in their variant interpretation.^{9,10}
 - ▶ Research: Patients may have participated in research studies that included germline genomic analysis.¹¹ In such cases, it is clinically indicated to review the patient's findings with a genetics professional and/or the reporting laboratory to establish whether the original report was generated by an appropriately certified laboratory, or whether confirmatory testing is clinically indicated.

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
4 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Tumor Genomic Testing: Potential Implications for Germline Testing

- Testing may provide information suggesting a potential germline finding. P/LP variants reported in the tumor may be of somatic or germline origin.
 - ▶ Because tumor genomic testing is designed to address treatment actionability, not germline status, a variant that may be considered as P/LP in the germline may not be reported at all, or reported as normal in the tumor if it lacks clinical implications.
 - ▶ The filtering of raw sequencing data may differ between tumor and germline testing labs so that variants reported out with one analysis may not be reported with the other.
 - ▶ Somatic P/LP variants seen in tumor specimens are common in some genes with germline implications (eg, *TP53*, *STK11*, *PTEN*) and may not indicate the need for germline testing unless the clinical/family history is consistent with a P/LP variant in the germline.
 - ▶ Tumor-only sequencing may not detect about 10% of clinically actionable P/LP germline variants (eg, deletion, duplication, and splicing variants).¹²
 - ▶ The fraction of PVs in cancer susceptibility genes identified through tumor-only testing, and also present in the germline, is highly variable between genes.^{13,14}
- Regardless of findings in the tumor, when germline testing is clinically indicated based on personal and familial factors, it should be performed in a CLIA-approved lab with established experience in germline testing because:
 - ▶ The germline panel performed by some labs offering paired tumor and germline testing may have incomplete coverage and analyze only a subset of those genes of interest to the clinician.
 - ▶ The sensitivity of most tumor genomic testing is lower (particularly for intermediate-sized deletions and duplications) than germline testing.
 - ▶ Similarly, circulating tumor DNA (ctDNA) has the potential to identify both somatic and germline variants with germline treatment implications. Some ctDNA assays, but not all, will alert providers that the particular gene variant identified has a high enough variant allele frequency (VAF) that it is suspicious for germline origin. However, most commercially available assays specializing in somatic ctDNA detection are neither intended nor validated for the reporting or interpretation of germline variants. Thus, variants detected by ctDNA that are suspected to be present in the germline should be evaluated via a CLIA-approved assay specializing in detection and interpretation of germline variants.
 - ▶ ctDNA, detected by mutation profile, copy number changes, altered methylation patterns, fragmentation, size alterations, or other approaches, has application for disease monitoring as well as early detection. For individuals at increased hereditary risk for cancer, use of pre-symptomatic ctDNA cancer detection assays should only be offered in the setting of prospective clinical trials, because the sensitivity, false-positive rates, and positive predictive value of ctDNA tests for early-stage disease, which are needed to derive clinical utility and determine clinical validity, are not fully defined.¹⁵⁻¹⁸ The psychological impact of ctDNA testing remains unknown. For these reasons, ctDNA should not be used, outside of the clinical trial setting, to replace well-established methods of cancer screening (eg, mammography).

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
5 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Post-Test Counseling

- When the testing provider/facility does not include pre-test counseling or have all of the resources or expertise for facilitating follow-up testing, management, or family testing, referral to a genetics provider is recommended. In particular, referral to a genetics provider is recommended for the following test results:
 - ▶ P/LP variant identified
 - ▶ Negative results but tumor profiling, personal history, or family history remain suggestive of inherited condition
 - ▶ Any VUS result that warrants further evaluation or for which a patient or provider considers using to guide management ([EVAL-A 9 of 11](#))
 - ▶ A mosaic/possibly mosaic result or clonal hematopoiesis
 - ▶ Discrepant interpretation of variants, including discordant results across laboratories
 - ▶ Interpretation of PRS, if they are being considered for use in clinical management, recognizing that the clinical value of PRS has not yet been established
 - ▶ Interpretation of P/LP variants for patients tested through DTC or consumer-initiated models
- Post-test counseling includes the following elements:
 - ▶ Discussion of results and associated medical risks
 - ▶ Interpretation of results in context of personal and family history of cancer
 - ▶ Discussion of recommended medical management options including discussion of therapeutic implications by a qualified health care provider if positive
 - ▶ Discussion of the importance of notifying family members and offering materials/resources for informing and testing family members who also have increased risk
 - ▶ Discussion of available resources such as high-risk clinics, disease-specific support groups, and research studies

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- **Positive results:**

- ▶ Some medical centers include services that are specialized in cancer screening, risk reduction, and treatment for individuals with a P/LP variant associated with increased risk for cancer. Where available, consider referring patients to these services, either on a consultative basis or for coordination of ongoing care.
- ▶ In patients being treated for cancer, identification of a P/LP variant may affect options and recommendations for treatment of their disease. A P/LP variant in certain genes is also a component of eligibility for some clinical trials. Specific circumstances are addressed in the [NCCN Treatment Guidelines](#) for breast, ovarian, and other cancers.
- ▶ Many patients who have been diagnosed with cancer and have a P/LP variant are at increased risk for additional primary cancers in the future. Management of those risks may be appropriate after treatment of the current cancer or may be combined with treatment for a current cancer.
- ▶ Multiple sources, including these NCCN Guidelines, provide estimated lifetime risks of cancer associated with specific P/LP variants. A discussion of risk should include:
 - ◊ Presenting risk estimates as a range rather than a single number (ie, 30%–40%)
 - ◊ Presenting absolute risk and minimizing use of relative risk terminology (ie, odds ratios or hazard ratios)
 - ◊ Acknowledging that risk estimates always have a margin of error^e
 - ◊ Identifying that these risk estimates change over time (ie, older patients will have lower remaining lifetime risk)
- ▶ Individuals with a P/LP variant should be informed of the importance of this information for their blood relatives. Knowledge of the P/LP variant may affect risk assessment and recommendations for genetic testing, early detection, and/or cancer risk reduction in those relatives. Where relationships allow, individuals should be encouraged to communicate this information to their blood relatives. A medical provider can assist by providing patients with information for relatives written in simple language and a copy of their genetic test results.
- ▶ Over time, patients with a P/LP variant benefit from re-consultation with a medical provider who is familiar with inherited risk for cancer. This re-consultation is important for:
 - ◊ Increasing adherence with screening guidelines, which is known to decrease over time
 - ◊ Re-evaluating personal choices about risk-reducing surgeries, based on changing life stage and circumstances
 - ◊ Ensuring patients are following up-to-date guidelines
 - ◊ Discussing additional genetic testing options
 - ◊ Reviewing improved risk models as appropriate
- ▶ The frequency of follow-up depends on many factors, such as age, reproductive planning, comorbidities, risk-reducing surgeries, and other risk factors.
- ▶ Some P/LP variants found in blood, saliva, or buccal samples, most notably in *TP53*, warrant consideration of testing of non-blood samples to try to distinguish between germline, constitutional mosaicism, and somatic findings
- ▶ For patients of reproductive age
 - ◊ Advise about options for prenatal diagnosis and assisted reproduction, including pre-implantation genetic testing and donor gametes. Discussion should include known risks, limitations, and benefits of these technologies. See [Discussion](#) for details.
 - ◊ Biallelic P/LP variants in some genes, included on gene panels, may be associated with rare autosomal recessive conditions, such as Fanconi anemia (FA) or constitutional mismatch repair (MMR) deficiency (CMMRD) ([GENE-B](#)). Thus, for these genes, consideration should be given to carrier testing the partner for P/LP variants in the same gene if it would inform reproductive decision-making and/or risk assessment and management.¹⁹ P/LP variant prevalence provides information regarding reproductive risk.²⁰

^e Risk estimates are influenced by the numbers of individuals with these mutations: the more individuals, the more precise the estimates are (ie, the confidence interval is narrower).

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
7 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- **Negative results:**

- ▶ These results reduce concern for cancer risk. However, the individual may still have increased cancer risk based on personal and family history. Also, other family members may have a P/LP variant that the tested individual did not inherit.
- ▶ Although negative results of genetic testing are generally reassuring, other reasons that a patient can test negative include:
 - 1) A gene P/LP variant may exist in the gene that was not recognized due to limitations in technology.
 - 2) P/LP variants exist in genes that were not evaluated by this testing.
 - 3) Family members may harbor a P/LP variant that the patient may not have inherited.
- ▶ Other family members may be appropriate candidates for testing, both to assess their own cancer risk as well as to clarify the overall contribution of known P/LP variants to the family history. If another family member tests positive for a P/LP variant, this might lower concern for the individuals who tested negative. The determination of a “true negative” result depends on the specific family history of cancer, the specific P/LP variant found, and the relationship to the family member(s) who tested positive.
- ▶ When an individual has tested negative, it may still be appropriate to consider increased screening and risk reduction measures for cancer based on family history. See appropriate screening based on family history in the NCCN Guidelines for [Breast Cancer Screening and Diagnosis](#) as well as the [Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines \(SUMM-1\)](#). Some medical centers include specialized high-risk clinics to offer this type of family history-based screening.
- ▶ Over time an individual who tested negative may be a candidate for additional genetic testing due to additional family history, as new genes are identified to be associated with cancer risk or technology advances.

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
8 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- Variants of uncertain significance (VUS)
 - ▶ VUS are alterations in the genetic code for which the impact on protein function is uncertain.
 - ▶ VUS are common, particularly with the use of large multigene panels. The more genes that are included on a genetic testing panel, the more likely a VUS will be identified.²¹
 - ▶ VUS are more commonly found during genetic testing of Asian and Black individuals compared with non-Hispanic white individuals.²¹
 - ▶ In VUS that are reclassified, approximately 80%–90% are reclassified as likely benign or benign and 10%–20% as P/LP.^{22,23}
 - ▶ There are discordant variant interpretations across labs,²⁴ requiring careful counseling and skilled interpretation. Resources are available to review the available data supporting pathogenic consequences of specific variants and identify discrepant results (eg, <https://www.ncbi.nlm.nih.gov/clinvar/>; <https://brcaexchange.org/about/app>; cangene-canvaruk.org/canvig-uk).
 - ▶ VUS should not be used to alter medical management. In the event additional discussion is needed for classification and management, additional genetic expertise is recommended. Screening and risk reduction strategies should be recommended on the basis of personal and family history.
 - ▶ RNA studies (when appropriate) may be a consideration to further define functional impact of variants. Testing family members for a VUS should not be done for clinical purposes, unless there are data to support discrepancy in interpretation of results. Consider a referral to research studies that aim to define the functional impact of variants such as variant reclassification programs through clinical labs or registries.
 - ▶ Updated results of VUS provided by the testing laboratory should be shared with the patient, and patients should be advised to recontact their testing provider periodically (every 3–5 years) to ask about updated results and/or medical re-review.

Note: All recommendations are category 2A unless otherwise indicated.

[References on](#)
[EVAL-A 11 of 11](#)

EVAL-A
9 OF 11



PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

Principles of genetic testing for patients with cancer (active diagnoses and previous history) when testing is performed outside of specialty genetics setting (often referred to as “point of care” testing)

There are clinical situations in which germline genetic testing is critical to therapeutic decision-making but comprehensive risk assessment and genetic counseling are not feasible. In these situations, the treating clinician (eg, oncologist, surgeon) may order germline genetic testing. They should be aware that there may be feasibility and cost limits on the type and number of genetic tests ordered for each individual patient.

To maximize the value of the testing experience they should ensure that they include in their discussion with the patient the following points:

- **Pre-test**
 - **Documentation**
 - ◊ Family history collection of both maternal and paternal relatives who have been diagnosed with cancer of any type, ideally from three generations
 - ◊ Pertinent medical and surgical history
 - ◊ Informed consent for genetic testing
 - **Understanding of the germline genetic test ordered and preparedness to counsel patients about any possible result outcomes, including future cancer risks**
 - ◊ There are many testing options and the choice of which multigene panel test to order can be complicated, eg, when the personal and/or family history may suggest more than one cancer syndrome ([EVAL-A 3 of 11](#))
 - ◊ Result outcomes: positive ([EVAL-A 7 of 11](#)), negative ([EVAL-A 8 of 11](#)), uncertain variant ([EVAL-A 9 of 11](#)), possible mosaic, and/or clonal hematopoiesis of indeterminate potential ([LIFR-A 3 of 6](#))
- **Post-test**
 - **Discussion of result including interpretation of result in the context of the patient’s diagnosis, impact on future cancer risk and management if applicable, impact on reproductive plans if applicable, and impact on family members if applicable**
 - **Referral to clinical genetics services should be offered in the following situations:**
 - ◊ for a P/LP variant result or one for which clinical management is uncertain. Local clinical genetics providers and those that provide telehealth services nationally can be located at <https://findageneticcounselor.nsgc.org>. Some genetic testing laboratories also offer this service.
 - ◊ when a patient has complex personal and/or family history suggestive of inherited risk, or has a result that may be difficult to interpret ([EVAL-A 6 of 11](#))
 - ◊ For patients of reproductive age, see [EVAL-A 7 of 11](#).
 - **Patients should be given a physical and/or electronic copy of their germline genetic test results, as this is often not available to patients through electronic medical record (EMR) portals, if the testing was sent to an outside laboratory. This document is an important reference for the patient and their relatives in the future.**
 - **For patients who test positive or need other genetics follow-up, consider revisiting this information over time, such as when initial treatment is completed and patient is entering a phase of maintenance or surveillance. This is a time when patients may have more ability to follow up on long-term implications of their genetic testing, such as increased screening for other cancers and informing family members.**
 - **It is expected for the ordering clinician to communicate a change in the status of a VUS to the patient, especially if it is an upgrade to pathogenic.**

Note: All recommendations are category 2A unless otherwise indicated.

[References on
EVAL-A 11 of 11](#)

**EVAL-A
10 OF 11**




PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING REFERENCES

- ¹ Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *J Clin Oncol* 2015;33:3660-3667.
- ² Berliner JL, Fay AM, Cummings SA, et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. *J Genet Couns* 2013;22:155-163.
- ³ American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins--Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. *Obstet Gynecol* 2009;113:957-966.
- ⁴ Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 2015;136:3-7.
- ⁵ Konstantinopoulos PA, Norquist B, Laccetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO Guideline. *J Clin Oncol* 2020;38:1222-1245.
- ⁶ Weitzel JN, Blazer KR, Macdonald DJ, et al. Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. *CA Cancer J Clin* 2011;61:327-359.
- ⁷ Committee on Bioethics; Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. *Pediatrics* 2013;131:620-622.
- ⁸ Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. *Genet Med* 2018;20:1515-1521.
- ⁹ Kilbride MK, Bradbury AR. Evaluating web-based direct-to-consumer genetic tests for cancer susceptibility. *JCO Precis Oncol* 2020 Mar 5;4:PO.19.00317.
- ¹⁰ Direct-to-Consumer Tests: <https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-tests>.
- ¹¹ Green R, Berg J, Grody W, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med* 2013;15:565-574.
- ¹² Terraf P, Pareja F, Brown DN, et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. *Ann Oncol* 2022;33:426-433.
- ¹³ Mandelker D, Donoghue M, Talukdar S, et al. Germline-focused analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. *Ann Oncol* 2019;30:1221-1231.
- ¹⁴ Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. *Ann Oncol* 2023;34:215-227.
- ¹⁵ Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? *Clin Chem Lab Med* 2021;59:1353-1361.
- ¹⁶ Offit K, Sharkey C, Green D, et al. Regulation of laboratory-developed tests in preventive oncology: Emerging needs and opportunities. *J Clin Oncol* 2023;41:11-21.
- ¹⁷ Hackshaw A, Clarke C, Hartman A-R. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening. *Cancer Cell* 2022;40:109-113.
- ¹⁸ Raoof S, Lee R, Jajoo K, et al. Multicancer early detection technologies: A review informed by past cancer screening studies. *Cancer Epidemiol Biomarkers Prev* 2022;31:1139-1145.
- ¹⁹ Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *J Natl Cancer Inst* 2003;95:1548-1551.
- ²⁰ Powers J, Wachtel H, Trujillo E, et al. Multi-ethnic heterozygote frequencies of cancer susceptibility genes to inform counseling of reproductive risk. *Genet Med* 2025;27:101246.
- ²¹ Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. *J Clin Oncol* 2021;39:1631-1640.
- ²² Esterling L, Wijayatunge R, Brown K, et al. Impact of a cancer gene variant reclassification program over a 20-year period. *JCO Precis Oncol* 2020; 4:PO.20.00020.
- ²³ Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. *JAMA* 2018;320:1266-1274.
- ²⁴ Balmaña J, Digiovanni L, Gaddam P, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. *J Clin Oncol* 2016;34:4071-4078.

Note: All recommendations are category 2A unless otherwise indicated.

PEDIGREE: FIRST-, SECOND-, AND THIRD-DEGREE RELATIVES OF PROBAND^a












[Common Pedigree Symbols \(EVAL-B 2 of 3\)](#)

^a First-degree relatives: parents, siblings, and children;
second-degree relatives: grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings;
third-degree relatives: great-grandparents, great-aunts, great-uncles, great-grandchildren, first cousins, and half aunts and uncles.

Note: All recommendations are category 2A unless otherwise indicated.



COMMON PEDIGREE SYMBOLS^b


Gender	Sex		
	Male	Female	Unassigned at Birth
Man/Boy		 AFAB (assigned female at birth)	 UAAB (unassigned at birth)
Woman/Girl	 AMAB (assigned male at birth)		 UAAB (unassigned at birth)
Non-binary/ Gender diverse	 AMAB (assigned male at birth)	 AFAB (assigned female at birth)	 UAAB (unassigned at birth)

[Continued](#)


^b Bennett R, French KS, Resta R, Austin J. Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: A practice resource of the National Society of Genetic Counselors. J Genet Couns 2022;31:1238-1248.

Note: All recommendations are category 2A unless otherwise indicated.


COMMON PEDIGREE SYMBOLS^b




**Consultand/
Proband**
(initiating genetic
workup, shade if
affected)




**Relationship
line**




**Sibship
line**




**Adopted into
a family**




Deceased



Consanguinity



**Dizygotic
twins**



**Monozygotic
twins**

AMAB = assigned male at birth

^b Bennett R, French KS, Resta R, Austin J. Practice resource-focused revision: Standardized pedigree nomenclature update centered on sex and gender inclusivity: A practice resource of the National Society of Genetic Counselors. J Genet Couns 2022;31:1238-1248.

Note: All recommendations are category 2A unless otherwise indicated.



GENERAL TESTING CRITERIA^a

Testing is clinically indicated in the following scenarios:

- Individuals with any blood relative with a known P/LP variant in a cancer susceptibility gene
- Individuals meeting the criteria below but who tested negative with previous limited testing (eg, single gene and/or absent deletion/duplication analysis) and are interested in pursuing multigene testing
- A P/LP variant identified on tumor genomic testing that has clinical implications if also identified in the germline
- To aid in systemic therapy and surgical decision-making (eg, PARP inhibitors for breast cancer)^b
- Individual who meets Li-Fraumeni syndrome (LFS) testing criteria ([CRIT-7](#)) or CS/PHTS testing criteria ([CRIT-8](#)) or Lynch syndrome (LS) [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#)
- For personal or family history of^c
 - ▶ Breast cancer [Testing Criteria for High-Penetrance Breast Cancer Susceptibility Genes \(CRIT-2\)](#)
 - ▶ Ovarian cancer [Testing Criteria for Ovarian Cancer Susceptibility Genes \(CRIT-4\)](#)
 - ▶ Pancreatic cancer [Testing Criteria for Pancreatic Cancer Susceptibility Genes \(CRIT-5\)](#)
 - ▶ Prostate cancer [Testing Criteria for Prostate Cancer Susceptibility Genes \(CRIT-6\)](#)
 - ▶ Colorectal cancer [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#)

Testing *may be* considered in the following scenario (with appropriate pre-test education and access to post-test management):

- An individual of Ashkenazi Jewish ancestry^d without additional risk factors^e
- Personal history of serous endometrial cancer^f

For a list of NCCN Guidelines that include content focused on inherited cancer conditions, including criteria for testing and/or cancer risk management based on a genetic test result, see [Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines \(SUMM-1\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on CRIT-1A](#)



FOOTNOTES FOR CRIT-1

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^b Eg, PARP inhibitors for ovarian cancer, prostate cancer, pancreatic cancer, and metastatic HER2-negative breast cancer; platinum therapy for prostate cancer and pancreatic cancer; and risk-reducing surgery. See the relevant [NCCN Treatment Guidelines](#) for further details.

^c Consideration of the limitations of unknown or limited family structure is indicated. See [EVAL-A](#).

^d Testing for three founder P/LP variants of *BRCA1/2* may be offered to individuals as early as age 18–25 years, who have one grandparent identified as of Ashkenazi Jewish ancestry, irrespective of cancer history in the family, as part of longitudinal studies. For those without access to longitudinal research studies, testing may be provided if there is access to pre-test education along with post-test counseling, additional genetic testing if indicated, and high-risk management. Testing should not be offered outside of a medical framework or clinical trial.

^e In addition to the *BRCA1* and *BRCA2* PV in those of Ashkenazi ancestry, there are other ancestries that demonstrate “Founder mutations.” See [Discussion](#).

^f This is a rare subtype of uterine cancer for which there is evolving evidence of an association with *BRCA1* P/LP variants.

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR HIGH-PENETRANCE BREAST CANCER SUSCEPTIBILITY GENES (Genes such as *BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, *STK11*, and *TP53*. See [GENE-A](#))^{a,g,h,i,j}

Testing is clinically indicated in the following scenarios:	
• See General Testing Criteria on CRIT-1 .	
• Personal history of breast cancer with specific features:	
▶ ≤50 y	
▶ Any age:	
◇ Treatment indications	
– To aid in systemic treatment decisions using PARP inhibitors for breast cancer in the metastatic setting ^{k,l} (See NCCN Guidelines for Breast Cancer)	
– To aid in adjuvant treatment decisions with olaparib for high-risk, ^m HER2-negative breast cancer ^j	
◇ Pathology/histology	
– Triple-negative breast cancer	
– Multiple primary breast cancers (synchronous or metachronous) ⁿ	
– Lobular breast cancer with personal or family history of diffuse gastric cancer (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric)	
◇ Male breast cancer	
◇ Ancestry: Ashkenazi Jewish	
▶ Any age (continued):	
◇ Family history ^o	
– ≥1 close blood relative ^p with ANY:	
▪ breast cancer at age ≤50 y	
▪ male breast cancer	
▪ ovarian cancer	
▪ pancreatic cancer	
▪ prostate cancer with metastatic, ^q or high- or very-high-risk group (Initial Risk Stratification and Staging Workup in NCCN Guidelines for Prostate Cancer)	
– ≥3 diagnoses of breast and/or prostate cancer (any grade) on the same side of the family including the patient with breast cancer	
• Family history criteria: unaffected; or affected but does not meet above criteria	
▶ Individual with a first- or second-degree blood relative meeting any of the criteria listed above (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making). ^r	
▶ Individuals who have a probability >5% of a <i>BRCA1/2</i> P/LP variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, CanRisk). ^s	

Criteria met → [GENE-1](#)

If testing criteria not met, consider testing criteria for other hereditary syndromes

If criteria for other hereditary syndromes not met, then cancer screening as per [NCCN Screening Guidelines](#)

Note: All recommendations are category 2A unless otherwise indicated.

[Continued on CRIT-3](#)

[Footnotes on CRIT-2A](#)



TESTING CRITERIA FOR HIGH-PENETRANCE BREAST CANCER SUSCEPTIBILITY GENES

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^g Testing for PVs in other genes should take into consideration factors such as patient preferences, turnaround time, and insurance restrictions to particular labs (and thus particular panels). The prevalence of VUS increases with testing of additional genes. Individuals should have pre-test education on the challenges in managing PVs in genes associated with specific syndromes (eg, *CDH1* and *TP53* given their expanding clinical phenotypes) in the absence of a family history typical of such syndromes (does not apply for de novo PVs). Patients should also have pre-test education regarding the uncertain clinical utility of identifying certain PVs (eg, monoallelic *MUTYH*).

^h Meeting one or more of these criteria warrants further personalized risk assessment, genetic counseling, and often genetic testing and management.

ⁱ For the purposes of these guidelines, invasive and ductal carcinoma in situ breast cancers should be included.

^j For personal or family history of ovarian cancer, see [CRIT-4](#); for pancreatic cancer, see [CRIT-5](#); for prostate cancer, see [CRIT-6](#).

^k Robson M, et al. N Engl J Med 2017;377:523-533; Litton JK, et al. N Engl J Med 2018;379:753-763.

^l As indicated in the criteria, testing is recommended for all triple-negative breast cancers, and these indications are specifically for PARP inhibitor eligibility.

^m The definition of high-risk disease is that used in the phase III OlympiA trial, which compared adjuvant olaparib to placebo among *BRCA1/BRCA2* carriers with high-risk disease (Tutt ANJ, et al. Engl J Med 2021;384:2394-2405). The definition includes:

- Triple-negative breast cancer treated with either:

- adjuvant chemotherapy with axillary node-positive disease or an invasive primary tumor ≥ 2 cm on pathology analysis, or

- neoadjuvant chemotherapy with residual invasive breast cancer in the breast or resected lymph nodes.

- Hormone receptor-positive disease treated with either:

- adjuvant chemotherapy with ≥ 4 positive pathologically confirmed lymph nodes, or

- neoadjuvant chemotherapy that did not have a complete pathologic response, with a CPS + EG score of ≥ 3 .

- The CPS + EG scoring system is based on a combination of clinical and pathologic stage, estrogen receptor status, and histologic grade. See [Neoadjuvant Therapy Outcomes Calculator](#) (Jeruss JS, et al. J Clin Oncol 2008;26:246-252; Mittendorf EA, et al. J Clin Oncol 2011;29:1956-1962). See [NCCN Guidelines for Breast Cancer](#) for further details.

ⁿ Weitzel JN, et al. Breast Cancer Res Treat 2021;188:759-768.

^o Consideration of the limitations of unknown or limited family structure is indicated in those aged ≥ 51 years. See [EVAL-A](#).

^p Close blood relatives include first-, second-, and third-degree relatives on the same side of the family ([EVAL-B](#)).

^q Metastatic prostate cancer is biopsy-proven and/or with radiographic evidence and includes distant metastasis and regional bed or nodes. It is not a biochemical recurrence only. Prostate cancer-specific mortality should be a surrogate for metastatic disease for family history purposes.

^r This may be extended to an affected third-degree relative if related through two male relatives (eg, paternal grandfather's mother or sister). If the affected first-degree relative underwent genetic testing and is negative for detectable P/LP variants and there is no other family history of cancer, there is a low probability that any finding will have documented clinical utility.

^s The approximate 5% threshold for probability of carrying *BRCA1/2* PVs is utilized because of availability of prior probability models; however, it is recognized that current model estimates vary substantially, and that different thresholds may be appropriate if other genes are included in the model utilized. If genes other than *BRCA1* and *BRCA2* are to be included in models evaluating the threshold for testing, the penetrance, clinical actionability, and phenotypic features of cancers associated with P/LP variants in these genes should be considered. The Panel encourages the development of validated models that include these parameters to determine eligibility and appropriateness for gene panel testing for inherited cancer risk. These models are only validated for *BRCA1/2*.

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR HIGH-PENETRANCE BREAST CANCER SUSCEPTIBILITY GENES (continued)

Testing *may be* considered in the following scenarios (with appropriate pre-test education and access to post-test management):

- Personal history of breast cancer ≤65 y not meeting any of the above criteria ([CRIT-2](#)).^{t,u} It is cautioned that the majority of those PVs will be in moderate-penetrance genes, which are over-represented in older affected individuals. Access to an experienced genetic counseling team to discuss management options is particularly important in this setting.
- Personal history of breast cancer diagnosed at any age with ≥1 close blood relative^p with intermediate-risk prostate cancer with intraductal/cribriform histology (see Initial Risk Stratification and Staging Workup in [NCCN Guidelines for Prostate Cancer](#)).
- Individuals (unaffected; or affected but does not meet above criteria [[CRIT-2](#)]) with a 2.5%-5% probability of BRCA1/2 P/LP variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, CanRisk).^g
- Personal history of malignant phyllodes tumors.^v

There is a low probability (<2.5%) that testing will have findings of documented high-penetrance genes in the following scenarios:

- Female diagnosed with breast cancer at age >65 y, with no close relative^p with breast, ovarian, pancreatic, or prostate cancer.
- Diagnosed with localized prostate cancer with Gleason Score <7 and no close relative^p with breast, ovarian, pancreatic, or prostate cancer.

^g Testing for PVs in other genes should take into consideration factors such as patient preferences, turnaround time, and insurance restrictions to particular labs (and thus particular panels). The prevalence of VUS increases with testing of additional genes. Individuals should have pre-test education on the challenges in managing PVs in genes associated with specific syndromes (eg, *CDH1* and *TP53* given their expanding clinical phenotypes) in the absence of a family history typical of such syndromes (does not apply for de novo PVs). Patients should also have pre-test education regarding the uncertain clinical utility of identifying certain PVs (eg, monoallelic *MUTYH*).

^p Close blood relatives include first-, second-, and third-degree relatives on the same side of the family ([EVAL-B](#)).

^t Bedrosian I, et al. J Clin Oncol 2024;42:584-604.

^u Testing includes breast cancer genes plus other inherited cancer genes consistent with family phenotype.

^v See [Discussion](#).

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR OVARIAN CANCER SUSCEPTIBILITY GENES^{a,w}

(Genes such as *ATM*, *BRCA1*, *BRCA2*, *BRIP1*, LS genes [*MLH1*, *MSH2*, *MSH6*, *EPCAM*], *PALB2*, *RAD51C*, and *RAD51D*; see [GENE-A](#))^x

Testing is clinically indicated in the following scenarios:

- See General Testing Criteria on [CRIT-1](#).
- Personal history of epithelial ovarian cancer^y (including fallopian tube cancer or peritoneal cancer) at any age
- Personal history of non-epithelial ovarian cancer (sex-cord tumors with annular tubules [SCTAT], small cell carcinoma of the ovary (hypercalcemic type) (SCCOHT) at any age^z
- Family history of cancer only
 - ▶ An individual unaffected with ovarian cancer with a first- or second-degree blood relative with epithelial ovarian cancer,^r (including fallopian tube cancer or peritoneal cancer) at any age^r
 - ▶ An individual unaffected with ovarian cancer who otherwise does not meet the criteria above but has a probability >5% of a *BRCA1/2* P/LP variant based on prior probability models (eg, Tyrer-Cuzick, BRCAPro, CanRisk)^s

Testing *may be considered* in the following scenarios (with appropriate pre-test education and access to post-test management):

- Personal history of serous tubal intraepithelial carcinoma (STIC) at any age^{aa}

Criteria met → [GENE-1](#)

If testing criteria not met, consider testing criteria for other hereditary syndromes

If criteria for other hereditary syndromes not met, then cancer screening as per [NCCN Screening Guidelines](#)

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^r This may be extended to an affected third-degree relative if related through two male relatives (eg, paternal grandfather's mother or sister). If the affected first-degree relative underwent genetic testing and is negative for detectable P/LP variants and there is no other family history of cancer, there is a low probability that any finding will have documented clinical utility.

^s The approximate 5% threshold for probability of carrying *BRCA1/2* PVs is utilized because of availability of prior probability models; however, it is recognized that current model estimates vary substantially, and that different thresholds may be appropriate if other genes are included in the model utilized. If genes other than *BRCA1* and *BRCA2* are to be included in models evaluating the threshold for testing, the penetrance, clinical actionability, and phenotypic features of cancers associated with P/LP variants in these genes should be considered. The Panel encourages the development of validated models that include these parameters to determine eligibility and appropriateness for gene panel testing for inherited cancer risk. These models are only validated for *BRCA1/2*.

^w For personal or family history of breast cancer, see [CRIT-2](#); for pancreatic cancer, see [CRIT-5](#); for prostate cancer, see [CRIT-6](#).

^x The listed genes differ in their levels of risk. See [GENE-A](#) for specific risks.

^y *BRCA*-related ovarian cancers are associated with epithelial, non-mucinous histology. LS can be associated with both non-mucinous and mucinous epithelial tumors. Be attentive for clinical evidence of LS (see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#)).

^z Specific types of non-epithelial ovarian cancers and tumors can also be associated with other rare syndromes. Examples include an association between sex-cord tumors with annular tubules and PJS or Sertoli-Leydig tumors, *DICER1*-related disorders, and SCCOHT with *SMARCA4*. The Panel acknowledges that testing for *DICER1* and *SMARCA4* is appropriate. Management guidelines are evolving and consultation with an expert gynecologic oncologist is recommended.

^{aa} There is evolving evidence that suggests STIC could be associated with higher rates of *BRCA1/2* P/LP variants.

Note: All recommendations are category 2A unless otherwise indicated.




TESTING CRITERIA FOR PANCREATIC CANCER SUSCEPTIBILITY GENES

(Genes such as *ATM*, *BRCA1*, *BRCA2*, *CDKN2A*, LS genes [*MLH1*, *MSH2*, *MSH6*, *EPCAM*], *PALB2*, *STK11*, and *TP53*) ([GENE-A](#))^{a,bb}

Testing is clinically indicated in the following scenarios:

- See General Testing Criteria on [CRIT-1](#).
- Exocrine pancreatic cancers
 - ▶ All individuals diagnosed with exocrine pancreatic cancer including acinar cell carcinoma^{cc,dd}
 - ▶ First-degree relatives of individuals diagnosed with exocrine pancreatic cancer^{ee}
- Neuroendocrine pancreatic tumors - [NCCN Guidelines for Neuroendocrine and Adrenal Tumors](#)



^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^{bb} For personal or family history of breast cancer, see [CRIT-2](#); for ovarian cancer, see [CRIT-4](#); for prostate cancer, see [CRIT-6](#).

^{cc} Pancreatic cancer risk is higher in individuals of Ashkenazi Jewish ancestry. Genetic testing of Ashkenazi Jewish patients with pancreatic cancer may have a higher yield of P/LP variants than of non-Ashkenazi Jewish patients. See [Discussion](#).

^{dd} Increasing evidence suggests that identification of a *BRCA1/2* P/LP variant may direct use of targeted therapies for patients with pancreatic cancer (see [NCCN Guidelines for Pancreatic Adenocarcinoma](#)). (Holter S, et al. J Clin Oncol 2015;33:3124-3129; Shindo K, et al. J Clin Oncol 2017;35:3382-3390; Golan T, et al. N Engl J Med 2019;381:317-327.)


^{ee} Testing of first-degree relatives should only be done if it is impossible to test the individual who has pancreatic cancer. Some second-degree relatives may meet testing criteria based on additional family history. Approximately 2%–5% of unselected cases of pancreatic adenocarcinoma will have a *BRCA1/2* P/LP variant. However, the disease is highly aggressive and the option to test the affected relative may not be available in the future. Thus, there may be significant benefit to family members in testing these patients near the time of diagnosis. Family history of pancreatic cancer of unknown histology is often assumed to be an exocrine pancreatic cancer.

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR PROSTATE CANCER SUSCEPTIBILITY GENES (Genes such as *ATM*, *BRCA1*, *BRCA2*, *CHEK2*, *HOXB13*,^{ff} *PALB2*, and *TP53*) ([GENE-A](#))^{a,gg,hh}

Testing is clinically indicated in the following scenarios:
<ul style="list-style-type: none">• See General Tumor Criteria on CRIT-1.• Personal history of prostate cancer at any age with:<ul style="list-style-type: none">‣ Metastatic^q (Stage IVB) or node-positive (Stage IVA) prostate cancer‣ Very high-risk or high-risk disease (See Initial Risk Stratification and Staging Workup [PROS-2] - NCCN Guidelines for Prostate Cancer)‣ Ancestry: Ashkenazi Jewish‣ Family history^c<ul style="list-style-type: none">◇ ≥1 close blood relative^p with ANY:<ul style="list-style-type: none">– breast cancer at age ≤50 y– male breast cancer– ovarian cancer– pancreatic cancer– metastatic,^q node positive, or very high-risk or high-risk prostate cancer◇ ≥3 close blood relatives^p with prostate cancer (any grade) and/or breast cancer on the same side of the family including the patient with prostate cancer◇ For additional family history considerations, see NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric• Family history criteria: unaffected; or affected but does not meet criteria above<ul style="list-style-type: none">◇ Individual with a first-degree or second-degree blood relative meeting any of the criteria listed above (except unaffected individuals whose relatives meet criteria only for systemic therapy decision-making)^r
Testing <i>may be</i> considered in the following scenario:
<ul style="list-style-type: none">• Personal history of prostate cancer ≤55 yⁱⁱ not meeting any of the above criteria• Personal history of prostate cancer with intermediate-risk prostate cancer with intraductal/criform histology (see Initial Risk Stratification and Staging Workup in NCCN Guidelines for Prostate Cancer) at any age
Refer for genetic testing in the following scenario:
<ul style="list-style-type: none">• Biochemical recurrence<ul style="list-style-type: none">‣ For this heterogeneous disease state, refer for genetic testing if: 1) Very high-risk or high-risk disease at diagnosis (see above), 2) family history of cancer criteria met, or if (and at time of) progression to metastatic disease



Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on CRIT-6A](#)



FOOTNOTES FOR CRIT-6

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^c Consideration of the limitations of unknown or limited family structure is indicated. See [EVAL-A](#).

^p Close blood relatives include first-, second-, and third-degree relatives on the same side of the family ([EVAL-B](#)).

^q Metastatic prostate cancer is biopsy-proven and/or with radiographic evidence and includes distant metastasis and regional bed or nodes. It is not a biochemical recurrence only. Prostate cancer-specific mortality should be a surrogate for metastatic disease for family history purposes.

^r This may be extended to an affected third-degree relative if related through two male relatives (eg, paternal grandfather's mother or sister). If the affected first-degree relative underwent genetic testing and is negative for detectable P/LP variants and there is no other family history of cancer, there is a low probability that any finding will have documented clinical utility.

^{ff} [NCCN Guidelines for Prostate Cancer](#).

^{gg} For personal or family history of breast cancer, see [CRIT-2](#); for ovarian cancer, see [CRIT-4](#); for pancreatic cancer, see [CRIT-5](#).

^{hh} Level of risk for prostate cancer varies by gene. There is emerging evidence for potential risk and/or therapeutic relevance for prostate cancer for additional genes.


ⁱⁱ Referring to data (Ewing C, et al N Engl J Med 2012;366:141-149; Kote-Jarai Z, et al. Ann Oncol 2015;26:756-761; Witte JS, et al. Cancer Epidemiol Biomarkers Prev 2013;22:675-680; Karlsson Q, et al; PRACTICAL consortium. Rare germline variants in ATM predispose to prostate cancer: A PRACTICAL consortium study. Eur Urol Oncol 2021;4:570-579) regarding early onset prostate cancer.

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR LI-FRAUMENI SYNDROME^a

Testing is clinically indicated in the following scenarios:*
<ul style="list-style-type: none">• See General Testing Criteria on CRIT-1.• Individual from a family with a known <i>TP53</i>^{jj} P/LP variant• Classic LFS criteria^{kk}:<ul style="list-style-type: none">▶ Combination of an individual diagnosed at age <45 years with a sarcoma^{ll} AND A first-degree relative diagnosed at age <45 years with cancer AND An additional first- or second-degree relative in the same lineage with cancer diagnosed at age <45 years, or a sarcoma at any age• Chompret criteria^{mm}:<ul style="list-style-type: none">▶ Individual with a tumor from LFS tumor spectrum (eg, soft tissue sarcoma, osteosarcoma, central nervous system [CNS] tumor, breast cancer, adrenocortical carcinoma [ACC]), diagnosed <46 years of age, AND at least one first- or second-degree relative diagnosed with any of the aforementioned cancers (other than breast cancer if the proband has breast cancer) at age <56 years or with multiple primaries at any age OR▶ Individual with multiple tumors (except multiple breast tumors), two of which belong to LFS tumor spectrum with the initial cancer occurring at age <46 years OR▶ Individual with ACC, or choroid plexus carcinoma or rhabdomyosarcoma of embryonal anaplastic subtype, at any age of onset, regardless of family history OR▶ Breast cancer diagnosed at age <31 years• Personal or family history of pediatric hypodiploid acute lymphoblastic leukemia• In individuals with cancer with a P/LP <i>TP53</i> variant identified on tumor-only genomic testing, germline testing should be considered for^{nn,oo,pp}:<ol style="list-style-type: none">1. Those meeting one or more of the other LFS testing criteria above after reevaluation of personal and family history2. Those diagnosed at age <30 years with any cancer3. Those with clinical scenario not meeting these criteria but warranting germline evaluation per clinician discretion
<ul style="list-style-type: none">• Family history criteria: unaffected; or affected but does not meet criteria above<ul style="list-style-type: none">◊ Individual with a first-degree or second-degree untested, deceased blood relative meeting any of the criteria listed above



* Other cancers associated with LFS but not in the testing criteria include: melanoma, colorectal, gastric, malignant phyllodes, and prostate.

[Footnotes on CRIT-7A](#)

Note: All recommendations are category 2A unless otherwise indicated.



FOOTNOTES FOR CRIT-7

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^{jj} When this gene is included as part of a multigene panel, an individual does not need to meet these testing criteria if testing criteria on other testing criteria pages are met.

^{kk} Li FP, et al. Cancer Res 1988;48:5358-5362.

^{ll} In contrast to other types of sarcoma, germline *TP53* P/LP variants are rare in those with Ewing sarcoma, gastrointestinal stromal tumor (GIST), desmoid tumor, or angiosarcoma.

^{mm} Chompret A, et al. J Med Genet 2001;38:43-47; Bougeard G, et al. J Clin Oncol 2015;33:2345-2352.

ⁿⁿ For testing in the pediatric setting, see Frebourg T, et al. Eur J Hum Genet 2020;28:1379-1386.

^{oo} This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic *TP53* P/LP variants are common in many tumor types in absence of a germline P/LP variant.


^{pp} Mandelker D, et al. Ann Oncol 2019;30:1221-1231.

Note: All recommendations are category 2A unless otherwise indicated.



TESTING CRITERIA FOR COWDEN SYNDROME (CS)/PTEN HAMARTOMA TUMOR SYNDROME (PHTS)^{a,qq,rr,ss}

Testing is clinically indicated in the following scenarios:
<ul style="list-style-type: none">• See General Testing Criteria on CRIT-1.
<ul style="list-style-type: none">• Individual from a family with a known <i>PTEN</i>^{jj} P/LP variant• Individual with a personal history of Bannayan-Riley-Ruvalcaba syndrome (BRRS)• Individual meeting clinical diagnostic criteria^{tt} for CS/PHTS• Individual not meeting clinical diagnostic criteria^{tt} for CS/PHTS with a personal history of:<ul style="list-style-type: none">▶ Adult Lhermitte-Duclos disease (cerebellar tumors); or▶ Autism spectrum disorder and macrocephaly; or▶ Two or more biopsy-proven trichilemmomas; or▶ Two or more major criteria (one must be macrocephaly); or▶ Three major criteria, without macrocephaly; or▶ One major and ≥3 minor criteria^{uu}; or▶ ≥4 minor criteria• Individual with a relative with a clinical diagnosis of CS/PHTS or BRRS for whom testing has not been performed<ul style="list-style-type: none">▶ Individual must have the following:<ul style="list-style-type: none">◇ Any one major criterion or◇ Two minor criteria• <i>PTEN</i> P/LP variant detected by tumor genomic testing on any tumor type in the absence of germline analysis^{vv}
<ul style="list-style-type: none">• Family history criteria: unaffected; or affected but does not meet criteria above<ul style="list-style-type: none">◇ Individual with a first-degree or second-degree untested, deceased blood relative meeting any of the criteria listed above



See major and minor criteria on [CRIT-8A](#).

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^{jj} When this gene is included as part of a multigene panel, an individual does not need to meet these testing criteria if testing criteria on other testing criteria pages are met.

^{qq} These are testing criteria; clinical diagnostic criteria can be found on [CRIT-8A](#).

^{rr} If two criteria involve the same structure/organ/tissue, both may be included as criteria.

^{ss} Current evidence does not support testing for succinate dehydrogenase (*SDH*) gene P/LP variants in patients with PHTS (Bayley J-P. Am J Hum Genet 2011;88:674-675).

^{tt} Pilarski R, et al. J Natl Cancer Inst 2013;105:1607-1616. See [CRIT-8A](#).

^{uu} If an individual has two or more major criteria, such as breast cancer and nonmedullary thyroid cancer, but does not have macrocephaly, one of the major criteria may be included as one of the three minor criteria to meet testing criteria.

^{vv} This should prompt a careful evaluation of personal and family history of the individual to determine the yield of germline sequencing. Somatic *PTEN* P/LP variants are common in many tumor types in absence of germline P/LP variant.

Note: All recommendations are category 2A unless otherwise indicated.



DIAGNOSTIC CRITERIA FOR COWDEN SYNDROME (CS)/*PTEN* HAMARTOMA TUMOR SYNDROME (PHTS)^{a,*}

Major criteria:

- Breast cancer
- Endometrial cancer (epithelial)
- Follicular thyroid cancer
- ≥3 GI hamartomas or ganglioneuromas^{ww}
- Lhermitte-Duclos disease (adult)
- Macrocephaly (megalcephaly) (ie, ≥97%, 58 cm in adult female, 60 cm in adult male)^{xx}
- Macular pigmentation of glans penis
- Mucocutaneous lesions^{yy}
 - ▶ Trichilemmoma (≥3, at least 1 biopsy-proven)
 - ▶ ≥3 palmoplantar keratotic pits and/or acral hyperkeratotic papules)
 - ▶ ≥3 mucocutaneous neuromas
 - ▶ Oral papillomas (particularly on tongue and gingiva) (≥3 or 1 biopsy-proven or dermatologist diagnosed)

Minor criteria^{zz}:

- Autism spectrum disorder
- Colon cancer
- ≥3 esophageal glycogenic acanthoses
- ≥3 lipomas
- Intellectual disability (ie, IQ ≤75)
- Renal cell carcinoma
- Testicular lipomatosis
- Papillary or follicular variant of papillary thyroid cancer
- Thyroid structural lesions (eg, adenoma, nodule[s], goiter)
- Single gastrointestinal (GI) hamartoma or ganglioneuroma
- Vascular anomalies (including multiple intracranial developmental venous anomalies)

* Melanoma is also associated with *PTEN* but is not included in the testing criteria.

REVISED CLINICAL DIAGNOSTIC CRITERIA FOR *PTEN* HAMARTOMA TUMOR SYNDROME^{tt}

Operational diagnosis in an individual (either of the following):

1. Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos disease, or GI hamartomas; or
2. Two major and three minor criteria.

Operational diagnosis in a family where one individual meets revised *PTEN* hamartoma tumor syndrome clinical diagnostic criteria or has a *PTEN* P/LP variant:

1. Any two major criteria with or without minor criteria; or
2. One major and two minor criteria; or
3. Three minor criteria.

^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).

^{tt} Pilarski R, et al. J Natl Cancer Inst 2013;105:1607-1616. See [CRIT-8A](#).


^{ww} Multiple polyp types are often seen in patients with PHTS, and less commonly may include adenomas, hyperplastic polyps, and other histologies.

^{xx} Roche AF, et al. Pediatrics 1987;79:706-712.

^{yy} The literature available on mucocutaneous lesions is not adequate to accurately specify the number or extent of mucocutaneous lesions required to be a major criterion for CS/PHTS. Clinical judgment should be used.

^{zz} Insufficient evidence exists in the literature to include fibrocystic disease of the breast, fibromas, and uterine fibroids as diagnostic criteria.

Note: All recommendations are category 2A unless otherwise indicated.



^a For further details regarding the nuances of genetic counseling and testing, see [EVAL-A](#).
^b If of Ashkenazi Jewish ancestry, in addition to the specific familial P/LP variant, test for all three founder P/LP variants.
^c If no P/LP variant is found, consider testing another family member with next highest likelihood of having a P/LP variant.
^d Patients meeting CS/PHTS clinical diagnostic criteria ([CRIT-8A](#)) should be cared for as P/LP variant carriers.

Note: All recommendations are category 2A unless otherwise indicated.

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
<i>ATM</i>	<p>Primary breast cancer</p> <ul style="list-style-type: none"> Absolute risk: 21%–24%^{3,4} Management:⁵ <ul style="list-style-type: none"> Screening: Annual mammogram at age 40 y and consider breast MRI with and without contrast starting at age 30–35 y^{c,d,e,f} Risk reduction: Evidence insufficient for risk-reducing mastectomy (RRM); manage based on family history Strength of evidence of association with cancer: Strong <p>Contralateral breast cancer</p> <ul style="list-style-type: none"> 10-year cumulative risk: 4%^{9,6} Strength of evidence of association with cancer: Limited 	<ul style="list-style-type: none"> Absolute risk: 2%–3%⁹⁻¹¹ Management: <ul style="list-style-type: none"> Risk reduction: Evidence insufficient for risk-reducing salpingo oophorectomy (RRSO); manage based on family history Strength of evidence of association with cancer: Strong 	<p>Pancreatic cancer</p> <ul style="list-style-type: none"> Absolute risk: ~5%–10%^{h,22} Management: Screening, see PANC-A. Strength of evidence of association with cancer: Strong <p>Prostate cancer</p> <ul style="list-style-type: none"> Emerging evidence for association with increased risk.²³ Consider prostate cancer screening starting at age 40 (NCCN Guidelines for Prostate Cancer Early Detection) <p>Colorectal cancer</p> <ul style="list-style-type: none"> NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric
<p>Comments: Heterozygous <i>ATM</i> P/LP variants should not lead to a recommendation to avoid RT at this time. <i>ATM</i> missense c.7271T>G variant is an example of a higher penetrance allele (60% by age 80 y; Goldgar DE, et al. Breast Cancer Res 2011;13:R73; Hall MJ, et al. Cancer Prev Res (Phila) 2021;14:433-440; Southey MC, et al. J Med Genet 2016;53:800-811) and risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history. See GENE-B for reproductive implications/recessive disease and partner testing considerations.</p>			
<i>BARD1</i>	<p>Primary breast cancer</p> <ul style="list-style-type: none"> Absolute risk: 17%–30%⁴ Management: <ul style="list-style-type: none"> Screening: Annual mammogram and consider breast MRI with and without contrast starting at age 40 y^{c,d,e,f} Risk reduction: Evidence insufficient for RRM, manage based on family history Strength of evidence of association with cancer: Strong^{4,6-8} 	<p>Evidence of increased risk: No established association</p>	<p>Other cancers</p> <ul style="list-style-type: none"> Unknown or insufficient evidence

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
BRCA1	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 60%–72%^{24,25}• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Very strong <p>Contralateral breast cancer^{i,j}</p> <ul style="list-style-type: none">• 20-year cumulative risk: 30%–40%^{6,26}• 15-year cumulative risk in premenopausal women: >20%^{6,26}• Strength of evidence of association with cancer: Strong <p>Male breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 0.2%–1.2% by age 70 y^{27,28}• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Strong	<ul style="list-style-type: none">• Absolute risk: 39%–58%³⁰• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Very strong	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: ≤5%²⁸• Management: Screen P/LP variant carriers with a family history of pancreatic cancer, see PANC-A• Strength of evidence of association with cancer: Strong <p>Prostate cancer</p> <ul style="list-style-type: none">• Absolute risk: 7%–26%³¹• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Strong
	<p>Comment: See GENE-B for reproductive implications/recessive disease and partner testing considerations. The risk for breast cancer appears to be lower for certain variants (eg, <i>BRCA1</i> R1699Q) (Spurdle AB, et al. J Med Genet 2012;49:525-532; Pal T, et al. NPJ Precis Oncol 2024;8:247) and risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history.</p>		
BRCA2	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 55%–69%^{24,25}• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Very strong <p>Contralateral breast cancer^{i,j}</p> <ul style="list-style-type: none">• 20-year cumulative risk: 25%^{6,26}• 15-year cumulative risk in premenopausal women: >20%^{6,26}• Strength of evidence of association with cancer: Strong <p>Male breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 1.8%–7.1% by age 70 y²⁷⁻²⁹• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Strong	<ul style="list-style-type: none">• Absolute risk: 13%–29%³⁰• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Very strong	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: 5%–10%²⁸• Management: Screening, see PANC-A• Strength of evidence of association with cancer: Very strong <p>Prostate cancer</p> <ul style="list-style-type: none">• Absolute risk: 19%–61%^{31,32}• Management: See BRCA Pathogenic Variant-Positive Management• Strength of evidence of association with cancer: Very strong <p>Melanoma</p> <ul style="list-style-type: none">• See BRCA Pathogenic Variant-Positive Management
	<p>Comment: See GENE-B for reproductive implications/recessive disease and partner testing considerations. The risk for breast cancer appears to be lower for certain missense and splicing variants (Pal T, et al. NPJ Precis Oncol 2024;8:247; Huang H, et al. Nature 2025;638:528-537) and risk appropriate management should be considered. Management should be based on best estimates of cancer risk for the specific P/LP variant in conjunction with personal and family history.</p>		

Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

GENE-A
2 OF 11



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
BRIP1	Primary breast cancer <ul style="list-style-type: none">• Absolute risk: Insufficient data to define• Management: Insufficient data; managed based on family history• Strength of evidence of association with cancer: Limited⁷	<ul style="list-style-type: none">• Absolute risk: 5%–15%^{9-11,36}• Management:<ul style="list-style-type: none">▶ Risk reduction: Recommend RRSO starting at age 45–50 y^k• Strength of evidence of association with cancer: Strong	Other cancers <ul style="list-style-type: none">• Unknown or insufficient evidence
	Comments: Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of a <i>BRIP1</i> P/LP variant justifies RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset of ovarian cancer. See GENE-B for reproductive implications/recessive disease and partner testing considerations.		
CDH1	Primary breast cancer <ul style="list-style-type: none">• Absolute risk: 37%–55%³³⁻³⁵• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram and consider breast MRI with and without contrast starting at age 30 y^{c,d,f}▶ Risk reduction: Discuss option of RRM• Strength of evidence of association with cancer: Strong	Evidence of increased risk: No established association	Hereditary diffuse gastric cancer (HDGC) <ul style="list-style-type: none">• Strength of evidence of association with cancer: Strong• See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric
	Comments: Cleft lip with or without cleft palate has been associated with <i>CDH1</i> P/LP variants (Frebours T, et al. J Med Genet 2006;43:138-142). There is some evidence that certain <i>CDH1</i> pathogenic variants (in particular c.760G>A, p.Asp254Asn) are associated with nonsyndromic cleft lip with or without cleft palate but may not be associated with elevated cancer risk (Gossner L, et al. Genes (Basel) 2024;15:1475; Brito LA, et al. Hum Mutat 2015;36:1029-1033). Additionally, <i>CDH1</i> pathogenic variants associated with blepharocheilodontic syndrome also may not be associated with increased cancer risk (Kievit A, et al. Eur J Hum Genet 2018;26:210-219).		

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
CDKN2A	Evidence of increased risk: No established association	Evidence of increased risk: No established association	<u>Pancreatic cancer</u> <ul style="list-style-type: none">• Absolute risk: >15%• Management: Screening, see PANC-A.• Strength of evidence of association with cancer: Very strong <u>Melanoma</u> <ul style="list-style-type: none">• Absolute risk: 28%–76% depending on other risk factors, including family history, geographic location, and other genetic modifiers^{39,40}• Strength of evidence of association with cancer: Strong• Management: See comment <u>Other cancers</u> <ul style="list-style-type: none">• See comment
Comments: Comprehensive skin examination by a dermatologist, supplemented with total body photography and dermoscopy is recommended every 6 mo for individuals with P/LP variants affecting biologically relevant <i>CDKN2A</i> isoforms (ie, p16INK4A and p14ARF). Because P/LP variants that specifically disrupt both the p14ARF and p16INK4A proteins cause a unique predisposition to nerve sheath tumors, sarcomas, melanoma, and other cancers, increased multidisciplinary cancer surveillance beyond pancreatic and dermatologic management has been recommended, which may include annual full-body and brain MRI based on the presentation in individuals/families (Sargen M, et al. Br J Dermatol 2016;175:785-789; Chan et al. Hered Cancer Clin Pract 2021;19:21).			
CHEK2	<u>Primary breast cancer</u> <ul style="list-style-type: none">• Absolute risk: 23%–27%^{3,4}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram at age 40 y and consider breast MRI with and without contrast starting at age 30–35 y^{c,d,e,f}▶ Risk reduction: Evidence insufficient for RRM, manage based on family history• Strength of evidence of association with cancer: Strong³⁶ <u>Contralateral breast cancer</u> ^{i,j,l} <ul style="list-style-type: none">• 10-year cumulative risk: 6%–8%^{8,38}• Strength of evidence of association with cancer: Limited	Evidence of increased risk: No established association	<u>Prostate cancer</u> <ul style="list-style-type: none">• Emerging evidence for association with increased risk.⁴¹ Consider prostate cancer screening starting at age 40 y (NCCN Guidelines for Prostate Cancer Early Detection)
Comments: The above risk data are based only on frameshift and missense P/LP variants other than Ile157Thr, Ser428Phe, and Thr476Met. There is emerging evidence that not all missense P/LP variants are low penetrance. For Ile157Thr, Ser428Phe, and Thr476Met, the risk for breast cancer appears to be lower. Additional cancer risk management based on these variants is not recommended. Management should be based on best estimates of cancer risk for the specific P/LP variant and family history. There are some data to indicate individuals with biallelic <i>CHEK2</i> P/LP variants have a higher risk for invasive breast cancer, are more likely to be diagnosed at ≤50 years of age, and are more likely to have multiple primary breast cancers. However, lifetime risk estimates are difficult to quantify due to small study sizes. Therefore, taking personal and family history into account to advise on cancer risk management is appropriate. Findings are conflicting for male breast cancer, potentially due to a lack of evidence in populations where c.1100del is prevalent.			

Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
<i>MSH2, MLH1, MSH6, PMS2, EPCAM</i>	<p>Primary breast cancer <u><i>MLH1, MSH2, MSH6, PMS2, and EPCAM</i></u></p> <ul style="list-style-type: none">• Absolute risk: <15%^{3,4,7}• Management: Insufficient data; managed based on family history• Strength of evidence of association with cancer: Limited	<p><u><i>MLH1</i></u></p> <ul style="list-style-type: none">• Absolute risk: 4%–20%^{44,45}• Strength of evidence: Strong <p><u><i>MSH2/EPCAM</i></u></p> <ul style="list-style-type: none">• Absolute risk: 8%–38%^{44,45,47,48}• Strength of evidence: Strong <p><u><i>MSH6</i></u></p> <ul style="list-style-type: none">• Absolute risk: ≤1%–13%^{46,47}• Strength of evidence: Strong <p><u><i>PMS2</i></u></p> <ul style="list-style-type: none">• Absolute risk: 1.3%–3%⁴⁸• Strength of evidence: Limited <p>• Management for all genes: NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric</p>	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: <5%–10% (excluding <i>PMS2</i>)• Management: Screen P/LP variant carriers with a family history of pancreatic cancer (insufficient evidence for <i>PMS2</i>), see PANC-A.• Strength of evidence of association with cancer: Strong <p>Colorectal, uterine, others</p> <ul style="list-style-type: none">• NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric
	Comments: Counsel for biallelic risk of P/LP variants that lead to CMMRD. See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric .		
<i>NF1</i>	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 20%–40%^{42,43}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram starting at age 30 y and consider breast MRI with and without contrast from ages 30–50 y^{c,d,f}▶ Risk reduction: Evidence insufficient for RRM, manage based on family history• Strength of evidence of association with cancer: Strong	<p>Evidence of increased risk: No established association</p>	<p>Malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors (GIST), others</p> <ul style="list-style-type: none">• Recommend referral to <i>NF1</i> specialist for evaluation and management
	Comments: At this time, there are no data to suggest an increased breast cancer risk after age 50 y. Consider possibility of false-positive MRI results due to presence of breast neurofibromas.		

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
PALB2	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 32%–53%^{3,4}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram and breast MRI with and without contrast at 30 y^{c,d,f}▶ Risk reduction: Discuss option of RRM• Strength of evidence of association with cancer: Strong <p>Contralateral breast cancer^{i,j,m}</p> <ul style="list-style-type: none">• 10-year cumulative risk: 5%–8%^{5,38}• Strength of evidence of association with cancer: Limited <p>Male breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 0.9% by age 70 y²¹• Management: See comment• Strength of evidence of association with cancer: Strong	<ul style="list-style-type: none">• Absolute risk: 3%–5%^{9-11,21,56,57}• Management:<ul style="list-style-type: none">▶ Risk reduction: Consider RRSO at age starting at 45–50 y^{k,58,59}• Strength of evidence of association with cancer: Strong	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: 2%–5%• Management: Screen P/LP variant carriers with a family history of pancreatic cancer, see PANC-A• Strength of evidence of association with cancer: Limited <p>Prostate cancer</p> <ul style="list-style-type: none">• Emerging evidence for association with increased risk. Consider prostate cancer screening starting at age 40 y (NCCN Guidelines for Prostate Cancer Early Detection) <p>Other cancers</p> <ul style="list-style-type: none">• Unknown or insufficient evidence
	Comments: See GENE-B for reproductive implications/recessive disease and partner testing considerations. For males, it is reasonable to consider breast cancer screening similar to that for carriers of a <i>BRCA1</i> P/LP variant. See BRCA-A .		
PTEN	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 40%–60% (historical cohort data), >60% (projected estimates)⁴⁹⁻⁵³• Management: See Cowden Syndrome Management• Strength of evidence of association with cancer: Strong^{54,55}	Evidence of increased risk: No established association	<p>Thyroid, colorectal, endometrial, and renal cancers</p> <ul style="list-style-type: none">• See Cowden Syndrome Management

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
<i>RAD51C</i>	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: ~20%^{3,4}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram and consider breast MRI with and without contrast starting at age 40 y^f▶ Risk reduction: Evidence insufficient for RRM; manage based on family history• Strength of evidence of association with cancer: Strong <p>Contralateral breast cancer^l</p> <ul style="list-style-type: none">• 10-year cumulative risk: same as sporadic breast cancer (<2%)⁶¹• Strength of evidence of association with cancer: Limited	<ul style="list-style-type: none">• Absolute risk: 10%–15%^{9-11,60,62}• Management:<ul style="list-style-type: none">▶ Risk reduction: Recommend RRSO starting at 45–50 y^k• Strength of evidence of association with cancer: Strong	<p>Other cancers</p> <ul style="list-style-type: none">• Unknown or insufficient evidence
Comments: Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of a <i>RAD51C</i> P/LP variant justifies RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset ovarian cancer. See GENE-B for reproductive implications of recessive disease.			
<i>RAD51D</i>	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: ~20%^{3,4}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram and consider breast MRI with and without contrast starting at age 40 y^f▶ Risk reduction: Evidence insufficient for RRM; manage based on family history• Strength of evidence of association with cancer: Strong <p>Contralateral breast cancer^l</p> <ul style="list-style-type: none">• 10-year cumulative risk: same as sporadic breast cancer (<2%)⁶¹• Strength of evidence of association with cancer: Limited	<ul style="list-style-type: none">• Absolute risk: 10%–20%^{9-11,60,62}• Management:<ul style="list-style-type: none">▶ Risk reduction: Recommend RRSO at starting at 45–50 y^k• Strength of evidence of association with cancer: Strong	<p>Other cancers</p> <ul style="list-style-type: none">• Unknown or insufficient evidence
Comments: Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of a <i>RAD51D</i> P/LP variant justifies RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45–50 y or earlier based on a specific family history of an earlier onset ovarian cancer.			

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Gene Summary: Risks and Management

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

Gene	Breast Cancer ^b	Epithelial Ovarian Cancer ^b	Pancreatic Cancer, ¹²⁻²¹ Prostate Cancer, and Other Cancer Risks
STK11	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: 32%–54%^{63,64}• Management:<ul style="list-style-type: none">▶ Screening: Annual mammogram and breast MRI with and without contrast starting at age 30 y^f NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric - Peutz-Jeghers syndrome (PJS)▶ Risk reduction: Discuss option of RRM• Strength of evidence of association with cancer: Strong	<p>Evidence of increased risk: No established association</p>	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: >15%• Management: Screening, see PANC-A• Strength of evidence of association with cancer: Strong <p><u>Non-epithelial ovarian neoplasms (usually benign) (sex cord tumor with annular tubules)</u></p> <ul style="list-style-type: none">• Absolute risk: >10%⁵⁶• Management: NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric - PJS <p><u>Other cancers</u></p> <ul style="list-style-type: none">• NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric - PJS
Comments: Case-control studies have consistently demonstrated germline STK11 PVs to be associated with high lifetime risks of pancreatic cancer. However, these variants are rare, and the risk estimates have wide confidence intervals.			
TP53	<p>Primary breast cancer</p> <ul style="list-style-type: none">• Absolute risk: >60%^{3,65-67}• Management: Li-Fraumeni Syndrome Management• Strength of evidence of association with cancer: Very strong⁷⁰ <p><u>Contralateral breast cancerⁱ</u></p> <ul style="list-style-type: none">• 10-year cumulative risk: 18%–49%^{38,67,69}• Strength of evidence of association with cancer: Strong	<p>Evidence of increased risk: No established association</p>	<p>Pancreatic cancer</p> <ul style="list-style-type: none">• Absolute risk: ~5%⁶⁶• Management: Screen P/LP variant carriers with a family history of pancreatic cancer, see PANC-A.• Strength of evidence of association with cancer: Limited <p><u>Prostate cancer</u></p> <ul style="list-style-type: none">• Absolute risk: 25%–50%⁷⁰• Management: Prostate cancer screening starting at age 40 y (NCCN Guidelines for Prostate Cancer Early Detection).• Strength of Evidence: Strong <p><u>Other cancersⁿ</u></p> <ul style="list-style-type: none">• Classical LFS spectrum cancers (in addition to breast): soft tissue sarcoma, osteosarcoma, CNS tumor, ACC• Many other cancers have been associated with LFS, especially melanoma, colorectal, and gastric.• Li-Fraumeni Syndrome Management
Comment: See Discussion for information on hypomorphic variants.			

Note: All recommendations are category 2A unless otherwise indicated.

[Footnotes on GENE-A 9 of 11](#)
[References on GENE-A 10 of 11](#) and [GENE-A 11 of 11](#)



FOOTNOTES FOR GENE TABLES

- ^a The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for: *FANCC*, *MRE11*, *MUTYH* heterozygotes, *NBN*, *RAD50*, *RECQL*, *RINT1*, *SLX4*, *SMARCA4*, or *XRCC2*. There is emerging evidence of an increased risk for breast cancer for *NTHL1* biallelic P/LP variant carriers (Weatherill CB, et al. Clin Genet 2023;103:231-235; Grolleman JE, et al. Cancer Cell 2019;35:256-266; Salo-Mullen EE, et al. JCO Precis Oncol 2021;5; Beck SH, et al. Fam Cancer 2022;21:453-462); however, there are not yet enough data to support increased breast cancer surveillance. There is emerging evidence of an increased risk for breast cancer for *RAD51B* P/LP variant carriers (Setton J, et al. NPJ Breast Cancer 2021;7:135) and breast screening may be considered.
- ^b Screening and risk-reduction management for breast and ovarian cancer is extrapolated from *BRCA1/2* data based on risk levels.
- ^c May be modified based on family history (typically beginning screening 5–10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene P/LP variant.
- ^d For patients with P/LP variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described.
- ^e The use of MRI in these patients depends on a number of risk factors, including family history, age, breast density, and patient preference.
- ^f Breast awareness; and clinical breast exam, every 6–12 months, starting at age 25 years or 5–10 years before the earliest known breast cancer in the family (whichever comes first). Age >75 years, management should be considered on an individual basis.
- ^g This estimate is based on <10 events, with wide confidence intervals; therefore, additional studies are needed to confirm and refine this estimate.
- ^h The higher range of risk is reflective of a prospective study of pancreatic cancer kindreds (Hsu FC, et al. JAMA Oncol 2021;7:1664-1668).
- ⁱ The risk of metachronous CBC in women >65 years of age with pathogenic variants in *BRCA1/2*, *CHEK2*, and *PALB2* appears similar to non-carriers (Yadav S, et al. J Clin Oncol 2023;41:1703-1713).
- ^j Risk varies depending on age at diagnosis of first breast cancer, ER status, and/or family history. See [Discussion](#).
- ^k Risks and benefits of premature surgical menopause versus risk of cancer and family history should all be carefully considered, and the Panel recommends patients seek expert care. Further details about salpingectomy included in the BRCA Pathogenic/Likely Pathogenic Variant-Positive Management (BRCA-A 3 of 5).
- ^l For *CHEK2* carriers, the risk of CBC is higher if the primary breast cancer was ER-positive (Yadav S, et al. J Clin Oncol 2023;41:1703-1713; Hanson H, et al. Genet Med 2023;25:100870).
- ^m For *PALB2* carriers, the risk of CBC is not significantly elevated except if the primary breast cancer was ER-negative (Yadav S, et al. J Clin Oncol 2023;41:1703-1713).
- ⁿ For risk associated with other LFS-associated cancers, see de Andrade KC, et al. Lancet Oncol 2021;22:1787-1798.

Strength of Evidence of Association with Cancer

- **Very strong:** Prospective cohort studies in a population-based setting have demonstrated risk.
- **Strong:** Traditional case-control studies or more than three case-control studies including those with cases ascertained by commercial laboratories or those without controls from the same population. Traditional case-control study: A retrospective study that compares patients with a disease or specific outcome (cases) with patients without the disease or outcome (controls).
- **Limited:** Small sample size or case series
- **None**

Population risk (per SEER registry data)

- **Breast cancer:** 12%–13%
- **Ovarian cancer:** 1%–2%
- **Pancreatic cancer:** 1%–2%
- **Prostate cancer:** 12–13%

Note: All recommendations are category 2A unless otherwise indicated.



REFERENCES FOR GENE TABLES

- 1 Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nat Rev Clin Oncol* 2017;13:581-588.
- 2 Domchek SM, Robson ME. Update on genetic testing in gynecologic cancer. *J Clin Oncol* 2019;37:2501-2509.
- 3 Breast Cancer Association Consortium. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. *JAMA Oncol* 2022;8:e216744.
- 4 Breast Cancer Association Consortium. Breast cancer risk genes – Association analysis in more than 113,000 women. *N Engl J Med* 2021;384:428-439.
- 5 Pal T, Schon KR, Astiazaran-Symonds E, et al. Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med* 2025;27:101243.
- 6 Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. *J Clin Oncol* 2023;41:1703-1713.
- 7 Hu C, Polley EC, Yadav S, et al. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. *J Natl Cancer Inst* 2020;112:1231-1241.
- 8 Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. *J Natl Cancer Inst* 2018;110:855-862.
- 9 Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. *Gynecol Oncol* 2017;147:375-380.
- 10 Kurian A, Hughes E, Handorf E, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. *Precis Oncol* 2017;1:1-12.
- 11 Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol* 2016;2:482-490.
- 12 Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. *Gastroenterology* 2015;148:556-564.
- 13 Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. *J Clin Oncol* 2015;33:3124-3129.
- 14 Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. *JAMA* 2018;319:2401-2409.
- 15 Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009;324:217.
- 16 Lowery MA, Wong W, Jordan EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. *J Natl Cancer Inst* 2018;110:1067-1074.
- 17 Rainone M, Singh I, Salo-Mullen EE, et al. An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. *JAMA Oncol* 2020;6:764-771.
- 18 Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov* 2012;2:41-46.
- 19 Salo-Mullen EE, O'Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. *Cancer* 2015;121:4382-4388.
- 20 Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. *J Clin Oncol* 2017;35:3382-3390.
- 21 Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. *J Clin Oncol* 2020;38:674-685.
- 22 Hsu FC, Roberts NJ, Childs E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. *JAMA Oncol* 2021;7:1664-1668.
- 23 Karlsson Q, Brook MN, Dadaev S, et al. Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study. *Eur Urol Oncol* 2021;4:570-579.
- 24 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25:1329-1333.
- 25 van den Broek AJ, van 't Veer LJ, Hoening MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. *J Clin Oncol* 2016;34:409-418.
- 26 Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017;317:2402-2416.
- 27 Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2007;99:1811-1814.
- 28 Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. *J Clin Oncol* 2022;40:1529-1541.
- 29 Evans D, Susnerwala I, Dawson J, et al. Risk of breast cancer in male BRCA2 carriers. *J Med Genet* 2010;47:710-711.
- 30 Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. *JNCI Cancer Spectr* 2020;4:pkaa029.
- 31 Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. *J Clin Oncol* 2017;35:2240-2250.
- 32 Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Eur Urol* 2020;77:24-35.
- 33 Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. *JAMA Oncol* 2019;5:1325-1331.
- 34 Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 variants and lifetime cancer risk. *JAMA* 2024;332:722-729.
- 35 Xicola RM, Li S, Rodriguez N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. *J Med Genet* 2019;56:838-843.
- 36 Weber-Lasselle N, Hauke J, Ramser J, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. *Breast Cancer Res* 2018;20:7.
- 37 Hu C, Hart S, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. *N Engl J Med* 2021;384:440-451.
- 38 Morra A, Mavaddat N, Muranen TA, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. *Am J Hum Genet* 2023;110:475-486.
- 39 Bishop DT, Dumenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A 36 mutations for melanoma. *J Natl Cancer Inst* 2002;94:894-903.
- 40 Begg CB, Orlov I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. *J Natl Cancer Inst* 2005;97:1507-1515.
- 41 Hanson H, Astiazaran-Symonds E, Amendola LM, et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med* 2023;25:100870.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)



REFERENCES FOR GENE TABLES

- 42 Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. *J Clin Oncol* 2016;34:1978-1986.
- 43 Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. *Br J Cancer* 2015;112:1546-1548.
- 44 Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304-2310.
- 45 Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. *J Clin Oncol* 2012;30:4409-4415.
- 46 Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304-2310.
- 47 Moller P, Seppala TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut* 2018;67:1306-1316.
- 48 Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. *Genet Med* 2020;22:15-25.
- 49 Pilarski R. Cowden syndrome: A critical review of the clinical literature. *J Genet Couns* 2009;18:13-27.
- 50 Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst* 2013;105:1607-1616.
- 51 Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet* 2013;50:255-263.
- 52 Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-407.
- 53 Hendricks L, Hoogerbrugge N, Venselaar H, et al. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort. *Eur J Med Genet* 2022;65:104632.
- 54 Walsh S, Carter M, Tubridy N, McDermott EW. Lhermitte-Duclos and Cowden diseases: breast cancer as an unusual initial presentation of these overlapping conditions. *BMJ Case Rep* 2011;2011:bcr0820114730.
- 55 Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. *Hum Pathol* 1998;29:47-53.
- 56 Lukomska A, Menkiszak J, Gronwald J, et al. Recurrent mutations in *BRCA1*, *BRCA2*, *RAD51C*, *PALB2* and *CHEK2* in Polish patients with ovarian cancer. *Cancers* 2021;13:849.
- 57 Song H, Dicks E, Tyrer J, et al. Population-based targeted sequencing of 54 candidate genes identifies *PALB2* as a susceptibility gene for high-grade serous ovarian cancer. *J Med Genet* 2021;58:305-313.
- 58 Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in *PALB2*: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med* 2021;23:1416-1423.
- 59 Hanson H, Kulkarni A, Long L, et al. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: *RAD51C*, *RAD51D*, *BRIP1* and *PALB2*. *J Med Genet* 2023;60:417-429.
- 60 Yang X, Song H, Leslie G, et al. Ovarian and breast cancer risks associated with pathogenic variants in *RAD51C* and *RAD51D*. *J Natl Cancer Inst* 2020;112:1242-1250.
- 61 Ramin C, Withrow DR, Davis Lynn BC, et al. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016. *Breast Cancer Res* 2021;23:24.
- 62 Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the *RAD51B*, *RAD51C*, and *RAD51D* genes to ovarian cancer in the population. *J Clin Oncol* 2015;33:2901-2907.
- 63 Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209-3215.
- 64 Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447-1453.
- 65 Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort. *Cancer* 2016;122:3673-3681.
- 66 de Andrade KC, Khincha PP, Hatton JN, et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. *Lancet Oncol* 2021;22:1787-1798.
- 67 Siegel A, Bremer R, Klein WMP, et al. Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. *Breast Cancer Res Treat* 2022;191:159-167.
- 68 Packwood K, Martland G, Sommerlad M, et al. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). *J Pathol Clin Res* 2019;5:189-198.
- 69 Gun Y, Wan Q, Ouyang T, et al. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients. *The Breast* 2022;65:55-60.
- 70 Maxwell KN, Cheng HH, Powers J, et al. Inherited TP53 variants and risk of prostate cancer. *Eur Urol* 2022;81:243-250.

Note: All recommendations are category 2A unless otherwise indicated.



AUTOSOMAL RECESSIVE RISK IN CANCER GENES – MULTIGENE PANEL TESTING

- Biallelic P/LP variants in some genes, included on gene panels, may be associated with rare autosomal recessive conditions, such as FA or CMMRD. For these genes, consideration should be given to carrier testing the partner for P/LP variants in the same gene if it would inform reproductive decision-making and/or risk assessment and management.

GENE and CONDITION	DESCRIPTION
ATM – Ataxia-Telangiectasia (AT)	AT is characterized by progressive cerebellar ataxia, telangiectasias, immune defects, and a predisposition to malignancy. Cells of individuals with AT are abnormally sensitive to ionizing radiation and resistant to inhibition of DNA synthesis by ionizing radiation.
BRCA1 – Fanconi anemia complementation group S (FANCS)	There are rare reports of compound heterozygous or biallelic <i>BRCA1</i> P/LP variants causing FANCS. FANCS is characterized by developmental delay apparent from infancy, short stature, microcephaly, and coarse dysmorphic features. It is associated with defective DNA repair and increased chromosomal breakage.
BRCA2 – Fanconi anemia complementation group D1	FA is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life. Adults with biallelic <i>BRCA2</i> (one allele hypomorphic) are reported. Biallelic PVs in <i>BRCA2</i> are associated with early-onset acute leukemia and solid tumors.
BRIP1 – Fanconi anemia complementation group J (FANCJ)	FA is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life.
MLH1, MSH2, MSH6, PMS2, EPCAM – CMMRD	CMMRD is a childhood cancer predisposition syndrome characterized by hematologic malignancies, brain/CNS tumors, colorectal tumors and multiple intestinal polyps, and other malignancies including embryonic tumors and rhabdomyosarcoma.
PALB2 – Fanconi anemia complementation group N (FANCN)	FA is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and an increased lifetime risk of cancer. Bone marrow failure with pancytopenia often presents in the first decade of life. Biallelic PVs in <i>PALB2</i> are associated with solid tumors, such as medulloblastomas and Wilms tumors.
RAD51C – Fanconi anemia complementation group O	FA is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life.

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

Site	Screening/Surveillance Procedure and Interval
General	<ul style="list-style-type: none">• Education regarding signs and symptoms of cancer(s), especially those associated with <i>BRCA</i> P/LP variants.
Breast cancer (female)	<ul style="list-style-type: none">• Breast awareness^a.• Clinical breast exam, every 6–12 months,^b starting at age 25 years.• Breast screening^{c,d}<ul style="list-style-type: none">▶ Age 25–29 years, annual breast MRI^e screening with and without contrast^f (or mammogram, only if MRI is unavailable) or individualized based on family history if a breast cancer diagnosis before age 30 is present.▶ Age 30–75 years, annual mammogram and breast MRI^e screening with and without contrast.▶ Age >75 years, management should be considered on an individual basis.▶ For individuals with a <i>BRCA</i> P/LP variant who are treated for breast cancer and have not had a bilateral mastectomy, screening with annual mammogram and breast MRI should continue as described above.▶ Discuss option of RRM<ul style="list-style-type: none">◊ Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.<ul style="list-style-type: none">– Address psychosocial and quality-of-life aspects of undergoing RRM.◊ Screening with clinical breast exam should continue after RRM. Routine screening with mammogram and breast MRI are not indicated.• Consider risk reduction agents as options for breast cancer, including discussion of risks and benefits (see Discussion for details). (NCCN Guidelines for Breast Cancer Risk Reduction).
Breast cancer (male)	<ul style="list-style-type: none">• Breast self-exam training and education starting at age 35 years.• Clinical breast exam, every 12 months, starting at age 35 years.• Consider annual mammogram, especially for those with <i>BRCA2</i> P/LP variants in whom the lifetime risk of breast cancer is up to 7%, starting at age 50 or 10 years before the earliest known male breast cancer in the family (whichever comes first).^{g,h}

^a Females should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent breast self examination (BSE) may facilitate breast self awareness. Premenopausal individuals may find BSE most informative when performed at the end of menses.

^b Randomized trials comparing clinical breast exam versus no screening have not been performed. Rationale for recommending clinical breast exam every 6–12 mo is the concern for interval breast cancers.

^c The appropriateness of imaging modalities and scheduling is still under study. Lowry KP, et al. Cancer 2012;118:2021-2030.

^d Lehman CD, et al. J Natl Cancer Inst 2016;108.

^e The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under MRI guidance, radiologists experienced in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal patients. [FDA Drug Safety Communication](#): FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.

^f Breast MRI is preferred due to the theoretical risk of radiation exposure in P/LP variant carriers.

^g Because of lack of screening, males diagnosed with breast cancer have historically presented with advanced stage disease. There are limited data describing the performance of breast screening for males at inherited risk; however, recent studies suggest that the detection rate is similar or better than for females at population risk. Gao Y, et al. Radiology 2019;293:282-291; Li S, et al. J Clin Oncol 2022;40:1529-1541.

^h In males, breast cancer risk in *BRCA1* carriers is lower than that in *BRCA2* carriers.

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

Site		
Ovarian/ Fallopian Tube/ Peritoneal/ Uterine Cancers	<ul style="list-style-type: none">• Counseling includes a discussion of reproductive options, extent of cancer risk balanced with cancer worry; degree of protection for breast, ovarian and uterine cancer; management of menopausal symptoms; hormone replacement therapy (HRT); and related medical or surgical history.• Considerations for salpingectomy with delayed oophorectomy, BSO, or non-surgical risk reduction strategies can apply to moderate-penetrance genes as well, with attention to age-related cancer risk of the known PV and family history.	
	Reproductive considerations in premenopausal women	<ul style="list-style-type: none">• If desired, refer to fertility specialists for discussion of age-related fertility considerations, options for in vitro fertilization, egg- and embryo-cryopreservation, and consideration of preimplantation genetic testing, gestational carrier, and adoption.• If eggs/embryos are cryopreserved, pregnancy may be achieved with uterus in place, with or without fallopian tubes or ovaries.• Individuals with P/LP <i>BRCA1</i> variant may have earlier menopause and oocyte aging.^{1,2}
	Non-surgical risk reduction	<ul style="list-style-type: none">• Consultation with gynecologic oncologist or gynecologist with expertise/experience in genetic susceptibility to gynecologic cancer recommended.• Consideration of combination estrogen/progestin (E/P) contraception (such as oral contraceptive pills [OCP]) for ovulation suppression. Overall, studies in P/LP variant carriers support significant risk reduction benefits for ovarian cancer.^{3,4,5} See Discussion for risk/benefits of OCP.• Levonorgestrel intrauterine device (LNG-IUD) has been shown to reduce risk for ovarian cancer in the average-risk population.^{6,7}
	Surgical risk reduction with bilateral salpingo-oophorectomy	<ul style="list-style-type: none">• Based on age-related risks of ovarian/fallopian tube cancer:<ul style="list-style-type: none">▶ <i>BRCA1</i>: Recommend RRSO between 35 and 40 years.▶ <i>BRCA2</i>: Because ovarian cancer onset in patients with <i>BRCA2</i> P/LP variants is an average of 8–10 years later than in patients with <i>BRCA1</i> P/LP variants,⁸ it is reasonable to delay RRSO for management of ovarian cancer risk until age 40–45 years in patients with <i>BRCA2</i> P/LP variants unless age at diagnosis in the family warrants earlier age for consideration of prophylactic surgery.• CA-125 and pelvic ultrasound are recommended for preoperative planning.• See Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol in NCCN Guidelines for Ovarian Cancer - Principles of Surgery. Appropriate surgical and pathologic expertise is strongly recommended. SEE-FIM (Sectioning and Extensively Examining the Fimbriated End) protocol for pathologic assessment and pelvic washings should be performed.• If serous tubal intraepithelial carcinoma (STIC lesion) is found, further consultation with a gynecologist oncologist is recommended.• In addition, in premenopausal individuals, oophorectomy likely reduces the risk of developing breast cancer but the magnitude is uncertain and may be gene-specific.• There is a residual risk for primary peritoneal cancer after risk reducing RRSO. See Discussion.• Address bone health, cardiovascular health, psychosocial health, neurologic health, sexual health, and generalized quality-of-life aspects of undergoing RRSO. Consider preoperative menopause management consultation if patient is still premenopausal at time of RRSO.^{9,10}• HRT is generally not contraindicated and thus should be discussed with premenopausal patients who do not have a personal history of breast cancer.^{11,12}

Note: All recommendations are category 2A unless otherwise indicated.

[References on
BRCA-A 5 of 5](#)

[Continued](#)
BRCA-A
2 OF 5



NCCN Guidelines Version 1.2026

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

Site		
Ovarian/ Fallopian Tube/ Peritoneal/ Uterine Cancers	Salpingectomy	<ul style="list-style-type: none"> Salpingectomy reduces the risk of ovarian cancer in the general population and is an option for premenopausal patients with hereditary cancer risk who are not yet ready for oophorectomy.^{13,14,15,16} If patients undergo salpingectomy, completion oophorectomy is recommended as per gene-specific guidelines, unless specified by clinical trial protocol. SEE-FIM protocol for pathologic assessment and pelvic washings should be performed at salpingectomy or completion oophorectomy. CA-125 and pelvic ultrasound are recommended for preoperative planning. Clinical trials of interval salpingectomy and delayed oophorectomy are ongoing. Strong consideration of surgical choice study participation if available¹ Consider continuation of combination OCP or hormonal IUD for continued ovarian cancer risk reduction while ovaries remain in place. Salpingectomy is also an option for average or uncertain risk patients if they also desire surgical sterilization.
	Considerations for hysterectomy	<ul style="list-style-type: none"> Limited data suggest that there may be a slightly increased risk of serous uterine cancer among individuals with a <i>BRCA1/2</i> P/LP variant. The clinical significance of these findings is unclear. Further evaluation of the risk of serous uterine cancer in the <i>BRCA</i> population is ongoing. The provider and patient should discuss the risks and benefits of concurrent hysterectomy at the time of RRSO for individuals with a <i>BRCA1/2</i> P/LP variant prior to surgery.¹⁷ Individuals who undergo hysterectomy at the time of RRSO are candidates for estrogen-alone HRT, which is associated with a decreased risk of breast cancer compared to combined estrogen and progesterone, which would be required when the uterus is left in situ.^{11,18,19} Risk of pelvic floor dysfunction or urinary incontinence after hysterectomy is influenced by factors other than hysterectomy alone; if no preceding pelvic organ prolapse, long-term follow up studies indicate risks are <5%.^{20,21}
	Hormone replacement options after risk-reducing surgery	<ul style="list-style-type: none"> In conjunction with a gynecologist or other qualified health care professional with expertise in menopause management: <ul style="list-style-type: none"> ▶ HRT recommendations should be tailored depending on each patient's personal history of breast cancer and/or breast cancer risk reduction strategies. ▶ HRT is an important consideration for premenopausal patients who do not carry a diagnosis of breast cancer or do not have other contraindications for HRT. ▶ Premature menopause due to RRSO can cause detriments to bone health, cardiovascular health, psychosocial health, neurologic health, sexual health, and generalized quality-of-life. HRT can reduce these risks. Studies examining the risk of subsequent breast cancer associated with HRT use after RRSO have primarily focused on average durations of HRT use up to 3–5 years, and the safety of longer-term use remains uncertain. If uterus is left in place at time of RRSO, consider options for hormone replacement <ul style="list-style-type: none"> ▶ LNG-IUD for uterine protection with oral or transdermal estrogen. LNG-IUD may have benefits over combined HRT including potential decreased risk for breast cancer.²² ▶ Combination E/P HRT with counseling regarding bleeding precautions and endometrial cancer risk/awareness. ▶ Combination estrogen with selective estrogen receptor modulator (such as bazedoxifene).²³ ▶ Combination OCPs that can be taken continuously without placebo week.

¹ Clinical trials are in progress. See [Discussion](#).

Note: All recommendations are category 2A unless otherwise indicated.

[References on BRCA-A 5 of 5](#)



NCCN Guidelines Version 1.2026

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

Site	Screening/Surveillance Procedure and Interval
Pancreatic cancer	<ul style="list-style-type: none">• For pancreatic cancer screening recommendations, see PANC-A.
Prostate cancer	<ul style="list-style-type: none">• Starting at age 40 years: (Guidelines for Prostate Cancer Early Detection)<ul style="list-style-type: none">▶ Recommend prostate cancer screening for <i>BRCA2</i> carriers.▶ Consider prostate cancer screening for <i>BRCA1</i> carriers.
Melanoma	<ul style="list-style-type: none">• No specific screening guidelines exist for melanoma, but general melanoma risk management is appropriate, such as annual full-body skin examination and minimizing ultraviolet (UV) exposure.
Risk to relatives	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).
Reproductive options	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).• See GENE-B for reproductive implications/recessive disease and partner testing considerations.

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

BRCA-Pathogenic/Likely Pathogenic Variant - Positive Management

BRCA PATHOGENIC/LIKELY PATHOGENIC VARIANT-POSITIVE MANAGEMENT

Ovarian/Fallopian Tube/Peritoneal/Uterine Cancers References

- ¹ Kobayashi M, Kitahara Y, Hasegawa Y, et al. Effect of salpingectomy on ovarian reserve: A systematic review and meta-analysis. J Obstet Gynaecol Res 2022;48:1513-1522.
- ² Vignarajan CP, Malhotra N, Singh N. Ovarian reserve and assisted reproductive technique outcomes after laparoscopic proximal tubal occlusion or salpingectomy in women with hydrosalpinx undergoing in vitro fertilization: A randomized controlled trial. J Minim Invasive Gynecol 2019;26:1070-1075.
- ³ Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
- ⁴ AlHilli MM, Pederson HJ. Controversies in hereditary cancer management. Obstet Gynecol 2021;137:941-955.
- ⁵ Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 2020;301:875-884. Erratum in: Arch Gynecol Obstet. 2022;305:1627.
- ⁶ Wheeler LJ, Desanto K, Teal SB, et al. Intrauterine device use and ovarian cancer risk: A systematic review and meta-analysis. Obstet Gynecol 2019;134:791-800.
- ⁷ Balayla J, Gil Y, Lasry A, Mitric C. Ever-use of the intra-uterine device and the risk of ovarian cancer. J Obstet Gynaecol 2021;41:848-853.
- ⁸ Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317:2402-2416.
- ⁹ Hickey M, Trainer A, Braat S, et al. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women. BMJ Open 2017;7:e018758;
- ¹⁰ Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: A nonrandomized controlled trial. JAMA Oncol 2021;7:1203-1212.
- ¹¹ Gordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019;153:192-200.
- ¹² "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767-794.
- ¹³ ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention. Obstet Gynecol 2019;133:e279-e284; SGO statement: <https://www.sgo.org/resources/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention>.
- ¹⁴ Gaba F, Goyal S, Marks D, et al; PROTECTOR team. Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. J Med Genet 2022;59:122-132.
- ¹⁵ Hanley GE, Pearce CL, Talhouk A, et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 2022; 5:1-10.
- ¹⁶ Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107:dju410.
- ¹⁷ de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: Multicenter cohort study. J Natl Cancer Inst 2021;113:1203-1211.
- ¹⁸ Marchetti C, De Felice F, Boccia S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 2018;132:111-115.
- ¹⁹ Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
- ²⁰ Kuittinen T, Tulokas S, Rahkola-Soisalo P, et al. Pelvic organ prolapse after hysterectomy: A 10-year national follow-up study. Acta Obstet Gynecol Scand 2023;102:556-566.
- ²¹ Tulokas S, Mentula M, Härkki P, et al. Stress urinary incontinence after hysterectomy: a 10-year national follow-up study. Arch Gynecol Obstet 2022;305:1089-1097.
- ²² Manyonda I, S Talaulikar V, Pirhadi R, Onwude J. Progestogens are the problem in hormone replacement therapy: Time to reappraise their use. Post Reprod Health 2020;26:26-31.
- ²³ Hoffman SR, Governor S, Daniels K, et al. Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin combination hormone therapy among women in the United States: a multidatabase cohort study. Menopause 2023;30:824-830.

Note: All recommendations are category 2A unless otherwise indicated.

**PANCREATIC CANCER SCREENING**

- Data on the efficacy of pancreatic cancer screening are largely derived from studies of individuals with P/LP germline variants in pancreatic cancer susceptibility genes and/or a family history of pancreatic cancer. This guideline addresses pancreatic cancer screening specifically in individuals with a germline P/LP variant associated with increased risk of exocrine pancreatic cancer. See table below for gene-specific recommendations.
- For individuals considering pancreatic cancer screening, the Panel recommends that screening be performed in experienced high-volume centers. The Panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or indeterminate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening.
- Consider screening using annual contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS), with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have potentially concerning abnormalities on screening. Studies have typically started screening with contrast-enhanced MRCP and/or EUS in individuals at increased risk for pancreatic cancer. The Panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention.

Consider pancreatic cancer screening (preferably in the setting of a longitudinal study) for the following:	
• Individuals with P/LP germline variants in <i>STK11</i>	• Beginning at age 30–35 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
• Individuals with P/LP germline variants in <i>CDKN2A</i>	• Beginning at age 40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
• Individuals with P/LP germline variants in <i>ATM</i> or <i>BRCA2</i>	• Beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier).
• Individuals with P/LP germline variants in one of the other pancreatic cancer susceptibility genes (<i>BRCA1</i> , <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>EPCAM</i> , <i>PALB2</i> , <i>TP53</i>)	<ul style="list-style-type: none">• GENE-A<ul style="list-style-type: none">▶ Beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in ≥1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified P/LP germline variant.^a▶ There are currently insufficient data regarding the yield and benefits of pancreatic cancer screening for carriers of P/LP variants in genes other than <i>ATM</i>, <i>BRCA2</i>, <i>STK11</i>, and <i>CDKN2A</i> in the absence of a close family history of exocrine pancreatic cancer.

^a Abe T, et al. J Clin Oncol 2019;37:1070-1080.**Note: All recommendations are category 2A unless otherwise indicated.**[Continued](#)**PANC-A**
1 OF 2



PANCREATIC CANCER SCREENING

Hereditary Pancreatitis Genes

- For individuals with P/LP variants in hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis^b
 - ▶ Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier.

^b The Panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in *PRSS1*, *SPINK1*, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the Panel recommends germline testing for *PRSS1*, *SPINK1*, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis.

Note: All recommendations are category 2A unless otherwise indicated.



TP53 P/LP VARIANT WORKUP – GENERAL CONSIDERATIONS

Establishing a Diagnosis and Management Plan for Patients with a P/LP TP53 Variant Found on Germline Genetic Testing

Introduction

- The presence of a *TP53* P/LP variant on a germline genetic test may indicate a diagnosis of LFS. However, it is important to recognize that somatic *TP53* variants frequently confound germline testing results, especially when testing is performed in older adults and/or patients with cancer.
- Late post-zygotic aberrant clonal expansions containing a *TP53* P/LP variant, limited to the hematologic compartment or to a tumor, may be detected in the blood or saliva through germline testing, particularly using NGS technology. The phenomenon of aberrant clonal expansion is well described and is most often due to CHIP, which can be demonstrated in healthy populations at increasing frequency with increasing age. If CHIP is misinterpreted as LFS, unwarranted clinical interventions may be advised (eg, LFS screening and prevention). Further, the finding of CHIP itself may portend adverse clinical outcomes, such as an increased risk of future development of hematologic neoplasia and increased non-hematologic mortality.
- Careful examination of the patient's complete blood count (CBC) and peripheral blood smear may be warranted in all cases reporting the discovery of a *TP53* P/LP variant, and testing of non-hematopoietic ancillary tissues and/or offspring may help to delineate bona fide mosaic involvement of different germ layers or other diagnoses (see [Table 1](#)).

Considerations Prior to Providing an LFS Diagnosis in a Patient Found to Have a TP53 P/LP Variant on a Germline Genetic Test

- Does the personal and/or family history meet LFS criteria ([CRIT-7](#))?
 - ▶ Yes: Review Tissue Source Considerations and Test Metrics; and if no concerns, provide LFS diagnosis and manage accordingly; see [LIFR-A 4 of 6](#) if LFS diagnosis
 - ▶ No: Review Tissue Source Considerations and Test Metrics; Consider testing of additional tissue sources and/or close relatives to delineate among possibilities in [Table 1](#).

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

LIFR-A
1 OF 6



TP53 P/LP VARIANT WORKUP – ADDITIONAL CONSIDERATIONS

Tissue Source Considerations: Was the tissue source used for germline genetic testing a reliable germline tissue for the patient?

- Blood and/or saliva

- ▶ Personal history of a hematologic malignancy with active blood involvement and/or prior allogeneic hematopoietic cell transplantation: Blood and/or saliva is an unsuitable source of DNA for germline testing for these patients. DNA from cultured skin fibroblasts, hair follicles, or other non-hematopoietic origin tissue(s) is required to confirm germline origin. Blood or saliva may be used for germline genetic testing in patients with a prior or well-controlled hematologic malignancy and no evidence of active disease.
- ▶ Personal history of CBC abnormalities at the time of sample collection: Peripheral blood smear review and evaluation by a hematologist is warranted to rule out an undiagnosed hematologic disorder, such as clonal cytopenia of undetermined significance or overt hematologic neoplasm. Testing of cultured skin fibroblasts, hair follicles, or other non-hematopoietic origin tissue(s) or offspring may be warranted to delineate the diagnosis (see [Table 1](#)).
- ▶ Age >60 and/or history of cytotoxic therapy prior to sample collection: These patients are at increased risk for clonal hematopoiesis and hematologic malignancies. Examination of the CBC is warranted to rule out an undiagnosed hematologic disorder. Referral to a hematologist for peripheral blood smear review and evaluation may be appropriate. Testing of cultured skin fibroblasts, hair follicles, or other non-hematopoietic origin tissue(s) or offspring may be warranted to delineate the diagnosis (see [Table 1](#)).

Test Metrics: Is the TP53 variant allele fraction <30% and/or are there other abnormal test metrics/results that raise the possibility of somatic interference (eg, multiple other mosaic variants or deletion/duplications)?

- Tissue source:

- ▶ Blood or saliva: Rule out a tissue source issue per "Tissue Source Considerations"
- ▶ Cultured skin fibroblasts: A low variant allele fraction variant in this tissue source can be due to:
 - ◊ Somatic variant acquired during the culturing process
 - ◊ Somatic variant previously acquired in only a subset of the skin cells sampled (eg, from prior sun exposure)
 - ◊ Multi-tissue post-zygotic mosaicism (see [Table 1](#), Mosaic LFS)
 - ◊ Technical issues (see below)

- Tumor somatic interference:

- ▶ Somatic TP53 variants restricted to a tumor can be detected in the peripheral blood or saliva on a germline test due to blood/saliva contamination with ctDNA and/or circulating tumor cells. Patients with a high volume of tumor burden, especially metastatic disease, and/or tumors involving the blood (eg, hematologic neoplasms, especially acute leukemias, myelodysplastic syndrome, and chronic lymphocytic leukemia) are at higher risk for tumor somatic interference. DNA from cultured skin fibroblasts, hair follicles, or other non-hematopoietic origin/non-tumor contaminated tissue(s) is required to confirm germline origin.

- Technical limitations:

- ▶ Standard NGS tests utilized by most commercial germline genetic testing companies are not quantitative. Thus, a VAF <30% can be due to technical issues such as differences in the efficiency of capture or sequencing of the normal versus variant-containing allele. Testing by an orthogonal method (eg, Sanger sequencing for single nucleotide variants [SNVs] or microarray for copy number variants [CNVs]) may help clarify this possibility.

- When a TP53 PV is identified for the first time in a family at an allele frequency near 50% suggesting it was present at the time of fertilization, testing for the variant should be performed on the patient's siblings and parents to determine if this was de novo or inherited. Particularly when the proband is a pediatric patient, the parents may not have developed cancer and family history alone may not be sufficient to distinguish between de novo or inherited variants. Germ cell mosaicism has been reported as a cause of LFS in siblings. Even if parents test negative for the variant, all children and future children should be tested due the possibility of recurrence due to germ cell mosaicism.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)



NCCN Guidelines Version 1.2026

Li-Fraumeni Syndrome Management

TP53 P/LP VARIANT WORKUP AND MANAGEMENT

Table 1: Workup and Management Depending on Etiology of *TP53* Mutation Found on Genetic Testing^a

	Blood or Saliva (VAF)	Fibroblast (VAF) ^b	Tumor (VAF) ^b	Parent Testing ^c	Offspring Testing ^c	Management
All/Majority of body tissues involved						
Li Fraumeni syndrome spectrum – inherited	Positive (40%–60%)	Positive (40%–60%)	Positive (0%–100%)	One parent positive	50% risk	LFS
Li Fraumeni syndrome spectrum – <i>de novo</i> ^d	Positive (40%–60%)	Positive (40%–60%)	Positive (0%–100%)	Both parents negative	50% risk ^d	LFS
Multiple body tissues involved (post-zygotic mosaicism)						
Multi-tissue, confirmed constitutional post-zygotic mosaicism	Positive in more than one tissue (>1%–100%)			Both parents negative	Negative or 50% risk (if gonadal mosaic)	LFS ^e Strongly consider consultation with LFS expert regarding management
TP53 mutation origin in blood disorder or cancer cells only						
Blood only hematologic neoplasm or precursor condition	Positive (>1% to 100%)	Negative	Positive (>1% to 100%)	Both parents negative	Negative	Hematologic workup and treatment
Tumor only somatic interference from tumor (ctDNA or circulating tumor cells in blood/saliva)	Positive (>1% to 100%) in setting of widely metastatic/advanced cancer	Negative	Positive (>1% to 100%)	Both parents negative	Negative	Cancer treatment
TP53 mutation origin uncertain ^a						
Unclear etiology (clonal hematopoiesis vs. constitutional post-zygotic mosaicism unable to be determined)	Positive (>1% to 50%)	Negative	Positive or Negative (VAF solid tumor <VAF blood)	Both parents negative	Negative	Strongly consider consultation with LFS expert regarding workup and management

[See footnotes on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.



TP53 P/LP VARIANT WORKUP AND MANAGEMENT

FOOTNOTES FOR TABLE 1

- ^a Despite ancillary testing of multiple tissues and/or parental and/or offspring testing, it is sometimes not possible to determine to which of the above diagnostic categories a patient belongs. Management should be individualized based on available information. Consultation with experts in LFS diagnosis is strongly recommended.
- ^b Testing of cultured skin fibroblasts, tumor, and/or other alternative tissues is recommended to aid in diagnostic clarity in all of these diagnostic categories if the personal and/or family history are not consistent with a diagnosis of LFS and/or if there are tissue source or test metric concerns as detailed in [LIFR-A 2 of 6](#) (Castillo D, et al. Cancer Epidemiol Biomarkers Prev 2022;31:1621-1629; Schwartz AN, et al. JCO Precis Oncol 2021;5:1677-1686).
- ^c Parental and offspring testing is recommended in all of these diagnostic categories to clarify the diagnosis and management of the patient and close relatives unless there is a clear alternative diagnosis (eg, the patient has an active hematologic neoplasm with blood involvement as the source of the TP53 P/LP variant).
- ^d Sibling testing should be performed in the case of presumed de novo LFS with negative parental testing given the possibility of gonadal mosaicism in one of the parents or non-paternity. Despite negative testing in ancillary tissues, consider LFS screening if the patient's personal cancer history may suggest a clinical diagnosis of LFS ([LIFR-A 4 of 6](#)).
- ^e Management for mosaic LFS is per usual LFS management at this time ([LIFR-A 4 of 6](#)). Strongly consider consultation with an LFS expert for further workup and management recommendations.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

LIFR-A
3A OF 6



LI-FRAUMENI SYNDROME: ADULT SURVEILLANCE

Site	Screening/Surveillance Procedure and Interval
Breast cancer (female)	<ul style="list-style-type: none">Breast awareness^fClinical breast exam, every 6–12 mo starting at age 20 y^g.Breast screening<ul style="list-style-type: none">Age 20–29^g y, annual breast MRI^h screening with and without contrastⁱ.Age 30–75 y, annual breast MRI^h screening with and without contrast and mammogram.Age >75 y, management should be considered on an individual basis.For individuals with a <i>TP53</i> P/LP variant who are treated for breast cancer, and who have not had a bilateral mastectomy, screening with annual breast MRI and mammogram should continue as described above.Discuss option of RRM<ul style="list-style-type: none">Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.Address psychosocial and quality-of-life aspects of undergoing RRM.
Other cancer risks	<ul style="list-style-type: none">Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors every 6–12 mo.Complete blood count with differential every 3–6 months in patients with prior cytotoxic chemotherapy or radiation exposuresColonoscopy and upper endoscopy every 2–5 y starting at 25 y or 5 y before the earliest known colorectal or gastric cancer in the family, respectively. For patients who have received whole body or abdominal therapeutic RT, colonoscopy screening is recommended 5 y after treatment of disease.Annual dermatologic examinationAnnual whole body MRI^{j,k,l}Annual brain MRI may be performed as part of the whole body MRI or as a separate exam.Annual prostate-specific antigen (PSA) starting at age 40 y for prostate cancer early detection.For pancreatic cancer screening recommendations, see PANC-A.

^f Females should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal individuals may find BSE most informative when performed at the end of menses.

^g Or at the age of the earliest diagnosed breast cancer in the family, if <20 y.

^h The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under MRI guidance, radiologists experienced in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal patients. [FDA Drug Safety Communication](#): FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.

ⁱ Or mammogram, if MRI is unavailable. Breast MRI is preferred because of concerns regarding the risk of radiation exposure in P/LP variant carriers.

^j Whole body MRI is not uniformly available. If whole body MRI is not available, then individuals with LFS are encouraged to participate in clinical trials or consider alternate comprehensive imaging methods. Other components of screening are being evaluated in protocols, including biochemical screening and regular blood screening for hematologic malignancies. [FDA Drug Safety Communication](#): FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.

^k Ballinger M, Best A, Mai P, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncol* 2017;3:1634-1639.

^l Screening through whole body MRI has been broadly demonstrated to be feasible and of potential utility in the early detection of cancer among classic LFS families, though it also results in the detection of false-positive findings and possible cancer overdiagnosis. Furthermore, screening utility has not been evaluated among those with a germline *TP53* P/LP variant without a classic family history of LFS, who are increasingly identified through multigene panel tests.

Note: All recommendations are category 2A unless otherwise indicated.

Continued



LI-FRAUMENI SYNDROME: ADULT SURVEILLANCE

	Screening/Surveillance Procedure and Interval
Other aspects of managing LFS	<ul style="list-style-type: none">• The screening and management of LFS is complex, and LFS is rare; it is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome.• Because of the remarkable risk of additional primary neoplasms, screening should be considered for cancer survivors with LFS and a good prognosis from their prior tumor(s).• Address limitations of screening for many cancers associated with LFS.• Pediatricians should be apprised of the risk of childhood cancers in affected families and review screening recommendations for children with LFS.^m• Therapeutic RT for cancer should be avoided when possible unless locoregional risk reduction or overall survival from RT is greater than the risk of downstream secondary malignancies; diagnostic radiation should be minimized to the extent feasible without sacrificing accuracy.<ul style="list-style-type: none">▶ For patients diagnosed with breast cancer, mastectomy is preferred over lumpectomy/radiation to reduce radiation-induced sarcoma risk.• Screening recommendations should take into account personal and family history of cancer (5–10 years before earliest diagnosis). Provide additional surveillance based on family history of cancer.• Provide education on signs and symptoms (eg, new sites of persistent pain without known explanation) that should be reported promptly to the care team for evaluation.• Address psychosocial and quality-of-life aspects of the complex management of LFS. Consider mental health screening at each visit and offer assistance with finding an appropriate mental health provider for any interested patient.• There is controversy over how to manage cancer risk in incidental <i>TP53</i> carriers who do not meet classic LFS criteria; some data suggest lower cancer risks in <i>TP53</i> P/LP carriers who do not have a family history consistent with LFS.
Reproductive options	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).
Risk to relatives	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).

[Pediatric Surveillance \(LIFR-A 6 of 6\)](#)

^m For additional information on the management of children with LFS, see Kratz C, et al. Clin Cancer Res 2017;23:e38-e45.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

LIFR-A
5 OF 6



LI-FRAUMENI SYNDROME: PEDIATRIC SURVEILLANCE

	Screening/Surveillance Procedure and Interval
Cancer risks	<ul style="list-style-type: none">• Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors every 3–4 months beginning in infancy.• Complete blood count with differential every 3–4 months in patients with prior cytotoxic chemotherapy or radiation exposures.• Annual whole body MRI^{j,k,l} beginning in infancy.<ul style="list-style-type: none">▶ Whole body MRI should include upper and lower extremities, whenever technically feasible, for osteosarcoma risk.• Annual brain MRI may be performed as part of the whole body MRI or as a separate exam beginning in infancy.• For ACC, ultrasound every 3–4 months beginning in infancy. Blood biochemistry (total testosterone, dehydroepiandrosterone sulfate, and androstenedione) if unsatisfactory ultrasound quality.• Annual dermatologic examination.• For breast cancer surveillance, see LIFR-A 4 of 6.

^j Whole body MRI is not uniformly available. If whole body MRI is not available, then individuals with LFS are encouraged to participate in clinical trials or consider alternate comprehensive imaging methods. Other components of screening are being evaluated in protocols, including biochemical screening and regular blood screening for hematologic malignancies. [FDA Drug Safety Communication](#): FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.

^k Ballinger M, Best A, Mai P, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncol* 2017;3:1634-1639.

^l Screening through whole body MRI has been broadly demonstrated to be feasible and of potential utility in the early detection of cancer among classic LFS families, though it also results in the detection of false-positive findings and possible cancer overdiagnosis. Furthermore, screening utility has not been evaluated among those with a germline *TP53* P/LP variant without a classic family history of LFS, who are increasingly identified through multigene panel tests.

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

COWDEN SYNDROME (CS)/PTEN HAMARTOMA TUMOR SYNDROME (PHTS) MANAGEMENT

Site	Screening/Surveillance Procedure and Interval
General	<ul style="list-style-type: none">• Due to the rarity of the syndrome and complexities of diagnosing and managing individuals with CS, referral to a specialized team or centers with expertise is recommended.• Annual comprehensive physical exam starting at age 18 years or 5 years before the youngest age of diagnosis of a component cancer in the family (whichever comes first), with particular attention to thyroid exam.• Education regarding the signs and symptoms of cancer.
Breast cancer (female)	<ul style="list-style-type: none">• Breast awareness^a.• Clinical breast exam, every 6–12 months, starting at age 25 years or 5–10 years before the earliest known breast cancer in the family (whichever comes first).• Breast screening<ul style="list-style-type: none">▶ Annual mammography and breast MRI screening with and without contrast starting at age 30 years or 10 years before the earliest known breast cancer in the family (whichever comes first).^{b,c}▶ Age >75 years, management should be considered on an individual basis.▶ For individuals with a <i>PTEN</i> P/LP variant who are treated for breast cancer, and have not had a bilateral mastectomy, screening with annual mammogram and breast MRI should continue as described above.• Discuss option of RRM in individuals with P/LP variants identified. For those with clinical CS/PHTS syndrome, consideration of risk-reducing surgery should be based on family history.<ul style="list-style-type: none">▶ Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.• Address psychosocial and quality-of-life aspects of undergoing RRM.
Colorectal cancer	<ul style="list-style-type: none">• Colonoscopy, starting at age 35 years unless symptomatic or if close relative with colorectal cancer (CRC) before age 40 years, then start 5–10 years before the earliest known CRC in the family. Colonoscopy should be done every 5 years or more frequently if patient is symptomatic or polyps are found.

^a Females should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal individuals may find BSE most informative when performed at the end of menses.

^b The appropriateness of imaging modalities and scheduling is still under study.

^c The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under MRI guidance by experienced radiologists in breast MRI, and regional availability. Breast MRI is preferably performed on days 7–15 of a menstrual cycle for premenopausal females. [FDA Drug Safety Communication](#): FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.

Note: All recommendations are category 2A unless otherwise indicated.

Continued

**COWD-A
1 OF 2**



NCCN Guidelines Version 1.2026

Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management

COWDEN SYNDROME (CS)/PTEN HAMARTOMA TUMOR SYNDROME (PHTS) MANAGEMENT

Site	Screening/Surveillance Procedure and Interval
Endometrial cancer	<ul style="list-style-type: none">• For endometrial cancer screening,^d consider starting by age 35 years.<ul style="list-style-type: none">▶ Encourage patient education and prompt response to symptoms (eg, abnormal bleeding). Patients are encouraged to keep a calendar in order to identify irregularities in their menstrual cycle.▶ Because endometrial cancer can often be detected early based on symptoms, individuals should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy.▶ Endometrial cancer screening does not have proven benefit in individuals with CS/PHTS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1 to 2 years can be considered.▶ Transvaginal ultrasound to screen for endometrial cancer in postmenopausal individuals has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician's discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal individuals due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle.• Discuss option of hysterectomy^e upon completion of childbearing and counsel regarding degree of protection, extent of cancer risk, and reproductive desires. Risk of ovarian cancer is not elevated; therefore, ovaries can be left in situ.• Address psychosocial and quality-of-life aspects of undergoing risk-reducing hysterectomy.
Kidney cancer	<ul style="list-style-type: none">• Consider renal ultrasound starting at age 40 years, then every 1–2 years.
Neurologic	<ul style="list-style-type: none">• Consider psychomotor assessment in children at diagnosis and brain MRI if there are symptoms.
Skin	<ul style="list-style-type: none">• There may be an increased risk of melanoma, and the prevalence of other skin characteristics with CS/PHTS may independently make routine dermatology evaluations of value. Annual dermatology exams are recommended.
Thyroid	<ul style="list-style-type: none">• Annual thyroid ultrasound starting at age 12 years. This may also be considered for children at 50% risk of inheriting a known P/LP variant whose parents wish to delay genetic testing until age 18 years.
Reproductive options	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).
Risk to relatives	<ul style="list-style-type: none">• Principles of Cancer Risk Assessment and Counseling (EVAL-A).

^d There are limited data regarding the lifetime risk of endometrial cancer in CS/PHTS. Surveillance screening and surgical intervention should be on an individual basis.

^e Oophorectomy is not indicated for CS/PHTS alone.

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

BREAST, OVARIAN, UTERINE, AND PROSTATE CANCER RISK REDUCTION STRATEGIES FOR TRANSGENDER, NON-BINARY, AND GENDER DIVERSE PEOPLE WITH HEREDITARY CANCER SYNDROMES

General

- The following section introduces special considerations for risk reduction strategies for individuals who are transgender, non-binary, and gender diverse and is anchored in the following principles:
 - ▶ The terms “transgender,” “non-binary,” and “gender diverse” include a wide variety of physical and psychological states referring to individuals whose gender identity differs from the biologic sex at birth (sometimes referred to as “sex assigned at birth”). Many of these individuals pursue gender-affirming hormonal and/or surgical treatments at some point in their lives, which may impact their cancer risks and risk reduction options.
 - ▶ Our focus is on hereditary increased cancer risks due to the presence of a germline P/LP in a cancer-related gene. These risks may be altered by gender-affirming treatments and should be considered in risk reduction strategies.
 - ▶ There are several variables associated with magnitude of cancer risk in transgender, non-binary, and gender diverse people who have a hereditary predisposition to cancer:
 - ◊ Status of decision regarding gender transition/affirmation
 - ◊ Age at transition/affirmation (can be a several-year process)
 - ◊ Use, dosage, and duration of gender-affirming hormones
 - ◊ Types of gender-affirming surgeries
 - ◊ Presence of additional traditional risk factors (eg, family history)
 - ▶ There are no prospective data on appropriate cancer risk reduction and/or screening options for transgender, non-binary, or gender diverse individuals who are at average or high risk, regardless of average risk or increased risk.
 - ▶ Recommendations for risk reduction must be made on a case-by-case basis depending on all of the variables involved.

Strategies for Risk Assessment and Care of Individuals Who Are Transgender, Non-binary, and Gender Diverse

- One way to approach risk reduction choices is to focus on those organs at risk based on biologic sex at birth.
 - ▶ Female organs at risk:
 - ◊ Ovaries/fallopian tubes
 - ◊ Uterus
 - ◊ Breasts
 - ▶ Male organs at risk:
 - ◊ Prostate
 - ◊ Breasts

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

BREAST, OVARIAN, UTERINE, AND PROSTATE CANCER RISK REDUCTION STRATEGIES FOR TRANSGENDER, NON-BINARY, AND GENDER DIVERSE PEOPLE WITH HEREDITARY CANCER SYNDROMES

Ovarian Cancer: Risk Reduction Principles and Strategies

- There are several PVs associated with an increased risk for ovarian cancer, including *BRCA1*, *BRCA2*, *ATM*, *BRIP1*, *PALB2*, *RAD51C*, *RAD51D*, and LS genes.
- There is no known effective screening for ovarian cancer.
- It is not known what effect gender-affirming hormones have on ovarian or fallopian tube tissue.
- RRSO is recommended for individuals with one or both intact ovaries and fallopian tubes, as it is for cisgender women—see [GENE-A](#) for RRSO recommendations and age at the time of surgery for the specific PV found.
- RRSO may be a consideration at an earlier age than recommended to alleviate gender dysphoria in conjunction with appropriate health care professionals.
- Individuals considering RRSO before natural menopause should be counseled about the adverse events, including loss of fertility, menopausal symptoms, cardiovascular disease, and bone loss associated with premature menopause.
- There are no data on the effect of medical ovarian suppression on ovarian cancer risk.

Uterine Cancer: Risk Reduction Principles and Strategies

- There are several PVs associated with an increased risk for uterine cancer, including *PTEN* and LS genes.
- It is not known what effect gender-affirming testosterone therapy has on uterine tissue. However, as androgens are partially aromatized to estrogen, this may increase circulating estrogen levels and pose a risk to the uterus.
- Screening with transvaginal ultrasound with or without random endometrial biopsies is done in some settings but its benefit is unclear.
- Hysterectomy may be a consideration at an earlier age than recommended to alleviate gender dysphoria in conjunction with appropriate health care professionals. See [GENE-A](#) and [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric](#) for PV-specific hysterectomy recommendations and recommended age at the time of surgery.
- All individuals with an intact uterus should be counseled about the early warning signs of uterine cancer.
- There are no data on the effect of medical ovarian suppression on uterine cancer risk.

Prostate Cancer: Risk Reduction Principles and Strategies

- There are several PVs associated with an increased risk for prostate cancer, including *BRCA1*, *BRCA2*, and possibly *ATM*.
- It is not known what effect gender-affirming estrogen or anti-androgens have on the risk of prostate cancer, although some studies have reported diffuse atrophy and basal cell hyperplasia in prostate tissue among individuals on hormone therapy. Theoretically these changes may make the prostate gland less prone to develop cancer, but there are no data to support this. Gender-affirming hormone therapy has also been shown to alter PSA levels, thus reducing their efficacy as a screening tool. The Panel still advises PSA screening as per the [NCCN Guidelines for Prostate Cancer Early Detection](#).
- See [GENE-A](#) and [NCCN Guidelines for Prostate Cancer](#) for PV-specific screening recommendations.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

BREAST, OVARIAN, UTERINE, AND PROSTATE CANCER RISK REDUCTION STRATEGIES FOR TRANSGENDER, NON-BINARY, AND GENDER DIVERSE PEOPLE WITH HEREDITARY CANCER SYNDROMES

Breast Cancer: Risk Reduction Principles and Strategies:

- There are several PVs associated with an increased risk for breast cancer, including *BRCA1*, *BRCA2*, *ATM*, *BARD1*, *CDH1*, *CHEK2*, *NF1*, *PALB2*, *PTEN*, *RAD51C*, *RAD51D*, *STK11*, and *TP53*. Risk reducing strategies may differ by biologic sex at birth.
- Level of risk differs by gene and may guide risk reduction decisions (see [GENE-A](#) for more details).
- For transgender male and/or non-binary individuals with a P/LP in a breast cancer gene who have had reduction mammoplasty with retention of breast tissue, or no surgery, breast screening may begin at an earlier age and may include mammography and breast MRI. See [GENE-A](#) for gene-specific screening recommendations, including age to begin screening.

Female sex at birth

- It is unclear if the use of gender-affirming hormone therapy with testosterone alters the risk of breast cancer in individuals with a hereditary susceptibility to breast cancer, although long-term testosterone in cisgender females has been shown to reduce breast glandular tissue and increase connective tissue.
- Gender-affirming breast surgery, known as “top surgery,” typically involves reduction mammoplasty with retention of some breast tissue and the nipple areolar complex.
- Individuals with a known P/LP in a breast cancer gene may want to consider RRM in which >95% of the breast tissue is removed. Nipple-sparing surgery is thought to be safe in this setting. However, even with nipple sparing the aesthetic outcome may not be as good as top surgery where some breast tissue is retained. For individuals with a personal or family history consistent with a breast cancer P/LP, it is recommended that genetic testing be performed prior to breast surgery to inform the type of surgery. Individuals considering removal of all breast tissue should be referred to a plastic surgeon to discuss options for using tissue or implants to create a masculine profile if desired.
- For transgender male individuals with a P/LP in a breast cancer gene who have had reduction mammoplasty with retention of some breast tissue, or no breast surgery, breast cancer screening may begin at an earlier age and may include mammography and breast MRI. See [GENE-A](#) for gene-specific screening recommendations, including age to begin screening. This approach is also supported by the ACR guidelines.
- The term “breast cancer” may be associated with femininity; thus, the term “chest cancer,” instead of breast cancer, may be preferred in individuals who identify as men.

Male sex at birth

- Gender-affirming hormone therapy with estrogens and anti-androgens in transgender women increases breast tissue, which includes the formation of ducts, lobules, and acini, similar to that in cisgender women, and this should not be described as gynecomastia. Breast changes occur within 6 months after starting therapy and result in increased breast density. In situ and invasive breast cancers have been reported in this population. Anecdotally, these breast tumors tend to occur at an earlier age than the average population. Breast cancer risk in individuals who are biologically male at birth, even with breast cancer P/LP variants, is low, and while estrogen and anti-androgens may increase breast cancer risk, they are not contraindicated in individuals taking female-promoting (gender-affirming) hormones.
- While there are limited data on the benefit of radiographic screening of breast tissue with mammography and/or breast MRI in transgender women at increased hereditary risk who are taking gender-affirming hormone therapy, there are case reports of breast cancer detection in this setting and NCCN supports the rationale for breast cancer screening of cisgender males at increased hereditary risk. This area clearly represents a major research gap in the care of transgender women who have a hereditary risk for breast cancer. Taking into account that the risk for breast cancer has been shown to be elevated in transgender women compared to cisgender men, breast screening modalities for transgender women at increased hereditary risk should be decided on a case-by-case basis, and may be based on age, family history, the duration of use of gender-affirming hormone therapy and/or the amount of breast tissue present; digital mammography and tomosynthesis rather than MRI is recommended by radiology guidelines. For those who have chosen implant reconstruction, MRI without contrast can be performed to assess implant integrity; however, this would not detect cancer.

[Continued](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

BREAST, OVARIAN, UTERINE, AND PROSTATE CANCER RISK REDUCTION STRATEGIES FOR TRANSGENDER, NON-BINARY, AND GENDER DIVERSE PEOPLE WITH HEREDITARY CANCER SYNDROMES

Additional Considerations

- Transgender, non-binary, and gender diverse individuals encounter many challenges to health care, including stigmatization, denial of services, discrimination, abuse, and possible higher rates of mortality due to lack of access to appropriate preventive care.
- Individuals pursuing gender-affirming care should be followed at centers of excellence with access to a multidisciplinary team that understands their unique needs and provides a safe and welcoming environment. The team should include surgeons, primary care specialists, oncologists, radiologists, pathologists, endocrinologists, pediatricians, psychologists, genetic counselors, and social workers, all of whom are trained in the appropriate care of the transgender population and can address medical, psychologic, and social care needs.
- There is a need for formal education in the care of transgender, non-binary, and gender diverse individuals at every level of the health care system, with a particular focus in breast/chest cancer screening.
- There is a need for research regarding the impact of gender-affirming hormones and puberty-blocking agents and how they interact with hereditary susceptibility to cancer syndromes as well as optimal prevention strategies for these populations.
- Most electronic health data, including SEER data, census data, and even EMRs do not incorporate gender identity, thus hindering the collection of health data in these populations and denying appropriate screening invitations to these individuals.
- A National Registry on the health outcomes of transgender, non-binary, and gender diverse populations is needed to fill the many gaps in the magnitude and management of risks associated with gender-affirming treatment in the setting of hereditary cancer susceptibilities.
- As in all research involving human participants, care must be taken to preserve the privacy and protection of this population.

References

- Corman V, Potorak J, Manto F, et al. Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation. *Endocr Relat Cancer* 2016;23:391-397.
- de Blok CJM, Klaver M, Wiepjes CM, et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: Results of a prospective multicenter study. *J Clin Endocrinol Metab* 2018;103:532-538.
- De Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands. *BMJ* 2019;365:l1652.
- Hodan R, Rodgers-Fouche L, Chittenden A, et al; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. Cancer surveillance for transgender and gender diverse patients with Lynch syndrome: a practice resource of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. *Fam Cancer* 2023;22:437-448.
- Lourenco AP, Niell BL, Cronin B, et al. ACR Appropriateness Criteria Transgender Breast Cancer Screening 2021;18:S502-S515.
- Parikh U, Mausner E, Chhor CM, et al. Breast imaging in transgender patients: What the radiologist should know. *Radiographics* 2020;40:13-27.
- Sieberg R, Soriano K, Zuurbier R. A rare case of breast cancer in a transgender woman. *Radiol Case Rep* 2021;16:3285-3288.
- Skop M, Lorentz J, Jassi M, et al. "Guys Don't Have Breasts": The lived experience of men who have BRCA gene mutations and are at risk for male breast cancer. *Am J Mens Health* 2018;12:961-972.
- Sonnenblick EB, Lebron-Zapata L, Yang R, et al. Breast imaging for transgender individuals: assessment of current practice and needs. *J Am Coll Radiol* 2022;19:221-231.
- Sutherland N, Espinel W, Grotzke M, Colonna S. Unanswered questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. *J Genet Couns* 2020;29:625-633.

Note: All recommendations are category 2A unless otherwise indicated.



Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines

NCCN Guideline	Specific Sections Included in Table of Contents or Text	Genes and/or Syndromes Included/Mentioned in Guideline
Treatment Guidelines		
Acute Lymphocytic Leukemia (ALL)	Familial Genetic Alterations in ALL	<i>RUNX1, ETV6, PAX5, IKZF1, TP53</i>
Acute Myeloid Leukemia (AML)	Refer to MDS on next page	<i>RUNX1, ANKRD26, CEBPA, DDX41, ETV6, GATA2, MBD4, MECOM/EVI1 complex, SAMD9/SAMD9L, TERC/TERT, ATG2B/GSKIP</i>
Basal Cell Skin Cancer	Principles of Cancer Risk Assessment and Counseling	Gorlin syndrome (<i>PTCH1</i>), xeroderma pigmentosa
Biliary Tract Cancers	Principles of Molecular Testing	Evidence remains insufficient for definitive recommendations regarding specific criteria to guide genetic risk assessment in hepatobiliary cancers or for universal germline testing in these tumors
Bladder Cancer Urothelial cancer (including renal pelvis and ureter)	Clinical Presentation and Initial Evaluation Urothelial Carcinoma of the Ureter	Lynch syndrome (LS)
Breast Cancer		Refers to Genetic/Familial: BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines
Central Nervous System Cancers	Cancer Risk Assessment and Counseling	<i>TP53</i> (Li-Fraumeni syndrome [LFS]), LS, familial adenomatous polyposis (FAP); refers to Genetic/Familial: BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines and Genetic/Familial: Colorectal, Endometrial, and Gastric Guidelines
Colon Cancer	Principles of Pathologic and Molecular Review	Refers to Genetic/Familial: Colorectal, Endometrial, and Gastric Guidelines
Esophageal and Esophagogastric Junction (EGJ) Cancers	Principles of Genetic Risk Assessment for Esophageal and Esophagogastric Junction (EGJ) Cancers	<i>RHBDF2</i> ; Bloom syndrome (BS)/ <i>BLM</i> , <i>RECQL3</i> ; Fanconi anemia (FA)/ <i>FANCD1</i> , <i>BRCA2</i> , <i>PALB2</i>
Gastric Cancer		Refers to Genetic/Familial: Colorectal, Endometrial, and Gastric Guidelines
Gastrointestinal Stromal Tumors (GIST)	Principles of Mutation Testing	<i>KIT</i> , <i>PDGFRA</i> , <i>SDHB</i> , <i>NF1</i>

Note: All recommendations are category 2A unless otherwise indicated.



Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines

NCCN Guideline	Specific Sections Included in Table of Contents or Text	Genes and/or Syndromes Included/Mentioned
Treatment Guidelines (Continued)		
Hepatocellular Carcinoma	Principles of Molecular Testing	Evidence remains insufficient for definitive recommendations regarding specific criteria to guide genetic risk assessment in hepatobiliary cancers or for universal germline testing in these tumors
Kidney Cancer	Hereditary Renal Cell Carcinoma section	von Hippel-Lindau (VHL) syndrome; hereditary papillary renal carcinoma (HPRC)/ <i>MET</i> ; Birt-Hogg-Dube syndrome (BHDS)/ <i>FLCN</i> ; tuberous sclerosis complex (TSC)/ <i>TSC1</i> , <i>TSC2</i> ; hereditary leiomyomatosis and renal cell carcinoma (HLRCC)/ <i>FH</i> ; <i>BAP1</i> tumor predisposition syndrome (TPDS)/ <i>BAP1</i> ; hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndrome/ <i>SDHA</i> / <i>SDHB</i> / <i>SDHC</i> / <i>SDHD</i>
Melanoma: Cutaneous	Risk Factors for Development of Single or Multiple Primary Melanomas	<i>CDKN2a</i> , <i>CDK4</i> , <i>MC1R</i> , <i>BAP1</i> (including uveal), <i>TERT</i> , <i>MITF</i> , <i>PTEN</i> and potential other genes
Melanoma: Uveal	Risk Factors for Development of Uveal Melanoma	<i>BAP1</i> , <i>PALB2</i> , <i>MBD4</i>
Mesothelioma: Peritoneal	Principles of Pathologic Review	<i>BAP1</i>
Mesothelioma: Pleural	Principles of Pathologic Review	<i>BAP1</i> TPDS
Myelodysplastic Syndromes	<ul style="list-style-type: none"> Genetic Familial High-Risk Assessment: Heritable Hematologic Malignancy Predisposition Syndromes Gene Mutations Associated with Heritable Hematologic Malignancy Predisposition Syndromes 	<i>CEBPA</i> , <i>DDX41</i> , <i>ATG2B/GSKIP</i> , <i>XP C/XPC</i> , <i>ERCC6L2</i> , <i>ANKRD26</i> , <i>ETV6</i> , <i>GATA2</i> , <i>RUNX1</i> , <i>LIG-4</i> , <i>SAMD9/SAMD9L</i> , <i>SRP72</i> , Diamond-Blackfan anemia, FA, Shwachman-Diamond syndrome, short telomere syndromes, congenital neutropenia, myeloid neoplasms associated with Down syndrome, constitutional mismatch repair deficiency (CMMRD), <i>BRCA1/BRCA2</i> , <i>LFS/TP53</i> , <i>RASopathies</i> , other rare DNA repair syndromes/ <i>BLM</i> , <i>MBD4</i> , <i>XPC</i>
Neuroblastoma	Principles of Pathology	<i>ALK</i>
Neuroendocrine and Adrenal Tumors	Principles of Hereditary Cancer Risk Assessment and Genetic Counseling	Hereditary PGL/PCC syndrome/ <i>MAX</i> , <i>SDHA</i> , <i>SDHAF2</i> , <i>SDHB</i> , <i>SDHC</i> , <i>SDHD</i> , <i>TMEM127</i> ; multiple endocrine neoplasia type 1 (MEN1); MEN type 2 (MEN2)/ <i>RET</i> ; MEN type 4 (MEN4)/ <i>CDKN1B</i> ; <i>NF1</i> (<i>NF1</i>); TSC (<i>TSC1</i> , <i>TSC2</i>); VHL syndrome; <i>LFS/TP53</i> ; LS (<i>MLH1</i> , <i>EPCAM/MSH2</i> , <i>MSH6</i> , <i>PMS2</i>); <i>FAP/APC</i>
Non-Small Cell Lung Cancer	Principles of Molecular and Biomarker Analysis	<i>EGFR</i> p.T790M

Note: All recommendations are category 2A unless otherwise indicated.



Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines

NCCN Guideline	Specific Sections Included in Table of Contents or Text	Genes and/or Syndromes Included/Mentioned
Treatment Guidelines (Continued)		
Ovarian Cancer		Refers to Genetic/Familial BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines
Pancreatic Adenocarcinoma	Principles of Cancer Risks Assessment and Counseling	Refers to Genetic/Familial BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines
Pediatric Acute Lymphoblastic Leukemia	Genetic Risk Groups for B-ALL	LFS/ <i>TP53</i> association with low hypodiploid ALL
Pediatric Central Nervous System Cancers	Introduction to Pediatric Diffuse High-Grade Gliomas; Principles of Neuropathology	NF1, LFS, LS/CMMRD, <i>APC</i> (FAP), <i>PTCH1</i> (Gorlin syndrome)
Prostate Cancer	Principles of Genetics and Molecular/Biomarker Analysis	<i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>PALB2</i> , <i>CHEK2</i> , <i>HOXB13</i> , LS/ <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i>
Rectal Cancer	Principles of Pathologic and Molecular Review	LS, FAP, attenuated FAP (AFAP)
Small Bowel Adenocarcinoma	Workup and Primary Treatment	Refers to Genetic/Familial: Colorectal, Endometrial, and Gastric Guidelines
Soft Tissue Sarcoma	Principles of Cancer Risk Assessment and Counseling	Neurofibromatosis/ <i>NF1</i> ; LFS/ <i>TP53</i> ; LS; FAP
Squamous Cell Skin Cancer	Principles of Cancer Risk Assessment and Counseling	XP and recessive dystrophic epidermolysis bullosa (RDEB); refers to Genetic/Familial BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines
Systemic Mastocytosis	Diagnostic Algorithm	<i>TPSAB1</i>
Thyroid Carcinoma	<ul style="list-style-type: none"> • Germline Mutation of <i>RET</i> PV • Principles of Cancer Risk Assessment and Counseling 	MEN2/ <i>RET</i>
Uterine Neoplasms	<ul style="list-style-type: none"> • Principles of Pathology and Molecular Analysis (Endometrial Carcinoma) • Principles of Pathology and Molecular Analysis (Uterine Sarcoma) 	LS, <i>POLE</i> , <i>SMARCA4</i>
Wilms Tumor (Nephroblastoma)	Principles of Cancer Risk Assessment and Counseling	Denys-Drash syndrome (<i>WT1</i>), WAGR/WAGRO syndrome (<i>WT1</i>), Perlman syndrome (<i>DIS2L2</i>), Beckwith-Wiedemann syndrome (<i>CDKN1C</i>), Frasier syndrome (<i>WT1</i>), Bohring-Opitz syndrome (<i>ASXL1</i>), MULIBREY syndrome (<i>TRIM37</i>), LFS (<i>TP53</i>), trisomy 18 syndrome

Note: All recommendations are category 2A unless otherwise indicated.



Summary of Genes and/or Syndromes Included/Mentioned in Other NCCN Guidelines

<u>NCCN Guideline</u>	<u>Specific Sections Included in Table of Contents</u>	<u>Genes and/or Syndromes Included/Mentioned</u>
Detection, Prevention, and Risk Reduction Guidelines		
Breast Cancer Risk Reduction	<ul style="list-style-type: none">• Familial Risk Assessment• Components of Risk/Benefit Assessment and Counseling• Comparison of Predictive Models of Risk of Breast Cancer and Risk of Carrying Pathogenic/Likely Pathogenic Variants of BRCA	Refers to Genetic/Familial BOPP (Breast, Ovarian, Pancreatic, and Prostate) Guidelines
Breast Cancer Screening and Diagnosis	<ul style="list-style-type: none">• Increased Risk, Screening/Follow-Up	
Colorectal Cancer Screening	<ul style="list-style-type: none">• Risk Assessment for Colorectal Cancer• Increased Risk Based on Personal History of Childhood, Adolescent, and Young Adult Cancer• Increased Risk Based on Positive Family History	LS
Prostate Cancer Early Detection	Baseline Evaluation, Risk Assessment, and Early Detection Evaluation	Such risk genes include, but are not limited to, <i>BRCA2</i> , <i>BRCA1</i> , <i>ATM</i> , <i>CHEK2</i> , <i>PALB2</i> , <i>HOXB13</i> , <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i> , <i>EPCAM</i> , and <i>TP53</i> .
Supportive Care Guidelines		
Survivorship	Principles of Cancer Risk Assessment and Counseling	Refers to some of the other NCCN Guidelines containing inherited cancer content
Special Populations		
Adolescent and Young Adult (AYA)	Comprehensive Initial Assessment	

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

ABBREVIATIONS

ACC	adrenocortical carcinoma	FA	Fanconi anemia	PJS	Peutz-Jeghers syndrome
AFAB	assigned female at birth	FAP	familial adenomatous polyposis	PRS	polygenic risk score
AFAP	attenuated familial adenomatous polyposis	GI	gastrointestinal	PSA	prostate-specific antigen
AMAB	assigned male at birth	GIST	gastrointestinal stromal tumor	PV	pathogenic variant
AT	ataxia-telangiectasia			RDEB	recessive dystrophic epidermolysis bullosa
BHDS	Birt-Hogg-Dubé syndrome	HDGC	hereditary diffuse gastric cancer	RRM	risk-reducing mastectomy
BRRS	Bannayan-Riley-Ruvalcaba syndrome	HLRCC	hereditary leiomyomatosis and renal cell cancer	RRSO	risk-reducing salpingo-oophorectomy
BS	Bloom syndrome	HPRC	hereditary papillary renal carcinoma	SCCOHT	small cell carcinoma of the ovary (hypercalcemic type)
BSE	breast self examination	HRT	hormone replacement therapy	SCTAT	sex cord tumor with annular tubules
BSO	bilateral salpingo-oophorectomy			SDH	succinate dehydrogenase
CBC	complete blood count	LFS	Li-Fraumeni syndrome	SEER	Surveillance, Epidemiology, and End Results
CHIP	clonal hematopoiesis of indeterminate potential	LS	Lynch syndrome	SNP	single nucleotide polymorphism
CLIA	Clinical Laboratory Improvement Amendments	LNG-IUD	levonorgestrel intrauterine device	SNV	single nucleotide variant
CMMRD	constitutional mismatch repair deficiency	MEN	multiple endocrine neoplasia	STIC	serous tubal intraepithelial carcinoma
CNS	central nervous system	MMR	mismatch repair	UUAB	unassigned at birth
CNV	copy number variant	MRCP	magnetic resonance cholangiopancreatography	UV	ultraviolet
CPS + EG	clinical-pathologic stage + estrogen receptor status and histologic grade	NF	neurofibromatosis	TPDS	tumor predisposition syndrome
CRC	colorectal cancer	NGS	next-generation sequencing	TSC	tuberous sclerosis complex
CS	Cowden syndrome			VAF	variant allele frequency
ctDNA	circulating tumor DNA	OCP	oral contraceptive pill	VHL	von Hippel-Lindau
		P/LP	pathogenic/likely pathogenic	VUS	variant of uncertain significance
DTC	direct to consumer	PCC	pheochromocytoma		
EMR	electronic medical record	PGL	paraganglioma	XP	xeroderma pigmentosum
EUS	endoscopic ultrasound	PHTS	<i>PTEN</i> hamartoma tumor syndrome		



NCCN Guidelines Version 1.2026

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate

NCCN Categories of Evidence and Consensus	
Category 1	Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Discussion

This discussion corresponds to the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Last updated: March 6, 2025.

Table of Contents

OverviewMS-2

Literature Search Criteria and Guidelines Update Methodology.....MS-3

Sensitive/Inclusive Language Usage.....MS-3

Genetic Risk Assessment and CounselingMS-3

Evaluating the Source of Genetic Testing Information.....MS-5

Tumor Genomic Testing.....MS-6

Multigene Testing.....MS-6

Pre- and Post-Test Counseling.....MS-8

High-Penetrance Breast and/or Ovarian Cancer Susceptibility

Genes.....MS-11

BRCA-Related Breast/Ovarian Cancer SyndromeMS-12

Breast Cancer Risk.....MS-12

Ovarian Cancer Risk.....MS-14

Prostate Cancer Risk.....MS-15

Pancreatic Cancer RiskMS-15

Other Cancer and Health Risks.....MS-15

Risk Management.....MS-17

Other P/LP Variants Associated with Breast, Ovarian, Pancreatic, and

Prostate CancersMS-26

ATMMS-27

BARD1MS-28

BRIP1.....MS-29

CDH1MS-29

CHEK2MS-29

MLH1, MSH2, MSH6, PMS2, and EPCAMMS-31

NF1MS-31

PALB2MS-32

RAD51C and RAD51DMS-33

STK11MS-34

Emerging Evidence.....MS-34

NCCN Genetic Testing Criteria.....MS-34

Testing Criteria Related to Prostate Cancer.....MS-35

Systemic Therapy Decision-Making.....MS-35

Founder MutationsMS-36

Breast Cancer Population TestingMS-36

Probability ModelsMS-38

Li-Fraumeni SyndromeMS-39

Risk Assessment, Counseling, and ManagementMS-41

Cowden Syndrome/*PTEN* Hamartoma Tumor SyndromeMS-42

Risk Assessment, Counseling, and ManagementMS-45

Hereditary Pancreatic CancerMS-48

Pancreas ScreeningMS-48

Cancer Risk Reduction Strategies for Transgender, Non-Binary, and

Gender Diverse People with Hereditary Cancer SyndromesMS-50

ReferencesMS-54

Overview

All cancers develop as a result of pathogenic or likely pathogenic (P/LP) variants in certain genes, such as those involved in the regulation of cell growth and/or DNA repair,^{1,2} although not all of these P/LP variants are inherited from a parent. For example, sporadic P/LP variants can occur in somatic/tumor cells only, and de novo P/LP variants can occur for the first time in a germ cell (ie, egg or sperm) or in the fertilized egg itself during early embryogenesis. However, family studies have long documented an increased risk for several forms of cancer among first-degree relatives (ie, parents, siblings, children) and second-degree relatives (ie, grandparents, aunts or uncles, grandchildren, nieces or nephews) of affected individuals. These individuals may have an increased susceptibility to cancer as the result of ≥ 1 P/LP variants present in parental germline cells; cancers developing in these individuals may be classified as hereditary or familial cancers.

Hereditary cancers are often characterized by P/LP variants associated with increased risk for certain cancers and transmission to offspring through the mother and/or father.^{3,4} They often have an early age of onset and exhibit an autosomal dominant inheritance pattern (ie, occur when the individual has a P/LP variant in only one copy of a gene). Familial cancers share some but not all features of hereditary cancers. For example, although familial breast cancers occur in a given family more frequently than in the general population, they generally do not exhibit the inheritance patterns or onset age consistent with hereditary cancers. Familial cancers may be associated with chance clustering of sporadic cancer cases within families, genetic variation in lower penetrance genes, a shared environment, or combinations of these factors.⁵⁻⁸

An individual suspected of being at risk for hereditary cancer should be offered genetic counseling.^{9,10} This is consistent with recommendations

from the U.S. Preventive Services Task Force (USPSTF).¹¹ Assessment of an individual's risk for familial or hereditary cancer is based on a thorough evaluation of the personal and family history. With respect to hereditary cancers, advances in molecular genetics have identified a number of genes associated with inherited susceptibility to breast, ovarian, pancreatic, and prostate cancer (eg, *BRCA1/2*, *PALB2*, *ATM*) and have provided a means of characterizing the specific P/LP variant present in certain individuals and families exhibiting an increased risk for cancer. The field of cancer genetics has implications for all aspects of cancer-related care of individuals with hereditary or familial cancers, including prevention, screening, and treatment.¹²

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate were developed with an acute awareness of the preliminary nature of much of our knowledge regarding the clinical application of the rapidly emerging field of molecular genetics, and with an appreciation for the need for flexibility when applying these guidelines to individual families. Furthermore, it should be emphasized that these Guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to: 1) serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; 2) guide decisions related to genetic testing; and 3) facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate focus primarily on assessment of P/LP variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including *BRCA1*, *BRCA2*, *CDH1*, *PALB2*, *PTEN*, and *TP53*, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. Where possible, P/LP



variants in more recently identified genes have been addressed to the extent possible given the limited information available. Recommendations regarding P/LP variants associated with pancreatic cancer, and pancreas screening for individuals harboring such variants, were added to the NCCN Guidelines in the 2020 update. Additionally, these Guidelines are now the primary NCCN source for testing criteria for those with or at risk for prostate cancer, as of 2024.

A glossary of genetic terms is included in Table 1 for reference.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, an electronic search of the PubMed database was performed to obtain key literature using the following search terms: (hereditary breast cancer) OR (familial breast cancer) OR (hereditary ovarian cancer) OR (familial ovarian cancer) OR (Li-Fraumeni syndrome) OR (tp53 breast cancer) OR (Cowden syndrome) OR (pten hamartoma tumor syndrome) OR (pten breast cancer) OR (brca breast cancer) OR (brca ovarian cancer) OR (brip1 ovarian cancer) OR (cdh1 breast cancer) OR (palb2 breast cancer) OR (stk11 breast cancer) OR (rad51c ovarian cancer) OR (rad51d ovarian cancer) OR (hereditary pancreas cancer) OR (hereditary pancreatic cancer) OR (familial pancreas cancer) OR (familial pancreatic cancer) OR (brca pancreas cancer) OR (brca pancreatic cancer) OR (cdkn2a pancreas cancer) OR (cdkn2a pancreatic cancer) OR (cancer genetic testing) OR (cancer genetic counseling). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types:

Practice Guidelines; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; Multicenter Study; and Validation Studies. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the Panel during the Guidelines update have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the Panel's review of lower-level evidence and expert opinion.

Sensitive/Inclusive Language Usage

NCCN Guidelines strive to use language that advances the goals of equity, inclusion, and representation. NCCN Guidelines endeavor to use language that is person-first; not stigmatizing; anti-racist, anti-classist, anti-misogynist, anti-ageist, anti-ableist, and anti-weight-biased; and inclusive of individuals of all sexual orientations and gender identities. NCCN Guidelines incorporate non-gendered language, instead focusing on organ-specific recommendations. This language is both more accurate and more inclusive and can help fully address the needs of individuals of all sexual orientations and gender identities. NCCN Guidelines will continue to use the terms men, women, female, and male when citing statistics, recommendations, or data from organizations or sources that do not use inclusive terms. Most studies do not report how sex and gender data are collected and use these terms interchangeably or inconsistently. If sources do not differentiate gender from sex assigned at birth or organs present, the information is presumed to predominantly represent cisgender individuals. NCCN encourages researchers to collect more specific data in future studies and organizations to use more inclusive and accurate language in their future analyses.

Genetic Risk Assessment and Counseling

Cancer genetic risk assessment and genetic counseling is a multi-step process involving the identification and counseling of individuals at risk for familial or hereditary cancer. The purpose of cancer genetic counseling is



to educate individuals about the genetic, biological, and environmental factors related to a cancer diagnosis and/or risk for disease to help derive personal meaning from cancer genetic information, and to empower them to make educated, informed decisions about genetic testing, cancer screening, and cancer prevention. Many patients undergoing genetic testing do not receive proper counseling.¹³ Further, testing rates are inadequate among some populations with higher risk, such as African American individuals.^{14,15} A genetic counselor, clinical geneticist, oncologist, surgeon, oncology nurse, or other health professional with expertise and experience in cancer genetics should be involved in every stage of the process.⁹

Testing is clinically indicated in individuals for whom there is a personal or family history suggesting genetic cancer susceptibility and for whom results will aid in risk management and treatment. The selection of genes for which testing is indicated is based on the personal and familial characteristics that determine the individual's prior probability of being a carrier of a P/LP variant, and on the psychosocial degree of readiness of the person to receive genetic test results. Genetic risk assessment is a dynamic process and can change if additional relatives are diagnosed with cancer. The genetic testing strategy is greatly facilitated when a P/LP variant has already been identified in another family member. In that case, the genetic testing laboratory can limit the search for P/LP variants in additional family members to the same location in the gene. However, if there is reason to suspect more than one P/LP variant in the family, then broader testing may be considered.

For the majority of families in whom presence of a P/LP variant is unknown, it is best to consider testing an affected family member first, especially a family member with early-onset disease, bilateral disease, or multiple primaries, because that individual has the highest likelihood of a positive test result. The testing of the unaffected individual (or of

unaffected family members) is reasonable when no affected family member is available for testing. In such cases, it is most informative to test the unaffected individual or unaffected close relative with the highest likelihood of testing positive for the P/LP variant. This may include the relative closest to the family member with the youngest age at diagnosis, bilateral disease, multiple primary tumors, or other cancers associated with a suspected hereditary syndrome. A negative test result in such cases, however, is considered indeterminate and does not provide the same level of information as when there is a known P/LP variant in the family. Thus, one should be mindful that, when testing unaffected individuals (in the absence of having tested affected family members), limitations may exist in interpreting the test results, and testing multiple family members may be indicated since absence of a P/LP variant in one unaffected relative does not rule out a P/LP variant in other family members. The maternal and paternal sides of the family should be considered independently for familial patterns of cancer. "Limited" family structure is defined as ≤ 2 first- or second-degree female relatives who survive past age 45 (on either side of the family) and/or possessing no or inadequate information about one's birth parents.¹⁶

Individuals who have received allogeneic hematopoietic cell transplantation (HCT) should not have molecular genetic testing performed on blood samples. In such cases, DNA of the individual being tested should be extracted from a fibroblast culture, if available. If this is not possible, buccal cells or saliva may be considered as an alternative source for DNA; however, a study has reported that over time, buccal epithelial cells are replaced by donor-derived cells in allogeneic HCT recipients.^{17,18} Therefore, genetic testing using saliva or buccal swab samples may be limited given this known risk of contamination or malignant cells from the hematologic malignancy. Fibroblasts are also indicated when testing individuals with active or recent hematologic malignancies.¹⁹



A counseling dilemma is posed by the finding of a variant of uncertain significance (VUS), a genetic alteration that may actually represent a benign polymorphism unrelated to an increased cancer risk or may indicate an increased cancer risk. Retrospective analyses have estimated that 82.1% to 91.2% of the time, if a VUS is reclassified, it is downgraded to benign or likely benign, while 8.7% to 17.9% are upgraded from VUS to pathogenic.^{20,21} Therefore, VUS should not be used to alter medical management. These patients should be considered for referral to research studies that aim to define the functional impact of the gene variant, such as variant reclassification programs through clinical labs or registries. Some examples of these programs and registries include ClinVar (the archival database at the National Center for Biotechnology Information [NCBI]); the NIH-funded Clinical Genome Resource (ClinGen; <https://www.clinicalgenome.org>); the international Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA; <https://enigmaconsortium.org>); and the International Society for Gastrointestinal Hereditary Tumors (InSIGHT; <http://insight-group.org>). It is important to note that there may be inconsistencies among how some programs and registries interpret the clinical actionability of some VUS,^{22,23} and there are discordant variant interpretations across laboratories.²⁴ These inconsistencies may lead to confusion regarding medical management, and careful counseling and skilled interpretation are required. RNA studies (when appropriate) may be a consideration to further define functional impact of variants.²⁵ Family members should not be tested for a VUS for the purposes of clinical management unless there are conflicting data between laboratories regarding the classification of a variant. In the event where there are discrepancies in classification, careful consideration must be taken regarding family history, testing family members, and if other functional studies could aid in variant classification. Clinicians and scientists should work together to develop a VUS classification system as more information is discovered in research

studies.²⁶ Risk management strategies in carriers of a VUS or likely benign variant should be based on family history of cancer.

Carriers of a P/LP variant should be encouraged to participate in clinical trials or genetic registries. Carriers should be encouraged to recontact their genetics providers every few years for updates, as laboratories may issue amended reports as the knowledge base surrounding hereditary cancer risk expands.

Evaluating the Source of Genetic Testing Information

Reports regarding germline findings that may impact medical management should come from laboratories that are certified by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), with some U.S. states (eg, New York) having additional reporting requirements. Direct-to-consumer (DTC) services and tumor profiling both provide genetic test results. The testing typically used by companies providing ancestry information directly to consumers is microarray-based single nucleotide polymorphism (SNP) testing that has not been validated for clinical use. These companies do not provide comprehensive genetic analysis that includes gross deletion or duplication analysis. Third-party services are available to assist patients with interpreting their raw data, but these services are not government-regulated. In addition to the errors inherent in working with raw uncured data from DTC labs, other limitations of these services include inadequate informed consent process, uncertain clinical validity and utility, and lack of medical oversight.²⁷ Currently available tests also only provide limited founder P/LP variant results without the benefit of family history. An analysis of concordance between DTC testing results and results from confirmatory testing for 49 patients showed a false-positive rate of 40%, as well as variant classification errors in 8 patients.²⁸ Given the limitations of the information obtained from DTC services, confirmatory germline testing by a certified laboratory is clinically indicated, and changes to medical



management based solely on DTC testing results are not recommended.²⁸ Testing offered through DTC services may have other limitations as well that could impact informed decision-making and interpretation of test results.²⁹ These limitations include use of terms that are not clearly defined for consumers (eg, “clinical grade,” “medical grade,” “diagnostic grade”); unclear procedures for processing and receiving results and for variant reclassification; inadequate genetic counseling; and unclear use of consumers’ health information.²⁹

Incidental germline findings discovered through other sources (eg, participation in a research study) should be reviewed by a genetics professional.³⁰ Confirmatory testing in these cases may be clinically indicated, especially if the reporting laboratory is not appropriately certified.

Tumor Genomic Testing

Tumor profiling can be considered complementary to germline testing. However, the absence of a P/LP variant for a given gene from tumor profiling does not rule out the possibility of a germline P/LP variant in that gene. Tumor genomic testing tends to be designed to address treatment actionability and prognosis.³¹ Therefore, a variant interpreted as P/LP in the germline may be interpreted as normal or as a VUS in the tumor, if that variant has no clear clinical implications. In addition, the sensitivity of most tumor testing is lower (particularly for intermediate-sized deletions and duplications) than that for most dedicated germline tests, sometimes due to filtering out of germline findings reported in tumor sequencing results. In a study of 21,333 patients with cancer who underwent both tumor and germline testing at an NCCN Member Institution, tumor-only sequencing missed 10.5% of clinically actionable P/LP variants.³² If a patient meets testing criteria for germline testing for a given gene, then confirmatory germline testing should be considered through a CLIA-approved lab despite tumor profiling results.

Circulating tumor DNA (ctDNA) assays may be used by some labs. ctDNA has the potential to identify both somatic and germline variants.³³ However, since the primary intent of tumor testing is to inform treatment decision-making, ctDNA assays are not validated for reporting or interpretation of germline variants. The sensitivity, false-positive rates, and positive predictive value of ctDNA tests for early-stage disease, which are needed to derive clinical utility and to determine clinical validity, are also not fully defined.^{34,35} The psychological impact of ctDNA testing also remains unknown. For these reasons, ctDNA should not be used, outside of the clinical trial setting, to replace well-established methods of cancer screening (eg, mammography). If a germline variant that could impact medical management is detected with a ctDNA assay, then confirmatory testing with a CLIA-approved assay intended for detection and interpretation of germline results is recommended.

Multigene Testing

Next-generation sequencing (NGS) allows for the sequencing of multiple genes simultaneously. This is referred to as multigene testing. Multigene testing can detect P/LP variants not found in single-gene testing.³⁶⁻³⁸ Since more than one gene can explain an inherited cancer syndrome, phenotype-directed testing based on personal and family history through a multigene panel test is often more efficient and/or cost-effective.³⁹⁻⁴¹ Multigene testing may also be considered for those who tested negative for one particular syndrome, but whose personal and family history is suggestive of an inherited susceptibility.^{39,42} It is now common practice to order multigene panel tests that include genes beyond the original indication for which testing is warranted. Phenotype needs to be considered when ordering multigene panel tests, to ensure that the relevant genes are included.⁴³

There are several issues to consider regarding multigene testing. First, commercially available tests may differ significantly on a number of



factors, such as number of genes analyzed, turnaround time, insurance coverage, laboratory expertise, variant reclassification protocol, methods of DNA/RNA analysis, and availability of financial assistance for cascade testing of relatives, among others. Therefore, the specific laboratory and multigene test should be chosen carefully.³⁹ In addition, P/LP variants identified for more than one gene add complexity that may lead to difficulty in making risk management recommendations.⁴² A management plan based on genetic test results should only be developed for identified P/LP variants that are clinically actionable.

A major dilemma regarding multigene testing is that there are limited data and a lack of clear guidelines regarding degree of cancer risk associated with some of the genes assessed, and how to communicate and manage risk for carriers of these genes.⁴⁴⁻⁴⁸ This issue is compounded by the low incidence rates of hereditary disease, leading to a difficulty in conducting adequately powered studies.⁴⁴ Multigene tests include moderate-penetrance genes, and they often also include low-penetrance genes for which there are little available data regarding degree of cancer risk and guidelines for risk management.^{39,49} Analysis from a prospective, multicenter cohort study including 2984 patients with cancer unselected based on cancer type, disease stage, family history of cancer, age of diagnosis, and ethnicity showed that, with use of an 80-gene panel test, a P/LP variant was found in 13.3%, with a highly penetrant variant found in 5%.⁵⁰ About half of the identified variants were of moderate or low penetrance, and a VUS was also found in about half the sample. In another study utilizing a 21-gene panel in 9714 patients diagnosed with multiple primary cancers, a P/LP variant was found in 13.6%, with P/LP variant frequency increasing with number of primaries diagnosed ($P = .00056$).⁵¹ The use of tailored panels that are disease-focused and include clinically actionable cancer susceptibility genes is preferred over large panels that include genes of uncertain clinical relevance. Also, certain variants in a gene may be associated with a different degree of risk than

other variants in that gene. For example, the presence of the c.7271T>G missense P/LP variant in *ATM* is associated with an increased risk for early-onset breast cancer.⁵²⁻⁵⁴

Multigene tests also increase the likelihood of detecting a VUS.^{37-39,45,55-57} An analysis of germline genetic testing results through 2019 for 200,000 patients with breast cancer and 15,000 patients with ovarian cancer diagnosed between 2013 and 2017 showed that VUS rates increased from 2013 to 2017 for both the patients diagnosed with breast cancer (8.5%–22.4%) and the patients diagnosed with ovarian cancer (8.1%–28.3%).⁵⁸ This study also demonstrated racial and ethnic differences in VUS rates, with Asian, Black, and Hispanic patients having significantly higher VUS rates than white patients in 2017 ($P < .001$), for both breast and ovarian cancer. There are mixed data about the potential for harm due to misinterpretation of VUS results (eg, overtreatment), with a 2017 study reporting that half of patients with VUS who were not considered at increased risk for carrying a P/LP variant undergo risk-reducing mastectomy (RRM), suggesting potential overtreatment.¹³ In contrast, a 2021 meta-analysis including 22 studies showed that individuals carrying a P/LP variant had higher rates of risk-reducing surgery compared to individuals with a VUS, indicating that individuals with a VUS may not be very commonly undergoing inappropriate risk management.⁵⁹

There is also an increase in the chance of finding genotypically distinct cell lines (ie, genetic mosaicism) with NGS.^{60,61} Clones of non-cancerous cells (ie, aberrant clonal expansion) containing a P/LP *TP53* variant have been found in healthy adults undergoing multigene testing. This phenomenon can often be attributed to clonal hematopoiesis, a condition in which a hematopoietic stem cell begins making blood cells with the same acquired P/LP variant.¹⁹ When there is no evidence of a hematologic malignancy, then it is referred to as clonal hematopoiesis of indeterminate potential (CHIP). Age-related CHIP is associated with increased risk of hematologic



malignancies,^{62,63} but may also lead to unnecessary clinical intervention. Ancillary testing of non-lymphoid non-cancerous tissue can be used to help determine the true presence of a germline variant.¹⁹

Polygenic risk scores (PRS) are now sometimes included in some genetic test reports. PRS are groups of SNPs associated with a specific disorder or disease, such as cancer. Studies evaluating the validity of PRS to refine risks in those with hereditary cancer have been conducted primarily with breast and prostate cancers. Two studies identified PRS that were strongly associated with estrogen receptor (ER)-negative breast cancer in carriers of a *BRCA1* P/LP variant, overall breast cancer in carriers of a *BRCA2* P/LP variant, and high-grade serous ovarian cancer in carriers of both *BRCA1* and *BRCA2* P/LP variants.^{64,65} Two studies of male carriers of a *BRCA1/2* P/LP variant identified PRS associated with breast cancer risk and prostate cancer risk.^{66,67} Studies have also evaluated the potential clinical utility of incorporating PRS into a risk-stratified approach for screening for prostate cancer⁶⁸ and for identifying age of onset of aggressive prostate cancer.⁶⁹ Studies of PRS have largely been done with those of European ancestry.^{70,71} Studies with larger samples from diverse populations are needed. Given that the clinical value of PRS has not yet been established, these should not be used to inform clinical management at this time.

Pre- and Post-Test Counseling

For individuals potentially meeting established criteria for ≥ 1 of the hereditary cancer syndromes, genetic testing should be considered along with appropriate pre- and post-test counseling. Pre-test counseling should include a discussion of why the test is being offered and how test results may impact medical management, cancer risks associated with the P/LP variant in question, the significance of possible test results (positive, true negative, uninformative negative, VUS, mosaic results; see *Principles of Cancer Risk Assessment and Counseling* in the algorithm for the complete

definitions of these terms), the likelihood of a positive result, technical aspects and accuracy of the test, cost considerations, risks of genetic discrimination, psychosocial aspects, confidentiality issues, implications for treatment decision-making, the potential significance of the test results for family members, and other topics.⁷ A discussion of confidentiality issues should include an explanation of the federal Genetic Information Nondiscrimination Act (GINA) enacted in 2008, which prohibits most health insurers and employers from discrimination on the basis of genetic test results.⁷² Since some patients with cancer who have a poor prognosis may be unable to receive results directly, a plan for results disclosure should be discussed, such as the patient consenting to Release of Information of test results to a spouse or other close relative. A detailed family history should be collected, which involves development of an expanded pedigree, beginning with the health of the individual diagnosed with cancer and proceeding outward to include first-, second-, and third-degree relatives on both the maternal and paternal sides. Factors that limit the informativeness of the pedigree are small family size, a small number of individuals of the susceptible gender for sex-limited cancers, reduced penetrance, early deaths in family members (which precludes the possibility that they will develop adult diseases), prophylactic surgeries that remove an organ from subsequent risk for cancer (eg, hysterectomy for uterine fibroids in which the ovaries are also removed), adoptions, and inaccurate or incomplete information on family members (eg, in the case of adoption or divorce).^{5,73} It is also important to know the ancestry/ethnicity of the individual, since members of certain groups (eg, Ashkenazi Jewish) have increased risks of carrying P/LP variants for specific diseases. Any family members who received genetic testing should also be noted, as well as testing results. Finally, a detailed medical and surgical history from the proband should be collected, and a physical examination should be performed by a qualified clinician when appropriate.



The presentation of testing information is most effective when tailored to the age and education of the person undergoing counseling, and that individual's personal exposure to the disease, level of risk, and social environment.⁷ Information could be delivered in person or over the phone.^{74,75} Telehealth (ie, real-time two-way videoconference) is also increasingly utilized as a feasible alternative for in-person genetic counseling.⁷⁵ Remote options (eg, telephone, telehealth) have the potential to help improve genetic testing rates in areas with inadequate access.⁷⁵

Post-test counseling includes disclosure of results, a discussion of the associated medical risks, an assessment of the impact of the results on the emotional state of the individual, a discussion of the impact of the results on the comprehensive care of the individual (including discussion of therapeutic implications by a qualified health care professional), and how and where the patient will be screened for cancer risk.⁹ Counseling should include making the individual aware of any available resources, such as disease-specific support groups, high-risk clinics, advocacy groups, and research studies.⁷⁶ The counselor should discuss the importance of genetic counseling and testing for relatives who also may be at increased risk.

Since some P/LP variants are associated with rare autosomal recessive conditions (eg, Fanconi anemia is associated with *BRCA2*, *BRIP1*, and *PALB2* variants), the proband should be advised regarding possible inherited cancer risk to relatives and their own options for risk assessment and management. Testing of a partner of a carrier of a P/LP variant may also be considered to inform reproductive decision-making.⁷⁷ See *Autosomal Recessive Risk in Cancer Genes – Multigene Panel Testing* in the algorithm for a full list of the P/LP variants covered in these Guidelines that are associated with autosomal recessive conditions.

Pre- and post-test genetic counseling with involvement of an expert in cancer genetics is recommended. However, the Panel acknowledges that most genetic testing is conducted by providers with limited expertise in genetics and often without pre-test genetic counseling.⁷⁸⁻⁸⁰ Shortages in genetics health providers,⁸¹ expansion of testing indications, aggressive marketing, and increased accessibility of testing due to plummeting costs inclusive of DTC models for testing provide the impetus for the Panel to identify scenarios in which referral to a genetics health provider should be considered. These scenarios are as follows: identification of a P/LP variant; negative results despite tumor profiling, personal history, or family history suggestive of inherited condition; VUS result that warrants further evaluation or for which a patient or provider considers using to guide management; mosaic/possibly mosaic result or clonal hematopoiesis (CH; discrepant interpretation of variants (eg, discordant results across laboratories); interpretation of PRS; and detection of P/LP variants from DTC testing.

Many patients who have been diagnosed with cancer and have a P/LP variant are at increased risk for additional primary cancers in the future. Management of those risks may be appropriate after treatment of the current cancer or may be combined with treatment for a current cancer. For example, a patient with breast cancer and a pathogenic variant (PV) in *BRCA1* or *BRCA2* may consider bilateral mastectomies to treat their current cancer and also to reduce the risk of a future primary breast cancer. These patients may also consider oophorectomy for treatment of hormone receptor-positive breast cancer and also for reducing ovarian cancer risk.

Best practices for communicating an individual's personal risk relative to published estimated lifetime risks of cancer include the following: 1) presenting risk estimates as a range rather than as a single estimate (eg, 30%–40%); 2) presenting absolute risk versus relative risk terminology; 3)



acknowledging the margin of error associated with risk estimates and how these are impacted by number of individuals with a P/LP variant; and 4) acknowledging that risk estimates can change over time. Specifically, patients who are older will have lower remaining lifetime risks. Over time, patients with a P/LP variant benefit from re-consultation with a medical provider who is familiar with inherited risk for cancer. This re-consultation is important for the following reasons: 1) increases adherence with screening guidelines, since screening behaviors may decrease over time; 2) allows the patient to re-evaluate personal choices about risk-reducing surgeries, based on changing life stage and circumstances; and 3) provides opportunities to “check in” with the patient about following up-to-date risk management guidelines, discuss additional or emerging genetic testing options, and review improved risk models. Cancer risk estimates can change based on larger case-control studies. Similarly, recommendations for screening and risk reduction can change based on new technologies and data. The frequency of follow-up with the patient will depend on factors such as age, reproductive planning, comorbidities, risk-reducing surgeries, and others as applicable.

Counseling may be warranted for those with negative or indeterminate results, as reasons for a negative result include the following scenarios: P/LP variant exists in a gene variant that was not recognized due to limitations in technology; P/LP variant exists in a gene variant that was not evaluated; and potential presence of a P/LP variant in a family member that was not detected in the individual. The determination of a “true negative” result depends on the specific family history of cancer, the specific P/LP variant found, and the relationship to any family members who test positive. When an individual has tested negative, it may still be appropriate to consider increased screening and risk reduction measures for cancer, based on family history. Over time, this individual may be a candidate for additional genetic testing due to additional family history or

as new genes are identified to be associated with cancer risk or as technology advances.

Additional information and the full list of elements that should be included in pre- and post-test genetic counseling can be found in the *Principles of Cancer Risk Assessment and Counseling* in the algorithm.

For the 2024 update, the Panel added guiding principles of genetic testing for patients with cancer (ie, those with active diagnosis and a previous cancer history) for whom testing is performed outside of a specialty genetics setting (ie, “point of care” testing). These principles include essential pre- and post-test areas of discussion. For the full list of these principles, see the *Principles of Cancer Risk Assessment and Counseling* in the algorithm.

Reproductive Options

The outcomes of genetic testing can have a profound impact on family planning decisions for individuals of reproductive age who are found to be carriers of a P/LP variant. Counseling for reproductive options such as prenatal diagnosis and assisted reproduction using preimplantation genetic testing (PGT) and donor gametes may therefore be warranted for couples expressing concern over their future offspring’s carrier status of a P/LP variant. Such counseling should include a comprehensive discussion of reproductive options; extent of cancer risk balanced with cancer worry; degree of protection for breast, ovarian, and uterine cancer; management of menopausal symptoms; hormone replacement therapy (HRT); related medical or surgical history; and consideration of a gestational carrier.

Prenatal diagnosis involves postimplantation genetic analysis of an early embryo, utilizing chorionic villi or amniotic fluid cell samples; genetic testing is typically conducted between week 12 and week 16 of gestation, and testing results may potentially lead to a couple’s decision to terminate the pregnancy.^{82,83} PGT has emerged as an alternative method of genetic

testing in early embryos. PGT involves the testing of 1 or 2 cells from embryos in very early stages of development (ie, 6–8 cells) after in vitro fertilization (IVF). This procedure allows for the selection of unaffected embryos to be transferred to the uterus,^{82,83} and may therefore offer the advantage of avoiding potential termination of pregnancy. The PGT process requires the use of IVF regardless of the fertility status of the couple (ie, also applies to couples without infertility issues), and IVF may not always lead to a successful pregnancy. Lastly, the technology or expertise may not be readily available in a couple's geographic location. If eggs/embryos are cryopreserved, pregnancy may be achieved with uterus in place, with or without fallopian tubes or ovaries.

Various factors, both medical and personal, must be weighed in the decision to utilize prenatal diagnosis or PGT. Medical considerations may include factors such as the age of onset of the hereditary cancer, penetrance, severity or associated morbidity and mortality of the cancer, and availability of effective cancer risk reduction methods or effective treatments.^{82,83} For example, results from two systematic reviews have suggested that carrying a P/LP *BRCA1/2* variant may be associated with diminished ovarian reserve.^{84,85} Although the use of prenatal diagnosis or PGT is relatively well established for severe hereditary disorders with very high penetrance and/or early onset (eg, Fanconi anemia), its use in conditions associated with lower penetrance and/or later onset (eg, hereditary breast or ovarian cancer syndrome) remains somewhat controversial from both an ethical and regulatory standpoint. Personal considerations for the decision to utilize prenatal diagnosis or PGT may include individual ethical beliefs, value systems, cultural and religious beliefs, and social and economic factors. Successful births have been reported with the use of PGT and IVF in carriers of a *BRCA1/2* P/LP variant,^{86,87} but data in the published literature are still very limited. In addition, data pertaining to long-term safety or outcomes of PGT and assisted reproduction in carriers of a P/LP variant are not yet available.

High-Penetrance Breast and/or Ovarian Cancer Susceptibility Genes

Specific patterns of hereditary breast and ovarian cancers have been found to be linked to P/LP variants in the *BRCA1/2* genes.^{88,89} In addition, two very rare hereditary cancer syndromes exhibiting an increased risk for breast cancer are Li-Fraumeni syndrome (LFS) and Cowden syndrome, which are related to germline P/LP variants in the *TP53* and *PTEN* genes, respectively.^{90,91} *PALB2*, *STK11*, and *CDH1* are also considered high penetrance breast cancer susceptibility genes.⁹²⁻⁹⁹ These hereditary syndromes share several features beyond elevation of breast cancer risk. These syndromes arise from germline P/LP variants that are not within sex-linked genes; hence, the variants can be inherited from either parent. The syndromes are associated with breast cancer onset at an early age and development of other types of cancer, and exhibit an autosomal dominant inheritance pattern (see Table 1). Offspring of an individual with one of these hereditary syndromes have a 50% chance of inheriting the P/LP variant. In addition, individuals with these hereditary syndromes share increased risks for multiple cases of early-onset disease as well as bilateral disease. The P/LP variants associated with these hereditary syndromes are considered to be highly penetrant. In addition, the manifestations (ie, expression) of these hereditary syndromes are often variable in individuals within a single family (eg, age of onset, tumor site, number of primary tumors). The risk of developing cancer in individuals with one of these hereditary syndromes depends on numerous variables including the sex and age of the individual.

Prior to 2020, the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian (Breast, Ovarian, Pancreatic, and Prostate as of 2024) focused largely on testing criteria for *BRCA1/2* and appropriate risk management for carriers of a *BRCA1* or *BRCA2* P/LP variant. Sections on LFS and Cowden syndrome/*PTEN* hamartoma tumor syndrome (PHTS) were also included. Based on strong evidence that



genes beyond *BRCA1/2*, *TP53*, and *PTEN* confer markedly increased risk of breast and/or ovarian cancers, these Guidelines have been expanded; see the sections below on other P/LP variants associated with breast/ovarian cancer.

BRCA-Related Breast/Ovarian Cancer Syndrome

Both the *BRCA1* and *BRCA2* genes encode for proteins involved in tumor suppression. *BRCA1/2* P/LP variants can be highly penetrant (for definition, see Table 1), although the probability of cancer development in carriers of *BRCA1/2* P/LP variants is variable, even within families with the same variant.¹⁰⁰⁻¹⁰² At present, it is unclear whether penetrance is related only to the specific P/LP variant identified in a family or whether additional factors, either genetic or environmental, affect disease expression. Epigenetic modification can also influence disease penetrance for a P/LP variant.¹⁰³ It is generally accepted, however, that carriers of *BRCA1/2* P/LP variants have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies.

Breast Cancer Risk

Estimates of penetrance for lifetime risk for primary breast cancer range from 60% to 72% for carriers of a *BRCA1* P/LP variant and 55% to 69% for carriers of a *BRCA2* P/LP variant.^{104,105} However, there exist variants established to have lower risks, such as *BRCA1* R1699Q, which has a breast cancer risk of 24% by age 70 years.¹⁰⁶ Risk for contralateral breast cancer in carriers of a *BRCA2* P/LP variant is age-dependent and greatest in those diagnosed with breast cancer at an early age (ie, <40 years).^{105,107} Risk is also greater in *BRCA1* P/LP variant carriers compared to *BRCA2* P/LP variant carriers (20-year cumulative risk of 30%–40% and 25%, respectively).^{105,107} A study of UK Biobank data showed that, among carriers of a *BRCA1/2* P/LP variant, breast cancer risk was greater in

those with a first-degree relative diagnosed with breast cancer, compared to those who did not have this family history.¹⁰⁸

While the evidence is mixed, we do not currently have evidence to support that *BRCA*-associated breast cancers are more aggressive and/or have poorer outcomes. A meta-analysis including 13 studies showed that carriers of a *BRCA1* P/LP variant with breast cancer had worse overall survival (OS) compared to those without a *BRCA1* or *BRCA2* P/LP variant (hazard ratio [HR], 1.50; 95% confidence interval [CI], 1.11–2.04), while OS did not significantly differ between those harboring a *BRCA2* P/LP variant and those without a *BRCA1* or *BRCA2* P/LP variant (HR, 0.97; 95% CI, 0.78–1.22).¹⁰⁹ Another meta-analysis including 60 studies and 105,220 patients with breast cancer also found that carriers of a *BRCA1* P/LP variant had worse OS compared to non-carriers (HR, 1.30; 95% CI, 1.11–1.52; *P* = .001).¹¹⁰ Carriers of a *BRCA2* P/LP variant had worse breast cancer-specific survival compared to non-carriers (HR, 1.29; 95% CI, 1.03–1.62; *P* = .03), though OS was not significantly different. This meta-analysis also showed that, among patients with triple-negative breast cancer, *BRCA1/2* P/LP variants are associated with better OS (HR, 0.49; 95% CI, 0.26–0.92; *P* = .03). However, this subgroup analysis only included two studies. A third meta-analysis including 66 studies also showed that a *BRCA2* P/LP variant was associated with worse breast cancer-specific survival (HR, 1.57; 95% CI, 1.29–1.86), but study results were too heterogeneous for the analysis to be conclusive.¹¹¹ Results of the prospective cohort Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) study including 2733 females with breast cancer showed no significant differences in OS between carriers of a *BRCA1/2* P/LP variant and non-carriers 2, 5, and 10 years after diagnosis.¹¹²

BRCA1/2 P/LP variants are associated with early-onset primary breast cancer. In a sample of 21,401 families who met German Consortium for Hereditary Breast and Ovarian Cancer testing criteria for *BRCA1/2* P/LP



variants, a P/LP variant was detected in 13.7% of families with a single case of breast cancer diagnosed at <36 years of age.¹¹³ An analysis of 6478 patients who were diagnosed with breast cancer before 50 years of age showed that carriers of a *BRCA1* P/LP variant had worse OS compared to patients who were not carriers of a P/LP *BRCA1/2* variant (HR, 1.28; 95% CI, 1.05–1.57; *P* = .01), but this association was no longer statistically significant when taking into account disease and treatment characteristics (HR, 1.20; 95% CI, 0.97–1.47; *P* = .09).¹¹⁴ *BRCA2* P/LP variants were not significantly associated with decreased OS in these analyses, except for the first 5 years of follow-up (HR, 1.56; 95% CI, 1.06–2.28; *P* = .02).

Some histopathologic features have been reported to occur more frequently in breast cancers of individuals with a germline *BRCA1/2* P/LP variant. For example, several studies have shown that *BRCA1*-related breast cancer is more likely to be characterized as ER-/PR-negative and HER2-negative (ie, “triple negative”).^{94,115–121} Studies have reported *BRCA1* P/LP variants in 4.4% to 16% of patients with triple-negative breast cancer.^{94,120,122–130} One cohort study showed an absolute lifetime risk of 40% for hormone receptor-positive (ER+ and/or progesterone receptor [PR]+) breast cancer in carriers of a P/LP *BRCA2* variant.⁹⁴ The case-control BRIDGES study showed an association between P/LP *BRCA2* variant and increased risk for hormone receptor-positive (ER+ and/or PR+) HER2-negative breast cancer (odds ratio [OR], 11.53; 95% CI, 8.92–14.90), though a significant association was also identified for triple-negative breast cancer (OR, 10.07; 95% CI, 7.61–13.32).¹²¹ The Breast Cancer Association Consortium and the CARRIERS case-control studies showed associations between a *BRCA2* P/LP variant and increased risk of ER-positive breast cancer (1.46%; OR, 5.68; 95% CI, 4.65–6.96 and 1.09%; OR, 4.66; 95% CI, 3.52–6.23, respectively).^{129,130} Another case-control study showed that the 20-year survival rate in carriers of a *BRCA2* P/LP variant with ER-positive tumors was 62.2%,

compared to 83.7% in those with ER-negative tumors, though this difference was only statistically significant in those <50 years of age (*n* = 199; 68.3% vs. 91.3%, respectively; *P* = .03).¹³¹ A case-control study of carriers of the Icelandic founder *BRCA2* variant 999del5 showed that ER-positive disease was associated with increased mortality risk, compared to those with ER-negative disease (HR, 1.94; 95% CI, 1.22–3.07; *P* = .005).¹³² However, prevalence of ER-negative disease was not significantly greater in carriers of a P/LP *BRCA2* variant than in non-carriers (75.6% vs. 70.2%, respectively; *P* = .11). The explanation for the association between *BRCA2* P/LP variant with ER-positive tumors and poor survival outcomes is currently unknown and warrants investigation, though one hypothesized explanation includes difference in estrogen signaling pathways and increased sensitivity to ovarian hormones for these tumors.^{132,133}

Among patients with triple-negative disease, carriers of a P/LP *BRCA* variant were diagnosed at a younger age compared with non-carriers.^{123,134} In a study of a large cohort of patients with triple-negative breast cancer (*N* = 403), the median age of diagnosis among carriers of a P/LP *BRCA1* variant (*n* = 65) was 39 years.¹²² Patients in this population-based study were unselected for family history or age. Among the group of patients with early-onset (age at diagnosis <40 years) triple-negative breast cancer (*n* = 106), the incidence of *BRCA1* P/LP variants was 36%; the incidence was 27% among those diagnosed before 50 years of age (*n* = 208). Results from the prospective cohort POSH study showed that, among 558 patients with triple-negative breast cancer, 2-year OS was greater in carriers of a *BRCA1/2* P/LP variant than in non-carriers (95% vs. 91%, respectively; HR, 0.59; 95% CI, 0.35–0.99; *P* = .047), but 5- and 10-year OS did not differ significantly between these groups.¹¹² A SEER analysis from California and Georgia including females diagnosed with breast cancer showed that, among 5461 patients diagnosed with triple-negative breast cancer, cancer-specific mortality was lower among

carriers of a P/LP *BRCA1* variant (HR, 0.49; 95% CI, 0.35–0.69) and carriers of a P/LP *BRCA2* variant (HR, 0.60; 95% CI, 0.41–0.89), compared to non-carriers.¹³⁵

Carriers of a P/LP *BRCA1/2* variant who were assigned male at birth (AMAB) also have a greater risk for cancer susceptibility.^{136–138} Among male patients with breast cancer unselected for family history, 4% to 14% tested positive for a germline *BRCA2* P/LP variant.^{139–142} For males carrying a P/LP *BRCA2* variant, the cumulative lifetime risk for breast cancer has been estimated at 1.8% to 7.1%.^{143–145} The cumulative lifetime risk for male carriers of a P/LP *BRCA1* variant is 0.2% to 1.2%.^{144,145} In contrast, for males who are not carriers of a P/LP *BRCA1/2* variant, the lifetime risk for breast cancer has been estimated at approximately 0.1% (1 in 1000).^{141,146}

Ovarian Cancer Risk

Increased risks for cancers of the ovary, fallopian tube, and peritoneum are observed in carriers of a P/LP *BRCA1/2* variant.^{147–149} In the setting of an invasive ovarian cancer diagnosis, a P/LP *BRCA1* variant has been found in 3.8% to 14.5% of patients, and a P/LP *BRCA2* variant has been found in 4.2% to 5.7% of patients.^{150–154} *BRCA1* variants have an estimated 48.3% (95% CI, 38.8%–57.9%) cumulative risk of ovarian cancer by age 70, while the cumulative risk by age 70 is 20.0% (95% CI, 13.3%–29.0%) for carriers of a P/LP *BRCA2* variant.¹⁵⁵

Several studies have reported more favorable survival outcomes among carriers of a P/LP *BRCA1/2* variant in patients with ovarian cancer compared with patients who are non-carriers.^{156–162} Survival outcomes appear to be most favorable for carriers of a P/LP *BRCA2* variant.^{156,160,163} A systematic review and meta-analysis including 13 references with 4565 patients (1131 *BRCA1/2* P/LP variant carriers) showed that 5-year survival was higher in the P/LP carriers than in non-carriers (risk difference, 14.9%; $P = .0002$; relative risk [RR], 1.36; $P = .001$), but the difference in risk was

less pronounced for 10-year survival (risk difference, 8.6%; $P = .042$; RR, 1.25; $P = .12$).¹⁶⁴ *BRCA2* P/LP variants are also associated with significantly higher response rates (compared with non-carriers or with carriers of a *BRCA1* P/LP variant) to primary chemotherapy. In contrast, *BRCA1* P/LP variants were not associated with prognosis or improved chemotherapy response.¹⁶⁰

The histology of ovarian cancers in carriers of a P/LP *BRCA1/2* variant is more likely to be characterized as serous adenocarcinoma and high grade compared with ovarian cancers in non-carriers, although endometrioid and clear cell ovarian cancers also have been reported in the former population.^{149,152,165–169} P/LP variants are also associated with non-mucinous ovarian carcinoma as opposed to mucinous.^{150,153} Non-epithelial ovarian carcinomas (eg, germ cell and sex cord-stromal tumors) are not significantly associated with a *BRCA1/2* P/LP variant,¹⁷⁰ though ovarian sex cord tumor with annular tubules is associated with *STK11* P/LP variants.^{98,99} Current data show that ovarian low malignant potential tumors (ie, borderline epithelial ovarian tumors) are also not associated with a *BRCA1/2* P/LP variant.¹⁵⁰

In studies of carriers of a P/LP *BRCA1/2* variant who underwent risk-reducing salpingo-oophorectomy (RRSO) for occult gynecologic neoplasia, both invasive carcinoma and intraepithelial lesions were identified in 4.5% to 9% of cases based on rigorous pathologic examinations of the ovaries and fallopian tubes.^{171–173} Tubal intraepithelial carcinoma (TIC) is thought to represent an early precursor lesion for serous ovarian cancers, and TIC (with or without other lesions) was detected in 5% to 8% of cases from patients carrying a P/LP *BRCA1/2* variant who underwent RRSO.^{171,174,175} The fimbriae or distal tube was reported to be the predominant site of origin for these early malignancies found in carriers of a P/LP *BRCA1/2* variant.^{171,175,176} Although TIC appeared to present more frequently among carriers of a P/LP *BRCA1/2*



variant compared with non-carriers undergoing RRSO,^{175,176} TIC has also been documented among patients with serous carcinomas unselected for family history or *BRCA* P/LP variant status.¹⁷⁷ Because TIC was identified in individuals who underwent surgery for risk reduction (for carriers of a P/LP *BRCA1/2* variant) or other gynecologic indications, the incidence and significance of these early lesions within the general population is unclear.

Prostate Cancer Risk

Germline *BRCA1/2* P/LP variants are associated with increased risk for prostate cancer.¹⁷⁸⁻¹⁸¹ Carriers of a P/LP *BRCA1* variant have an estimated 7% to 26% cumulative lifetime risk of prostate cancer, while the cumulative lifetime risk is 19% to 61% for carriers of a P/LP *BRCA2* variant.^{66,145,182} There is evidence that advanced or metastatic prostate cancer is associated with carrying a *BRCA2* P/LP variant; it is not yet known if an aggressive phenotype is also associated with *BRCA1* P/LP variant.¹⁸³⁻¹⁸⁵ An international study including 5545 patients with prostate cancer (with European ancestry) showed that the frequency of a *BRCA2* P/LP variant was significantly higher in patients with aggressive disease (ie, died from prostate cancer, metastatic disease, T4 disease, or T3 with Gleason score ≥ 8) than in patients with non-aggressive disease (OR, 3.19; 95% CI, 1.94–5.25).¹⁸⁵ A study of a large cohort of patients from Spain with prostate cancer (N = 2019) showed that carriers of a P/LP *BRCA1/2* variant had significantly higher rates of aggressive prostate cancer (Gleason score ≥ 8), nodal involvement, and distant metastasis compared with non-carriers.¹⁸⁶ In a sample of 692 patients with metastatic prostate cancer, unselected for family history or age at diagnosis, 5.3% carried a *BRCA2* P/LP variant, and 0.9% carried a *BRCA1* P/LP variant.¹⁸⁴ In addition, analyses from a treatment center database showed that *BRCA1/2* and *ATM* (see below under *NCCN Genetic Testing Criteria: Testing Criteria Related to Prostate Cancer*) P/LP variant rates were highest in patients with metastatic disease (8.2%). This study also showed that carriers with prostate cancer had significantly decreased survival,

compared with patients who were non-carriers (5 years vs. 16 years, respectively; $P < .001$).¹⁸⁷ This association remained statistically significant when controlling for race, age, prostate-specific antigen (PSA), and Gleason score. Ashkenazi Jewish ancestry is also associated with *BRCA1/2* P/LP variants in patients with prostate cancer, with rates for *BRCA1* being 0% to 2%, and rates for *BRCA2* being 1% to 3%.^{178,188-191}

Pancreatic Cancer Risk

Prior to more widespread testing of individuals with pancreatic cancer for germline variants in cancer predisposition genes, studies showed that *BRCA1/2* P/LP variant rates in pancreatic cancer cases ranged from 1% to 11% for *BRCA1* and 0% to 17% for *BRCA2*.¹⁹²⁻²⁰⁰ However, some of these studies included only patients with familial pancreatic cancer^{195,196,199} or those of Ashkenazi Jewish ancestry,¹⁹⁷ both of whom may have a greater likelihood of testing positive for a *BRCA1/2* P/LP variant. More recent studies that used panel testing confirm that some pancreatic cancers harbor actionable *BRCA1/2* P/LP variants (0%–3% for *BRCA1* and 1%–6% for *BRCA2*).²⁰¹⁻²⁰⁵ Cumulative lifetime risk of pancreatic cancer is as high as 3% for males with a *BRCA1/2* P/LP variant and 2.3% for females with a *BRCA1/2* P/LP variant.¹⁴⁵ Patients with pancreatic cancer and Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a *BRCA1/2* P/LP variant, with prevalence of detected P/LP variants in this group ranging from 5.5% to 19%, with P/LP variants being more common for *BRCA2*.^{197,198,200,206}

More information on genes associated with pancreatic cancer can be found below, under *Hereditary Pancreatic Cancer*.

Other Cancer and Health Risks

Some studies have suggested an increased risk specifically of serous uterine cancer in carriers of a P/LP *BRCA1/2* variant.²⁰⁷⁻²¹¹ Analyses from a multicenter prospective cohort study including 1083 carriers of a P/LP *BRCA1* variant who underwent RRSO without hysterectomy showed an



increased risk for serous and/or serous-like endometrial cancer.²¹² A Dutch cohort study including 5980 carriers of a P/LP *BRCA1/2* variant showed a 2- to 3-fold increased risk for endometrial cancer, with the highest risks for serous-like (HR, 10.48; 95% CI, 2.95–37.20) and *p53*-abnormal endometrial cancer (HR, 15.71; 95% CI, 4.62–53.40) in carriers of a P/LP *BRCA1* variant.²¹¹ A systematic review and meta-analysis including 11 studies with 13,871 carriers of a P/LP *BRCA1/2* variant showed that the prevalence of endometrial cancer was 0.62% in carriers of a P/LP *BRCA1* variant and 0.47% in carriers of a P/LP *BRCA2* variant (relative RR, 1.18; 95% CI, 0.7–2.0).²¹³ For uterine papillary serous carcinoma, the prevalence rates were 0.20% for *BRCA1* and 0.08% for *BRCA2* (relative RR, 1.39; 95% CI, 0.5–3.7). It has been suggested that the increased risk for endometrial cancer observed in some carriers of *BRCA1/2* P/LP variants may be due to the use of tamoxifen therapy by these patients rather than the presence of a P/LP variant.^{214–216}

A meta-analysis including five studies of patients with uterine serous cancer and Ashkenazi Jewish ancestry showed that *BRCA1/2* P/LP variant prevalence was greater in those with uterine serous cancer than in controls (also of Ashkenazi Jewish ancestry) (OR, 5.4; 95% CI, 2.2–13.1).²⁰⁷ In a retrospective case-control study including 2627 Jewish Israeli carriers of a P/LP *BRCA1/2* variant (88% Ashkenazi Jewish), risk of developing uterine cancer was increased, with an observed-to-expected ratio of 3.98 (95% CI, 2.17–6.67; $P < .001$).²¹⁰ This association persisted regardless of uterine cancer histology.

The absolute risk of uterine cancer in carriers of a P/LP *BRCA1/2* variant appears low overall, despite some evidence of increased risk. However, genetic testing, including for a P/LP *BRCA1* variant, may be considered for patients diagnosed with serous endometrial cancer.

Studies that investigated associations between *BRCA2* P/LP variant and cutaneous melanoma have drawn inconsistent conclusions, though there

is some evidence of an association.²¹⁷ One study showed that females carrying a P/LP *BRCA2* variant have an elevated risk for leukemia (standardized incidence ratio [SIR], 4.76; 95% CI, 1.21–12.96; $P = .03$), particularly females who have received chemotherapy (SIR, 8.11; 95% CI, 2.06–22.07; $P = .007$).²¹⁸ Analyses of 3184 *BRCA1* and 2157 *BRCA2* families in the Consortium of Investigators of Modifiers of *BRCA1/2* showed that the cumulative lifetime risk of gastric cancer is 3.5% in both male and female carriers of a *BRCA2* PV (compared to 1.6% and 0.7% in male and female carriers of a *BRCA1* PV, respectively).¹⁴⁵ A case-control analysis from Japan including 65,108 patients showed associations between gastric cancer and *BRCA1* (OR, 5.2; 95% CI, 2.6–10.5) and *BRCA2* (OR, 4.7; 95% CI, 3.1–7.1) P/LP variants, biliary tract cancer and P/LP *BRCA1* variant (OR, 17.4; 95% CI, 5.8–51.9), and esophageal cancer and P/LP *BRCA2* variant (OR, 5.6; 95% CI, 2.9–11.0).²¹⁹ Finally, an analysis of 490 families with a known *BRCA1/2* P/LP variant showed an increased risk for ocular melanoma in carriers of a P/LP *BRCA2* variant (RR, 99.4; 95% CI, 11.1–359.8), though absolute risk is low.²²⁰

In cases where both partners carry a P/LP *BRCA2* variant, there may be a high risk for the offspring to develop Fanconi anemia, a rare autosomal recessive condition.⁷⁷ A review of 27 patients with Fanconi anemia with biallelic P/LP variants in *BRCA2* (FA-D1) showed a 97% cumulative risk of malignancy by age 5.2 years (79% risk of leukemia by age 10 years, 83% risk of any solid tumor by age 6.7 years, 85% risk of a brain tumor by age 9 years, and 63% risk of a Wilms tumor by age 6.7 years).²²¹ Some case reports have also identified biallelic *BRCA1* P/LP variants causing Fanconi anemia-like disorder,^{222,223} particularly FANCS, a severe form of Fanconi anemia characterized by developmental delay, short stature, and microcephaly.^{224,225}



Risk Management

Recommendations for the medical management of *BRCA*-related cancers are based on an appreciation of the early onset and increased risk for associated cancers. An individual from a family with a known *BRCA1/2* P/LP variant who tests negative for the familial variant should be followed according to the recommendations for the general population for breast cancer (eg, the NCCN Guidelines for Breast Cancer Screening and Diagnosis [available at www.NCCN.org]).

Breast Cancer Risk Management

Screening

Mammography has served as the standard screening modality for detection of breast cancer during the last few decades. There are currently no data indicating that mammography on its own reduces mortality in females with genetically increased risk for breast cancer.²²⁶ Also, false-negative mammography results are common and have been correlated with factors such as presence of a *BRCA1/2* P/LP variant and high breast tissue density,²²⁷⁻²³⁰ both of which may occur more frequently among younger females. Rapidly growing or aggressive breast tumors—also more common among younger females—have also been associated with decreased sensitivity of mammographic screening methods.^{227,231}

Prospective studies on comparative surveillance modalities in females at high risk for familial breast cancer (ie, confirmed or suspected *BRCA1/2* P/LP variant based on family history) have consistently reported higher sensitivity of MRI screening (77%–94%) compared with mammography (33%–59%) in detecting breast cancers. False-positive rates were higher with MRI in some reports, resulting in a slightly lower or similar specificity with MRI screening (81%–98%) compared with mammography (92%–100%).²³²⁻²³⁷ The sensitivity with ultrasound screening (33%–65%) appeared similar to that of mammography in this high-risk population.^{233,235-237} In a prospective screening trial (conducted from 1997–

2009) that evaluated the performance of annual MRI and mammography in females (aged 25–65 years; N = 496) with confirmed P/LP *BRCA1/2* variant, sensitivity with MRI was significantly higher compared with mammography during the entire study period (86% vs. 19%; $P < .0001$).²³⁸ Factors such as age, P/LP variant type, or invasiveness of the tumor did not significantly influence the relative sensitivity of the two screening modalities. Importantly, the large majority (97%) of cancers detected by MRI screening were early-stage tumors.²³⁸ At a median follow-up of 8 years from diagnosis, none of the survivors (n = 24) had developed distant recurrence. In an analysis of 606 females with either a family history of breast cancer or who harbor a P/LP variant associated with increased risk for breast cancer, sensitivity of breast MRI screening was reported to be 79%, while specificity was reported to be 86%.²³⁹

All of these studies discussed above evaluated a screening strategy that was conducted on an annual basis, and many of the studies included individuals without known *BRCA1/2* P/LP variant status. A study of 1219 carriers of a P/LP *BRCA1* variant and 732 carriers of a P/LP *BRCA2* variant showed that the increased sensitivity of mammography in addition to MRI was greater for carriers of a P/LP *BRCA2* variant (12.6%) than for carriers of a P/LP *BRCA1* variant (3.9%).²⁴⁰ In a retrospective study, a different screening interval was evaluated, using alternating mammography and MRI screening every 6 months in females with a confirmed P/LP *BRCA1/2* variant (N = 73).²⁴¹ After a median follow-up of 2 years, 13 breast cancers were detected among 11 females; 12 of the tumors were detected by MRI screening but not by mammography obtained 6 months earlier. The sensitivity and specificity with MRI screening was 92% and 87%, respectively.²⁴¹ A cohort study including 2488 carriers of a P/LP *BRCA1/2* variant showed that MRI surveillance (any breast MRI done in the year prior to a breast cancer diagnosis) was associated with a reduction in breast cancer mortality in carriers of a P/LP



BRCA1 variant (HR, 0.20; 95% CI, 0.10–0.43; $P < .001$), but not in carriers of a P/LP *BRCA2* variant (HR, 0.87; 95% CI, 0.10–17.25).²⁴²

The optimal surveillance approach in individuals assigned female at birth (AFAB) who are at high risk for familial breast cancer remains uncertain, especially for those between the ages of 25 and 30 years. While some studies have reported an association between radiation exposure from mammography and increased risk for breast cancer in carriers of a P/LP *BRCA1/2* variant,^{243,244} current data are insufficient to support risks of radiation. Nevertheless, one of the potential benefits of incorporating MRI modalities into surveillance strategies may include minimizing the radiation risks associated with mammography, in addition to the higher sensitivity of MRI screening in detecting tumors. The use of MRI, however, may potentially be associated with higher false-positive results and higher costs relative to mammography. The combined use of digital mammography (two-dimensional, 2D) in conjunction with digital breast tomosynthesis (DBT) appears to improve cancer detection and reduce false-positive call back rates.^{245–254} Tomosynthesis allows acquisition of three-dimensional (3D) data using a moving x-ray and digital detector. These data are reconstructed using computer algorithms to generate thin sections of images. The combined use of 2D and DBT results in double the radiation exposure compared with mammography alone. However, this increase in radiation dose falls below dose limits of radiation set by the U.S. Food and Drug Administration (FDA) for standard mammography. The radiation dose can be minimized by newer tomosynthesis techniques that create a synthetic 2D image, which may obviate the need for a conventional digital image.^{246,255,256} In carriers of a *BRCA1/2* P/LP variant who are <30 years of age, breast MRI screening is preferred over mammography due to lack of data to support benefit due to less sensitivity for detection of tumors associated with mammography. Studies have reported that deposits of gadolinium, a component of MRI contrast agents, remain in the brain of some patients who undergo ≥ 4 contrast MRI scans, long after the last

administration.^{257,258} Retention of gadolinium has also been seen in the bone.²⁵⁹ In 2017, the FDA issued an update stating that its review of available data had not identified adverse health effects from gadolinium retained in the brain and that patients should read a medication guide prior to receiving gadolinium. However, review of the evidence will continue.

The appropriate imaging modalities and surveillance intervals are still under investigation. In a report based on a computer simulation model that evaluated different annual screening strategies in carriers of a P/LP *BRCA1/2* variant, a screening approach that included annual MRI starting at 25 years of age combined with alternating digital mammography/MRI starting at 30 years of age was shown to be the most effective strategy when radiation risks, life expectancy, and false-positive rates were considered.²⁶⁰ Future prospective trials are needed to evaluate the different surveillance strategies in individuals at high risk for familial breast cancer. For an individual AFAB who is a carrier of a *BRCA1/2* P/LP variant, training in breast awareness with regular monthly practice should begin at 18 years of age, and clinical breast examinations should be conducted every 6 to 12 months, beginning at 25 years of age. Between the ages of 25 and 29 years, these individuals should have annual breast MRI screening with contrast (to be performed on days 7 to 15 of menstrual cycle for premenopausal individuals) or annual mammograms only if MRI is not available. The age to begin screening can be individualized if the family history includes a breast diagnosis prior to 30 years of age.^{232,234,237,261,262} Breast MRI screening is preferred over mammogram in the 25- to 29-year age group. High-quality breast MRI screening should consist of the following: dedicated breast coil, ability to perform biopsy under MRI guidance, experienced radiologists in breast MRI, and regional availability. Between 30 and 75 years of age, annual mammogram and breast MRI with contrast should both be done. After 75 years of age, management should be considered on an individual basis. In females treated for breast cancer who have not had bilateral mastectomy,



mammography and breast MRI screening with contrast should continue as recommended based on age. Emerging evidence suggests that abbreviated-protocol breast MRI is a screening strategy that warrants further investigation in carriers of a *BRCA1/2* P/LP variant.^{263,264}

Carriers of a *BRCA1/2* P/LP variant who were AMAB should have an annual clinical breast examination and undergo training in breast self-examination with regular monthly practice starting at 35 years of age. A 12-year longitudinal observational study evaluated the outcomes of mammography screening in 1869 males who were at increased risk of developing breast cancer (ie, personal or family history of breast cancer and/or germline P/LP variant associated with breast cancer, mostly *BRCA1* and *BRCA2*).²⁶⁵ Node-negative breast cancer was identified in five males (18 per 1000 examinations), which is greater than the cancer detection rates in both females at average and high-risk who undergo breast screening. Harboring a P/LP variant ($n = 47$) was associated with breast cancer (OR, 7; 95% CI, 2–29; $P = .006$). Because of the lack of screening, males diagnosed with breast cancer have historically presented with advanced stage disease.²⁶⁶ Annual mammogram in males may be considered, especially in those carrying a *BRCA2* P/LP variant, beginning at age 50 or 10 years before the earliest known male breast cancer in the family (whichever comes first). Though gynecomastia may be associated with breast cancer, it is not a risk factor for breast cancer.²⁶⁷ As per the American College of Radiology (ACR) Appropriateness Criteria, gynecomastia does not need to be present in order to obtain a diagnostic mammogram.²⁶⁸

Bilateral Total Mastectomy

Two meta-analyses show that prophylactic bilateral mastectomy reduces the risk for breast cancer.^{269,270} Only one of these analyses showed that risk-reducing surgery is significantly associated with reduced mortality.²⁷⁰ Retrospective studies and small prospective studies provide support for

concluding that RRM provides a high degree of protection against breast cancer in females carrying a P/LP *BRCA1/2* variant.²⁷¹⁻²⁷⁴

It is important that the potential psychosocial effects of RRM are addressed. A 2018 Cochrane review including 20 studies that evaluated psychosocial effects of RRM showed that patients are generally satisfied with their decision, with reported decreases in worry about breast cancer, but negative impacts on body image and sexuality have also been reported. Additional research is needed to further evaluate the psychosocial impact of RRM.²⁷⁵ RRM is also associated with long-term physical symptoms, such as lower sensitivity to touch, pain, tingling, infection, and edema.²⁷⁰ Multidisciplinary consultations are recommended prior to surgery and should include the discussions of the risks and benefits of surgery, and surgical breast reconstruction options. Immediate breast reconstruction is an option following RRM, and early consultation with a reconstructive surgeon is recommended for those considering either immediate or delayed breast reconstruction.²⁷⁶ Nipple-sparing mastectomy has been suggested to be a safe and effective risk reduction strategy for patients carrying a *BRCA1/2* P/LP variant,²⁷⁷ although more data and longer follow-up are needed.

The NCCN Guidelines Panel supports discussion of the option of RRM for individuals AFAB on a case-by-case basis. Counseling for this risk-reducing surgery should include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, breast reconstructive options, and management of menopausal symptoms. Since risk of breast cancer remains increased with age in carriers of a *BRCA1/2* P/LP variant,²⁷⁸ age and life expectancy should also be considered during this counseling, as well as family history. It is important to address the psychosocial and quality-of-life aspects of undergoing risk-reducing surgical procedures.²⁷⁹



Chemoprevention

The use of selective ER modulators (ie, tamoxifen, raloxifene) has been shown to reduce the risk for invasive breast cancer in individuals considered at high risk of developing breast cancer, especially ER-positive disease.²⁸⁰⁻²⁸⁷ However, only limited data are available on the specific use of these agents for primary prevention in patients with *BRCA1/2* P/LP variants. As previously discussed, patients with *BRCA1/2* P/LP variants who are diagnosed with breast cancer have elevated risks for developing contralateral breast tumors. In one of the largest prospective series of carriers of a P/LP *BRCA1/2* variant evaluated, the mean cumulative lifetime risks for contralateral breast cancer were estimated to be 83% for carriers of a P/LP *BRCA1* variant and 62% for carriers of a P/LP *BRCA2* variant.¹⁰⁴ Patients carrying a P/LP *BRCA1/2* variant who have intact contralateral breast tissue (and who do not undergo oophorectomy or receive chemoprevention) have an estimated 40% risk for contralateral breast cancer at 10 years, though risk is dependent on age of first breast cancer diagnosis.²⁸⁸ Case-control studies from the Hereditary Breast Cancer Clinical Study Group reported that the use of tamoxifen protected against contralateral breast cancer with an OR of 0.38 (95% CI, 0.19–0.74) to 0.50 (95% CI, 0.30–0.85) among carriers of a P/LP *BRCA1* variant and 0.42 (95% CI, 0.17–1.02) to 0.63 (95% CI, 0.20–1.50) among carriers of a P/LP *BRCA2* variant.^{289,290} This translates to an approximately 45% to 60% risk reduction for contralateral tumors among carriers of a P/LP *BRCA1/2* variant with breast cancer. The data were not consistent in regard to the protective effects of tamoxifen in the subset of carriers of a P/LP *BRCA1/2* variant who also underwent oophorectomy. In addition, no data were available on the ER status of the tumors. An evaluation of the subset of healthy carriers of a P/LP *BRCA1/2* variant in the Breast Cancer Prevention Trial revealed that breast cancer risk was reduced by 62% in carriers of a P/LP *BRCA2* variant receiving tamoxifen relative to placebo (risk ratio, 0.38; 95% CI, 0.06–1.56).²⁹¹ However, an analysis of 288 females who developed breast cancer during their participation in this trial

showed that tamoxifen use was not associated with a reduction in breast cancer risk in carriers of a P/LP *BRCA1* variant.²⁹¹ These findings may be related to the greater likelihood for development of ER-negative tumors in carriers of a P/LP *BRCA1* variant relative to carriers of a P/LP *BRCA2* variant. However, this analysis was limited by the very small number of individuals with a P/LP *BRCA1/2* variant (n = 19; 7% of participants diagnosed with breast cancer). Common single-nucleotide polymorphisms have been identified in genes (*ZNF423* and *CTSO*) that are involved in estrogen-dependent regulation of *BRCA1* expression.²⁹² These gene variants were associated with alterations in breast cancer risk during treatment with selective ER modulators, and may eventually pave the way for predicting the likelihood of benefit with these chemopreventive approaches in individual patients.

The aromatase inhibitors (AIs) exemestane and anastrozole have been demonstrated to be effective in preventing breast cancer in postmenopausal individuals considered to be at high risk of developing breast cancer.^{293,294} However, to date, there is little evidence supporting the use of AIs as an effective chemopreventive approach for individuals with a *BRCA1/2* P/LP variant. A retrospective study showed that AIs may reduce the risk of contralateral breast cancer in females with a *BRCA1/2* P/LP variant and ER-positive breast cancer who take AIs as adjuvant therapy, but these data are currently published in abstract form only.²⁹⁵

Studies on the effect of oral contraceptive use on breast cancer risk among carriers of a P/LP *BRCA1/2* variant have reported conflicting data. In one case-control study, use of oral contraceptives was associated with a modest but statistically significant increase in breast cancer risk among carriers of a P/LP *BRCA1* variant (OR, 1.20; 95% CI, 1.02–1.40), with breast cancer risk in these carriers being associated with ≥ 5 years of oral contraceptive use (OR, 1.33; 95% CI, 1.11–1.60), breast cancer diagnosed at < 40 years of age (OR, 1.38; 95% CI, 1.11–1.72), and use of



oral contraceptives before 1975 (OR, 1.42; 95% CI, 1.17–1.75).²⁹⁶ Oral contraceptive use was not significantly associated with breast cancer in carriers of a *BRCA2* P/LP variant in this study. In another case-control study, use of oral contraceptives for at least 5 years was associated with a significantly increased risk for breast cancer in carriers of a P/LP *BRCA2* variant (OR, 2.06; 95% CI, 1.08–3.94); results were similar when only the cases with oral contraceptive use on or after 1975 were considered.²⁹⁷ Oral contraceptive use for at least 1 year was not significantly associated with breast cancer risk in carriers of a P/LP *BRCA1* or *BRCA2* variant in this study. In a third case-control study, the use of low-dose oral contraceptives for at least 1 year was associated with significantly decreased risks for breast cancer among carriers of a P/LP *BRCA1* variant (OR, 0.22; 95% CI, 0.10–0.49; $P < .001$), though not for carriers of a P/LP *BRCA2* variant.²⁹⁸ A case-control study found an increase in breast cancer risk for *BRCA1* mutation carriers who started oral contraception at <20 years of age (OR, 1.45; 95% CI, 1.20–1.75; $P = .0001$). Associations ≥ 20 years of age were not found to be statistically significant.²⁹⁹

To summarize, findings from case-control studies are inconsistent regarding the effect of oral contraceptive use on the association of P/LP *BRCA1* or *BRCA2* variant and breast cancer risk. Oral contraceptive use for >5 years may be associated with increased risk. Findings from meta-analyses are also conflicting, with several showing that oral contraceptive use is not significantly associated with breast cancer risk in carriers of a P/LP *BRCA1/2* variant,³⁰⁰⁻³⁰² while others show mixed results based on subgroup analysis, study type, and population.³⁰³⁻³⁰⁵ Another 2022 meta-analysis including 12 studies showed that the use of oral contraceptives was associated with an increased risk of breast cancer in carriers of both *BRCA1* and *BRCA2* P/LP variants, particularly in those who used oral contraceptives for ≥ 5 years.³⁰⁶ A study examining a hypothetical cohort of 10,000 females found that the use of combined oral contraceptives was associated with increased breast cancer risk in those with a P/LP *BRCA1*

variant, assuming 10 years of continuous oral contraceptive use. The breast cancer risk difference attributable to oral contraceptive use increased throughout life for carriers of a P/LP *BRCA1/2* variant (compared to ovarian and endometrial cancers, which showed decreasing incidences as age increased).³⁰⁷

Differences in the study design used by these case-control studies make it difficult to compare outcomes between studies, and likely account for the conflicting results. The design of these studies might have differed with regard to factors such as the criteria for defining the “control” population for the study (eg, non-*BRCA1/2* carriers vs. P/LP variant carriers without a cancer diagnosis), consideration of family history of breast or ovarian cancer, baseline demographics of the population studied (eg, nationality, ethnicity, geographic region, age groups), age of onset of breast cancer, and formulations or duration of oral contraceptives used.

Ovarian/Uterine Cancer Risk Management

Bilateral Salpingo-Oophorectomy

Carriers of a confirmed *BRCA1/2* P/LP variant are at increased risk for both breast and ovarian cancers (including fallopian tube cancer and primary peritoneal cancer).^{147,148} Although the risk for ovarian cancer is generally considered to be lower than the risk for breast cancer in carriers of a P/LP *BRCA1/2* variant,³⁰⁸⁻³¹⁰ the absence of reliable methods of early detection and the poor prognosis associated with advanced ovarian cancer have lent support for the performance of bilateral RRSO after completion of childbearing.

A 2014 observational prospective study of 5783 females carrying a P/LP *BRCA1/2* variant showed that ovarian cancer is more prevalent in individuals carrying a *BRCA1* (4.2%) P/LP variant than those carrying a *BRCA2* (0.6%) P/LP variant.³¹¹ In carriers of a P/LP *BRCA1* variant, prevalence of ovarian, fallopian tube, and peritoneal cancers found during

risk-reducing surgery was 1.5% for those <40 years of age and 3.8% in those between the ages of 40 and 49 years.³¹¹ The highest incidence rate for carriers of a P/LP *BRCA1* variant was observed between the ages of 50 and 59 years (annual risk, 1.7%); for carriers of a P/LP *BRCA2* variant, the highest incidence rate was observed between the ages of 60 and 69 years (annual risk, 0.6%). A more recent retrospective cohort study including 474 carriers of a P/LP *BRCA1/2* variant who were diagnosed with high-grade serous ovarian cancer showed that age of diagnosis was significantly greater in carriers of a P/LP *BRCA2* variant, compared to carriers of a P/LP *BRCA1* variant (58.4 vs. 53.3 years; $P = .001$).³¹² Therefore, the recommended age for RRSO should be younger for carriers of a P/LP *BRCA1* variant than for carriers of a P/LP *BRCA2* variant.

The effectiveness of RRSO in reducing the risk for ovarian cancer in carriers of a *BRCA1/2* P/LP variant has been demonstrated in a number of studies. For example, results of a meta-analysis involving 10 studies of carriers of a *BRCA1/2* P/LP variant showed an approximately 80% reduction in the risk for ovarian or fallopian tube cancer following RRSO.³¹³ In a large prospective study of females who carried deleterious *BRCA1/2* variants (N = 1079), RRSO significantly reduced the risk for *BRCA1*-associated gynecologic tumors (including ovarian, fallopian tube, or primary peritoneal cancers) by 85% compared with observation during a 3-year follow-up period (HR, 0.15; 95% CI, 0.04–0.56; $P = .005$).³¹⁴ An observational study of 5783 females carrying a P/LP *BRCA1/2* variant showed that risk-reducing oophorectomy reduces risk for ovarian, fallopian tube, or peritoneal cancer by 80% (HR, 0.20; 95% CI, 0.13–0.30) and all-cause mortality by 77% (HR, 0.23; 95% CI, 0.13–0.39).³¹¹ RRSO reduces mortality at all ages in carriers of a P/LP *BRCA1* variant, but among carriers of a P/LP *BRCA2* variant, RRSO is only associated with reduced mortality in those between the ages of 41 and 60 years.³¹¹ A more recent longitudinal cohort study published in 2024 showed that bilateral

oophorectomy was associated with lower all-cause mortality in both carriers of a P/LP *BRCA1* variant (HR, 0.28; 95% CI, 0.20–0.38; $P < .001$) and carriers of a P/LP *BRCA2* variant (HR, 0.43; 95% CI, 0.22–0.90; $P = .03$).³¹⁵

A 1% to 4.3% residual risk for a primary peritoneal carcinoma has been reported in some studies.^{172,313,316–320} An analysis of 36 carriers of a *BRCA1/2* P/LP variant who developed peritoneal carcinomatosis following RRSO showed that 86% were carriers of a *BRCA1* P/LP variant specifically.³²¹ When comparing to 113 carriers of a P/LP *BRCA1/2* variant who did not develop peritoneal carcinomatosis following RRSO, females who eventually developed peritoneal carcinomatosis were older at time of RRSO ($P = .025$) and had a greater percentage of serous tubal intraepithelial carcinoma (STIC) in their RRSO specimen ($P < .001$), supporting the removal of the fallopian tubes as part of the risk-reducing procedure. In a cohort study in which 55 out of 6310 carriers of a P/LP *BRCA1/2* variant who underwent preventive bilateral oophorectomy eventually were diagnosed with primary peritoneal cancer, there were no cases of peritoneal cancer in *BRCA1* P/LP variant carriers who received oophorectomy <36 years of age, and no cases of peritoneal cancer in *BRCA2* P/LP variant carriers who received oophorectomy <41 years of age.³²⁰ A systematic review and individual patient data meta-analysis including 17 studies and 3121 patients showed that STIC at RRSO was strongly associated with increased risk of peritoneal carcinomatosis (HR, 33.9; 95% CI, 15.6–73.9; $P < .001$).³²² Further, an analysis from a multicenter prospective cohort study (N = 1083) showed an increased risk for serous and/or serous-like endometrial cancer in females carrying a P/LP *BRCA1* variant who underwent RRSO without hysterectomy.²¹²

RRSO may provide an opportunity for gynecologic cancer detection in carriers of a P/LP *BRCA1/2* variant. An analysis of 966 RRSO procedures showed that invasive or intraepithelial ovarian, tubal, or peritoneal



neoplasms were detected in 4.6% of carriers of a P/LP *BRCA1* variant and 3.5% of carriers of a P/LP *BRCA2* variant.³²³ Carrying a *BRCA1/2* P/LP variant was associated with detection of clinically occult neoplasms during RRSO ($P = .006$). Another study including 2557 asymptomatic carriers of P/LP *BRCA1/2* variant enrolled in the Hereditary Breast and Ovarian Cancer in the Netherlands Study showed that high-grade serous carcinoma was detected in 1.5% of carriers of a P/LP *BRCA1* variant and in 0.6% of carriers of a P/LP *BRCA2* variant at time or RRSO.³²⁴ The fallopian tubes were the primary location of cancer in 73.3% of carriers for whom cancer was detected.

In early studies, RRSO was reported to reduce the risk for breast cancer in carriers of a P/LP *BRCA1/2* variant.^{269,313,318,319,325-328} In the case-control international study by Eisen et al, a 56% (OR, 0.44; 95% CI, 0.29–0.66; $P < .001$) and a 43% (OR, 0.57; 95% CI, 0.28–1.15; $P = .11$) breast cancer risk reduction (adjusted for oral contraceptive use and parity) were reported following RRSO in carriers of a *BRCA1* and a *BRCA2* P/LP variant, respectively.³²⁵ A study comparing breast cancer risk in females carrying a P/LP *BRCA1/2* variant who had undergone RRSO with carriers of these P/LP variants who opted for surveillance only also showed reduced breast cancer risk in females who underwent RRSO (HR, 0.47; 95% CI, 0.29–0.77).³¹⁹ These studies were further supported by a meta-analysis that found similar reductions in breast cancer risk of approximately 50% for carriers of a P/LP *BRCA1/2* variant following RRSO.³¹³

Results of a prospective cohort study suggested that RRSO may be associated with a greater reduction in breast cancer risk for carriers of a P/LP *BRCA2* variant compared with carriers of a *BRCA1* P/LP variant.³¹⁴ Another retrospective analysis including 676 females with stage I or II breast cancer and a P/LP *BRCA1/2* variant showed that oophorectomy was associated with decreased risk of mortality from breast cancer in

carriers of a P/LP *BRCA1* variant (HR, 0.38; 95% CI, 0.19–0.77; $P = .007$), but not in carriers of a P/LP *BRCA2* variant ($P = .23$).³²⁹

The reduction in breast cancer risk following RRSO was questioned in a prospective cohort study from the Netherlands (N = 822), which did not find a statistically significant difference in breast cancer incidence between carriers of a *BRCA1/2* P/LP variant who opted for an RRSO and females who did not, regardless of whether the P/LP variant was *BRCA1* or *BRCA2*.³³⁰ Study investigators argued that previous study findings showing a 50% decrease in breast cancer risk may have been influenced by bias, specifically inclusion of patients with a history of breast or ovarian cancer in the comparison group and immortal person-time bias. One study that corrected for immortal person-time bias as a result of this analysis continued to find a protective effect of RRSO on breast cancer incidence in carriers of a P/LP *BRCA1/2* variant (HR, 0.59; 95% CI, 0.42–0.82; $P < .001$).³³¹ Another prospective cohort analysis including 1289 carriers of a P/LP *BRCA1/2* variant unaffected with breast cancer (196 eventually being diagnosed) also showed that, when RRSO was treated as a time-dependent variable, it was no longer associated with breast cancer risk.³³² A meta-analysis including 19 studies of the association between RRSO and breast cancer risk and mortality showed a protective effect in studies published earlier than 2016, but not in studies published in 2016 or later ($n = 3$).³²⁶

Results from one of the earlier studies showed that greater reductions in breast cancer risk were observed in females carrying a P/LP *BRCA1* variant who had an RRSO at ≤ 40 years of age (OR, 0.36; 95% CI, 0.20–0.64) relative to carriers of a P/LP *BRCA1* variant aged 41 to 50 years who had this procedure (OR, 0.50; 95% CI, 0.27–0.92).³²⁵ A nonsignificant reduction in breast cancer risk was found for females aged ≥ 51 years, although only a small number of females were included in this group.³²⁵ However, results from another early study also suggested that RRSO after



50 years of age is not associated with a substantial decrease in breast cancer risk.³¹⁸ A 2017 study showed that oophorectomy was not significantly associated with decreased risk of breast cancer in carriers of a P/LP *BRCA1/2* variant ($N = 3722$).³³³ However, stratified analyses in carriers of a P/LP *BRCA2* variant who were diagnosed with breast cancer before 50 years of age showed that oophorectomy was associated with an 82% reduction in breast cancer (HR, 0.18; 95% CI, 0.05–0.63; $P = .007$). The risk reduction in carriers of a P/LP *BRCA1* variant was not statistically significant ($P = .51$). A 2020 study including 853 premenopausal carriers of a P/LP *BRCA1/2* variant showed the opposite: that premenopausal RRSO decreased breast cancer risk in carriers of a *BRCA1* P/LP variant (HR, 0.45; 95% CI, 0.22–0.92), but not in carriers of a *BRCA2* P/LP variant (HR, 0.77; 95% CI, 0.35–1.67).³³⁴ Analysis for this study began observation 6 months after genetic testing to avoid event-free time bias.

A large case series published in 2021 addressed the permanent exposure hypothesis that has potentially dampened the strength of the conclusions drawn from previous studies on the association between RRSO and breast cancer risk reduction.³³⁵ Specifically, some of these earlier studies assumed that this association remains constant each year following RRSO. This study, which included 876 families with a known *BRCA1* or *BRCA2* P/LP variant, showed that RRSO reduced risk of breast cancer within 5 years following the surgery (HR, 0.28; 95% CI, 0.10–0.63 and HR, 0.19; 95% CI, 0.06–0.71, respectively). More than 5 years after RRSO, breast cancer risk reduction diminished but continued to be significant for carriers of a *BRCA1* P/LP variant (HR, 0.64; 95% CI, 0.38–0.97), while the reduction was no longer statistically significant for carriers of a *BRCA2* P/LP variant (HR, 0.99; 95% CI, 0.84–1.00).

To summarize, studies suggest a benefit of RRSO on breast cancer risk, but the magnitude of the effect based on age remains uncertain.

Two systematic reviews showed that HRT does not negate the reduction in breast cancer risk associated with the surgery.^{336,337} One of these reviews showed that breast cancer risk tended to be lower in females who received estrogen only, compared to estrogen plus progesterone (OR, 0.62; 95% CI, 0.29–1.31).³³⁶ It is important to have a discussion about the potential risks and benefits of HRT in carriers of a P/LP variant following RRSO, given the limitations inherent in nonrandomized studies.^{338,339}

Salpingectomy (surgical removal of the fallopian tube with delayed oophorectomy) reduces the risk of ovarian cancer in the general population and is an option for premenopausal patients with hereditary cancer risk who are not yet ready for oophorectomy in the context of a clinical trial.^{340–342} Salpingectomy is currently not proven to improve outcomes and continues to be a procedure still under investigation. CA-125 and pelvic ultrasound are recommended for preoperative planning. Continuation of combination oral contraceptives or hormonal intrauterine device (IUD) for continued ovarian cancer risk reduction while ovaries remain in place may be considered. Clinical trials of interval salpingectomy with delayed oophorectomy are ongoing (eg, NCT02321228, NCT01907789, NCT04294927).

Some studies suggest a link between *BRCA* P/LP variants and development of serous uterine cancer (primarily with *BRCA1*),²¹¹ although the overall risk for uterine cancer was not increased when controlling for tamoxifen use.^{207,208,212} Individuals who undergo hysterectomy at the time of RRSO are candidates for estrogen-alone HRT, which is associated with a decreased risk of breast cancer, compared to combined estrogen and progesterone, which is required when the uterus is left in situ.^{336,337,343} Risk of pelvic floor dysfunction or urinary incontinence after hysterectomy is influenced by factors other than hysterectomy alone. Long-term follow-up studies indicate that the risks are <5% if there is no preceding pelvic organ prolapse.^{344,345} For patients who choose to undergo RRSO, the provider



may discuss the risks and benefits of concurrent hysterectomy, but more data are needed to determine the magnitude of the association between *BRCA* variants and development of serous uterine cancer.

HRT is generally not contraindicated and thus should be discussed with premenopausal patients who do not have a personal history of breast cancer.³⁴⁶ HRT recommendations should be tailored depending on each patient's personal history of breast cancer and/or breast cancer risk reduction strategies. In patients for whom the uterus is left in place at time of RRSO, there are several hormone replacement options. There is evidence that levonorgestrel IUD is associated with lower risk of breast cancer compared to risk of breast cancer from orally administered progestin.³⁴⁷ However, combination estrogen/progestin HRT continues to be an option after RRSO, though counseling should include bleeding precautions and uterine cancer risk awareness. Combined estrogen with a selective ER modulator (eg, bazedoxifene) is also an option.³⁴⁸

The NCCN Guidelines Panel recommends RRSO for carriers of a known *BRCA1/2* P/LP variant, typically between 35 and 40 years of age for carriers of a *BRCA1* P/LP variant. Since ovarian cancer onset tends to be later in carriers of a *BRCA2* P/LP variant, it is reasonable to delay RRSO for management of ovarian cancer risk until between 40 and 45 years of age, unless age at diagnosis in the family warrants earlier age for consideration of this prophylactic surgery.³¹¹ Peritoneal washings should be performed at surgery, and pathologic assessment should include fine sectioning of the ovaries and fallopian tubes.^{173,174} The protocol published by CAP (2009) can be consulted for details on specimen evaluation.³⁴⁹ See the NCCN Guidelines for Ovarian Cancer for treatment of findings (available at www.NCCN.org). If STIC lesion is found, then further consultation with a gynecologic oncologist is recommended.

The decision to undergo RRSO is a complex one and should be made ideally in consultation with a gynecologic oncologist, especially when the

patient wishes to undergo RRSO before the age at which it is typically recommended. Topics that should be addressed include impact on reproduction, impact on breast and ovarian cancer risk, risks associated with premature menopause (eg, osteoporosis, cardiovascular disease, cognitive changes, changes to vasomotor symptoms, sexual concerns), and other medical issues. Preoperative menopause management consultation may be considered for patients who are premenopausal at time of RRSO.^{350,351}

Chemoprevention

With respect to the evidence regarding the effect of oral contraceptives on cancer risks in carriers of a known *BRCA1/2* P/LP variant, case-control studies have demonstrated that oral contraceptives reduced the risk for ovarian cancer by 45% to 50% in carriers of a P/LP *BRCA1* variant and by 60% in carriers of a P/LP *BRCA2* variant.^{352,353} Moreover, risks appeared to decrease with longer duration of oral contraceptive use.³⁵³ An analysis of four meta-analyses, one review, one case-control study, and one retrospective cohort study showed that oral contraceptive use was associated with reduced risk of ovarian cancer in carriers of a known *BRCA1/2* P/LP variant.³⁵⁴ This review also showed that longer duration of use was associated with decreased ovarian cancer risk. A modeling study including hypothetical cohorts of 10,000 females with a P/LP *BRCA1* variant and 10,000 females with a P/LP *BRCA2* variant showed that combined oral contraceptive use was associated with short-term increased risk of breast cancer, but decreased long-term risk of ovarian cancer and endometrial cancer (regardless of variant).³⁰⁷ However, this study found that the long-term benefit was reduced following menopausal HRT after bilateral salpingo-oophorectomy (BSO). Oral contraceptives may be considered for the purpose of ovulation suppression and are not contraindicated for birth control purposes.

Screening

Studies assessing whether ovarian cancer screening procedures are sufficiently sensitive or specific have yielded mixed results. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which assessed multimodality screening with transvaginal ultrasound (TVUS) and CA-125 versus either TVUS alone or no screening, showed that multimodality screening is more effective at detecting early-stage cancer; however, after a median of 11 years of follow-up, a significant mortality reduction was not observed.^{355,356} In phase II of the UK Familial Ovarian Cancer Screening Study (UK FOCSS), 4348 females with an estimated lifetime ovarian cancer risk $\geq 10\%$ underwent ovarian cancer screening via serum CA-125 tests every 4 months (with the risk of ovarian cancer algorithm [ROCA] used to interpret results) and TVUS (annually or within 2 months if abnormal ROCA score).³⁵⁷ Thirteen patients were diagnosed with ovarian cancer as a result of the screening protocol, with 5 of the 13 patients being diagnosed with early-stage cancer. Sensitivity, positive predictive value, and negative predictive value of the screening protocol for detecting ovarian cancer within 1 year were 94.7%, 10.8%, and 100%, respectively. A third study including 3692 females who were at increased familial/genetic risk of ovarian cancer (ie, known P/LP *BRCA1/2* variant in the family and/or family history of multiple breast and/or ovarian cancers) showed that a ROCA-based screening protocol (ie, serum CA-125 testing every 3 months with annual TVUS annually or sooner depending on CA-125 test results) identified 6 incidental ovarian cancers, of which 50% were early stage.³⁵⁸ The results of these studies suggest a potential stage shift when a ROCA-based ovarian cancer screening protocol is followed in females at high-risk, though it remains unknown whether this screening protocol impacts survival. TVUS and serum CA-125 screening are recommended for preoperative planning.

Risk Management for Other Cancers

Screening for prostate cancer starting at 40 years of age is recommended for carriers of a P/LP *BRCA2* variant and should be considered for carriers of a P/LP *BRCA1* variant.¹⁸¹ See the NCCN Guidelines for Prostate Cancer Early Detection (available at www.NCCN.org). General melanoma risk management is also indicated, such as annual full body skin exam and minimizing ultraviolet (UV) exposure. There are no specific screening guidelines for melanoma, though more information can be found at the website for the Skin Cancer Foundation (www.skincancer.org). Information on pancreas screening can be found below under *Hereditary Pancreatic Cancer*.

Other P/LP Variants Associated with Breast, Ovarian, Pancreatic, and Prostate Cancers

Prior to 2020, the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate focused largely on testing criteria for *BRCA1/2*, *PTEN*, and *TP53* and appropriate risk management for carriers of these P/LP variants. There is now strong evidence that genes beyond *BRCA1/2* confer markedly increased risk of breast and/or ovarian cancers. These genes include *ATM*, *BARD1*, *BRIP1*, *CDH1*, *CHEK2*, *MSH2*, *MSH6*, *MLH1*, *PMS2*, *EPCAM*, *NF1*, *PALB2*, *RAD51C*, *RAD51D*, and *STK11*. The Panel's recommendations for cancer risk management intervention for carriers of P/LP variants associated with breast and/or ovarian cancer risk are based on absolute lifetime risk estimates. Cancer risk management intervention may be recommended when a carrier's absolute risk exceeds that of the average-risk population (ie, 12%–13% for breast cancer and 1%–2% for ovarian cancer, based on SEER registry data^{359,360}).^{47,361} Strength of the evidence supporting risk estimates should also be evaluated when determining appropriate risk management for carriers of a P/LP variant. For example, prospective cohort studies in a population-based setting can be considered very strong



evidence, while limited conclusions can be drawn from case series or studies with small samples.³⁶¹

The age at which breast screening is recommended may be impacted by the presence of risk factors such as family history of breast cancer, especially early-onset breast cancer.⁴⁷ In those with a family history of early-onset breast cancer, breast screening may begin 5 to 10 years earlier than the youngest breast cancer diagnosis in the family. In individuals AFAB treated for breast cancer who have not had bilateral mastectomy, breast screening should continue as recommended based on age. Currently there is insufficient evidence to recommend RRM in carriers of moderately penetrant P/LP variants,⁴⁷ though this option may be considered and discussed in the presence of a family history of breast cancer. Breast awareness in carriers of a moderately penetrant P/LP variant is recommended starting at age 18 years. Clinical breast examinations should be conducted every 6 to 12 months, beginning at 25 years of age (or 5–10 years before the earliest known breast cancer in the family [whichever comes first]). After 75 years of age, management should be considered on an individual basis. Absolute risk estimates for breast cancer provided in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are for primary breast cancer unless otherwise noted. With the exception of *BRCA2*, risk of hereditary contralateral breast cancer decreases once the patient is postmenopausal and is equivalent to sporadic breast cancer risk > 65 years of age.¹⁰⁷

RRSO may be considered when risk of developing ovarian cancer exceeds that of the average-risk population. The Panel uses a threshold of 5% for a recommendation to discuss RRSO. For P/LP variants for which lifetime risk estimates are <5% but greater than population risk (eg, *PALB2*), RRSO may be considered based on family history.³⁶² The decision to carry out RRSO should not be made lightly, given the impact of

premature menopause.⁴⁷ RRSO is recommended for ovarian cancer risk management in carriers of a P/LP variant in an ovarian cancer susceptibility gene. However, some may choose not to receive an RRSO.

The P/LP variants described below may be included concurrently in panel testing (see *Multigene Testing* above). Lower penetrance genes that may be included as part of multigene testing but for which there is currently insufficient evidence of an association with breast and/or ovarian cancer include: *FANCC*, *MRE11A*, *MUTYH* heterozygotes, *NBN*, *RECQL4*, *RAD50*, *RINT1*, *SLX4*, *SMARCA4*, and *XRCC2*. Risk management recommendations for these genes should take into account family history and other clinical factors.

Information regarding testing criteria and risk management for LFS (associated with germline *TP53* P/LP variant) and Cowden syndrome/PHTS (associated with germline *PTEN* P/LP variant) can be found in their respective sections, below.

ATM

P/LP variants in the *ATM* gene may increase the risk for breast cancer. A meta-analysis including 19 studies showed that the cumulative lifetime risk for primary breast cancer in individuals with an *ATM* P/LP variant is 6% by age 50 years and 33% by age 80 years.³⁶³ An analysis of 251 females who tested positive for ≥1 P/LP variant in a breast cancer susceptibility gene showed that the cumulative lifetime risk for primary breast cancer in individuals with an *ATM* P/LP variant is 31.2% by age 70 years.³⁶⁴ A comparative modeling analysis published in 2022 showed that the mean model-estimated lifetime risk of developing primary breast cancer was 20.9% (95% CI, 23.4%–31.7%) in females who carry an *ATM* P/LP variant.³⁶⁵ A meta-analysis of three cohort studies of relatives with ataxia-telangiectasia showed an estimated RR of 2.8 (90% CI, 2.2–3.7; *P* < .001).³⁶⁶ Other analyses of patients with breast cancer showed that about 1% had an *ATM* P/LP variant.^{94,121,126,129,130,367-370} Studies to date suggest



lifetime risk of developing primary breast cancer in females who carry an *ATM* P/LP variant in the range of 21% to 24%.^{121,129} Ten-year cumulative risk of developing contralateral breast cancer in females who carry an *ATM* P/LP variant is 4%, though this estimate is based on 7 cases.¹⁰⁷ Therefore, additional studies are needed to confirm and refine this estimate.

The association between specific types of *ATM* genetic variants and breast cancer susceptibility is less clear,³⁷¹⁻³⁷⁴ with some evidence showing that certain missense P/LP variants may act in a dominant-negative fashion to increase cancer risk, relative to truncating P/LP variants.^{371,372} A meta-analysis including five studies showed that carriers of an *ATM* P/LP variant have a 38% lifetime risk of developing primary breast cancer, with carriers of the c.7271T>G missense P/LP variant having a 69% risk of developing primary breast cancer by 70 years of age.⁵² An analysis from a case-control study (42,671 breast cancer cases and 42,164 controls) showed a significant association between the c.7271T>G variant and primary breast cancer risk (OR, 11.60; 95% CI, 1.50–89.90; *P* = .001).⁵³ An analysis of 27 families in which P/LP *ATM* variants were identified showed an association between the c.7271T>G variant and increased risk for primary breast cancer (60% risk by age 80).⁵⁴

The 2022 comparative modeling analysis by Lowry et al showed that beginning annual MRI screening at age 30 to 35 years may reduce breast cancer mortality by >55% in carriers with a P/LP *ATM* variant.³⁶⁵ The Panel also recommends annual mammogram for carriers with a P/LP *ATM* variant beginning at 40 years of age. Age at which to initiate MRI in carriers with a P/LP *ATM* variant depends on a number of risk factors, including family history, age, breast density, and patient preference. There are no data on the benefit of RRM for carriers of a P/LP *ATM* variant,⁴⁷ but this procedure may be considered based on family history. Results of the

case-control WECARE study suggested that radiation exposure may be associated with increased risk for contralateral breast cancer in females who are carriers of very rare *ATM* missense variants.³⁷⁵ However, these variants are not P/LP, and a meta-analysis including five studies showed that radiation therapy (with conventional dosing) is not contraindicated in patients with a heterozygous *ATM* P/LP variant.⁵² Therefore, radiation therapy does not need to be avoided in these carriers who are diagnosed with cancer.

Large studies of patients with ovarian cancer have shown that there may be a slightly increased risk for ovarian cancer in carriers of an *ATM* P/LP variant,^{163,368,376,377} but there is currently insufficient evidence to recommend RRSO in these carriers.³⁶¹ Given the association between *ATM* and development of the autosomal recessive condition ataxia telangiectasia, counseling for carriers of *ATM* P/LP variants should include a discussion of reproductive options.

There is emerging evidence that *ATM* P/LP variants are associated with increased risk for prostate cancer.^{180,181,187,378-380} Prostate cancer screening may be considered at age 40 years (see the NCCN Guidelines for Prostate Cancer Early Detection, available at www.nccn.org).

ATM P/LP variants have been found in patients with pancreatic cancer, with a lifetime risk of about 5% to 10% (see *Hereditary Pancreatic Cancer*, below).^{202,381,382}

BARD1

A modest association between breast cancer and P/LP variants in the *BARD1* gene has been found in case-control studies with a prevalence rate of 0.1% to 0.51% in patients with breast cancer.^{94,367,368,383-385} Studies show that *BARD1* is prevalent in 0.41% to 0.90% of patients with triple-negative breast cancer.^{94,128-130} The Breast Cancer Association Consortium and the CARRIERS case-control studies also found



associations between a *BARD1* P/LP variant and increased risk of triple-negative breast cancer (0.42%; OR, 9.29; 95% CI, 4.58–18.85 and 0.41%; OR, 3.18; 95% CI, 1.16–7.42, respectively).^{129,130} The Panel recommends annual mammogram for carriers of a P/LP *BARD1* variant beginning at 40 years of age, with consideration of annual breast MRI. Age at which to initiate MRI in carriers with a P/LP *BARD1* variant depends on a number of risk factors, including family history, age, breast density, and patient preference. RRM is not recommended in carriers of a *BARD1* P/LP variant, but this procedure may be considered based on family history.

BRIP1

Panel testing of germline DNA in patients with ovarian cancer has shown that the prevalence rate of P/LP variants in *BRIP1*, a Fanconi anemia gene, is about 1%.^{163,368,376,377,386} An analysis of 3236 females with epithelial ovarian cancer, 3431 controls, and 2000 unaffected high-risk females from an ovarian cancer screening trial (UKFOCSS) showed that *BRIP1* is associated with an increased risk for ovarian cancer ($P < .001$), with the RR for invasive epithelial ovarian cancer being 11.22 (95% CI, 3.22–34.10; $P < .001$) and 14.09 for high-grade serous disease (95% CI, 4.04–45.02; $P < .001$).³⁸⁷ A German study including 706 patients with ovarian cancer who do not carry a P/LP *BRCA1/2* variant showed a significant association between a *BRIP1* P/LP variant and ovarian cancer risk (OR, 20.97; 95% CI, 12.02–36.57; $P < .0001$), including late-onset ovarian cancer risk, with the highest OR for ovarian cancer diagnosed > 60 years (OR, 29.91; 95% CI, 14.99–59.66; $P < .0001$).³⁸⁸ An analysis of an Icelandic population (656 ovarian cancer cases, 3913 controls) also showed an association between *BRIP1* and increased risk for ovarian cancer (OR, 8.13; 95% CI, 4.74–13.95; $P < .001$).³⁸⁹ The cumulative lifetime risk of developing ovarian cancer by 80 years of age in carriers of a *BRIP1* P/LP variant is estimated to be 5.8% (95% CI, 3.6–9.1),³⁸⁷ though lifetime risk of developing ovarian cancer may also be as high as 12%.³⁶¹ The Panel recommends RRSO in carriers of a *BRIP1* P/LP variant at 45 to

50 years of age. A discussion about risk-reducing surgery may be initiated earlier if there is a family history of early-onset ovarian cancer. Ultimately, large prospective trials are needed to make a firm age recommendation regarding when a discussion about RRSO should begin in these variant carriers.

Regarding breast cancer, a case-control study including 10,901 patients with triple-negative breast cancer showed that *BRIP1* was prevalent in 0.43% of cases.¹²⁸ The Panel has determined that more evidence is needed to provide breast screening recommendations in these carriers. *BRIP1* is associated with Fanconi anemia (group FANCF), inherited in an autosomal recessive manner. Therefore, counseling for carriers of *BRIP1* P/LP variants should include a discussion of reproductive options.

CDH1

Germline P/LP variants in *CDH1* are associated with hereditary diffuse gastric cancer and lobular breast cancer, and studies have reported a cumulative lifetime risk for breast cancer of 37% to 55%.^{390,391} Given the considerable risk for lobular breast cancer in carriers of a *CDH1* P/LP variant, the Panel recommends screening with annual mammogram (or consideration of breast MRI) beginning at 30 years of age. Alternatively, screening may begin 5 to 10 years earlier than the youngest breast cancer diagnosis in the family. RRM may be discussed with these carriers. See the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (available at www.NCCN.org) for more information and for screening recommendations for gastric cancer for individuals with a *CDH1* P/LP variant.

CHEK2

Another breast cancer susceptibility gene that has been identified is *CHEK2*. Panel testing of germline DNA in large samples of patients with primary breast cancer has shown that the prevalence rate of a *CHEK2* P/LP variant is about 1% to 2%.^{121,367-370,377} Deleterious *CHEK2* P/LP



variants have been reported to occur with a higher frequency in Northern and Eastern European countries compared with North America.³⁹²⁻³⁹⁵ The cumulative lifetime risk for primary breast cancer in females with *CHEK2* P/LP variants range from approximately 23% to 27%,^{121,129} and is higher in females with stronger family histories of breast cancer than in those without.^{364,365,396,397} The estimated RR for primary breast cancer, based on data from two large case-control studies, was 3.0 (90% CI, 2.6–3.5).³⁶⁶ The Breast Cancer Association Consortium and the CARRIERS case-control studies showed associations between a *CHEK2* P/LP variant and increased risk of ER-positive primary breast cancer (OR, 2.67; 95% CI, 2.30–3.11 and OR, 2.60; 95% CI, 2.05–3.31, respectively).^{129,130} The BRIDGES study showed that carrying a *CHEK2* P/LP variant was associated with all breast cancer subtypes except for triple-negative breast cancer.¹²¹

Studies investigating the association between primary breast cancer risk and specific *CHEK2* variants have primarily been based on the truncating variant 1100delC. An analysis from the Copenhagen General Population Study (N = 86,975) showed that *CHEK2* 1100delC heterozygotes had an increased risk for primary breast cancer when analyses were stratified by age and sex (HR, 2.08; 95% CI, 1.51–2.85).³⁹⁸ A case-control study (10,860 cases and 9,065 controls) carried out by the *CHEK2* Breast Cancer Case-Control Consortium of Europe and Australia showed that the 1100delC variant is associated with increased risk for primary breast cancer, even in females unselected for family history (OR, 2.34; 95% CI, 1.72–3.20; $P < .001$).³⁹⁹ Another case-control study (44,777 cases and 42,997 controls) showed that heterozygous 1100delC carriers have a significantly increased risk of developing ER-positive breast cancer (OR, 2.55; 95% CI, 2.10–3.10; $P < .001$), but not ER-negative breast cancer (OR, 1.32; 95% CI, 0.93–1.88; $P = 0.12$).⁴⁰⁰ Results from a meta-analysis including 18 case-control studies (26,336 cases and 44,219 controls) showed that the missense variant I157T is associated with a modestly

increased risk for primary breast cancer (OR, 1.58; 95% CI, 1.42–1.75; $P < .001$).⁴⁰¹ There is also some evidence of low risk of breast cancer in carriers of the missense variant Ser428Phe.^{402,403} A retrospective cohort study including 3783 carriers of a *CHEK2* P/LP variant showed that primary breast cancer risk was elevated in carriers of c.444 + 1G>A (OR, 2.63; 95% CI, 1.59–4.35; $P < .001$), ex8_9del (OR, 2.36; 95% CI, 1.53–3.64; $P < .001$), p.R117G (OR, 1.65; 95% CI, 1.12–2.44; $P = .01$), and 1100delC variants (OR, 1.76; 95% CI, 1.55–2.00; $P < .001$), compared to *CHEK2* wild-type.⁴⁰⁴

Ten-year cumulative risk of developing contralateral breast cancer in carriers of a *CHEK2* P/LP variant is 6% to 8%.^{107,405} The 15-year cumulative risk of developing contralateral breast cancer in premenopausal individuals who carry a *CHEK2* P/LP variant is 20.5% (95% CI, 8.9%–47.4%), though this estimate is based on 7 cases and a wide CI.¹⁰⁷ The risk of metachronous contralateral breast cancer in women >65 years of age is not significantly different compared to non-carriers. Risk of contralateral breast cancer is higher if the primary breast cancer was ER-positive.⁴⁰²

The 2022 comparative modeling analysis by Lowry et al showed that beginning annual MRI screening at age 30 to 35 years may reduce breast cancer mortality by >55% in carriers with a P/LP *CHEK2* variant.³⁶⁵ The Panel also recommends annual mammogram for carriers of a P/LP *CHEK2* variant beginning at 40 years of age. Age at which to initiate MRI in carriers with a P/LP *CHEK2* variant depends on a number of risk factors, including family history, age, breast density, and patient preference. There are no data on the benefit of RRM for carriers of a P/LP *CHEK2* variant, but this procedure may be considered based on family history.

There is emerging evidence that *CHEK2* P/LP variants are associated with increased risk for prostate cancer.^{180,398,402,406} Prostate cancer screening



may be considered at age 40 years (see the NCCN Guidelines for Prostate Cancer Early Detection, available at www.nccn.org).

Data regarding increased risks for thyroid, kidney, and pancreatic cancers in carriers of a P/LP *CHEK2* variant are inconclusive at this time.⁴⁰²

MLH1, MSH2, MSH6, PMS2, and EPCAM

Lynch syndrome results from a germline P/LP variant in 1 of 4 DNA mismatch repair (MMR) genes (*MLH1*, *MSH2*, *MSH6*, or *PMS2*).⁴⁰⁷ Additionally, deletions in the *EPCAM* gene, which lead to hypermethylation of the *MSH2* promoter and subsequent *MSH2* silencing, cause Lynch syndrome.^{408,409} Females with Lynch syndrome are at heightened risk for endometrial cancer.⁴¹⁰⁻⁴¹³ With a lifetime risk of up to 60%, endometrial cancer is the second most common cancer in females with Lynch syndrome.⁴¹¹ For ovarian cancer, estimates vary depending on the specific gene, with risk estimates ranging from 4% to 20% for *MLH1*, 8% to 38% for *MSH2/EPCAM*, and ≤1% to 13% for *MSH6*.^{410,414-417} Risk for ovarian cancer is not increased in carriers of a P/LP *PMS2* variant.⁴¹⁷

TVUS and serum CA-125 testing to screen for ovarian cancer in postmenopausal individuals has not been shown to be sufficiently sensitive or specific to warrant a routine recommendation.⁴¹⁸⁻⁴²⁰ Since there is no effective screening for ovarian cancer, individuals should be educated on the symptoms that may be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or increased urinary frequency or urgency. Symptoms that persist for several weeks and are a change from baseline should prompt physician evaluation. BSO may reduce the incidence of ovarian cancer.^{419,421-425} The decision and timing of BSO as an option should be individualized based on whether childbearing is complete, menopausal status, comorbidities, family history, patient preference, and Lynch syndrome gene, as risks for ovarian cancer vary by mutated gene. Estrogen replacement after premenopausal oophorectomy

may be considered. There is insufficient evidence to recommend RRSO in *MSH6* and *PMS2* P/LP variant carriers. Risk reduction agents should be considered, with detailed discussion between the physician and patient outlining the associated risks and benefits.

While studies have found that 42% to 51% of breast cancers in patients with Lynch syndrome are MMR deficient (dMMR) with abnormal immunohistochemistry (IHC) corresponding to their germline pathogenic MMR gene variant,^{426,427} there are insufficient data supporting an increased risk for breast cancer for patients with Lynch syndrome.^{129,130,414,417,428-430}

Patients of reproductive age should be advised regarding their options for prenatal diagnosis and assisted reproduction, including PGT. This discussion should include known risks, limitations, and benefits of these technologies. If both partners are a carrier of a P/LP variant in the same MMR or *EPCAM* gene, then they should also be advised about the risk for constitutional MMR deficiency (CMMRD) syndrome, a rare recessive syndrome.⁴³¹ More information regarding Lynch syndrome can be found in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (available at www.NCCN.org).

NF1

Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary cancer syndrome that is caused by an *NF1* P/LP variant. NF1 is a neurocutaneous syndrome characterized by café-au-lait spots and axillary/inguinal freckling, associated with non-cancerous tumors of the nerve tissues. Individuals with NF1 have an increased risk for malignant peripheral nerve sheath tumors, other central nervous system (CNS) tumors, and gastrointestinal stromal tumors.⁴³²⁻⁴³⁶ A population-based study in Finland of 1404 patients with NF1 showed an estimated lifetime cancer risk of 59.6%.⁴³² This study showed a significant association between NF1 and increased risk for breast cancer (SIR, 3.04; 95% CI,

2.06–4.31; $P < .001$). Among patients with breast cancer, NF1 was associated with poorer survival, with 5-year survival rates for patients with NF1 being 67.9%, compared to 87.8% in patients without NF1. Excess incidence was highest in females <40 years of age (SIR, 11.10; 95% CI, 5.56–19.50; $P < .001$). A population-based study in England of 848 patients with NF1 also showed an increased risk for breast cancer (SIR, 3.5; 95% CI, 1.9–5.9), especially among females <50 years (SIR, 4.9; 95% CI, 2.4–8.8).⁴³⁷

Given the increased risk for early-onset breast cancer in carriers of these P/LP variants, annual breast screening with mammography should begin at 30 years of age.^{436,438} Screening with breast MRI could also be considered. The presence of neurofibromas in the breast may lead to false-positive MRI results, but more data are needed to determine the sensitivity and specificity of breast MRI in individuals with NF1. A prospective study of patients with NF1 from the United Kingdom (N = 448) showed that breast cancer risk in carriers of these P/LP variants is not significantly increased at ≥50 years of age.⁴³⁵ Case-control analyses of females with NF1 from England showed that RR estimates for women aged 30 to 39 years was 6.5 (95% CI, 2.6–13.5) and 4.4 for women aged 40 to 49 years (95% CI, 2.5–7.0).⁴³⁹ RR estimates then drop for women aged 50 to 59 years (RR, 2.6; 95% CI, 1.5–4.2) and continue to drop as age increases (RR, 1.9; 95% CI, 1.0–3.3 for women aged 60–69 years and RR, 0.8; 95% CI, 0.2–2.2 for women aged 70–79 years). These studies show that, beginning at age 50, breast cancer risk in women with NF1 may not significantly differ from that of women in the general population. Therefore, breast MRI screening in patients with NF1 may be discontinued at 50 years of age. There are no data regarding the benefit of RRM for carriers of NF1 P/LP variants. Therefore, RRM is not recommended in these patients, but this procedure may be considered based on family history. Complications related to NF1 (eg, neurologic complications) may appear early in life, and these have the potential to be

severe.⁴⁴⁰ Therefore, referral to a neurofibromatosis specialist for management is recommended.⁴³⁶

PALB2

PALB2 (partner and localizer of *BRCA2*) is a Fanconi anemia gene. *PALB2* P/LP variants are associated with increased risk for breast cancer, with studies of patients with breast cancer showing that 0.4% to 3% harbor a *PALB2* P/LP variant.^{94,125,367-370,377,383,441,442} A meta-analysis of three studies estimated an RR of 5.3 (90% CI, 3.0–9.4),³⁶⁶ while the most robust analysis to date included 524 families with a known P/LP *PALB2* variant and estimated an RR of 7.18 (95% CI, 5.82–8.85) for female breast cancer.⁹³ The Breast Cancer Association Consortium study, CARRIERS study, and BRIDGES study all showed associations between a *PALB2* P/LP variant and increased risk of triple-negative breast cancer.^{121,129,130} *PALB2* P/LP variant is associated with a 32% to 53% lifetime risk of breast cancer.^{121,129} Risk increases with increasing number of relatives affected with breast cancer. An analysis, which included 524 families with a known P/LP *PALB2* variant, showed that lifetime risk of breast cancer is as high as 76% when there is a family history of two first-degree relatives with breast cancer.⁹³ In a study of patients with breast cancer from Poland who underwent genetic testing, contralateral breast cancer was reported in 10% of *PALB2* carriers.⁴⁴² This study also showed that 10-year survival among *PALB2* carriers with breast cancer was 48%, compared to 72% in carriers of a *BRCA1* P/LP variant and 75% in non-carriers ($P < .001$). The cumulative lifetime risk for male carriers of a P/LP *PALB2* variant is 0.9% (by age 70).⁹³

Ten-year cumulative risk of developing contralateral breast cancer in carriers of a *PALB2* P/LP variant is 5% to 8%.^{107,405} The 15-year cumulative risk of developing contralateral ER-negative breast cancer in premenopausal individuals who carry a *PALB2* P/LP variant is 35.5% (95% CI, 15.0%–84.0%), though this estimate is based on 4 cases and a

wide CI.¹⁰⁷ The risk of contralateral breast cancer in carriers of a *PALB2* P/LP variant is only elevated in ER-negative disease. The risk of metachronous contralateral breast cancer in women >65 years of age is also not significantly different compared to non-carriers.

The Panel recommends annual mammogram for carriers of a *PALB2* P/LP variant AFAB beginning at 30 years of age. Breast MRI screening may also be considered. RRM for carriers of a *PALB2* P/LP variant may be considered. For individuals AMAB, breast cancer screening similar to that for carriers of a *BRCA1* P/LP variant is reasonable.

Some studies suggest an association between *PALB2* and increased ovarian cancer risk.^{163,443-446} The most robust data to date showing an association between *PALB2* and increased ovarian cancer risk come from the international study, which included 524 families with a known P/LP *PALB2* variant.⁹³ This study showed a 5% lifetime risk of ovarian cancer in carriers of a *PALB2* P/LP variant. RRSO may be considered in carriers of a *PALB2* P/LP variant starting at 45 to 50 years of age.^{447,448}

PALB2 is associated with Fanconi anemia, inherited in an autosomal recessive manner.⁴⁴⁹ Therefore, counseling for carriers of *PALB2* P/LP variants should include a discussion of reproductive options.

RAD51C* and *RAD51D

Genes in the *RAD51* protein family are involved in homologous recombination and DNA repair. *RAD51C* and *RAD51D* have been shown to be associated with increased risk for ovarian cancer. Panel testing of germline DNA in females with ovarian cancer has shown that the prevalence rate of the *RAD51C* or *RAD51D* P/LP variant is about 1%.^{163,368,376,386} In a comparison of 1132 probands with a family history of ovarian cancer and 1156 controls, *RAD51C* was associated with an increased risk for ovarian cancer (RR, 5.88; 95% CI, 2.91–11.88; $P < .001$).⁴⁵⁰ Analyses from the same trial (911 probands and 1060 controls)

also showed an association between *RAD51D* and increased risk for ovarian cancer (RR, 6.30; 95% CI, 2.86–13.85; $P < .011$).⁴⁵¹ In a case-control analysis of 3429 females with epithelial ovarian cancer and 2772 controls, both *RAD51C* (OR, 5.2; 95% CI, 1.1–24; $P = .035$) and *RAD51D* (OR, 12.0; 95% CI, 1.5–90; $P = .019$) were associated with an increased risk for ovarian cancer.⁴⁵² A study including 6178 and 6690 families with a known P/LP *RAD51C* and *RAD51D* variant, respectively, showed that the cumulative risk of developing ovarian cancer by age 80 was 11% for carriers of a *RAD51C* P/LP variant and 13% for carriers of a *RAD51D* P/LP variant.⁴⁵³

The Panel recommends RRSO in carriers of *RAD51C* and *RAD51D* P/LP variants starting at 45 to 50 years of age. A discussion about risk-reducing surgery may be initiated earlier if there is a family history of early-onset ovarian cancer. As with *BRIP1* P/LP variants, large prospective trials are needed to make a firm age recommendation regarding when a discussion about RRSO should begin in carriers of *RAD51C* and *RAD51D* P/LP variants.³⁶¹

Regarding breast cancer, studies have shown prevalence rates of 0.23% to 0.45% for *RAD51C* and 0.29% to 0.38% for *RAD51D* in patients with triple-negative breast cancer.^{125,128,454} Two large case-control analyses showed that both *RAD51C* and *RAD51D* P/LP variants were significantly associated with triple-negative disease.^{94,121} The Breast Cancer Association Consortium study and the CARRIERS study showed associations between increased risk for ER-negative breast cancer and both *RAD51C* P/LP variant (OR, 3.99; 95% CI, 2.20–7.26 and OR, 2.19; 95% CI, 0.97–4.49, respectively) and *RAD51D* P/LP variant (OR, 2.92; 95% CI, 1.47–5.78 and OR, 3.93; 95% CI, 1.40–10.29, respectively), with prevalence rates of 0.26% and 0.24% for *RAD51C*, respectively, and 0.17% and 0.18% for *RAD51D*, respectively.^{129,130} The Panel recommends annual mammogram for carriers of a P/LP *RAD51C* and *RAD51D* variant



beginning at 40 years of age, with consideration of annual breast MRI. There are no data on the benefit of RRM for carriers of a P/LP *ATM* variant, but this procedure may be considered based on family history. *RAD51C* is associated with Fanconi anemia, inherited in an autosomal recessive manner. Therefore, counseling for carriers of a *RAD51C* P/LP variant should include a discussion of reproductive options.

STK11

Germline *STK11* P/LP variants are associated with Peutz-Jeghers syndrome (PJS), an autosomal dominant disorder characterized by gastrointestinal polyps, mucocutaneous pigmentation, and elevated risk for gastrointestinal cancers as well as breast and non-epithelial ovarian cancers, such as Sertoli-Leydig tumors. Breast cancer risk in females with PJS is 8% at 40 years of age, 13% at 50 years of age, 31% at 60 years of age, and 45% at 70 years of age.⁹⁸ Though there are no data on the benefit of RRM for carriers of *STK11* P/LP variants, RRM may be considered for these patients. Absolute risk of developing non-epithelial ovarian cancer (sex cord with annular tubules) is 18% to 21%.^{98,99}

Information regarding screening for patients with PJS can be found in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (available at www.NCCN.org).

Emerging Evidence

A systematic review of 21 papers including 47 patients with biallelic P/LP variants in *NTHL1* showed that 55% of the female patients were diagnosed with breast cancer.⁴⁵⁵ Another study including 29 carriers of biallelic *NTHL1* P/LP variants showed that 60% of females were diagnosed with breast cancer.⁴⁵⁶ Though breast cancer risk may be elevated, the evidence currently does not support screening beyond that which is recommended for the general population.

In a study including 3422 patients with breast or ovarian cancer who underwent tumor and germline sequencing, a *RAD51B* P/LP variant was

found in 0.26%, which is comparable to prevalence rates for *RAD51C* and *RAD51D*.⁴⁵⁷ Breast screening may be considered in these carriers.

NCCN Genetic Testing Criteria

The NCCN genetic testing criteria for high-penetrance breast, ovarian, pancreatic, and prostate cancer are organized into three sections: 1) testing is clinically indicated; 2) testing may be considered; and 3) there is a low probability of testing results having documented clinical utility (ie, finding of high-penetrance genes). The testing criteria listed are for cancer susceptibility genes with strong or moderate evidence of actionability for breast, ovarian, pancreatic, and prostate cancer (eg, *BRCA1/2*, *CDH1*, *PALB2*, *PTEN*, *STK11*, and *TP53* for breast cancer; additionally, testing criteria for LFS and Cowden syndrome continue to be contained in their own dedicated sections; see below). Included genes may change with emerging clinical data. Further, the personal and/or family history criteria included may suggest the possibility of additional syndromes and would necessitate additional unlisted genes to be evaluated.

The NCCN Panel recommends that individuals from a family with a known P/LP variant in a breast, ovarian, pancreatic, and/or prostate cancer susceptibility gene be tested for the known variant. However, multigene panel testing is often indicated in these individuals if the family history suggests a different syndrome in addition to the known variant. In individuals from a family without a known P/LP variant, germline multigene testing is recommended for those individuals who meet the testing criteria described in the *Hereditary Testing Criteria* section in the algorithm. Multigene testing may be considered for individuals who meet testing criteria and who previously underwent single-gene and/or absent deletion duplication analysis but tested negative. Both first- and second-degree relatives of individuals who meet these testing criteria are also eligible for testing, except for second-degree relatives of individuals with pancreatic cancer or prostate cancer, for whom prior probability of a high-penetrance



cancer susceptibility gene is low in the absence of additional family history of cancer; only first-degree relatives of these affected individuals should be offered testing, unless indicated based on additional family history.

Testing Criteria Related to Prostate Cancer

Approximately 11% of patients with prostate cancer and at least 1 additional primary cancer carry germline P/LP variants associated with increased cancer risk.³⁷⁸ As described above, germline *BRCA1/2* P/LP variants are associated with increased risk for prostate cancer (see *BRCA-Related Breast/Ovarian Cancer Syndrome*, above).¹⁷⁸⁻¹⁸¹

There is also emerging evidence of other genes and increased risk for prostate cancer (eg, *ATM*, *CHEK2*).^{180,181,187,378-380,402} *HOXB13* P/LP variants have been found in 1.4% to 4.5% of patients with prostate cancer.^{180,378,458-460} A case-control study conducted in the United Kingdom including 8652 patients diagnosed with prostate cancer (comparing to 5252 healthy controls) showed that carrying a *HOXB13* P/LP variant was associated with a 2.93-fold increased risk of prostate cancer.⁴⁵⁹ Risk was especially increased for prostate cancer diagnosed ≤ 55 years of age (OR, 3.11; 95% CI, 1.98–5.00). Increased risk of early-onset prostate cancer in carriers of a *HOXB13* P/LP variant was also found in an earlier case-control study conducted in the United States.⁴⁶⁰ Based on these studies of carriers of a *HOXB13* P/LP variant, genetic testing may be considered in individuals diagnosed with prostate cancer at ≤55 years. There is currently no established association between *HOXB13* and aggressive prostate cancer.⁴⁵⁹ However, results have been mixed with some studies suggesting more aggressive localized disease features.^{461,462}

Testing criteria related to prostate cancer include diagnosis of metastatic prostate cancer, as well as diagnosis of prostate cancer in an individual with Ashkenazi Jewish ancestry or suspicious family history (ie, breast cancer diagnosed at an early age or in a male blood relative, ovarian cancer, pancreatic cancer, metastatic or high- or very-high-risk prostate

cancer).¹⁸¹ Any patient in the high- or very-high-risk stratification group as defined in the NCCN Guidelines for Prostate Cancer (available at www.NCCN.org) is also eligible for testing without any additional testing criteria.

Prostate tumors with intraductal or cribriform histology may have increased prevalence of somatic MMR gene alterations.⁴⁶³ In addition, limited data suggest that germline homologous DNA repair gene mutations may be more common in prostate tumors of ductal or intraductal origin.⁴⁶⁴ Studies examining the association between carrying a germline *BRCA2* P/LP variant and intraductal histology have been conflicting.^{465,466} By definition, intraductal carcinoma includes cribriform proliferation of malignant cells, as long as they remain confined to a preexisting gland that is surrounded by basal cells. These features are seen frequently with an adjacent invasive cribriform component and would be missed without the use of basal cell markers. Genetic testing may be considered in individuals diagnosed with intermediate-risk prostate cancer with intraductal/cribriform histology.

Systemic Therapy Decision-Making

Some of the NCCN treatment guidelines for *BRCA*-related cancers (Breast, Ovarian, Pancreatic Adenocarcinoma, Prostate, available at www.NCCN.org) recommend treatment with PARP inhibitors for patients with germline or somatic *BRCA1/2* P/LP variants, as PARP inhibitors have been demonstrated to be active in these patients. These agents include olaparib^{467,468} and talazoparib⁴⁶⁹ for HER2-negative metastatic disease and as adjuvant treatment for high-risk HER2-negative breast cancer (olaparib only); niraparib,⁴⁷⁰ olaparib,^{471,472} and rucaparib^{473,474} for chemotherapy-refractory ovarian cancer; olaparib⁴⁷⁵ and rucaparib⁴⁷⁶ for metastatic castration-resistant prostate cancer that has progressed following previous treatment; and olaparib and rucaparib as maintenance therapy options for metastatic pancreatic cancer.^{477,478} Even though the



focus of these Guidelines continues to be on management of breast, ovarian, pancreatic, and/or prostate cancer risk in individuals with associated hereditary syndromes, the Guidelines now identify intent to aid in systemic therapy and surgical decision-making as a scenario in which germline testing is clinically indicated. If a P/LP variant is detected through tumor profiling that has clinical implications if identified in the germline, then germline testing for this variant is indicated.

Founder Mutations

The rate of the three founder P/LP variants in those of Ashkenazi Jewish ancestry is 2.2% to 2.5%.⁴⁷⁹⁻⁴⁸¹ Studies have shown that genetic testing based on clinical guidelines emphasizing family history of breast, ovarian, pancreatic, prostate, or other cancers missed about 38% to 56% of P/LP variant carriers in those of Ashkenazi ancestry.^{479,480,482,483} Therefore, there is some evidence to support population-based genetic testing for individuals with Ashkenazi Jewish ancestry. However, there are concerns about the demand on genetic counseling resources, the preparedness of health care professionals to provide cancer genetic counseling and management, and participants' fears and concerns about testing, including those regarding privacy, stigmatization, and the need for appropriate medical and or surgical treatment in patients and family members found to have a founder P/LP variant. Thus, universal testing for founder *BRCA1/2* P/LP variants in individuals of Ashkenazi Jewish ancestry, regardless of personal or family history, should be offered primarily in the setting of longitudinal research studies. If there is no access to longitudinal studies, then testing may be offered when pre- and post-test genetic counseling are available (see above). For individuals of Ashkenazi Jewish descent, complete gene panel analysis, including specific Ashkenazi Jewish founder mutations should be considered based on family history. Testing limited to Ashkenazi Jewish founder testing may be appropriate for families segregating known mutations, or in population screening in which a negative test is followed by more complete testing depending on

personal and/or family history. There remains a vital need for longitudinal data from research studies exploring various methods of providing population-based genetic testing of individuals with Ashkenazi Jewish ancestry in the United States.

In addition to the *BRCA1* and *BRCA2* PVs in those of Ashkenazi ancestry, there are other ancestries in which founder mutations have been identified. In these circumstances, the decision to test will depend on the prevalence of the PV in the local population, family history, clinical features, and age of cancer diagnosis. Examples where ancestry may, along with personal and/or family history, contribute to decisions about genetic testing include the following associations: numerous *BRCA1* and *BRCA2* PV in those of Spanish, Mexican, Central American, and South American descent⁴⁸⁴⁻⁴⁸⁶; *BRCA1* PV and Polish ancestry^{487,488}; *BRCA1* and *BRCA2* PV and Bahamian ancestry⁴⁸⁹; *BRCA2* PV and Icelandic ancestry⁴⁸⁶; *BRCA1* and *BRCA2* PV in those of French Canadian ancestry⁴⁸⁶; and *BRCA1* and *BRCA2* PV and Hungarian ancestry.⁴⁸⁶ While emerging data derived from populations of Asian, Middle Eastern, and African origin have documented recurring mutations in *BRCA1* and *BRCA2* genes,⁴⁹⁰⁻⁴⁹² population allele frequency data are not yet available to inform testing individuals based solely on ancestry in the absence of personal and/or family history. Other founder mutations that are not *BRCA1* and *BRCA2* include the *TP53* PV c.1010G>A (p.Arg337His) PV, which has been observed in a subset of those of Brazilian ancestry,⁴⁹³ and *CDKN2A* founder c.225_243del (p.Ala76fs) in those of Dutch ancestry.⁴⁹⁴

Breast Cancer Population Testing

The rapid advent of multigene testing and recent availability of PARP inhibitors for patients with breast cancer who carry a *BRCA1/2* or *PALB2* P/LP variant highlights the need for evolving and up-to-date recommendations for genetic testing criteria for patients with breast cancer. In 2019, the American Society of Breast Surgeons (ASBrS)



published a consensus statement recommending genetic testing for all patients with breast cancer.⁴⁹⁵ This recommendation was based on studies showing that criteria in testing guidelines miss some patients with breast cancer who harbor a P/LP variant^{496,497} and that population-based multigene testing is more cost-effective than testing based on personal and family history criteria.^{41,498} However, only 4.4% of patients with a high-penetrance mutation (ie, *BRCA1/2*, *PALB2*, *TP53*, *PTEN*) were missed in the Beitsch et al study.^{496,499}

In 2024, a joint ASCO-SSO panel published guidance regarding germline testing in patients with breast cancer, in which all patients with newly diagnosed disease at age ≤65 years should be offered *BRCA1/2* testing.⁵⁰⁰ This recommendation was based on a systematic review of 6 studies regarding prevalence of *BRCA1/2* mutations in patients with breast cancer, as well as age cutoffs for *BRCA1/2* testing. A registry study including 3907 women diagnosed with breast cancer analyzed sensitivity and specificity of various age threshold criteria for genetic testing, including 9 breast cancer predisposition genes (*ATM*, *BRCA1*, *BRCA2*, *CDH1*, *CHEK2*, *NF1*, *PALB2*, *PTEN*, and *TP53*).⁵⁰¹ A threshold of age ≤65 years had a sensitivity value of 92.1% (95% CI, 88.0–94.9%) and a specificity value of 22.0% (95% CI, 20.7–23.4). This threshold was associated with an additional 31% of patients being tested compared to NCCN criteria, and a 21% decrease in testing compared to the ASBrS recommendation of testing for all patients. The VUS to PV ratio for this threshold was 1.6 (compared to 1.9 for ASBrS recommendations and 1.4 for NCCN recommendations). An update of this study showed optimal sensitivity values with an age threshold of ≤60 years (90.6 for *BRCA1/2*, 78.7% for the 9 predisposition genes, 86.2% for 6 high-penetrance genes), compared to an age threshold of ≤65 years (88.3% for *BRCA1/2*, 75.0% for the 9 predisposition genes, 83.2% for 6 high-penetrance genes).⁵⁰² This study^{501,502} was limited by a lack of racial and ethnic diversity.

To summarize, the aim of the ASCO-SSO age cut-off recommendation was to optimize sensitivity for detection of *BRCA1/2*.⁵⁰⁰ Use of a ≤65-year threshold is associated with good sensitivity both for *BRCA1/2* and for other breast cancer predisposition genes. An analysis of postmenopausal patients with breast cancer from the Women's Health Initiative showed a *BRCA1/2* prevalence of 2.2% if diagnosed at age ≤65 years, an estimate comparable to prevalence among those with Ashkenazi Jewish ancestry.⁵⁰³

Additional tailoring of testing criteria in patients with breast cancer could be done based on histopathology or the presence of multiple primary breast cancers. An analysis of females >65 years (N = 26,707) from population-based case-control studies showed that 3.42% of females with ER-negative breast cancer and 3.01% of females with triple-negative breast cancer harbored a P/LP variant in a high-penetrance breast cancer susceptibility gene (*BRCA1*, *BRCA2*, and *PALB2*).⁵⁰⁴ Multiple studies also show that individuals with multiple primary breast cancers may be more likely than individuals with a single breast cancer to harbor a P/LP variant associated with breast cancer (7.1%–13.2% vs. 4.2%–9.4%).^{370,505,506} For the 2023 Guidelines update, the Panel expanded the testing criterion for multiple primary breast cancers (synchronous or metachronous) to apply to all patients with breast cancer regardless of age of initial breast cancer diagnosis, which formerly applied only to patients with breast cancer diagnosed at ages 46 to 50 years. In one study including patients with phyllodes tumors, a P/LP variant was found in 8.8% of 34 patients who underwent testing (1 *BRCA1*, 2 *TP53*).⁵⁰⁷ Diagnosis of a malignant phyllodes tumor may prompt consideration of testing.

The NCCN Panel continues to endorse a risk-stratified approach for patients with breast cancer. For patients diagnosed with breast cancer at age ≤65 years who do not meet other testing criteria, testing may be considered, including breast cancer genes plus other inherited cancer



genes consistent with family phenotype. The Panel continues to not endorse universal testing of all patients with breast cancer due to limitations of this approach, such as low specificity, shortages in trained genetics health professionals to provide appropriate pre- and post-test genetic counseling, and lack of evidence to support risk management for genes included in many multigene panels. Though all patients with breast cancer should be evaluated to determine the appropriateness of germline genetic testing, testing should ultimately be based on patient characteristics, such as those specified in the *Testing Criteria for High-Penetrance Breast Cancer Susceptibility Genes* in the algorithm.⁴⁹⁹ It is estimated that the age ≤ 65 years threshold will lead to a recommendation of testing 80% of women with breast cancer. Therefore, the Panel developed minimal standards of genetic testing to take into account the increased demand for testing with a shortage of resources. For the full list of these principles, see the *Principles of Cancer Risk Assessment and Counseling* in the algorithm.

Probability Models

Decision models developed to estimate the likelihood that a *BRCA1/2* P/LP variant is present include BRCAPRO,^{508,509} Penn II,⁵¹⁰ and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA).⁵⁰⁸ Validated clinical and family history-based models that incorporate PRS are also emerging as precision risk estimation tools.⁵¹¹⁻⁵¹³ A lifetime risk for breast cancer of 20% to 25% or greater as assessed by models based largely on family history has been used in some guidelines to identify females as being at high risk for breast cancer. For example, this risk threshold was used in updates to the American Cancer Society (ACS) guidelines on breast screening, which incorporate MRI.^{261,514} Penn II has been validated in families with ≥ 2 cases of breast and/or ovarian cancer.^{510,515} Therefore, caution should be taken in applying this model to individuals with only one case of breast or ovarian cancer. In addition, this model was developed specifically to

evaluate the likelihood of a *BRCA1/2* P/LP variant, and not the appropriateness of multigene testing.

If an individual does not meet the criteria for testing for high-penetrance breast and/or ovarian cancer susceptibility genes that are described above, then testing may be considered in those who are determined to have a 2.5% to 5% probability of harboring a *BRCA1/2* P/LP variant, based on probability models validated for *BRCA1/2* (eg, Tyrer-Cuzick, BRCAPRO, BOADICEA). However, the Panel cautions that model estimates vary substantially, and different thresholds may be applied if other genes are utilized in a specific model. If genes other than *BRCA1/2* are to be included in models that evaluate the threshold for testing, then penetrance, clinical actionability, and phenotypic features of cancers associated with these genes should be taken into account. Models that take these parameters into account to determine eligibility and appropriateness of multigene testing should be developed and validated. Subgroup analyses of 1075 carriers of a *BRCA1/2* P/LP variant from the Breast Cancer Prospective Family Study Cohort showed that BRCAPRO underpredicted breast cancer risk, but BOADICEA was well-validated.⁵¹⁶ In 2020, the web-based CanRisk tool was developed to apply BOADICEA for clinical use and is now available. Further development and testing is needed to increase acceptability of the tool by clinicians.⁵¹⁷ Besides *BRCA1/2*, BOADICEA also includes *PALB2*, *CHEK2*, and *ATM*. In 2022, BOADICEA was expanded to also take into account associations between *BARD1*, *RAD51C*, and *RAD51D* with breast cancer risk.⁵¹⁸ PREMMplus has also been developed at an NCCN Member Institution to evaluate the likelihood of a germline mutation in a number of P/LP variants (*APC*, *BRCA1*, *BRCA2*, *CDH1*, *EPCAM*, *MLH1*, *MSH2*, *MSH6*, biallelic *MUTYH*, *PMS2*, *TP53*, *ATM*, *BRIP1*, *CDKN2A*, *CHEK2*, *PALB2*, *PTEN*, *RAD51C*, and *RAD51D*).⁵¹⁹

Li-Fraumeni Syndrome

LFS is a rare hereditary cancer syndrome that is frequently associated with germline *TP53* P/LP variants.⁹¹ The classic form of LFS is highly penetrant and characterized by a wide spectrum of neoplasms occurring at a young age and throughout the lifespan. An observational cohort study including 480 carriers with a *TP53* P/LP variant enrolled in National Cancer Institute's (NCI) longitudinal Li-Fraumeni syndrome study showed that LFS is associated with a greater incidence of cancer than the general population (SIR, 23.9; 95% CI, 21.9–26.0), with the highest comparative incidence from childhood to age 30 years.⁵²⁰ An analysis from the NCI Li-Fraumeni Syndrome study (N = 286) showed a cumulative lifetime cancer incidence of nearly 100%.⁵²¹ Soft tissue sarcomas, osteosarcomas (except Ewing sarcoma), premenopausal breast cancer, adrenocortical tumors, and brain tumors are referred to as the “core” cancers of LFS since they account for the majority of cancers observed in individuals with germline *TP53* P/LP variants. In one study, of 91 carriers of a germline *TP53* P/LP variant, at least one of these cancers was found in ≥1 members of all families with a germline *TP53* P/LP variant.⁵²² Certain cancers are strongly associated with LFS, for example, hypodiploid acute lymphoblastic leukemia,^{523–525} choroid plexus tumor,⁵²⁶ and anaplastic rhabdomyosarcoma.^{527,528} Beyond the core cancers, LFS has also been associated with other leukemias, colon cancer, gastric cancer, bronchoalveolar and other lung cancers, prostate cancer, melanoma, and other CNS tumors.^{91,520,522,529–538} However, it is important to mention that estimations of cancer risks associated with LFS are limited to at least some degree by selection bias since dramatically affected kindreds are more likely to be identified and become the subject of further study. In addition, the majority of data are from LFS cohorts composed of self-identified white individuals.

Given the broad tumor types seen in LFS families, a number of different sets of criteria have been used to help identify individuals who have a high

likelihood of having LFS including Classic, Chompret, Eeles, and Birch criteria. For the purposes of the NCCN Guidelines, two of these criteria, Classic and Chompret, are used to facilitate the identification of individuals who are candidates for testing for *TP53* P/LP variants.

Classic LFS criteria include, based on a study by Li and Fraumeni involving 24 LFS kindreds,⁵³⁹ a member of a kindred with a known *TP53* P/LP variant; a combination of an individual diagnosed at ≤45 years of age with a sarcoma and a first-degree relative diagnosed with cancer at ≤45 years of age; and an additional first- or second-degree relative in the same lineage with cancer diagnosed at <45 years of age or a sarcoma diagnosed at any age (see *Testing Criteria for Li-Fraumeni Syndrome* in the algorithm). Classic LFS criteria have been estimated to have a high positive predictive value (estimated at >50% and in >70% in some studies) as well as a high specificity, although the sensitivity is relatively low (estimated at 40%).^{91,522,540} Because individuals with *TP53* P/LP variants are likely to have cancers beyond the LFS core cancers, the classic criteria will miss a significant portion of families.^{532,541}

Other groups have broadened the classic LFS criteria to facilitate identification of individuals with LFS.^{542,543} For example, criteria for *TP53* testing proposed by Chompret and colleagues recommend testing for patients with multiple primary tumors of at least two “core” tumor types (ie, sarcoma, breast cancer, adrenocortical carcinoma, brain tumors) diagnosed at <36 years of age or patients with adrenocortical carcinoma diagnosed at any age, regardless of family history (see *Testing Criteria for Li-Fraumeni Syndrome* in the algorithm).⁵⁴³ The Chompret criteria have an estimated positive predictive value of 20% to 35%,^{522,543} and, when incorporated as part of *TP53* testing criteria in conjunction with classic LFS criteria, have been shown to improve the sensitivity to 95% (ie, the Chompret criteria added to classic LFS criteria detected 95% of patients with *TP53* P/LP variants).⁵²² Although not part of the original published



criteria set forth by Chompret et al, the Panel recommends adopting the 2015 Revised Chompret Criteria, including testing individuals with choroid plexus carcinoma or rhabdomyosarcoma of embryonal anaplastic subtype diagnosed at any age and regardless of family history (for inclusion in criterion 3), based on reports of considerable incidence of *TP53* P/LP variants found in patients with these rare forms of cancer.^{522,530,544-546} The Panel supports the broader age cut-offs proposed by Tinat et al, based on a study in a large number of families, which detected germline *TP53* P/LP variants in affected individuals with later tumor onsets.^{544,546} These age cut-offs are: 1) individuals diagnosed with LFS spectrum cancer <46 years of age who also have at least one first-degree relative (FDR) or second-degree relative (SDR) diagnosed with an LFS spectrum cancer <56 years of age or with multiple tumors; and 2) individuals with multiple tumors from an LFS spectrum cancer, with the first diagnosed at <46 years of age.⁵⁴⁶

Patients with early-onset breast cancer (age of diagnosis ≤30 years) who were AFAB, with or without family history of core tumor types, are another group for whom *TP53* gene P/LP variant testing may be considered.⁵⁴⁵ Several studies have investigated the likelihood of a germline *TP53* P/LP variant in this population.^{522,544,547-550} Among females <30 years of age with breast cancer and without a family history, the incidence of *TP53* P/LP variants has been reported at 3% to 8%.^{522,548,550,551} Some studies have also suggested that amplification of *HER2* may arise in conjunction with germline *TP53* P/LP variants.^{94,552-554} *TP53* P/LP variants are a common finding across cancer types on tumor-only genomic testing,^{555,556} but usually do not warrant consideration of germline testing.⁵⁵⁷ A recent analysis showed that the germline conversion rate (GCR, defined as the fraction of patients with a *TP53* P/LP variant on tumor-only testing that is determined to be germline on blood- or saliva-based genetic testing) of *TP53* P/LP variants was only 0.9% for tumors from all age patients and 5.1% for patients age <30.⁵⁵⁷ In the absence of paired germline analysis, germline testing should be offered if the personal or family history provides

sufficient clinical suspicion of a germline P/LP variant. Consistent with European Society of Medical Oncology (ESMO) recommendations,⁵⁵⁸ the Panel also recommends that germline testing be offered to all patients who were diagnosed with any cancer at age <30 years.

Lastly, when *TP53* is included on multigene germline panels, the NCCN testing criteria for LFS are often not met. It has been argued that a spectrum of heritable *TP53*-related cancer syndromes exist.⁵⁵⁹ One study described families with *TP53* P/LP variants falling into a spectrum from classic LFS to attenuated families who do not meet criteria. These definitions will help future LFS research describe the populations being studied, but at this time LFS management is recommended for all individuals with P/LP *TP53* variants regardless of the presentation in the family.⁵⁶⁰

If a *TP53* P/LP variant is found in blood, saliva, or buccal samples, especially in individuals whose personal or family history does not meet LFS criteria, this warrants consideration of testing of an alternative tissue, usually cultured skin fibroblasts, and close relatives to try to distinguish between germline, constitutional mosaicism, and somatic findings, such as CH or tumor contamination of peripheral blood. For patients who have a personal history of cancer, the Panel also recommends looking for signs of tumor somatic interference and technical limitations.

A table describing workup and management depending on etiology of *TP53* P/LP variant found on genetic testing was added to the Guidelines for the 2024 update. The intent of this new table was to expand on potentially mosaic *TP53* findings. Prior to publication of this table, the Guidelines did not sufficiently point out the possibility of post-zygotic (somatic or constitutional) mosaicism (PZM) versus abnormal clonal expansions (ACE; including CHIP and clonal cytopenia of undetermined significance [CCUS]) and did not provide adequate guidance regarding how to care for these patients. A review of 84 *TP53*-positive probands



identified through multigene testing on blood or saliva from 2012 to 2019 showed constitutional mosaicism in 8.3% of probands.⁵⁶¹ CHIP and mosaic chromosomal alterations are associated with increased risk of breast cancer.⁵⁶² Ancillary tissue testing and cascade testing of children in all PZM and ACE *TP53* P/LP variant carriers is recommended, as this will further facilitate diagnosis and management.⁵⁶³ In addition, the clinical features that suggest CH versus PZM when a *TP53* P/LP variant is in the range of 30% to 70% variant allele frequency (VAF), in a patient with no prior chemotherapy and no hematologic abnormality, continue to be unknown.

Risk Assessment, Counseling, and Management

Discussions with patients about LFS management should address the limitations of screening for the many cancers associated with this syndrome. It is also important to address the psychosocial and quality-of-life aspects of this syndrome. Given the complexity of LFS management and that LFS is rare, individuals with LFS should be followed at centers with expertise in management of this syndrome. Personal and family history of cancer should be taken into consideration for screening (ie, specific screenings, 5 to 10 years before earliest diagnosis). It is also important for patients' primary care providers and/or pediatricians to be informed about patients' diagnoses of LFS. Patients should be advised about the risk to relatives, and genetic counseling for relatives is recommended.⁵⁶⁴ For the 2024 Guidelines update, the Panel added a section on pediatric surveillance in LFS.

Breast screening in adults with LFS includes clinical examination, breast imaging (MRI and mammogram, as indicated), and breast awareness. Although there are no data regarding risk reduction surgery, individuals with LFS who were AFAB have increased breast cancer risk that warrants consideration of RRM. Given the high risk of contralateral breast cancer in LFS, the option of contralateral RRM should be discussed with patients

diagnosed with breast cancer.⁵⁶⁵ Counseling for risk-reducing surgeries may include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, degree of age-specific cancer risk, reconstructive options, and competing risks from other cancers. Family history and life expectancy should also be considered.

Use of a screening protocol that includes MRI may improve early cancer detection in individuals with LFS.^{564,566} Whole-body MRI for screening of cancers associated with LFS continues to be evaluated in multiple international trials. Use of whole-body MRI is appealing due to its wide anatomic coverage, lack of radiation, and the potential to reduce the number of imaging studies that a patient undergoes.⁵⁶⁷ A meta-analysis including 578 individuals with *TP53* P/LP variants across 13 prospective cohorts showed that baseline whole-body MRI identified cancer in 7% of the sample, with 83% of the cancers being localized and able to treat with curative intent.⁵⁶⁸ In a prospective observational study, a clinical surveillance protocol for carriers of a *TP53* P/LP variant from families affected by LFS was incorporated.⁵⁶⁹ Eleven-year follow-up of this study, which included 89 carriers of a *TP53* P/LP variant, showed that this surveillance protocol may be beneficial, with 84% (16 of 19) of patients who were diagnosed with cancer while under surveillance being alive at final follow-up, compared to 49% (21 of 43) of patients who were not being surveilled and were diagnosed with cancer due to symptoms ($P = .012$).⁵⁷⁰ Five-year OS was greater for patients undergoing surveillance (88.8%) compared to patients not undergoing surveillance (59.6%; $P = .013$). Based on these study results, the Panel recommends annual whole-body MRI.⁵⁶⁴ It is important to note that, to date, data on the effectiveness of whole-body MRI have come from centers performing a high volume of these cancer screenings. Also, whole-body MRI protocols may vary. The Panel acknowledges that this surveillance method may not be uniformly available or affordable. Patients who do not have access to whole-body MRI should be encouraged to enroll in clinical trials and to work with their

clinicians to develop an alternative screening program based on available cancer screening approaches. The Panel also acknowledges that whole-body MRI screening of all individuals with LFS may result in false positives and overdiagnosis.^{568,571} Further, the utility of whole-body MRI has not been evaluated in individuals with a *TP53* P/LP variant who do not have a classic family history of LFS, a group that is increasingly being identified through multigene testing. The brain may be examined as part of whole body MRI or as a separate exam.

In addition to whole body MRI, the Panel recommends additional screening modalities for certain cancers. Individuals AFAB should begin breast cancer screening with annual clinical breast exam and breast MRI at age 20 and the addition of annual mammogram at age 30. The Panel recommends colonoscopy and upper endoscopy every 2 to 5 years starting at ≤25 years in the context of prior abdominal radiation or family history. Dermatologic exams are recommended. Finally, prostate cancer screening with PSA is recommended beginning at age 40.

Many of the other cancers associated with germline *TP53* P/LP variants do not lend themselves to early detection. Thus, additional recommendations for adults with LFS are general and include comprehensive physical examinations (including neurologic examination) every 6 to 12 months, especially when there is a high index of suspicion for second malignancies in cancer survivors and rare cancers. Clinicians should address screening limitations for other cancers associated with LFS. Screening methods for other LFS-associated cancers include periodic colonoscopy and upper endoscopy, dermatologic examination, and PSA. Education regarding signs and symptoms of cancer is important. Cancer screening in LFS should take into account prior treatment with radiation therapy.

Individuals with a *TP53* P/LP variant are at increased risk of second malignant neoplasms.^{545,572} Radiosensitivity in individuals with a *TP53*

P/LP variant is not significantly different than in the general population,^{573,574} but carriers seem to be more susceptible to radioresistance.^{526,574,575} Though use of therapeutic RT should generally be avoided in individuals with a *TP53* P/LP variant, clinical decision-making should take into account the availability of other curative treatment options.

There is little evidence regarding care of *TP53* P/LP variant carriers with PZM or hypomorphic variants. Until there are more data on these carriers, they should be cared for as LFS, as opposed to patients with *TP53* CH, which should not be managed as LFS. Instead, given *TP53* mutation is considered a high-risk clinical feature in CH, patients with *TP53* CH may be referred to hematology expertise.^{576,577}

Cowden Syndrome/*PTEN* Hamartoma Tumor Syndrome

The spectrum of disorders resulting from germline P/LP variants in *PTEN*⁵⁷⁸ are referred to as PHTS. The spectrum of PHTS includes Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome (BRRS), adult Lhermitte-Duclos disease (LDD), Proteus-like syndrome,^{90,579,580} and autism spectrum disorders with macrocephaly.^{90,580,581} Cowden syndrome is rare, with an incidence of 1 in 200,000, although it is likely to be underestimated due to difficulties associated with making a clinical diagnosis of the disease.^{582,583} Cowden syndrome is an autosomal dominant disorder, and most cases are associated with germline *PTEN* P/LP variants, though one study found that germline *KILLIN* methylation may also be associated with this syndrome.⁵⁸⁴ The frequency of germline *PTEN* P/LP variant in Cowden syndrome cases is high, at approximately 80%.⁵⁸⁵

Hamartomas (benign tumors resulting from an overgrowth of normal tissue) are a common manifestation of the PHTS syndromes. Cowden syndrome is associated with multiple hamartomatous and/or cancerous

lesions in various organs and tissues, including the skin, mucous membranes, breast, thyroid, endometrium, and brain.^{90,586} However, it has been suggested that patients with other PHTS diagnoses associated with *PTEN* P/LP variants should be assumed to have Cowden syndrome-associated cancer risks.

The lifetime risk for breast cancer for females diagnosed with Cowden syndrome/PHTS has been estimated at 40% to 60%, with an average age of 38 to 50 years at diagnosis.^{90,587} Some studies (as discussed above) have reported a higher cumulative lifetime risk for breast cancer (77%–85%) in individuals with Cowden syndrome/PHTS or *PTEN* P/LP variants.^{588–591} A large European cohort study estimated lifetime risk for breast cancer in females as 54.3% to 75.8%.⁵⁹² There have been only two cases of breast cancer reported in males with Cowden syndrome/PHTS.⁵⁸⁷ Although many females with Cowden syndrome/PHTS experience benign breast disease,⁹⁰ there is no evidence that the rate is higher than in the general population.⁵⁸⁷

Thyroid disease, including benign multinodular goiter, adenomatous nodules, and follicular adenomas, has been reported to occur in approximately 30% to 68% of adults with *PTEN* P/LP variants,^{580,593} and the lifetime risk for thyroid cancer (follicular or papillary) has been estimated at 3% to 16.5%.^{90,592,594} However, data tend to be aggregated, so it is difficult to calculate rates for multinodular goiter versus solitary nodules.⁵⁸⁷ A retrospective chart review of 47 children with *PTEN* P/LP variants showed that 26% had abnormal thyroid imaging.⁵⁹⁵ The youngest reported case of thyroid cancer in a child with Cowden syndrome/PHTS was at age 7.⁵⁹⁶

Macrocephaly (defined as head circumference >97th percentile)⁵⁹⁷ is a common finding in patients with Cowden syndrome/PHTS. It has been estimated that approximately 80% to 100% of individuals with this syndrome will exhibit this clinical finding.⁵⁸⁷ Adult LDD and autism

spectrum disorder characterized by macrocephaly are strongly associated with Cowden syndrome/PHTS.^{579,585,589,598} A rare, slow-growing, benign hamartomatous lesion of the brain, LDD, is a dysplastic gangliocytoma of the cerebellum.^{90,589} In a multicenter prospective study examining 3042 probands who met clinical criteria for Cowden syndrome/PHTS, 6% met criteria for LDD.⁵⁹³ In a study of individuals meeting the diagnostic criteria for Cowden syndrome/PHTS, the cumulative lifetime risk for LDD was reported to be 32%.⁵⁸⁹ The preponderance of evidence supports a strong association between adult-onset LDD and the presence of a *PTEN* P/LP variant,^{585,599} although exceptions have been reported.⁶⁰⁰ In addition, there is a relatively large body of evidence to support that 10% to 20% of individuals with autism spectrum disorder and macrocephaly carry germline *PTEN* P/LP variants.^{581,601–604}

As in many other hereditary cancer syndromes, affected individuals are more likely to develop bilateral and multifocal cancer in paired organs.⁵⁸⁵ Although not well defined, females with Cowden syndrome/PHTS may have a 5% to 22% risk for endometrial cancer.^{90,587,592,605} While many females with Cowden syndrome/PHTS may also have uterine fibroids, this risk is not likely to be much greater than in females without Cowden syndrome/PHTS or *PTEN* P/LP variant.⁵⁸⁷

In addition, brain tumors and vascular malformations affecting any organ are occasionally seen in individuals with Cowden syndrome/PHTS, although the risks for developing these conditions are not well defined.^{90,587} It is important to note, however, that most of the data on the frequencies of the clinical features of Cowden syndrome/PHTS are from compilations of case reports of relatively young individuals who may have subsequently developed additional signs of the disease (ie, new cancerous lesions), and these data are also likely to be confounded by selection bias.⁹⁰ Furthermore, a considerable number of these studies were published prior to the establishment in 1996 of the International



Cowden Consortium operational diagnostic criteria for the syndrome, which were based on published data and the expert opinion of individuals representing a group of centers mainly in North America and Europe.^{90,606}

Benign skin lesions are experienced by most to all patients with Cowden syndrome/PHTS.^{580,586,595} Skin lesions associated with Cowden syndrome/PHTS include trichilemmomas (ie, benign tumors derived from the outer root sheath epithelium of a hair follicle), oral papillomas, mucocutaneous neuromas (hamartoma of the peripheral nerve sheath), palmoplantar keratoses, penile pigmentation, lipomas and vascular anomalies, and fibromas.^{587,595,607} Trichilemmomas associated with Cowden syndrome/PHTS tend to appear on the face, particularly the eyes, mouth, nose, and forehead.⁵⁸⁷ Most individuals with Cowden syndrome/PHTS exhibit characteristic mucocutaneous lesions by their twenties, and such lesions have been reported to occur in 99% of individuals with Cowden syndrome/PHTS, showing nearly complete penetrance, although this may be a reflection of selection bias in the cases reported.^{166,579} The presence of three or more mucocutaneous neuromas is considered a major diagnostic criterion of Cowden syndrome/PHTS,⁵⁸⁷ while the presence of two or more trichilemmomas has been reported to be pathognomonic for Cowden syndrome/PHTS.^{608,609} However, since most of the evidence regarding trichilemmomas is from the older literature, it is possible that the association with Cowden syndrome/PHTS is somewhat overestimated.⁹⁰ There are reports of individuals with a solitary trichilemmoma who do not have Cowden syndrome/PHTS.^{608,609} Nevertheless, due to the strong association between these lesions and Cowden syndrome/PHTS and the difficulty in clinically distinguishing between a trichilemmoma and another mucocutaneous lesion, it is important that a diagnosis of trichilemmoma is histologically confirmed.

It was previously estimated that about half of individuals with Cowden syndrome/PHTS have gastrointestinal polyps.⁶¹⁰ However, this was almost

certainly an underestimate.^{610,611} In an analysis of 67 *PTEN* P/LP variant carriers undergoing colonoscopy, colorectal polyps were found in 92.5% of patients.⁶¹⁰ About half of the patients undergoing colonoscopy had hyperplastic polyps, and about 25% had polyps that were hamartomatous, ganglioneuromatous, or adenomatous.⁶¹⁰ Adenomatous or hyperplastic polyps were associated with development of colorectal cancer in this sample. Out of 39 carriers of a *PTEN* P/LP variant undergoing esophagogastroduodenoscopy (EGD), upper gastrointestinal polyps were found in 67% of patients.⁶¹⁰ A systematic review of published case series (N = 102) regarding gastrointestinal manifestations in Cowden syndrome/PHTS and component syndromes showed that 92.5% of these patients had polyps, with 64% having ≥ 50 .⁶¹² Histologies were described as: hyperplastic (44%), adenomatous (40%), hamartomatous (38%), ganglioneuroma (33%), and inflammatory (24.5%). Other studies have also reported ganglioneuromatous polyps (ie, rare, benign peripheral nervous system tumors) in this population.^{587,613} A retrospective chart review of 47 children with *PTEN* P/LP variants showed that only 13% had gastrointestinal polyps, but 34% had other gastrointestinal symptoms such as abdominal pain, rectal bleeding, and/or constipation.⁵⁹⁵ Early-onset (<50 years of age) colorectal cancer has been reported in 13% of patients with *PTEN* P/LP variant-associated Cowden syndrome/PHTS, suggesting that routine colonoscopy may be warranted in this population.⁶¹⁰ The lifetime risk for colorectal cancer has been estimated as 9% to 16%.^{589,590}

Several studies have projected lifetime estimates of cancer risk that are significantly higher than previously estimated. In a study of patients meeting diagnostic criteria for Cowden syndrome/PHTS (N = 211; identified from published literature and records from a single institution), the cumulative lifetime risk for any cancer was 89%.⁵⁸⁹ *PTEN* P/LP variants had been identified in 97 of 105 patients (92%) who underwent testing. The cumulative lifetime cancer risks for all patients (n = 210) were 81% for female breast cancer, 21% for thyroid cancer, 19% for

endometrial cancer, 15% for renal cancer, and 16% for colorectal cancer.⁵⁸⁹ In a prospective study that evaluated genotype-phenotype associations between *PTEN* P/LP variants and cancer risks,⁵⁹⁰ deleterious germline P/LP variants in *PTEN* were identified in 368 patients.

Calculation of age-adjusted SIRs using cancer incidence data from the SEER database showed elevated SIRs among individuals with *PTEN* P/LP variants for breast cancer (25), thyroid cancer (51), endometrial cancer (43), colorectal cancer (10), renal cancer (31), and melanoma (8.5). The estimated cumulative lifetime cancer risks were 85% for breast, 35% for thyroid, 28% for endometrial, 9% for colorectal, 34% for renal, and 6% for melanoma.⁵⁹⁰ In another study in individuals with PHTS found to have deleterious germline *PTEN* P/LP variants (N = 154; detailed information available in n = 146), age- and gender-adjusted SIRs were elevated for female breast cancer (39), endometrial cancer (49), female thyroid cancer (43), male thyroid cancer (199.5), female melanoma (28), and male melanoma (39).⁵⁸⁸ The cumulative lifetime risks in these individuals were 77% for female breast cancer and 38% for thyroid cancer. The cumulative lifetime risk for any cancer was 85% overall, and females with Cowden syndrome/PHTS were found to have a 2-fold greater cancer risk compared with males with Cowden syndrome/PHTS.⁵⁸⁸ It is important to note, however, that all three of these studies suffer from significant ascertainment biases, in that patients were usually selected for *PTEN* testing based on the presence of these malignancies, which would inflate the projected lifetime cancer estimates. An observational study of 180 patients with *PTEN* P/LP variants used Kaplan-Meier methods to estimate that female carriers (n = 99) have an 87% cumulative risk of developing any cancer and/or LDD by 60 years of age, while male carriers have a cumulative risk of 56%.⁶¹⁴

The BRRS variant of Cowden syndrome/PHTS has been characterized by the presence of multiple lipomas, gastrointestinal hamartomatous polyps, macrocephaly, hemangiomas, developmental delay, and pigmented

macules on the glans penis,⁶¹⁵ although formal diagnostic criteria have not been established for this syndrome. *PTEN* gene P/LP variants testing in individuals characterized with BRRS have been reported in approximately 60% of these patients.⁶¹⁶ Further, in another study, 10% of patients with BRRS for whom a *PTEN* P/LP variant test was negative were shown to be carriers of large *PTEN* gene deletions.⁵⁹⁸

Risk Assessment, Counseling, and Management

The assessment of individuals suspected of having Cowden syndrome/PHTS incorporates both a history of the benign and malignant conditions associated with the syndrome and a targeted physical examination, including the skin and oral mucosa, breast, thyroid gland, and head circumference (see *Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm). The NCCN Guidelines Panel has established a list of criteria to help indicate which individuals are candidates for testing for *PTEN* P/LP variants (see *Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm). These criteria are used to assess the need for further risk assessment and genetic testing. When *PTEN* is included on multigene panels, these testing criteria do not need to be met. Clinical diagnostic criteria have also been developed to help identify clinical features associated with Cowden syndrome/PHTS (see *Diagnostic Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm, and discussed below under *Diagnostic Criteria*). Patients who meet clinical diagnostic criteria for Cowden syndrome/PHTS as described in this section are candidates for testing for *PTEN* P/LP variants.

Testing Criteria

Testing criteria for Cowden syndrome/PHTS are grouped into three general categories. A patient is considered for testing for *PTEN* P/LP variants based on whether they meet certain criteria or combinations of criteria from these three categories. The first criteria category includes



individuals meeting diagnostic criteria for Cowden syndrome⁶¹⁷: a personal history of BRRS, adult LDD, autism spectrum disorder with macrocephaly, or ≥ 2 biopsy-proven trichilemmomas. Any individual presenting with ≥ 1 of these diagnoses warrants *PTEN* testing. Previously, some of the criteria from this group have been referred to as “pathognomonic,” although it is unlikely that any of these conditions can stand alone as a definitive diagnostic criterion for Cowden syndrome/PHTS. Another criterion that can be considered to be sufficient to warrant testing for *PTEN* P/LP variants is a family history that includes the presence of a known *PTEN* P/LP variant.

The next category of criteria represents “major” features associated with Cowden syndrome/PHTS and are described in the Guidelines (see *Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm).^{580,583,593,597,617} With respect to decisions related to the presence of mucocutaneous lesions, the Panel did not consider the available literature to be adequate to accurately specify the number or extent of these lesions required for the condition to be defined as a major criterion for Cowden syndrome/PHTS, and clinical judgment is needed when evaluating such lesions. An individual exhibiting ≥ 2 major criteria where one criterion is macrocephaly meets the testing threshold. An individual with ≥ 3 major criteria (without macrocephaly) is also considered to meet the threshold for testing. In addition, individuals exhibiting one major criterion with ≥ 3 minor criteria (see *Testing Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm) also meet the testing threshold; if an individual exhibits ≥ 2 major criteria but does not have macrocephaly, then one of the major criteria may be included as one of the three minor criteria to meet the testing threshold.

The final category of criteria represents features with a “minor” association with Cowden syndrome/PHTS.^{580,583,593,617} These criteria are described in the Guidelines (see *Testing Criteria for Cowden Syndrome/PTEN*

Hamartoma Tumor Syndrome in the algorithm). An individual would need to exhibit ≥ 4 minor criteria or as discussed above, ≥ 3 minor criteria and one major criterion to meet testing.

Lastly, an individual who has a first-degree relative diagnosed with Cowden syndrome/PHTS or BRRS for whom testing has not been performed would also meet the threshold for *PTEN* testing if the individual meets at least one major criterion or ≥ 2 minor criteria. *PTEN* P/LP variants are commonly found in tumor tissue.⁶¹⁸⁻⁶²⁰ If a *PTEN* variant is detected through tumor profiling and would be classified as P/LP if present in the germline, then germline testing for *PTEN* should be considered.

Diagnostic Criteria

The frequency of *PTEN* P/LP variant in individuals meeting International Cowden Consortium diagnostic criteria for Cowden syndrome has previously been estimated at about 80%.^{587,616} However, evaluation of data based on samples analyzed at a single academic pathology laboratory (N = 802 evaluable) reported a much lower frequency (34%) of *PTEN* P/LP variants among individuals meeting diagnostic criteria⁵⁸³ for Cowden syndrome.⁵⁸⁰ The authors concluded that the current Consortium diagnostic criteria are not as sensitive in identifying individuals with *PTEN* P/LP variants as previously estimated. Since *PTEN* P/LP variants are relatively rare, recommendations regarding Cowden syndrome diagnostic criteria may be based on studies with a small number of patients. Studies with larger samples have their flaws as well, as patients are selected for testing based on the number and magnitude of clinical features, which may lead to overestimation of the features of Cowden syndrome.⁵⁸⁷ A review was conducted examining each consortium diagnostic criterion, and revised criteria were proposed that are more stringent and take into account clinical features that are often seen in PHTS.⁵⁸⁷ The criteria were designed by focusing on clinical features associated with *PTEN* P/LP variants. The Panel recommends using these criteria for clinical diagnosis



of PHTS (see *Diagnostic Criteria for Cowden Syndrome/PTEN Hamartoma Tumor Syndrome* in the algorithm).

Screening Recommendations

Cancer is the major health risk associated with Cowden syndrome/PHTS. Therefore, the NCCN Panel has outlined guidelines for prevention and early detection screening of commonly associated cancers with Cowden syndrome/PHTS. Current medical management recommendations for Cowden syndrome/PHTS include annual physical examinations, starting at 18 years of age (or 5 years before the youngest age of diagnosis of a component cancer in the family).

The recommendations for individuals with Cowden syndrome/PHTS who were AFAB focus on primary and secondary prevention options for breast cancer since this is the most commonly associated cancer in individuals with Cowden syndrome/PHTS based on the available literature. Individuals AFAB should begin regular monthly breast self-examinations at 18 years of age and have a semiannual clinical breast examination beginning at 25 years of age or 5 to 10 years earlier than the earliest known breast cancer in the family (whichever comes first). Individuals AFAB should also have an annual mammogram and breast MRI screening with and without contrast starting at 30 years of age, or 10 years earlier than the earliest known breast cancer in the family (whichever comes first). After 75 years of age, management should be considered on an individual basis. In patients treated for breast cancer who were AFAB and who have not had bilateral mastectomy, mammography and breast MRI screening with contrast should continue as recommended based on age. A single-center retrospective study including 65 females diagnosed with PHTS showed that the yield of breast cancer screening (MRI and mammography) is comparable in this population, compared to other carriers of high-penetrance breast cancer susceptibility genes (eg, *BRCA1/2*).⁶²¹

Although there are no data regarding risk reduction surgery in individuals with Cowden syndrome who were AFAB, the option of RRM and hysterectomy should be discussed. Oophorectomy is not indicated for Cowden syndrome since ovarian cancer risk is not elevated in these patients. Counseling for risk-reducing surgeries may include discussion of extent of cancer risk reduction/protection, risks associated with surgeries, and reproductive options. It is also important to address the psychosocial and quality-of-life aspects of undergoing risk-reducing surgical procedures.

Given that Cowden syndrome is rare, there are no data on screening for endometrial cancer in these patients, though consideration of screening can begin as early as age 35. The Panel recommends patient education regarding the symptoms of endometrial cancer including the necessity of a prompt response to symptoms such as abnormal bleeding. Prompt reporting promotes early detection of endometrial cancer. The evaluation of these symptoms should include an endometrial biopsy. Though endometrial cancer screening does not have proven benefit in individuals with Cowden syndrome, endometrial biopsy is highly sensitive and specific as a diagnostic procedure. Therefore, screening through endometrial biopsy every 1 to 2 years may be considered.

Routine TVUS to screen for endometrial cancer in postmenopausal individuals has not been shown to be sufficiently sensitive or specific to warrant a positive recommendation but may be considered at the clinician's discretion. However, TVUS is not recommended as a screening tool in premenopausal individuals due to the wide range of endometrial strip thickness throughout the normal menstrual cycle.

Individuals with Cowden syndrome/PHTS have approximately at least a 3% to 10% lifetime risk of developing thyroid cancer,⁹⁰ compared to about 1% in the general population.⁶²² An annual thyroid ultrasound should be performed, starting at age 7.⁶²³ Children at risk for a *PTEN* P/LP variant (based on a parent's carrier status) whose parents wish to delay genetic



testing may also undergo annual thyroid ultrasound, since this is a noninvasive procedure. Colonoscopy is recommended starting at 35 years of age, or earlier if symptomatic. If a close relative was diagnosed with colon cancer before 40 years of age, then colonoscopy screening should begin 5 to 10 years before the age of the earliest known diagnosis. Colonoscopy should be performed every 5 years or more frequently in cases where the patient is symptomatic or polyps are found. To screen for renal cell carcinoma, renal ultrasound should be considered every 1 to 2 years beginning at 40 years of age. Annual dermatologic examination is recommended. If there are symptoms in children, then assessment of psychomotor abilities should be considered, as well as a brain MRI. Education regarding the signs and symptoms of cancer is important; patients should also be advised about the risk to relatives, and genetic counseling is recommended for relatives as indicated.

No published data exist on the use of prenatal diagnostics/genetic testing for *PTEN* P/LP variants in families with Cowden syndrome. For a general discussion on the topic of reproductive options and counseling considerations, see the Discussion section above on *Reproductive Options* under *Genetic Risk Assessment and Counseling*.

Hereditary Pancreatic Cancer

Pancreatic cancer is thought to have a familial or hereditary component in approximately 10% of cases.^{204,205,624-626} Harboring a P/LP variant has been found to be associated with a greater incidence of pancreatic cancer than family history alone (without the presence of an associated germline variant).⁶²⁷ An analysis of 250 patients with pancreatic cancer who underwent multigene panel testing with a >80 gene panel showed that 15% harbored a P/LP variant.⁶²⁸ Germline P/LP variants found in pancreatic adenocarcinoma include *BRCA1*, *BRCA2*, *CDKN2A*, *ATM*, *PALB2*, *STK11*, *TP53*, as well as MMR genes associated with Lynch syndrome (specifically *MSH2*, *MLH1*, *MSH6*, and

EPCAM).^{93,198,200,202,205,381,382,625,627,629-639} *BRCA2* and *CDKN2A* are generally the most prevalent, with rates in families at moderate to high risk ranging from 2% to 6% for *BRCA2* and 1.5% to 2.5% for *CDKN2A*.^{195,199,204,205} In addition, hereditary pancreatitis, which is associated with increased risk for pancreatic cancer, is associated with the genes *PRSS1* and *SPINK1*.⁶²⁵ Patients with pancreatic cancer and Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a *BRCA1/2* P/LP variant, with prevalence of detected P/LP variants in this group ranging from 5.5% to 19%, with P/LP variants being more common for *BRCA2*.^{197,198,200,206}

Given the considerable rate of predisposing P/LP variants in patients with pancreatic cancer, as well as the fact that typical clinical factors (eg, young age of onset, family history of cancer) are poorly predictive for identifying carriers of a P/LP variant, universal genetic testing for these individuals is warranted. Given the elevated rates of P/LP variants in pancreatic cancer and that pancreatic cancer risk increases when there is a family history,⁶⁴⁰⁻⁶⁴² testing of first-degree relatives of patients may be beneficial. However, testing the patient is preferred. Testing of second-degree relatives is generally not recommended but may be considered in select cases. Given that mortality rates for this cancer are high,^{643,644} it may be beneficial to family members to test patients near the time of diagnosis, since the option to test the patient may not be available for very long. Family history of pancreatic cancer with unknown histology is often presumed to be exocrine. Detecting a germline P/LP variant can potentially aid in treatment decision-making, particularly regarding systemic therapy options (see *Systemic Therapy Decision-Making* above).

Pancreas Screening

Evidence to support screening for pancreatic cancer comes from studies including those who harbor an associated germline P/LP variant and/or those who have a particularly strong family history of pancreatic cancer (at



least one first-degree relative and at least one second-degree relative on the same side of the family). The multicenter CAPS5 prospective cohort study, which included 1461 individuals considered high risk (ie, P/LP carriers of *CDKN2A*, *STK11*, *ATM*, *BRCA1*, *BRCA2*, *MSH2*, *MLH1*, *MSH6*, *EPCAM*, or *PALB2*; or family history of ≥ 1 first-degree and 1 second-degree relative with pancreatic cancer), evaluated stage at diagnosis and outcome of individuals diagnosed with pancreatic cancer who underwent an annual pancreas imaging surveillance protocol.⁶⁴² Out of 10 patients diagnosed with pancreatic cancer, seven were diagnosed with stage I disease. Median OS was significantly greater in patients diagnosed with screening-detected pancreatic cancer, compared to patients diagnosed outside of the surveillance protocol (9.8 years vs. 1.5 years, respectively; HR, 0.13; 95% CI, 0.03–0.50; $P = .003$). An analysis of outcomes from three European centers including 411 asymptomatic individuals showed that pancreatic cancer was detected in 7% of carriers of a *CDKN2A* P/LP variant and $<1\%$ of those with familial pancreatic cancer.⁴⁹⁴ For the carriers of a *CDKN2A* P/LP variant for whom a lesion was detected, 75% were resectable, with a 5-year OS rate of 24%. A prospective study including 347 carriers of a germline *CDKN2A* P/LP variant who participated in a 20-year pancreatic cancer surveillance protocol at a medical center in the Netherlands showed that pancreatic adenocarcinoma was diagnosed in 20.7% of patients by age 70 years.⁶⁴⁵ Out of the 36 pancreatic cancers diagnosed, 83.3% were resectable, and 33.3% were diagnosed as stage I. Five-year OS in those who underwent resection was 44.1% (95% CI, 27.2–71.3). In a retrospective cohort study from Israel including 180 asymptomatic carriers of a P/LP *BRCA1/2* variant undergoing pancreatic cancer surveillance, adenocarcinoma was detected in four patients. Disease was resectable in three out of the four patients.⁶⁴⁶ In another analysis from six high-volume centers in Italy including 187 individuals at high risk, abnormalities were detected in about 28% of patients.⁶⁴⁷ Out of the cysts detected, 62.2% were branch-duct intraductal papillary mucinous neoplasms. Pancreatic adenocarcinomas

made up 2.6% of the findings ($n = 5$). Another analysis including screening of 354 asymptomatic individuals at high risk showed suspicious pancreas lesions in 19%.⁶⁴⁸ Out of the lesions detected from screening, 90% were resectable, and the 3-year OS rate was 85% in those with resectable lesions. Finally, a comparative cohort study conducted in the U.S. hospitals participating in the CAPS program compared 26 individuals at high risk (ie, based on family history or carrier of a germline P/LP variant associated with increased risk of pancreatic cancer [ie, *ATM*, *BRCA1*, *BRCA2*, *CDKN2A*, *PALB2*, or *STK11*]) who underwent annual pancreas surveillance to 1504 SEER control participants.⁶⁴⁹ In the individuals who underwent screening, median primary tumor size was smaller (2.5 cm vs. 3.6 cm, respectively; $P < .001$), stage of diagnosis was lower ($P < .001$), and survival outcomes were better, compared to the controls.

The considerable rate of resectable asymptomatic lesions found from routine screening of individuals at high risk demonstrates the potential for downstaging (ie, identification of lesions at an earlier stage). There is also the potential for impact on mortality rates, though long-term studies are needed in this area. Lesions detected through routine screening may not always require resection (eg, sporadic branch-duct intraductal papillary mucinous neoplasms). Although there is much more experience with evaluating and managing pancreatic cysts and other pancreatic imaging abnormalities, determination of the overall risk/benefits of pancreatic surveillance requires further study. Results of surveillance of individuals at high risk performed in tertiary care/high-volume centers under clinical trial settings may not be the same as those performed in routine clinical practice. Data are beginning to better define which screen-detected lesions in individuals at high risk should be considered to be at particularly high risk for neoplastic progression (eg, those with a solid pancreatic mass, those with pancreatic duct abnormalities, those with growing pancreatic cysts⁶⁵⁰), but further data are needed to better define the



threshold for surgical intervention in individuals at high risk undergoing pancreatic cancer screening.

With the exception of *CDKN2A*, *STK11*, *ATM*, and *BRCA2* pancreas cancer screening in individuals who have a P/LP variant associated with increased risk of exocrine pancreatic cancer (ie, *BRCA1*, *MSH2*, *MLH1*, *MSH6*, *EPCAM*, *PALB2*, *TP53*) is not recommended unless there is additional family history of pancreatic cancer (at least 1 first- or second-degree relative).⁶⁵¹ If family history criteria are met, then pancreas screening may be considered at age 50, or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier.⁶⁵¹ The International Cancer of the Pancreas Screening Consortium recommendations for pancreas screening in individuals with increased risk for hereditary pancreatic cancer do not include carriers of a *TP53* P/LP variant in this group,⁶⁵¹ as there are very limited data on pancreatic cancer screening in these carriers. However, the NCCN Guidelines Panel recommends that pancreatic cancer screening be considered in carriers of a *TP53* P/LP variant, if there is additional family history of pancreatic cancer (at least 1 first- or second-degree relative), as there is some evidence of a modestly increased risk of pancreatic cancer in these carriers.^{202,205}

For carriers of a *CDKN2A*, *STK11*, *ATM*, or *BRCA2* P/LP variant, no additional family history is needed to warrant screening. For carriers of an *ATM*, or *BRCA2* P/LP variant, screening may be considered at age 50, or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier.⁶⁵² For carriers of a *CDKN2A* P/LP variant, screening may be considered at age 40, or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier.⁶⁵¹ For carriers of a *STK11* P/LP variant, screening may be considered beginning at ages 30 to 35 years, or 10 years younger than the earliest pancreatic cancer diagnosis in the family, whichever is earlier.^{422,651}

Hereditary pancreatitis is defined by the presence of a causative P/LP variant such as *PRSS1* or *SPINK1*, or a suspicious family history of chronic pancreatitis (two first-degree relatives or three second-degree relatives across ≥ 2 generations) without precipitating factors and with a negative workup for other known causes of pancreatitis.⁶⁵³ Hereditary pancreatitis is associated with increased lifetime risk of exocrine pancreatic cancer.⁶⁵³⁻⁶⁵⁵ The clinical significance of the P/LP variant such as *PRSS1* or *SPINK1* is unclear without a clinical history of pancreatitis. Therefore, germline testing for *PRSS1*, *SPINK1*, and other genes associated with pancreatitis is generally not recommended unless one's personal or family history is suggestive of hereditary pancreatitis.⁶⁵³ Pancreas cancer screening is recommended in individuals harboring one of these variants only in the presence of a clinical phenotype consistent with hereditary pancreatitis. For individuals meeting these criteria, screening may begin at age 40, or 20 years after onset of pancreatitis, whichever is earlier.⁶⁵¹

When screening is recommended, it may be done with contrast-enhanced MRI/magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS).^{648,650,651} MRI and EUS have been shown to be superior in detection of subcentimeter pancreatic cysts, compared to CT.⁶⁵⁰ Screening at a high-volume center of expertise is recommended, preferably in the context of a longitudinal research study. In those for whom screening shows potentially concerning features that suggest progression, shorter screening intervals may be indicated.

Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender Diverse People with Hereditary Cancer Syndromes

Risk reduction strategies for ovarian cancer (including ovarian, fallopian tube, and peritoneal cancer), uterine cancer, prostate cancer, and breast cancer for transgender, non-binary, and gender diverse people who have



a hereditary predisposition to cancer were added to these Guidelines in 2023. This addition is part of an ongoing NCCN initiative that began in 2020, which states that the Guidelines recommendations should fully address the needs of individuals of all sexual orientations and gender identities. The terms transgender, non-binary, and gender diverse include a wide variety of physical and psychological states referring to individuals whose gender identity differs from the biological sex assigned at birth. According to a recent Gallup poll, transgender individuals represent 0.7% of all U.S. adults and 2.1% of those born from 1997 to 2003.⁶⁵⁶ A 2022 Pew Research Center survey of U.S. adults showed that 5.1% of individuals <30 of age identify as transgender or nonbinary.⁶⁵⁷

Transgender, nonbinary, and gender diverse people encounter many challenges to health care, including stigmatization, discrimination, abuse, and possible higher rates of mortality due to lack of access to appropriate preventive care and guidance.⁶⁵⁸ In addition, these individuals face health inequities associated with cancer. Most electronic health data, including SEER data, census data, and electronic health records (EHR) do not incorporate gender identity, thus hindering the collection of health data in these populations and denying appropriate screening invitations to these individuals.

Transgender women may have lower prostate cancer incidence relative to cisgender men.^{659,660} A retrospective cohort study including 95,460 transgender women in the United States showed that gender-affirming hormone therapy was associated with lower incidence of prostate cancer (OR, 0.60; 95% CI, 0.56–0.89; $P < .001$), but among those diagnosed with prostate cancer ($n = 589$), was associated with biochemical recurrence (OR, 1.83; 95% CI, 1.21–2.86; $P < .001$) and bone metastases (OR, 3.96; 95% CI, 1.50–9.99; $P < .001$).⁶⁶⁰ A propensity score-matched analysis including 1194 patients with prostate cancer (199 transgender women and 995 cisgender men) showed that OS was improved in transgender women

(HR, 0.67; $P = .014$), compared to cisgender men, though no other prostate cancer disease outcomes (metastatic disease, high-risk localized disease, prostate cancer-specific mortality) were significantly different between these groups.⁶⁶¹ The study investigators noted that the study was underpowered to detect modest differences. A case-control matched cohort study using 2018–2020 BRFSS data (including 255 transgender women and 1020 cisgender men) showed that transgender women were less likely to have reported PSA screening in the past 2 years, compared to cisgender men (OR, 0.65; 95% CI, 0.46–0.92; $P = .02$).⁶⁶² This difference was no longer statistically significant when adding clinician recommendation of a PSA test to the hierarchical regression model (OR, 0.83; 95% CI, 0.45–1.27; $P = .21$). Transgender women were less likely to report receiving a recommendation for a PSA by a clinician, compared to cisgender men (32.9% vs. 41.8%, respectively; $P < .001$). These results demonstrate the significance of clinician communication regarding the importance of prostate cancer screening among transgender women. More research is needed on appropriate threshold values for PSA screening in transgender women, given the effects of gender-affirming hormone therapy.⁶⁶³ For breast cancer, incidence is greater among transgender women than cisgender men, but lower among transgender men than cisgender women.⁶⁵⁹

Many transgender individuals pursue gender-affirming hormonal and/or surgical treatments at some point in their lives, which may impact their cancer risks, though management of their risk is challenging as a result of limited data on the impact of these treatments on cancer risk in transgender individuals. A retrospective cohort study conducted in the Netherlands showed that estrogen therapy may be associated with increased risk of breast cancer in transgender women, compared to cisgender men (SIR, 46.7; 95% CI, 27.2–75.4).⁶⁶⁴ However, the incidence of breast cancer in transgender women receiving hormone treatment was not significantly greater than breast cancer incidence in cisgender women



(SIR, 0.3; 95% CI, 0.2–0.4). Testosterone, a gender-affirming hormone therapy that may be used by transgender men, has been shown to reduce breast glandular tissue and increase connective tissue in these individuals.^{665,666}

There are no prospective data on appropriate prevention and/or screening options for transgender, nonbinary, or gender diverse individuals, regardless of whether they are at average risk or hereditary risk.

Therefore, recommendations for risk reduction must be made on a case-by-case basis depending on variables involved, which include age, family history, presence of a PV in relevant genes, and duration of use of gender-affirming hormone therapy. One way to approach risk reduction choices is to focus on those organs at risk based on biologic sex at birth. Specifically, organs at risk in those AFAB include the ovaries and uterus, while organs at risk in those AMAB include the prostate. Breast cancer risk should be considered elevated regardless of whether AMAB or AFAB. See the NCCN Guidelines for a complete list of cancer risk reduction strategies for transgender individuals with a hereditary risk for these cancers.

Individuals pursuing gender-affirming care should be followed at centers of excellence with access to a multidisciplinary team that understands their unique needs and provides a safe and welcoming environment. The team should include surgeons, primary care specialists, oncologists, radiologists, pathologists, endocrinologists, pediatricians, psychologists, genetic counselors, and social workers, all of whom are trained in the appropriate care of the transgender population and can address medical, psychologic, and social care needs. There is a need for formal education in the care of transgender, nonbinary, and gender diverse individuals at every level of the health care system. There is also a need for research regarding the impact of gender-affirming hormones and puberty-blocking agents and how they interact with hereditary susceptibility to cancer syndromes so that optimal prevention strategies for these populations may

be developed. Finally, a National Registry on the health outcomes of transgender, nonbinary, and gender diverse populations is needed to fill the many gaps in the magnitude and management of risks associated with gender-affirming treatment in the setting of hereditary cancer susceptibilities. As in all research involving human participants, care must be taken to preserve the privacy and protection of this population.

Table 1. Glossary of Relevant Genetic Terms (from the National Cancer Institute [NCI])

Autosomal dominant

Autosomal dominant inheritance refers to genetic conditions that occur when a P/LP variant is present in one copy of a given gene (ie, the person is heterozygous).

Autosomal recessive

Autosomal recessive inheritance refers to genetic conditions that occur only when P/LP variants are present in both copies of a given gene (ie, the person is homozygous for a P/LP variant, or carries two different variants of the same gene, a state referred to as compound heterozygosity).

de novo mutation

An alteration in a gene that is present for the first time in one family member as a result of a P/LP variant in a germ cell (egg or sperm) of one of the parents, or a P/LP variant that arises in the fertilized egg itself during early embryogenesis. Also called new P/LP variant.

Familial

A phenotype or trait that occurs with greater frequency in a given family than in the general population; familial traits may have a genetic and/or nongenetic etiology.

Family history

The genetic relationships within a family combined with the medical history of individual family members. When represented in diagram form using standardized symbols and terminology, it is usually referred to as a pedigree or family tree.

Founder effect

A P/LP variant observed with high frequency in a population founded by a small ancestral group that was once geographically or culturally isolated, in which one or more of the founders was a carrier of the mutant gene.

Germline

The cells from which eggs or sperm (ie, gametes) are derived.

Kindred

An extended family.

Pedigree

A graphic illustration of family history.

Penetrance

A characteristic of a genotype; it refers to the likelihood that a clinical condition will occur when a particular genotype is present.

Proband

The individual through whom a family with a genetic disorder is ascertained. In males this is called a propositus, and in females it is called a proposita.

Sporadic cancer

This term has two meanings. It is sometimes used to differentiate cancers occurring in people who do not have a germline P/LP variant that confers increased susceptibility to cancer from cancers occurring in people who are known to carry a variant. Cancer developing in people who do not carry a high-risk P/LP variant is referred to as sporadic cancer. The distinction is not absolute, because genetic background may influence the likelihood of cancer even in the absence of a specific predisposing variant. Alternatively, sporadic is also sometimes used to describe cancer occurring in individuals without a family history of cancer.



References

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759-767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2188735>.
2. Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet* 1993;9:138-141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8516849>.
3. Lynch HT, Watson P, Conway TA, Lynch JF. Clinical/genetic features in hereditary breast cancer. *Breast Cancer Res Treat* 1990;15:63-71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2322650>.
4. Pharoah PD, Day NE, Duffy S, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer* 1997;71:800-809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9180149>.
5. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2007;16:241-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17508274>.
6. Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med* 2008;359:2143-2153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19005198>.
7. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. *J Genet Couns* 2004;13:83-114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15604628>.
8. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. *Nat Genet* 2002;31:33-36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11984562>.
9. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 2015;136:3-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25238946>.
10. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. *Ann Oncol* 2015;26:1291-1299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25605744>.
11. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:271-281. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24366376>.
12. Weitzel JN, Blazer KR, MacDonald DJ, et al. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. *CA Cancer J Clin* 2011;61:327-359. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21858794>.
13. Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. *J Clin Oncol* 2017;35:2232-2239. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28402748>.
14. Ademuyiwa FO, Salyer P, Ma Y, et al. Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. *Breast Cancer Res Treat* 2019;178:151-159. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31325073>.
15. Kurian AW, Abrahamse P, Furgal A, et al. Germline genetic testing after cancer diagnosis. *JAMA* 2023;330:43-51. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37276540>.
16. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. *JAMA* 2007;297:2587-2595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17579227>.
17. Hong YC, Liu HM, Chen PS, et al. Hair follicle: a reliable source of recipient origin after allogeneic hematopoietic stem cell transplantation.



Bone Marrow Transplant 2007;40:871-874. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17704789>.

18. Tran SD, Pillemer SR, Dutra A, et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. *Lancet* 2003;361:1084-1088. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12672312>.

19. Weitzel JN, Chao EC, Nehoray B, et al. Somatic TP53 variants frequently confound germ-line testing results. *Genet Med* 2018;20:809-816. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29189820>.

20. Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. *JAMA* 2018;320:1266-1274. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/30264118>.

21. Esterling L, Wijayatunge R, Brown K, et al. Impact of a cancer gene variant reclassification program over a 20-year period. *JCO Precis Oncol* 2020;4. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32923914>.

22. Vail PJ, Morris B, van Kan A, et al. Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases. *J Community Genet* 2015;6:351-359. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/25782689>.

23. Lincoln SE, Yang S, Cline MS, et al. Consistency of BRCA1 and BRCA2 variant classifications among clinical diagnostic laboratories. *JCO Precis Oncol* 2017;1. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28782058>.

24. Balmana J, Digiovanni L, Gaddam P, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. *J Clin Oncol* 2016;34:4071-4078. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27621404>.

25. Horton C, Hoang L, Zimmermann H, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary

cancer testing. *JAMA Oncol* 2023. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/37924330>.

26. Eccles DM, Mitchell G, Monteiro AN, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. *Ann Oncol* 2015;26:2057-2065. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26153499>.

27. Badalato L, Kalokairinou L, Borry P. Third party interpretation of raw genetic data: an ethical exploration. *Eur J Hum Genet* 2017;25:1189-1194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28832567>.

28. Tandy-Connor S, Guiltinan J, Krempely K, et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. *Genet Med* 2018;20:1515-1521. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29565420>.

29. Kilbride MK, Bradbury AR. Evaluating web-based direct-to-consumer genetic tests for cancer susceptibility. *JCO Precis Oncol* 2020;4. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34970636>.

30. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med* 2013;15:565-574. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/23788249>.

31. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 2015;33:3660-3667. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26324357>.

32. Terraf P, Pareja F, Brown DN, et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. *Ann Oncol* 2022;33:426-433. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/35074424>.

33. Slavin TP, Banks KC, Chudova D, et al. Identification of incidental germline mutations in patients with advanced solid tumors who underwent



cell-free circulating tumor DNA sequencing. J Clin Oncol 2018;36:JCO1800328. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30339520>.

34. Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med 2021;59:1353-1361. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33856748>.

35. Offit K, Sharkey CM, Green D, et al. Regulation of laboratory-developed tests in preventive oncology: emerging needs and opportunities. J Clin Oncol 2022;JCO2200995. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35944238>.

36. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-1388. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16551709>.

37. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;32:2001-2009. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24733792>.

38. Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol 2018;4:1066-1072. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29801090>.

39. Hall MJ, Forman AD, Pilarski R, et al. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 2014;12:1339-1346. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25190699>.

40. Hall MJ, Obeid E, Daly MB. Multigene panels to evaluate hereditary cancer risk: reckless or relevant? J Clin Oncol 2016;34:4186-4187.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27551136>.

41. Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2

mutation testing in unselected general population women. J Natl Cancer Inst 2018;110:714-725. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29361001>.

42. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010;107:12629-12633. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20616022>.

43. LaDuca H, Polley EC, Yussuf A, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med 2020;22:407-415. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31406321>.

44. Bombard Y, Bach PB, Offit K. Translating genomics in cancer care. J Natl Compr Canc Netw 2013;11:1343-1353. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24225968>.

45. Rainville IR, Rana HQ. Next-generation sequencing for inherited breast cancer risk: counseling through the complexity. Curr Oncol Rep 2014;16:371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24488544>.

46. Blazer KR, Slavin T, Weitzel JN. Increased reach of genetic cancer risk assessment as a tool for precision management of hereditary breast cancer. JAMA Oncol 2016;2:723-724. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26869327>.

47. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016;13:581-588. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/27296296>.

48. van Marcke C, De Leener A, Berliere M, et al. Routine use of gene panel testing in hereditary breast cancer should be performed with caution. Crit Rev Oncol Hematol 2016;108:33-39. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27931838>.



49. LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. *Genet Med* 2014;16:830-837. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24763289>.
50. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. *JAMA Oncol* 2021;7:230-237. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33126242>.
51. Bychkovsky BL, Lo MT, Yussuf A, et al. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics. *Cancer* 2022;128:1275-1283. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34875721>.
52. van Os NJ, Roeleveld N, Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. *Clin Genet* 2016;90:105-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26662178>.
53. Southey MC, Goldgar DE, Winqvist R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet* 2016;53:800-811. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27595995>.
54. Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. *Breast Cancer Res* 2011;13:R73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21787400>.
55. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. *Genet Med* 2014;16:407-412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24113346>.
56. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. *Cancer* 2015;121:25-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25186627>.
57. Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. *Ann Surg Oncol* 2015;22:3282-3288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26219241>.
58. Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. *J Clin Oncol* 2021;39:1631-1640. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33560870>.
59. Makhnoon S, Bednar EM, Krause KJ, et al. Clinical management among individuals with variant of uncertain significance in hereditary cancer: a systematic review and meta-analysis. *Clin Genet* 2021;100:119-131. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33843052>.
60. Renaux-Petel M, Charbonnier F, Thery JC, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. *J Med Genet* 2018;55:173-180. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29070607>.
61. Berry DK, Gillis N, Padron E, et al. Interpretation of ambiguous TP53 test results: mosaicism, clonal hematopoiesis, and variants of uncertain significance. *J Genet Couns* 2024;33:916-926. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37715966>.
62. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014;371:2488-2498. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25426837>.
63. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med* 2014;371:2477-2487. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25426838>.
64. Kuchenbaecker KB, McGuffog L, Barrowdale D, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in



BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2017;109.
Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28376175>.

65. Barnes DR, Rookus MA, McGuffog L, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med 2020;22:1653-1666. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32665703>.

66. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol 2017;35:2240-2250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28448241>.

67. Barnes DR, Silvestri V, Leslie G, et al. Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores. J Natl Cancer Inst 2022;114:109-122. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34320204>.

68. Pashayan N, Pharoah PD, Schleutker J, et al. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer 2015;113:1086-1093. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26291059>.

69. Seibert TM, Fan CC, Wang Y, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ 2018;360:j5757. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29321194>.

70. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020;12:44. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32423490>.

71. Lakeman IMM, Rodriguez-Gironde MDM, Lee A, et al. Clinical applicability of the polygenic risk score for breast cancer risk prediction in familial cases. J Med Genet 2023;60:327-336. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36137616>.

72. Genetic Information Non-Discrimination Act of 2008 (GINA). Vol. Public Law No. 110-233. Available at: <https://www.eeoc.gov/laws/statutes/gina.cfm>.

73. Calzone KA, Soballe PW. Genetic testing for cancer susceptibility. Surg Clin North Am 2008;88:705-721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18672137>.

74. Forrest LE, Young MA. Clinically significant germline mutations in cancer-causing genes identified through research studies should be offered to research participants by genetic counselors. J Clin Oncol 2016;34:898-901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26786918>.

75. Cohen SA, Bradbury A, Henderson V, et al. Genetic counseling and testing in a community setting: quality, access, and efficiency. Am Soc Clin Oncol Educ Book 2019;39:e34-e44. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31099680>.

76. Berliner JL, Fay AM, Cummings SA, et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 2013;22:155-163. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23188549>.

77. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003;95:1548-1551. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14559878>.

78. Cragun D, Camperlengo L, Robinson E, et al. Differences in BRCA counseling and testing practices based on ordering provider type. Genet Med 2015;17:51-57. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24922460>.

79. Katz SJ, Ward KC, Hamilton AS, et al. Gaps in receipt of clinically indicated genetic counseling after diagnosis of breast cancer. J Clin Oncol 2018;36:1218-1224. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29528794>.



80. Vadaparampil ST, Scherr CL, Cragun D, et al. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. Clin Genet 2015;87:473-477. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24735105>.

81. Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns 2018;27:16-20. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29052810>.

82. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. J Clin Oncol 2006;24:4775-4782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16840542>.

83. Offit K, Sagi M, Hurley K. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA 2006;296:2727-2730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17164459>.

84. Gasparri ML, Di Micco R, Zuber V, et al. Ovarian reserve of women with and without BRCA pathogenic variants: a systematic review and meta-analysis. Breast 2021;60:155-162. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34627117>.

85. Turan V, Lambertini M, Lee DY, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol 2021;39:2016-2024. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33891474>.

86. Jasper MJ, Liebelt J, Hussey ND. Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn 2008;28:292-298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18302307>.

87. Sagi M, Weinberg N, Eilat A, et al. Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn 2009;29:508-513. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19248143>.

88. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998;16:1969-1977. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9586917>.

89. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11832208>.

90. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009;18:13-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18972196>.

91. Schneider KA, Garber J. Li-Fraumeni syndrome. GeneReviews; 2013. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1311/>.

92. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371:497-506. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25099575>.

93. Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 2020;38:674-685. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31841383>.

94. Hu C, Polley EC, Yadav S, et al. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst 2020;112:1231-1241. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32091585>.

95. Xicola RM, Li S, Rodriguez N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019;56:838-843. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31296550>.

96. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007;297:2360-2372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17545690>.



97. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. *JAMA Oncol* 2015;1:23-32. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26182300>.
98. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209-3215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16707622>.
99. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447-1453. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11113065>.
100. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. *Am J Hum Genet* 1997;60:505-514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9042909>.
101. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. *Am J Hum Genet* 1997;60:1059-1067. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9150153>.
102. Petrucelli N, Daly MB, Bars Culver JO, Feldman GL. BRCA1 and BRCA2 hereditary breast/ovarian cancer. *GeneReviews*; 2011. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1247/>.
103. Avraham A, Feldman S, Cho SS, et al. Breast-specific epigenetic regulation of deltaNp73 and its role in DNA-damage-response of BRCA1-mutated human mammary epithelial cells. *Cancers (Basel)* 2020;12:2367. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32825620>.
104. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013;105:812-822. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23628597>.
105. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017;317:2402-2416. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28632866>.
106. Spurdle AB, Whiley PJ, Thompson B, et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *J Med Genet* 2012;49:525-532. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22889855>.
107. Yadav S, Boddicker NJ, Na J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. *J Clin Oncol* 2023;41:1703-1713. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36623243>.
108. Jackson L, Weedon MN, Green HD, et al. Influence of family history on penetrance of hereditary cancers in a population setting. *EClinicalMedicine* 2023;64:102159. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37936660>.
109. Zhong Q, Peng HL, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. *Clin Cancer Res* 2015;21:211-220. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25348513>.
110. Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. *Medicine (Baltimore)* 2016;95:e4975. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27749552>.
111. van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. *PLoS One* 2015;10:e0120189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25816289>.
112. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a



prospective cohort study. *Lancet Oncol* 2018;19:169-180. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29337092>.

113. Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. *J Med Genet* 2016;53:465-471. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26928436>.

114. Schmidt MK, van den Broek AJ, Tollenaar RA, et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. *J Natl Cancer Inst* 2017;109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28376189>.

115. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. *J Clin Oncol* 2008;26:4282-4288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18779615>.

116. Eerola H, Heikkilä P, Tamminen A, et al. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. *Breast Cancer Res* 2005;7:R465-469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15987451>.

117. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res* 2005;11:5175-5180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16033833>.

118. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. *J Clin Oncol* 2002;20:2310-2318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11981002>.

119. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. *J Clin Oncol* 2011;29:4373-4380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22010008>.

120. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. *BMC Cancer* 2009;9:86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19298662>.

121. Breast Cancer Association Consortium, Mavaddat N, Dorling L, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. *JAMA Oncol* 2022;8:e216744. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35084436>.

122. Fostira F, Tsiitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group study. *Breast Cancer Res Treat* 2012;134:353-362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22434525>.

123. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clin Cancer Res* 2011;17:1082-1089. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21233401>.

124. Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. *Breast Cancer Res Treat* 2013;137:119-125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23192404>.

125. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol* 2015;33:304-311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25452441>.

126. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. *J Clin Oncol* 2016;34:1460-1468. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26976419>.

127. Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary



cancer genes. Cancer 2017;123:1721-1730. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28085182>.

128. Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst 2018;110:855-862. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/30099541>.

129. Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med 2021;384:428-439. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/33471991>.

130. Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021;384:440-451. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33471974>.

131. Metcalfe K, Lynch HT, Foulkes WD, et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer 2019;120:398-403. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/30723304>.

132. Jonasson JG, Stefansson OA, Johannsson OT, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer 2016;115:776-783. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27537391>.

133. Olafsdottir EJ, Borg A, Jensen MB, et al. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. Br J Cancer 2020;123:1608-1615. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/32939053>.

134. Lee LJ, Alexander B, Schnitt SJ, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011;117:3093-3100. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21264845>.

135. Kurian AW, Abrahamse P, Bondarenko I, et al. Association of genetic testing results with mortality among women with breast cancer or ovarian

cancer. J Natl Cancer Inst 2022;114:245-253. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/34373918>.

136. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;22:735-742. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/14966099>.

137. Chamseddine RS, Wang C, Yin K, et al. Penetrance of male breast cancer susceptibility genes: a systematic review. Breast Cancer Res Treat 2022;191:31-38. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/34642874>.

138. Cheng HH, Shevach JW, Castro E, et al. BRCA1, BRCA2, and associated cancer risks and management for male patients: a review. JAMA Oncol 2024;10:1272-1281. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/39052257>.

139. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:R2. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11879560>.

140. Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123-125. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/8673091>.

141. Ding YC, Steele L, Kuan CJ, et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011;126:771-778. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20927582>.

142. Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313-319. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9012404>.



143. Evans DG, Susnerwala I, Dawson J, et al. Risk of breast cancer in male BRCA2 carriers. *J Med Genet* 2010;47:710-711. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20587410>.
144. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2007;99:1811-1814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18042939>.
145. Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. *J Clin Oncol* 2022;40:1529-1541. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35077220>.
146. What are the key statistics about breast cancer in men? 2015. Available at: <http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics>. Accessed May 28, 2015.
147. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *J Clin Oncol* 2003;21:4222-4227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14615451>.
148. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. *Cancer* 1993;71:2751-2755. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8467455>.
149. Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. *Eur J Cancer* 2016;61:137-145. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27209246>.
150. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 2005;104:2807-2816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16284991>.
151. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *J Natl Cancer Inst* 2006;98:1694-1706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17148771>.
152. Schrader KA, Hurlburt J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. *Obstet Gynecol* 2012;120:235-240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22776961>.
153. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. *Gynecol Oncol* 2011;121:353-357. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21324516>.
154. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Hum Mol Genet* 2014;23:4703-4709. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24728189>.
155. Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. *JNCI Cancer Spectr* 2020;4:pkaa029. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32676552>.
156. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol* 2012;30:2654-2663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22711857>.
157. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;307:382-390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22274685>.
158. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer:



the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18165636>.

159. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008;26:5530-5536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18955455>.

160. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-1565. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21990299>.

161. Dong F, Davineni PK, Howitt BE, Beck AH. A BRCA1/2 mutational signature and survival in ovarian high-grade serous carcinoma. Cancer Epidemiol Biomarkers Prev 2016;25:1511-1516. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27496093>.

162. Wang Y, Li N, Ren Y, Zhao J. Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: an updated meta-analysis. J Obstet Gynaecol Res 2022;48:2270-2284. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35698734>.

163. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482-490. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26720728>.

164. Nahshon C, Barnett-Griness O, Segev Y, et al. Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis. Int J Gynecol Cancer 2022;32:48-54. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32522775>.

165. Borge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004;91:1829-1834. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15477862>.

166. Jazaeri AA, Lu K, Schmandt R, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-59. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12557260>.

167. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-2481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15073127>.

168. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18208621>.

169. Witjes VM, van Bommel MHD, Ligtenberg MJL, et al. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecol Oncol 2022;164:221-230. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34702566>.

170. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:29-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14668547>.

171. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3990. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17761984>.

172. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16137750>.

173. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-



pathological protocol. *Int J Gynecol Cancer* 2011;21:846-851. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21670699>.

174. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. *J Clin Oncol* 2005;23:127-132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15625367>.

175. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. *Mod Pathol* 2009;22:1133-1138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19543244>.

176. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006;30:230-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16434898>.

177. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. *Am J Surg Pathol* 2007;31:161-169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17255760>.

178. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. *Clin Cancer Res* 2009;15:1112-1120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19188187>.

179. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. *Br J Cancer* 2012;106:1697-1701. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22516946>.

180. Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. *JAMA Oncol* 2019;5:523-528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30730552>.

181. Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol* 2020;38:2798-2811. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32516092>.

182. Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Eur Urol* 2020;77:24-35. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31495749>.

183. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. *JCO Precis Oncol* 2017;2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28825054>.

184. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. *N Engl J Med* 2016;375:443-453. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27433846>.

185. Darst BF, Dadaev T, Saunders E, et al. Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate cancer. *J Natl Cancer Inst* 2021;113:616-625. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32853339>.

186. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol* 2013;31:1748-1757. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23569316>.

187. Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. *Eur Urol* 2017;71:740-747. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27989354>.

188. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. *Clin Cancer Res* 2004;10:2918-2921. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15131025>.



189. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115-2121. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20215531>.

190. Hamel N, Kotar K, Foulkes WD. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 2003;4:7. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/12911837>.

191. Nastiuk KL, Mansukhani M, Terry MB, et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999;40:172-177. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/10398279>.

192. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-5364. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8968085>.

193. Lal G, Liu G, Schmock B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000;60:409-416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10667595>.

194. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-3793. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12097290>.

195. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-346. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17301269>.

196. Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet 2012;49:164-170. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22368299>.

197. Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013;19:3396-3403. Available at:

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959126/>.

198. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 2015;33:3124-3129. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25940717>.

199. Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 2015;17:569-577. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25356972>.

200. Salo-Mullen EE, O'Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 2015;121:4382-4388. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26440929>.

201. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 2017;318:825-835. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28873162>.

202. Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 2017;35:3382-3390. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28767289>.

203. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell 2018;173:355-370 e314. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29625052>.

204. Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germline mutations in cancer genes among pancreatic cancer patients with a



positive family history. Genet Med 2018;20:119-127. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28726808>.

205. Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 2018;319:2401-2409. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29922827>.

206. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-438. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19064968>.

207. de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. Eur J Cancer 2017;72:215-225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28049106>.

208. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma--still a debate. Int J Gynecol Cancer 2010;20:1531-1534. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21119368>.

209. Saule C, Mouret-Fourme E, Briaux A, et al. Risk of serous endometrial carcinoma in women with pathogenic BRCA1/2 variant after risk-reducing salpingo-oophorectomy. J Natl Cancer Inst 2018;110. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28954295>.

210. Laitman Y, Michaelson-Cohen R, Levi E, et al. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer 2019;125:698-703. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30489631>.

211. de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study. J Natl Cancer Inst 2021;113:1203-1211. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33710348>.

212. Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with

BRCA mutations. JAMA Oncol 2016;2:1434-1440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27367496>.

213. Matanes E, Volodarsky-Perel A, Eisenberg N, et al. Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis. J Minim Invasive Gynecol 2021;28:947-956. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33249269>.

214. Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16962648>.

215. Lee YC, Milne RL, Lheureux S, et al. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2017;84:114-120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28802188>.

216. Lu G, Lu T, Pan J, et al. Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis. Arch Gynecol Obstet 2021;303:1569-1579. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33215232>.

217. Gumaste PV, Penn LA, Cymerman RM, et al. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol 2015;172:1498-1506. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25524463>.

218. Iqbal J, Nussenzweig A, Lubinski J, et al. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. Br J Cancer 2016;114:1160-1164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26986251>.

219. Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 2022;8:871-878. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35420638>.

220. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012;11:235-242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22187320>.



221. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. *J Med Genet* 2007;44:1-9. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/16825431>.

222. Keupp K, Hampp S, Hubbel A, et al. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. *Mol Genet Genomic Med* 2019;7:e863. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31347298>.

223. Chirita-Emandi A, Andreescu N, Popa C, et al. Biallelic variants in BRCA1 gene cause a recognisable phenotype within chromosomal instability syndromes reframed as BRCA1 deficiency. *J Med Genet* 2021;58:648-652. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/32843487>.

224. Sawyer SL, Tian L, Kahkonen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. *Cancer Discov* 2015;5:135-142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25472942>.

225. Freire BL, Homma TK, Funari MFA, et al. Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients. *Eur J Med Genet* 2018;61:130-133. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29133208>.

226. Berg WA. How well does supplemental screening magnetic resonance imaging work in high-risk women? *J Clin Oncol* 2014;32:2193-2196. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24934782>.

227. Buist DS, Porter PL, Lehman C, et al. Factors contributing to mammography failure in women aged 40-49 years. *J Natl Cancer Inst* 2004;96:1432-1440. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15467032>.

228. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-

detected cancers. *J Natl Cancer Inst* 2000;92:1081-1087. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10880551>.

229. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. *Int J Cancer* 2002;102:91-95. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12353239>.

230. van Gils CH, Otten JD, Verbeek AL, et al. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. *J Epidemiol Community Health* 1998;52:267-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9616416>.

231. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. *J Natl Cancer Inst* 2000;92:743-749. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10793111>.

232. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 2004;351:427-437. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15282350>.

233. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. *J Clin Oncol* 2005;23:8469-8476. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16293877>.

234. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). *Lancet* 2005;365:1769-1778. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15910949>.

235. Riedl CC, Ponhold L, Flory D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast



cancer. Clin Cancer Res 2007;13:6144-6152. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17947480>.

236. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007;242:698-715. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17244718>.

237. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-1325. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15367553>.

238. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012;107:24-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22588560>.

239. Lehman CD, Lee JM, DeMartini WB, et al. Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 2016;108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26744477>.

240. Phi XA, Saadatmand S, De Bock GH, et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. Br J Cancer 2016;114:631-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26908327>.

241. Le-Petross HT, Whitman GJ, Atchley DP, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011;117:3900-3907. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21365619>.

242. Lubinski J, Kotsopoulos J, Moller P, et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol 2024;10:493-499. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38421676>.

243. Goldfrank D, Chuai S, Bernstein JL, et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006;15:2311-2313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17119064>.

244. Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006;7:402-406. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16648044>.

245. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol 2013;14:583-589. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23623721>.

246. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 2013;267:47-56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23297332>.

247. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. Radiology 2013;266:104-113. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23169790>.

248. Friedewald SM, Rafferty EA, Conant EF. Breast cancer screening with tomosynthesis and digital mammography-reply. JAMA 2014;312:1695-1696. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25335157>.

249. Lourenco AP, Barry-Brooks M, Baird GL, et al. Changes in recall type and patient treatment following implementation of screening digital breast tomosynthesis. Radiology 2015;274:337-342. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25247407>.

250. Rose SL, Tidwell AL, Ice MF, et al. A reader study comparing prospective tomosynthesis interpretations with retrospective readings of



the corresponding FFDM examinations. Acad Radiol 2014;21:1204-1210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25107868>.

251. Destounis S, Arieno A, Morgan R. Initial experience with combination digital breast tomosynthesis plus full field digital mammography or full field digital mammography alone in the screening environment. J Clin Imaging Sci 2014;4:9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24744966>.

252. Margolies L, Cohen A, Sonnenblick E, et al. Digital breast tomosynthesis changes management in patients seen at a tertiary care breast center. ISRN Radiol 2014;2014:658929. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24967297>.

253. Lang K, Andersson I, Rosso A, et al. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 2016;26:184-190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25929946>.

254. Gilbert FJ, Tucker L, Gillan MG, et al. Accuracy of digital breast tomosynthesis for depicting breast cancer subgroups in a UK retrospective reading study (TOMMY Trial). Radiology 2015;277:697-706. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26176654>.

255. Zuckerman SP, Conant EF, Keller BM, et al. Implementation of synthesized two-dimensional mammography in a population-based digital breast tomosynthesis screening program. Radiology 2016;281:730-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27467468>.

256. Skaane P, Bandos AI, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 2014;271:655-663. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24484063>.

257. McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in

adult patients without intracranial abnormalities. Radiology 2017;285:546-554. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28653860>.

258. Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology 2016;58:433-441. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26873830>.

259. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1:479-488. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21305156>.

260. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 2012;118:2021-2030. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21935911>.

261. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17392385>.

262. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095-1102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11459871>.

263. Naranjo ID, Sogani J, Saccarelli C, et al. MRI screening of BRCA mutation carriers: comparison of standard protocol and abbreviated protocols with and without T2-weighted images. AJR Am J Roentgenol 2022;218:810-820. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34935399>.

264. Thomas M. Abbreviated breast MRI-good, but not all the same. AJR Am J Roentgenol 2022;218:821. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34985317>.



265. Gao Y, Goldberg JE, Young TK, et al. Breast cancer screening in high-risk men: a 12-year longitudinal observational study of male breast imaging utilization and outcomes. *Radiology* 2019;293:282-291. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31526252>.

266. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. *Lancet* 2006;367:595-604. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16488803>.

267. Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. *Virchows Arch* 2022;480:85-93. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34458944>.

268. Expert Panel on Breast Imaging, Niell BL, Lourenco AP, et al. ACR Appropriateness Criteria evaluation of the symptomatic male breast. *J Am Coll Radiol* 2018;15:S313-S320. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30392600>.

269. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. *Clin Cancer Res* 2016;22:3971-3981. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26979395>.

270. Honold F, Camus M. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers. *Medwave* 2018;18:e7161. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30052622>.

271. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9887158>.

272. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst* 2001;93:1633-1637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11698567>.

273. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001;345:159-164. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11463009>.

274. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2004;22:1055-1062. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14981104>.

275. Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. *Cochrane Database Syst Rev* 2018;4:CD002748. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29620792>.

276. Morrow M, Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction. *Br J Surg* 2009;96:1-2. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19109821>.

277. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. *JAMA Surg* 2018;153:123-129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28903167>.

278. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25:1329-1333. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17416853>.

279. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. *N Engl J Med* 2016;374:454-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26840135>.

280. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. *JAMA* 1999;281:2189-2197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10376571>.



281. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. *Lancet* 2013;381:1827-1834. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23639488>.

282. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. *Clin Cancer Res* 2006;12:5242-5247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16951244>.

283. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. *J Natl Cancer Inst* 2004;96:1751-1761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15572757>.

284. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-2741. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16754727>.

285. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. *Cancer Prev Res (Phila)* 2010;3:696-706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20404000>.

286. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. *J Natl Cancer Inst* 2007;99:283-290. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17312305>.

287. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005;97:1652-1662. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16288118>.

288. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2004;22:2328-2335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197194>.

289. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *Int J Cancer* 2006;118:2281-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16331614>.

290. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet* 2000;356:1876-1881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11130383>.

291. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. *JAMA* 2001;286:2251-2256. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11710890>.

292. Ingle JN, Liu M, Wickerham DL, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. *Cancer Discov* 2013;3:812-825. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23764426>.

293. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med* 2011;364:2381-2391. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21639806>.

294. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet* 2014;383:1041-1048. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24333009>.



295. Nemati Shafae M, Gutierrez-Barrera AM, Lin HY, Arun B. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. *J Clin Oncol* 2015;33:3-3. Available at: http://ascopubs.org/doi/abs/10.1200/jco.2015.33.28_suppl.3.
296. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2002;94:1773-1779. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12464649>.
297. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *Cancer Epidemiol Biomarkers Prev* 2006;15:1863-1870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17021353>.
298. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. *Cancer Epidemiol Biomarkers Prev* 2005;14:350-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15734957>.
299. Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. *Breast Cancer Res Treat* 2014;143:579-586. Available at:
300. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. *Eur J Cancer* 2010;46:2275-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20537530>.
301. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *J Clin Oncol* 2013;31:4188-4198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24145348>.
302. Barańska A, Kanadys W. Oral contraceptive use and breast cancer risk for BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis of case-control studies. *Cancers (Basel)* 2022;14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/36230696>.
303. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. *Expert Rev Anticancer Ther* 2011;11:1197-1207. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21916573>.
304. Friebe TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. *J Natl Cancer Inst* 2014;106:dju091. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24824314>.
305. Park B, Hopper JL, Win AK, et al. Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. *Oncotarget* 2017;8:102110-102118. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24458845>.
306. Park J, Huang D, Chang YJ, et al. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. *Carcinogenesis* 2022;43:231-242. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34958358>.
307. Schrijver LH, Mooij TM, Pijpe A, et al. Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits. *J Natl Cancer Inst* 2022;114:540-552. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35048954>.
308. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. *Br J Cancer* 2000;83:1301-1308. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11044354>.
309. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117-1130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12677558>.
310. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. *Clin Cancer*



Res 2002;8:3776-3781. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12473589>.

311. Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. *J Clin Oncol* 2014;32:1547-1553. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24567435>.

312. Marchetti C, Ataseven B, Cassani C, et al. Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients. *Int J Gynecol Cancer* 2023;33:257-262.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36581488>.

313. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst* 2009;101:80-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19141781>.

314. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol* 2008;26:1331-1337. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18268356>.

315. Kotsopoulos J, Gronwald J, Huzarski T, et al. Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations. *JAMA Oncol* 2024;10:484-492. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/38421677>.

316. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002;346:1609-1615. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12023992>.

317. Kemel Y, Kauff ND, Robson ME, et al. Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. *J Clin Oncol* (Meeting Abstracts) 2005;23(Supple 16):Abstract 1013. Available at:

http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/1013.

318. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. *J Natl Cancer Inst* 1999;91:1475-1479. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10469748>.

319. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 2002;346:1616-1622. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12023993>.

320. Narod SA, Gronwald J, Karlan B, et al. Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2024;116:1753-1760. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/38937272>.

321. Harmsen MG, Piek MJ, Bulten J, et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. *Cancer* 2018;124:952-959. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29315498>.

322. Steenbeek MP, van Bommel MHD, Bulten J, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. *J Clin Oncol* 2022;40:1879-1891. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35302882>.

323. Sherman ME, Piedmonte M, Mai PL, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. *J Clin Oncol* 2014;32:3275-3283.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25199754>.

324. Stroot IAS, Brouwer J, Bart J, et al. High-grade serous carcinoma at risk-reducing salpingo-oophorectomy in asymptomatic carriers of BRCA1/2 pathogenic variants: prevalence and clinical factors. *J Clin Oncol* 2023;41:2523-2535. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/36809028>.

325. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international



case-control study. J Clin Oncol 2005;23:7491-7496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16234515>.

326. Xiao YL, Wang K, Liu Q, et al. Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review. Clin Breast Cancer 2019;19:e48-e65. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30470623>.

327. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16510331>.

328. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20810374>.

329. Metcalfe K, Lynch HT, Foulkes WD, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015;1:306-313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26181175>.

330. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25788320>.

331. Chai X, Domchek S, Kauff N, et al. RE: Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26264690>.

332. Terry MB, Daly MB, Phillips KA, et al. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J Natl Cancer Inst 2019;111:331-334. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30496449>.

333. Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2017;109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27601060>.

334. Stjepanovic N, Villacampa G, Nead KT, et al. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: maximising bias-reduction. Eur J Cancer 2020;132:53-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32325420>.

335. Choi YH, Terry MB, Daly MB, et al. Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 2021;7:585-592. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33630024>.

336. Marchetti C, De Felice F, Boccia S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 2018;132:111-115. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30447915>.

337. Gordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019;153:192-200. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30661763>.

338. Chlebowski RT, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst 2008;100:1341-1343. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18812547>.

339. Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol 2004;22:978-980. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14981100>.

340. ACOG committee opinion no. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Obstet Gynecol



2019;133:e279-e284. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30913199>.

341. Hanley GE, Pearce CL, Talhouk A, et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 2022;5:e2147343. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35138400>.

342. Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25628372>.

343. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12117397>.

344. Kuittinen T, Tulokas S, Rahkola-Soisalo P, et al. Pelvic organ prolapse after hysterectomy: a 10-year national follow-up study. Acta Obstet Gynecol Scand 2023;102:556-566. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/37014706>.

345. Tulokas S, Mentula M, Harkki P, et al. Stress urinary incontinence after hysterectomy: a 10-year national follow-up study. Arch Gynecol Obstet 2022;305:1089-1097. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35061067>.

346. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022;29:767-794. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35797481>.

347. Manyonda I, V ST, Pirhadi R, Onwude J. Progestogens are the problem in hormone replacement therapy: time to reappraise their use. Post Reprod Health 2020;26:26-31. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31875415>.

348. Hoffman SR, Governor S, Daniels K, et al. Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin

combination hormone therapy among women in the United States: a multidatabase cohort study. Menopause 2023;30:824-830. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/37449720>.

349. College of American Pathologists (CAP). Protocol for the Examination of Specimens From Patients With Carcinoma of the Ovary. 2009. Available at:

http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2009/Ovary_09protocol.pdf. Accessed March 2011.

350. Hickey M, Trainer A, Braat S, et al. What happens after menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women. BMJ Open 2017;7:e018758. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29138210>.

351. Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial. JAMA Oncol 2021;7:1203-1212. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34081085>.

352. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17196508>.

353. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9700175>.

354. Huber D, Seitz S, Kast K, et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 2020;301:875-884. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/32140806>.

355. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening



(UKCTOCS): a randomised controlled trial. *Lancet* 2016;387:945-956. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26707054>.

356. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol* 2009;10:327-340. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19282241>.

357. Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. *J Clin Oncol* 2017;35:1411-1420. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28240969>.

358. Skates SJ, Greene MH, Buys SS, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials. *Clin Cancer Res* 2017;23:3628-3637. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28143870>.

359. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. *CA Cancer J Clin* 2019;69:438-451. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31577379>.

360. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin* 2018;68:284-296. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29809280>.

361. Domchek SM, Robson ME. Update on genetic testing in gynecologic cancer. *J Clin Oncol* 2019;37:2501-2509. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31403865>.

362. Liu YL, Breen K, Catchings A, et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. *JCO Oncol Pract* 2022;18:201-209. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34582274>.

363. Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. *Genet Epidemiol* 2016;40:425-431. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27112364>.

364. Fan X, Wynn J, Shang N, et al. Penetrance of breast cancer susceptibility genes from the eMERGE III network. *JNCI Cancer Spectr* 2021;5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34377931>.

365. Lowry KP, Geuzinge HA, Stout NK, et al. Breast cancer screening strategies for women with ATM, CHEK2, and PALB2 pathogenic variants: a comparative modeling analysis. *JAMA Oncol* 2022;8:587-596. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35175286>.

366. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372:2243-2257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26014596>.

367. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3:1190-1196. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28418444>.

368. Kurian AW, Hughes E, Handorf EA, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. *JCO Precision Oncology* 2017;1:1-12. Available at: <http://ascopubs.org/doi/abs/10.1200/PO.16.00066>.

369. Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. *JAMA Oncol* 2019;5:51-57. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30128536>.

370. Hauke J, Horvath J, Gross E, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. *Cancer Med* 2018;7:1349-1358. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29522266>.



371. Brunet J, Gutierrez-Enriquez S, Torres A, et al. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clin Genet 2008;73:465-473. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18384426>.

372. Heikkinen K, Rapakko K, Karppinen SM, et al. Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer 2005;116:69-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15756685>.

373. Thompson D, Antoniou AC, Jenkins M, et al. Two ATM variants and breast cancer risk. Hum Mutat 2005;25:594-595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15880680>.

374. Tommiska J, Jansen L, Kilpivaara O, et al. ATM variants and cancer risk in breast cancer patients from Southern Finland. BMC Cancer 2006;6:209. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16914028>.

375. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst 2010;102:475-483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20305132>.

376. Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol 2017;147:375-380. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28888541>.

377. Kurian AW, Ward KC, Howlander N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 2019;37:1305-1315. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30964716>.

378. Pilie PG, Johnson AM, Hanson KL, et al. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 2017;123:3925-3932. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28657667>.

379. Lang SH, Swift SL, White H, et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 2019;55:597-616. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31322208>.

380. Karlsson Q, Brook MN, Dadaev T, et al. Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study. Eur Urol Oncol 2021;4:570-579. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33436325>.

381. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2015;148:556-564. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25479140>.

382. Hsu FC, Roberts NJ, Childs E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncol 2021;7:1664-1668. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34529012>.

383. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 2016;34:1455-1459. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26786923>.

384. Weber-Lassalle N, Borde J, Weber-Lassalle K, et al. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res 2019;21:55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31036035>.

385. Slavin TP, Maxwell KN, Lilyquist J, et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 2017;3:22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28649662>.

386. Carter NJ, Marshall ML, Susswein LR, et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol 2018;151:481-488. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30322717>.



387. Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. *J Natl Cancer Inst* 2015;107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26315354>.

388. Weber-Lassalle N, Hauke J, Ramser J, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. *Breast Cancer Res* 2018;20:7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29368626>.

389. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet* 2011;43:1104-1107. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21964575>.

390. Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. *JAMA Oncol* 2019;5:1325-1331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31246251>.

391. Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 variants and lifetime cancer risk. *JAMA* 2024;332:722-729. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38873722>.

392. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. *Biomed Res Int* 2013;2013:747318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23586058>.

393. Friedrichsen DM, Malone KE, Doody DR, et al. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. *Breast Cancer Res* 2004;6:R629-635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15535844>.

394. Iniesta MD, Gorin MA, Chien LC, et al. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. *Cancer Genet Cytogenet* 2010;202:136-140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20875877>.

395. Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-

risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. *Breast Cancer Res* 2011;13:R20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21356067>.

396. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol* 2011;29:3747-3752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21876083>.

397. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol* 2008;26:542-548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18172190>.

398. Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. *J Clin Oncol* 2016;34:1208-1216. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26884562>.

399. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 2004;74:1175-1182. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15122511>.

400. Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. *J Clin Oncol* 2016;34:2750-2760. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27269948>.

401. Han FF, Guo CL, Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol* 2013;32:329-335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23713947>.

402. Hanson H, Astiazaran-Symonds E, Amendola LM, et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical



Genetics and Genomics (ACMG). Genet Med 2023;25:100870. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37490054>.

403. Mundt E, Mabey B, Rainville I, et al. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants. Cancer Genet 2023;278-279:84-90. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37839337>.

404. Bychkovsky BL, Agaoglu NB, Horton C, et al. Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2. JAMA Oncol 2022;8:1598-1606. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36136322>.

405. Morra A, Mavaddat N, Muranen TA, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet 2023;110:475-486. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36827971>.

406. Wu Y, Yu H, Zheng SL, et al. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate 2018;78:607-615. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29520813>.

407. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087 e2073. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20420947>.

408. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011;13:93-99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21227399>.

409. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011;12:49-55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21145788>.

410. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch

syndrome. JAMA 2011;305:2304-2310. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21642682>.

411. Kohlmann W, Gruber S. Lynch Syndrome. GeneReviews at GeneTests: Medical Genetics Information Resource 2014. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1211/>.

412. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-1517. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17003399>.

413. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444-449. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18398828>.

414. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409-4415. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23091106>.

415. Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018;67:1306-1316. Available at: <https://pubmed.ncbi.nlm.nih.gov/28754778/>.

416. Ryan NAJ, Morris J, Green K, et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 2017;3:1702-1706. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28772289>.

417. Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 2020;22:15-25. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31337882>.



418. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. *Acta Obstet Gynecol Scand* 2011;90:437-444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21306348>.
419. Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. *Obstet Gynecol* 2007;110:18-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17601891>.
420. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol* 2009;27:4793-4797. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19720893>.
421. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. *J Clin Oncol* 2015;33:209-217. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25452455>.
422. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* 2015;110:223-262. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25645574>.
423. ACOG Practice Bulletin No. 147: Lynch syndrome. *Obstet Gynecol* 2014;124:1042-1054. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25437740>.
424. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006;354:261-269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16421367>.
425. Stuckless S, Green J, Dawson L, et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. *Clin Genet* 2013;83:359-364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22775459>.
426. Walsh MD, Buchanan DD, Cummings MC, et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. *Clin Cancer Res* 2010;16:2214-2224. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20215533>.
427. Schwartz CJ, da Silva EM, Marra A, et al. Morphologic and genomic characteristics of breast cancers occurring in individuals with Lynch syndrome. *Clin Cancer Res* 2022;28:404-413. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34667028>.
428. Harkness EF, Barrow E, Newton K, et al. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study. *J Med Genet* 2015;52:553-556. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26101330>.
429. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet* 2009;75:141-149. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19215248>.
430. Stoll J, Rosenthal E, Cummings S, et al. No evidence of increased risk of breast cancer in women with Lynch syndrome identified by multigene panel testing. *JCO Precis Oncol* 2020;4:51-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35050728>.
431. Wimmer K, Kratz CP, Vasen HF, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). *J Med Genet* 2014;51:355-365. Available at: <http://jmg.bmj.com/content/51/6/355.full.pdf>.
432. Uusitalo E, Rantanen M, Kallionpaa RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. *J Clin Oncol*



2016;34:1978-1986. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26926675>.

433. Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. *Childs Nerv Syst* 2010;26:663-667. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19937438>.

434. Nishida T, Tsujimoto M, Takahashi T, et al. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. *J Gastroenterol* 2016;51:571-578. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26511941>.

435. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. *Br J Cancer* 2006;95:233-238. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/16786042>.

436. Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med* 2018;20:671-682. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30006586>.

437. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. *J Med Genet* 2007;44:481-484.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17369502>.

438. Evans DG. Are we ready for targeted early breast cancer detection strategies in women with NF1 aged 30-49 years? *Am J Med Genet A* 2012;158a:3054-3055. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22987630>.

439. Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. *Br J Cancer* 2015;112:1546-1548.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25742481>.

440. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet* 2007;44:81-88. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17105749>.

441. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. *Cancer Res* 2011;71:2222-2229. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21285249>.

442. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. *Lancet Oncol* 2015;16:638-644. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25959805>.

443. Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - providing evidence of cancer predisposition genes. *Gynecol Oncol* 2019;153:452-462. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30733081>.

444. Song H, Dicks EM, Tyrer J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. *J Med Genet* 2021;58:305-313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32546565>.

445. Lukomska A, Menkiszak J, Gronwald J, et al. Recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish patients with ovarian cancer. *Cancers (Basel)* 2021;13:849. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33670479>.

446. Narayan P, Ahsan MD, Webster EM, et al. Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. *Gynecol Oncol* 2023;177:72-85. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/37651980>.

447. Tischkowitz M, Balmana J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet*



Med 2021;23:1416-1423. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33976419>.

448. Hanson H, Kulkarni A, Loong L, et al. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet 2023;60:417-429. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36411032>.

449. Tischkowitz M, Xia B. PALB2/FANCD1: recombining cancer and Fanconi anemia. Cancer Res 2010;70:7353-7359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20858716>.

450. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44:475-476; author reply 476. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22538716>.

451. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43:879-882. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21822267>.

452. Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 2015;33:2901-2907. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26261251>.

453. Yang X, Song H, Leslie G, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst 2020;112:1242-1250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32107557>.

454. Li N, McInerney S, Zethoven M, et al. Combined tumor sequencing and case-control analyses of RAD51C in breast cancer. J Natl Cancer Inst 2019;111:1332-1338. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30949688>.

455. Beck SH, Jelsig AM, Yassin HM, et al. Intestinal and extraintestinal neoplasms in patients with NTHL1 tumor syndrome: a systematic review.

Fam Cancer 2022;21:453-462. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35292903>.

456. Grolleman JE, de Voer RM, Elsayed FA, et al. Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. Cancer Cell 2019;35:256-266 e255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30753826>.

457. Setton J, Selenica P, Mukherjee S, et al. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. NPJ Breast Cancer 2021;7:135. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34635660>.

458. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012;366:141-149. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22236224>.

459. Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol 2015;26:756-761. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25595936>.

460. Witte JS, Mefford J, Plummer SJ, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev 2013;22:675-680. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23396964>.

461. Darst BF, Hughley R, Pfennig A, et al. A rare germline HOXB13 variant contributes to risk of prostate cancer in men of African ancestry. Eur Urol 2022;81:458-462. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35031163>.

462. Storebjerg TM, Hoyer S, Kirkegaard P, et al. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU Int 2016;118:646-653. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26779768>.



463. Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. *Eur Urol* 2019;75:378-382. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30337059>.

464. Isaacsson Velho P, Silberstein JL, Markowski MC, et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. *Prostate* 2018;78:401-407. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29368341>.

465. Risbridger GP, Taylor RA, Clouston D, et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. *Eur Urol* 2015;67:496-503. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25154392>.

466. Lozano R, Salles DC, Sandhu S, et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. *Eur J Cancer* 2021;147:74-83. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33626496>.

467. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 2017;377:523-533. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28578601>.

468. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med* 2021;384:2394-2405. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34081848>.

469. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med* 2018;379:753-763. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30110579>.

470. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label,

single-arm, phase 2 trial. *Lancet Oncol* 2019;20:636-648. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30948273>.

471. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol* 2015;33:244-250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25366685>.

472. Penson RT, Valencia RV, Cibula D, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial. *J Clin Oncol* 2020;38:1164-1174. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32073956>.

473. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2017;18:75-87. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27908594>.

474. Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. *Lancet Oncol* 2022;23:465-478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35298906>.

475. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. *N Engl J Med* 2020;382:2091-2102. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32343890>.

476. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. *J Clin Oncol* 2020;38:3763-3772. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32795228>.

477. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med* 2019;381:317-327. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31157963>.



478. Reiss KA, Mick R, O'Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. *J Clin Oncol* 2021;39:2497-2505. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33970687>.

479. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proc Natl Acad Sci U S A* 2014;111:14205-14210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25192939>.

480. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. *J Natl Cancer Inst* 2015;107:379. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25435541>.

481. Best AF, Tucker MA, Frone MN, et al. A pragmatic testing-eligibility framework for population mutation screening: the example of BRCA1/2. *Cancer Epidemiol Biomarkers Prev* 2019;28:293-302. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30692095>.

482. Metcalfe KA, Poll A, Royer R, et al. A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. *Br J Cancer* 2013;109:777-779. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23778531>.

483. Lieberman S, Tomer A, Ben-Chetrit A, et al. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. *Genet Med* 2017;19:754-762. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27929526>.

484. Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. *J Clin Oncol* 2013;31:210-216. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23233716>.

485. Alvarez C, Tapia T, Perez-Moreno E, et al. BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. *Oncotarget* 2017;8:74233-74243. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29088781>.

486. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat* 2018;39:593-620. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29446198>.

487. Gorski B. Selected aspects of molecular diagnostics of constitutional alterations in BRCA1 and BRCA2 genes associated with increased risk of breast cancer in the Polish population. *Hered Cancer Clin Pract* 2006;4:142-152. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20223018>.

488. Kluz T, Jasiewicz A, Marczyk E, et al. Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in south-east Poland. *Hered Cancer Clin Pract* 2018;16:6. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29492181>.

489. Trottier M, Lunn J, Butler R, et al. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. *Clin Genet* 2016;89:328-331. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25920394>.

490. Friebel TM, Andrulis IL, Balmana J, et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Hum Mutat* 2019;40:1781-1796. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31112363>.

491. Kwong A, Shin VY, Ho JC, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *J Med Genet* 2016;53:15-23. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26187060>.

492. Laitman Y, Friebel TM, Yannoukakos D, et al. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern,



North African, and South European countries. Hum Mutat 2019;40:e1-e23. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31209999>.

493. Pinto EM, Zambetti GP. What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer 2020;126:4678-4686. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32875577>.

494. Vasen H, Ibrahim I, Ponce CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 2016;34:2010-2019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27114589>.

495. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 2019;26:3025-3031. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31342359>.

496. Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 2019;37:453-460. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30526229>.

497. Yang S, Axilbund JE, O'Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol 2018;25:2925-2931. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29998407>.

498. Sun L, Brentnall A, Patel S, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol 2019;5:1718-1730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31580391>.

499. Pal T, Agnese D, Daly M, et al. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020;22:681-685. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31831881>.

500. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol 2024;42:584-604. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38175972>.

501. Yadav S, Hu C, Hart SN, et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 2020;38:1409-1418. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32125938>.

502. Desai NV, Yadav S, Batalini F, et al. Germline genetic testing in breast cancer: rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years. Cancer 2021;127:828-833. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33146899>.

503. Kurian AW, Bernhisel R, Larson K, et al. Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer. JAMA 2020;323:995-997. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32154851>.

504. Boddicker NJ, Hu C, Weitzel JN, et al. Risk of late-onset breast cancer in genetically predisposed women. J Clin Oncol 2021;39:3430-3440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34292776>.

505. Weitzel JN, Kidd J, Bernhisel R, et al. Multigene assessment of genetic risk for women for two or more breast cancers. Breast Cancer Res Treat 2021;188:759-768. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33826040>.

506. Maxwell KN, Wenz BM, Kulkarni A, et al. Mutation rates in cancer susceptibility genes in patients with breast cancer with multiple primary cancers. JCO Precis Oncol 2020;4. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32954205>.

507. Rosenberger LH, Thomas SM, Nimbkar SN, et al. Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi-gene panel testing. Ann Surg Oncol



2020;27:3633-3640. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/32504368>.

508. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. *J Med Genet* 2008;45:425-431. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18413374>.

509. Parmigiani G, Chen S, Iversen ES, Jr., et al. Validity of models for predicting BRCA1 and BRCA2 mutations. *Ann Intern Med* 2007;147:441-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17909205>.

510. Lindor NM, Johnson KJ, Harvey H, et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. *Fam Cancer* 2010;9:495-502. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20512419>.

511. Hughes E, Tshiaba P, Wagner S, et al. Integrating clinical and polygenic factors to predict breast cancer risk in women undergoing genetic testing. *JCO Precis Oncol* 2021;5. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34036224>.

512. Lakeman IMM, Rodriguez-Gironde M, Lee A, et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genet Med* 2020;22:1803-1811. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/32624571>.

513. Rosner B, Tamimi RM, Kraft P, et al. Simplified breast risk tool integrating questionnaire risk factors, mammographic density, and polygenic risk score: development and validation. *Cancer Epidemiol Biomarkers Prev* 2021;30:600-607. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/33277321>.

514. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. *Cancer* 2008;113:3116-3120. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18932252>.

515. Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. *BMC Med Genet* 2008;9:116. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19102775>.

516. Terry MB, Liao Y, Whittemore AS, et al. 10-year performance of four models of breast cancer risk: a validation study. *Lancet Oncol* 2019;20:504-517. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/30799262>.

517. Archer S, Babb de Villiers C, Scheibl F, et al. Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: a multi-methods study. *PLoS One* 2020;15:e0229999. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/32142536>.

518. Lee A, Mavaddat N, Cunningham A, et al. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. *J Med Genet* 2022;59:1206-1218. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/36162851>.

519. Yurgelun MB, Uno H, Furniss CS, et al. Development and validation of the PREMMplus model for multigene hereditary cancer risk assessment. *J Clin Oncol* 2022;40:4083-4094. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/35960913>.

520. de Andrade KC, Khincha PP, Hatton JN, et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. *Lancet Oncol* 2021;22:1787-1798. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34780712>.

521. Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. *Cancer* 2016;122:3673-3681. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27496084>.

522. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.



J Clin Oncol 2009;27:1250-1256. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19204208>.

523. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45:242-252. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23334668>.

524. Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014;35:654-662. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24706533>.

525. Qian M, Cao X, Devidas M, et al. TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children. J Clin Oncol 2018;36:591-599. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29300620>.

526. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010;28:1995-2001. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20308654>.

527. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009;115:4218-4226. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19536876>.

528. Hettmer S, Archer NM, Somers GR, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 2014;120:1068-1075. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24382691>.

529. Garber JE, Goldstein AM, Kantor AF, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991;51:6094-6097. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1933872>.

530. Krutikova V, Trkova M, Fleitz J, et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 2005;41:1597-1603. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15925506>.

531. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1978757>.

532. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer 1997;76:1-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9218725>.

533. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011;13:651-657. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21552135/>.

534. Maxwell KN, Cheng HH, Powers J, et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol 2022;81:243-250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34863587>.

535. Curiel-Lewandrowski C, Speetzen LS, Cranmer L, et al. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol 2011;147:248-250. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21339461>.

536. Giavedoni P, Ririe M, Carrera C, et al. Familial melanoma associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: total-body digital photography, dermoscopy and confocal microscopy. Acta Derm Venereol 2017;97:720-723. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28218344>.

537. Katona BW, Powers J, McKenna DB, et al. Upper gastrointestinal cancer risk and surveillance outcomes in Li-Fraumeni syndrome. Am J Gastroenterol 2020;115:2095-2097. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32969947>.

538. MacFarland SP, Zelle K, Long JM, et al. Earlier colorectal cancer screening may be necessary in patients with Li-Fraumeni syndrome. Gastroenterology 2019;156:273-274. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30243621>.



539. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. *Cancer Res* 1988;48:5358-5362. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3409256>.

540. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11219776>.

541. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. *Oncogene* 1998;17:1061-1068. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9764816>.

542. Chompret A. The Li-Fraumeni syndrome. *Biochimie* 2002;84:75-82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11900879>.

543. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. *J Med Genet* 2001;38:43-47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11332399>.

544. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. *J Med Genet* 2008;45:535-538. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18511570>.

545. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. *J Clin Oncol* 2015;33:2345-2352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26014290>.

546. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. *J Clin Oncol* 2009;27:e108-109; author reply e110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19652052>.

547. Ginsburg OM, Akbari MR, Aziz Z, et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Fam Cancer 2009;8:563-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19714488>.

548. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. *Eur J Cancer* 2006;42:1143-1150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16644204>.

549. Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. *Breast Cancer Res* 2012;14:R66. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22507745>.

550. Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. *Cancer Res* 2010;70:4795-4800. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20501846>.

551. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? *Fam Cancer* 2012;11:607-613. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22851211>.

552. Packwood K, Martland G, Sommerlad M, et al. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the cohort study of TP53 carrier early onset breast cancer (COPE study). *J Pathol Clin Res* 2019;5:189-198. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31041842>.

553. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. *Cancer* 2012;118:908-913. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21761402>.

554. Sandoval RL, Bottosso M, Tianyu L, et al. TP53-associated early breast cancer: new observations from a large cohort. *J Natl Cancer Inst*



2024;116:1246-1254. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/38569880>.

555. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 2014;35:672-688. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24665023>.

556. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-339.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24132290>.

557. Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol 2023;34:215-227. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/36529447>.

558. Mandelker D, Donoghue M, Talukdar S, et al. Germline-focused analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol 2019;30:1221-1231.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31050713>.

559. Foulkes WD, Polak P. Li-Fraumeni syndrome in the cancer genomics era. J Natl Cancer Inst 2021;113:1615-1617. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34240211>.

560. Kratz CP, Freycon C, Maxwell KN, et al. Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an International Agency for Research on Cancer TP53 database analysis. JAMA Oncol 2021;7:1800-1805. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34709361>.

561. Schwartz AN, Hyman SR, Stokes SM, et al. Evaluation of TP53 variants detected on peripheral blood or saliva testing: discerning germline from somatic TP53 variants. JCO Precis Oncol 2021;5:1677-1686.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34994652>.

562. Desai P, Zhou Y, Grenet J, et al. Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality. Cancer 2024;130:3879-3887. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/39012906>.

563. Castillo D, Yuan TA, Nehoray B, et al. Clonal hematopoiesis and mosaicism revealed by a multi-tissue analysis of constitutional TP53 status. Cancer Epidemiol Biomarkers Prev 2022;31:1621-1629. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35654360>.

564. Kratz CP, Achatz MI, Brugieres L, et al. Cancer screening recommendations for individuals with Li-Fraumeni Syndrome. Clin Cancer Res 2017;23:e38-e45. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28572266>.

565. Siegel A, Bremer RC, Klein WMP, et al. Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome. Breast Cancer Res Treat 2022;191:159-167. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/34652547>.

566. Mai PL, Khincha PP, Loud JT, et al. Prevalence of cancer at baseline screening in the National Cancer Institute Li-Fraumeni syndrome cohort. JAMA Oncol 2017;3:1640-1645. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28772286>.

567. Greer MC, Voss SD, States LJ. Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res 2017;23:e6-e13.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28572262>.

568. Ballinger ML, Best A, Mai PL, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 2017;3:1634-1639. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28772291>.

569. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011;12:559-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21601526>.



570. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. *Lancet Oncol* 2016;17:1295-1305. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27501770>.

571. Asdahl PH, Ojha RP, Hasle H. Cancer screening in Li-Fraumeni Syndrome. *JAMA Oncol* 2017;3:1645-1646. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28772307>.

572. Shin SJ, Dodd-Eaton EB, Gao F, et al. Penetrance estimates over time to first and second primary cancer diagnosis in families with Li-Fraumeni syndrome: a single institution perspective. *Cancer Res* 2020;80:347-353. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31719099>.

573. McEvoy M, Robison N, Manley P, et al. Successful treatment of recurrent Li-Fraumeni Syndrome-related choroid plexus carcinoma. *J Pediatr Hematol Oncol* 2017;39:e473-e475. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28859040>.

574. Thariat J, Chevalier F, Orbach D, et al. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. *Lancet Oncol* 2021;22:e562-e574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34856153>.

575. Kappel S, Janschek E, Wolf B, et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. *Breast Cancer Res Treat* 2015;151:671-678. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25981898>.

576. Weeks LD, Niroula A, Neuberg D, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. *NEJM Evid* 2023;2. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37483562>.

577. Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. *Nature* 2018;559:400-404. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29988082>.

578. Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. *Oncogene* 2008;27:5387-5397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18794875>.

579. Eng C. PTEN hamartoma tumor syndrome (PTHS). *GeneReviews*; 2009. Available at: Available at: <http://www.ncbi.nlm.nih.gov/books/NBK1488/>.

580. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. *J Med Genet* 2011;48:505-512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21659347>.

581. Varga EA, Pastore M, Prior T, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet Med* 2009;11:111-117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19265751>.

582. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. *Eur J Hum Genet* 1999;7:267-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10234502>.

583. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet* 2004;41:323-326. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15121767>.

584. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. *JAMA* 2010;304:2724-2731. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21177507>.

585. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. *Genet Med* 2009;11:687-694. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19668082>.

586. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. *Clin Genet* 1986;29:222-233. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3698331>.



587. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst* 2013;105:1607-1616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24136893>.

588. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet* 2013;50:255-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23335809>.

589. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. *Hered Cancer Clin Pract* 2010;8:6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20565722>.

590. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22252256>.

591. Yehia L, Plitt G, Tushar AM, et al. Longitudinal analysis of cancer risk in children and adults with germline PTEN variants. *JAMA Netw Open* 2023;6:e239705. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37093598>.

592. Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, et al. Cancer risks by sex and variant type in PTEN Hamartoma Tumor Syndrome. *J Natl Cancer Inst* 2023;115:93-103. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36171661>.

593. Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. *Am J Hum Genet* 2011;88:42-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21194675>.

594. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. *Nat Clin Pract Gastroenterol Hepatol* 2007;4:492-502. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17768394>.

595. Hansen-Kiss E, Beinkampen S, Adler B, et al. A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. *J Med Genet* 2017;54:471-478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28526761>.

596. Smith JR, Marqusee E, Webb S, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. *J Clin Endocrinol Metab* 2011;96:34-37. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20962022>.

597. Roche AF, Mukherjee D, Guo SM, Moore WM. Head circumference reference data: birth to 18 years. *Pediatrics* 1987;79:706-712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3575026>.

598. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. *Am J Hum Genet* 2003;73:404-411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12844284>.

599. Zhou XP, Marsh DJ, Morrison CD, et al. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. *Am J Hum Genet* 2003;73:1191-1198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14566704>.

600. Andres RH, Guzman R, Weis J, et al. Lhermitte-Duclos disease with atypical vascularization--case report and review of the literature. *Clin Neuropathol* 2009;28:83-90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19353838>.

601. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet* 2005;42:318-321. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15805158>.

602. Herman GE, Butter E, Enrile B, et al. Increasing knowledge of PTEN germline mutations: Two additional patients with autism and



macrocephaly. Am J Med Genet A 2007;143:589-593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17286265>.

603. Herman GE, Henninger N, Ratliff-Schaub K, et al. Genetic testing in autism: how much is enough? Genet Med 2007;9:268-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17505203>.

604. Orrico A, Galli L, Buoni S, et al. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin Genet 2009;75:195-198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18759867>.

605. Black D, Bogomolnii F, Robson ME, et al. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 2005;96:21-24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15589575>.

606. Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8673088>.

607. Schaffer JV, Kamino H, Witkiewicz A, et al. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol 2006;142:625-632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16702501>.

608. Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden's syndrome. Br J Dermatol 1979;100:667-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/465314>.

609. Brownstein MH, Mehregan AH, Bilowski JB. Trichilemmomas in Cowden's disease. JAMA 1977;238:26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/577252>.

610. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010;139:1927-1933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20600018>.

611. Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc 2011;86:489-492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21628613>.

612. Stanich PP, Pilarski R, Rock J, et al. Colonic manifestations of PTEN hamartoma tumor syndrome: case series and systematic review. World J Gastroenterol 2014;20:1833-1838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24587660>.

613. Al-Thihli K, Palma L, Marcus V, et al. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol 2009;6:184-189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19190598>.

614. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer 2014;13:57-63. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23934601>.

615. Gorlin RJ, Cohen MM, Jr., Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992;44:307-314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1336932>.

616. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-515. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9467011>.

617. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000;37:828-830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11073535>.

618. Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget 2017;8:32043-32054. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28410191>.



619. Feldman R, Gatalica Z, Knezetic J, et al. Molecular profiling of head and neck squamous cell carcinoma. *Head Neck* 2016;38 Suppl 1:E1625-1638. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26614708>.
620. Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. *Clin Sci (Lond)* 2017;131:197-210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28057891>.
621. Hoxhaj A, Drissen M, Vos JR, et al. The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome. *Cancer* 2022;128:2883-2891. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36533707>.
622. SEER Stat Fact Sheets: Thyroid Cancer. 2015. Available at: <http://seer.cancer.gov/statfacts/html/thyro.html>. Accessed May 28, 2015.
623. Schultz KAP, Rednam SP, Kamihara J, et al. PTEN, DICER1, FH, and their associated tumor susceptibility syndromes: clinical features, genetics, and surveillance recommendations in childhood. *Clin Cancer Res* 2017;23:e76-e82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28620008>.
624. Humphris JL, Johns AL, Simpson SH, et al. Clinical and pathologic features of familial pancreatic cancer. *Cancer* 2014;120:3669-3675. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25313458>.
625. Petersen GM. Familial pancreatic cancer. *Semin Oncol* 2016;43:548-553. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27899186>.
626. Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. *Genet Med* 2019;21:213-223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29961768>.
627. Abe T, Blackford AL, Tamura K, et al. Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. *J Clin Oncol* 2019;37:1070-1080. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30883245>.
628. Uson PLS, Jr., Samadder NJ, Riegert-Johnson D, et al. Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study. *Clin Transl Gastroenterol* 2021;12:e00414. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34620795>.
629. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov* 2012;2:41-46. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22585167>.
630. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010;78:490-494. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20412113>.
631. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009;324:217. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19264984>.
632. Hu C, Hart SN, Bamlet WR, et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. *Cancer Epidemiol Biomarkers Prev* 2016;25:207-211. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26483394>.
633. Lowery MA, Wong W, Jordan EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. *J Natl Cancer Inst* 2018;110:1067-1074. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29506128>.
634. Cremin C, Lee MK, Hong Q, et al. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. *Cancer Med* 2020;9:4004-4013. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32255556>.
635. Rainone M, Singh I, Salo-Mullen EE, et al. An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. *JAMA Oncol* 2020;6:764-771. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32053139>.



636. Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. *J Gastroenterol* 2021;56:713-721. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34255164>.

637. Gardiner A, Kidd J, Elias MC, et al. Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes. *J Natl Cancer Inst* 2022;114:996-1002. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35445726>.

638. Zeng C, Bastarache LA, Tao R, et al. Association of pathogenic variants in hereditary cancer genes with multiple diseases. *JAMA Oncol* 2022;8:835-844. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35446370>.

639. Sargen MR, Helgadottir H, Yang XR, et al. Impact of transcript (p16/p14ARF) alteration on cancer risk in CDKN2A germline pathogenic variant carriers. *JNCI Cancer Spectr* 2022;6. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36269225>.

640. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004;64:2634-2638. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15059921>.

641. Porter N, Laheru D, Lau B, et al. Risk of pancreatic cancer in the long-term prospective follow-up of familial pancreatic cancer kindreds. *J Natl Cancer Inst* 2022;114:1681-1688. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36029239>.

642. Dbouk M, Katona BW, Brand RE, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. *J Clin Oncol* 2022;40:3257-3266. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35704792>.

643. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018;68:7-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29313949>.

644. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. *CA Cancer J Clin* 2012;62:118-128. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22281605>.

645. Klatte DCF, Bokestijn B, Wasser M, et al. Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. *J Clin Oncol* 2022;40:3267-3277. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35658523>.

646. Laish I, Schechter M, Dancour A, et al. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants. *Cancer* 2024;130:256-266. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37861363>.

647. Paiella S, Capurso G, Cavestro GM, et al. Results of first-round of surveillance in individuals at high-risk of pancreatic cancer from the AISP (Italian Association for the Study of the Pancreas) registry. *Am J Gastroenterol* 2019;114:665-670. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30538291>.

648. Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. *Gastroenterology* 2018;155:740-751 e742. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29803839>.

649. Blackford AL, Canto MI, Dbouk M, et al. Pancreatic cancer surveillance and survival of high-risk individuals. *JAMA Oncol* 2024;10:1087-1096. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38959011>.

650. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology* 2012;142:796-804. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22245846>.

651. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated



recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020;69:7-17. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31672839>.

652. Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc 2022;95:817-826. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35183358>.

653. Patel MR, Eppolito AL, Willingham FF. Hereditary pancreatitis for the endoscopist. Therap Adv Gastroenterol 2013;6:169-179. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23503650>.

654. Weiss FU. Pancreatic cancer risk in hereditary pancreatitis. Front Physiol 2014;5:70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24600409>.

655. Rebours V, Levy P, Ruzsniowski P. An overview of hereditary pancreatitis. Dig Liver Dis 2012;44:8-15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21907651>.

656. LGBT Identification in U.S. Ticks Up to 7.1%. Gallup; 2022. Available at: <https://news.gallup.com/poll/389792/lgbt-identification-ticks-up.aspx>. Accessed

657. About 5% of young adults in the U.S. say their gender is different from their sex assigned at birth. 2022. Available at: <https://www.pewresearch.org/short-reads/2022/06/07/about-5-of-young-adults-in-the-u-s-say-their-gender-is-different-from-their-sex-assigned-at-birth/>. Accessed

658. Sutherland N, Espinel W, Grotzke M, Colonna S. Unanswered questions: hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. J Genet Couns 2020;29:625-633. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32304336>.

659. Leone AG, Trapani D, Schabath MB, et al. Cancer in transgender and gender-diverse persons: a review. JAMA Oncol 2023;9:556-563. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36757703>.

660. Manfredi C, Franco A, Ditunno F, et al. Prevalence and factors associated with prostate cancer among transgender women. JAMA Oncol 2024;10:1697-1700. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39361307>.

661. Meagher M, Morgan K, Deshler L, et al. Prostate cancer in transgender women: a propensity score-matched analysis of disease severity and survival. Cancer 2024;130:3863-3869. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39033478>.

662. Kalavacherla S, Riviere P, Kalavacherla S, et al. Prostate cancer screening uptake in transgender women. JAMA Netw Open 2024;7:e2356088. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38353948>.

663. Nik-Ahd F, De Hoedt AM, Butler C, et al. Prostate-specific antigen values in transgender women receiving estrogen. JAMA 2024;332:335-337. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38922607>.

664. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019;365:l1652. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31088823>.

665. Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010;20:553-558. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20122869>.

666. Slagter MH, Gooren LJ, Scorilas A, et al. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006;54:905-910. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16618941>.